SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 1996 COMMISSION FILE NUMBER 0-19890
LIFECELL CORPORATION
A DELAWARE IRS EMPLOYER IDENTIFICATION
CORPORATION NO. 76-0172936
3606 RESEARCH FOREST DRIVE
THE WOODLANDS, TEXAS 77381
Telephone Number (281) 367-5368
SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:
NONE
SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT:
Common Stock, $.001 Par Value
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [ ]
Aggregate market value of the voting stock (Common Stock and Series B Preferred
Stock, assuming conversion of such Preferred Stock into Common Stock at the
current conversion rate) held by non-affiliates of registrant as of March
26, 1997 $40,933,000
Number of shares of registrant's Common Stock 6,754,761
outstanding as of March 26, 1997
DOCUMENTS INCORPORATED BY REFERENCE:
Portions of registrant's proxy statement relating to the 1997 annual meeting of
stockholders have been incorporated by reference into Part III hereof.
<PAGE>
TABLE OF CONTENTS
DESCRIPTION
ITEM PAGE
- ---- ----
PART I ................................................................... 1
1. BUSINESS....................................................... 1
2. PROPERTIES..................................................... 21
3. LEGAL PROCEEDINGS.............................................. 21
4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS............ 22
PART II ................................................................... 22
5. MARKET FOR THE REGISTRANT'S COMMON EQUITY AND
RELATED STOCKHOLDER MATTERS............................... 22
6. SELECTED FINANCIAL DATA........................................ 24
7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS....................... 25
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.................... 27
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL DISCLOSURE....................... 27
PART III ................................................................... 27
10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT............ 27
11. EXECUTIVE COMPENSATION........................................ 28
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT................................................ 28
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS................ 28
PART IV ................................................................... 28
14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS
ON FORM 8-K............................................... 28
GLOSSARY .......................................................... 31
<PAGE>
PART I
THIS ANNUAL REPORT ON FORM 10-K CONTAINS, IN ADDITION TO HISTORICAL
INFORMATION, FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES.
THE COMPANY'S ACTUAL RESULTS COULD DIFFER MATERIALLY. FACTORS THAT COULD CAUSE
OR CONTRIBUTE TO SUCH DIFFERENCES INCLUDE, BUT ARE NOT LIMITED TO, THOSE
DISCUSSED IN "BUSINESS", "BUSINESS--RISK FACTORS", "MANAGEMENT'S DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS" AND ELSEWHERE IN THIS
ANNUAL REPORT ON FORM 10-K.
ITEM 1. BUSINESS
CERTAIN TECHNICAL TERMS USED IN THIS ITEM ARE DESCRIBED OR DEFINED IN
THE GLOSSARY COMMENCING ON PAGE 33 OF THIS ANNUAL REPORT ON FORM 10-K.
GENERAL
LifeCell Corporation ("LifeCell" or the "Company") develops and
commercializes universal tissue grafts and blood cell preservation products.
The Company's universal tissue grafts are derived from a patented
platform technology for processing and preserving human (allograft) and animal
(xenograft) tissues to preclude rejection of transplanted foreign tissues by the
human body. LifeCell removes cells that cause tissue rejection while preserving
the extracellular tissue matrix and its essential biochemical and structural
composition. This matrix does not cause an immune rejection response and has
been clinically proven to function as a natural template or scaffold into which
a patient's own cells will migrate following transplantation for effective
tissue engraftment.
The clinical use of a preserved tissue matrix as a natural template for
tissue regeneration has been established by others through the use of processed,
freeze-dried allograft bone for orthopedic and periodontal procedures.
LifeCell's expertise is the ability to preserve the more delicate and
sophisticated tissue matrix of soft tissues, which would otherwise be destroyed
by the allograft bone process.
AlloDerm(R) processed universal dermal tissue graft ("AlloDerm") is
LifeCell's first commercial application of its technology. Additional universal
tissue products under development include composite skin graft, XenoDermTM
processed porcine dermis, heart valves for replacement surgeries and vascular
conduits for bypass procedures.
Using its core preservation technology, LifeCell is also developing
products and patented formulations to facilitate storage, transportation and
delivery of transfusable blood cells. The Company is developing ThromboSolTM
platelet storage solution to permit refrigerated storage of transfusable blood
platelets and intends to develop other potential preservation technologies for
red blood cells and other mammalian cells.
LifeCell was organized in 1986 to commercialize its core preservation
technology, a process developed by The University of Texas Health Science Center
in Houston and exclusively licensed from The Board of Regents of the University
of Texas System involving ultra-rapid cooling and ultra-low temperature
freeze-drying of biological cells and tissues.
PRODUCTS
ALLODERM
AlloDerm is human donor (allograft) dermis that has been processed
using LifeCell's patented technology. The AlloDerm process removes the cells
from donated human (allograft) skin and preserves the critical structural and
biochemical components of the dermal matrix which are key to the eventual
engraftment of the dermal matrix.
The AlloDerm process preserves an immunologically inert human dermal
matrix which is freeze-dried and packaged for distribution to end-users.
AlloDerm grafts are rehydrated in the operating room in a ten-minute
3
<PAGE>
procedure prior to grafting. The intact human dermal matrix functions as a graft
or implant, permanently integrating and guiding the reconstitution of dermal
tissue.
AlloDerm grafts consist entirely of and are intended to perform the
same function as human dermis. As a result, the Company believes AlloDerm tissue
products are not subject to the lengthy United States Food and Drug
Administration ("FDA") approval or clearance process associated with medical
devices or drugs. See "--Government Regulation" and "--Risk Factors--FDA
Regulatory Status of AlloDerm". LifeCell procures human skin through sources
that screen donors to meet all FDA requirements for banked human tissue and
conduct blood testing recommended by the Centers for Disease Control and
Prevention. Additionally, the AlloDerm process includes de-cellularization
(extraction of living cells from human tissue matrix) and viral inactivation
(the treatment of the tissue with a documented anti-viral agent). The AlloDerm
process has been independently validated to inactivate concentrated suspensions
of HIV, the virus that causes AIDS.
LifeCell procures allograft skin from unaffiliated tissue banks. To
date, the Company has not experienced any material difficulty in procuring
adequate supplies of cadaveric skin. Additionally, LifeCell believes it has
established what it believes to be adequate sources of cadaveric skin at
acceptable costs to satisfy the foreseeable demand for AlloDerm tissue products.
AlloDerm products address multiple clinical markets including the
treatment of third-degree burns, periodontal surgery and plastic and
reconstructive surgery. Since its commercial introduction, AlloDerm has been
used as a dermal graft or transplant to treat over 5,000 patients.
THIRD-DEGREE BURNS. AlloDerm grafts may be used in the treatment of any
and all burns that require skin grafts. The Company estimates that approximately
55,000 people are hospitalized each year in the United States due to burns and
that approximately 20,000 patients are admitted with major burns. LifeCell began
marketing AlloDerm for use in the treatment of third-degree burns in December
1993. To date, AlloDerm grafts have been used to treat third-degree burn
patients at approximately 60 of the 140 burn centers in the United States.
Skin is the body's largest organ and is the first line of defense
against invasion of foreign substances. It contains two functional layers, the
upper surface consisting primarily of cells (epidermis) and an underlying
foundational layer of extracellular matrix proteins and collagen (dermis). The
epidermis functions as a water barrier and maintains hydration. The dermis
provides other important skin properties including tensile strength, durability
and elasticity.
Third-degree burns and other acute full-thickness skin wounds destroy
both the epidermis and the dermis. Destruction of dermis is of particular
concern because the body has lost the framework, I.E., the extracellular
matrix, to guide and support the regrowth of new cells and blood vessels. Like
most organs of the body, the skin can perform some repairs but it cannot
regenerate its basic structure. Instead, damaged or missing dermis is replaced
with scar tissue, which lacks the important elastic and tensile properties of
skin. Scar tissue also is disfiguring and can cause restricted mobility of limbs
and body areas near joints. For this reason, full-thickness burns are treated
with split-thickness skin grafts of the patient's own skin (autograft) taken
from an uninjured area of the body. This procedure is painful and causes an
additional wound at the autograft donor site. Autografts that include the dermal
layer generate relatively deep donor sites which can cause medical complications
including infection and hypertrophic scarring. Autografts that are too thin
(containing minimal dermis) typically result in poor wound healing quality, with
scarring and contracture at the wound site. AlloDerm grafts are used in
conjunction with thin autografts to supply an adequate dermal layer for optimum
healing of the wound. The use of AlloDerm reduces the thickness of
split-thickness grafts required from the patient in treating such wounds,
thereby minimizing the substantial donor site trauma associated with taking such
grafts.
PERIODONTAL SURGERY. LifeCell began marketing AlloDerm to periodontists
in September 1995. LifeCell estimates that there are in excess of 4,000
periodontal surgeons in the United States. Periodontal surgeons use AlloDerm
tissue in free-gingival grafting, a procedure used to increase the amount of
attached gum tissue supporting tooth roots. This procedure previously required
the use of autograft tissue, which was excised from the roof of the patient's
mouth and then transplanted to the gum. In several clinical case studies,
AlloDerm grafts functioned as well or better than the patient's own (autologous)
graft, spared the patient the pain and discomfort associated with
4
<PAGE>
the excision of the autograft, reduced surgical time and
eliminated the cost of the dressing that was needed for the autograft donor
site.
AlloDerm tissue products are also used as barrier membranes in guided
tissue regeneration. In this function, the AlloDerm tissue serves as a barrier
membrane over allograft bone grafts, which are used to restore a degenerated jaw
bone and surrounding gingival tissue. The AlloDerm tissue barrier engrafts over
the bone, preventing the cells of the surrounding soft tissue from extruding the
bone graft during the normal healing process. Jaw bones restored by this
procedure were suitable for supporting artificial tooth implants.
PLASTIC AND RECONSTRUCTIVE SURGERY. In November 1995, LifeCell began
marketing AlloDerm to plastic and reconstructive surgeons. The Company estimates
that there are approximately 8,000 physicians practicing plastic surgery in the
United States. Plastic surgeons use AlloDerm tissue as a graft to release
contractures and revise scarring resulting from previously grafted burn wounds,
and as an implant to correct soft tissue (dermal) defects and to revise scars
resulting from trauma or surgical excisions.
TEMPORARY WOUND COVERAGE--CRYOPRESERVED ALLOGRAFT SKIN
In April 1995, LifeCell began processing and distributing cryopreserved
allograft skin for use as a temporary or transitional covering for severe burn
wounds. For patients with extensive burns, allograft skin assists in stabilizing
the patient and preparing the wound bed for a permanent graft.
PRODUCT DEVELOPMENT
In addition to AlloDerm tissue products, the Company is developing
composite skin grafts, XenoDerm porcine dermis, universal cardiovascular
products (heart valves and vascular conduits) and blood cell preservation
products.
COMPOSITE SKIN GRAFTS. LifeCell intends to develop a composite,
full-thickness skin replacement tissue product containing an AlloDerm dermal
layer and an epidermis consisting of keratinocytes (epidermal cells) isolated
from the patient and expanded under cell culture conditions. Successfully
developed, a composite skin graft product would effectively eliminate the
requirement of taking an autologous skin graft from burn patients.
In 1994, LifeCell received and completed a Phase I, Small Business
Innovative Research (SBIR) grant from the National Science Foundation ("NSF") to
assess the feasibility of a co-cultured composite skin product. In 1996,
LifeCell received a Phase II SBIR grant from the NSF to continue the development
of and initiate animal studies with this composite skin graft product. Also in
1996, LifeCell received a two-year Cooperation Agreement award from the U.S.
Army Medical Research and Material Command to support the development of a
composite skin graft product using AlloDerm and biopsy-sized microskin grafts
from the burn patient.
XENODERM TISSUE PRODUCTS. LifeCell is developing XenoDermTM processed
porcine dermis, which is processed in a manner similar to the AlloDerm process
to remove the targets for immune rejection and preserve the dermal matrix.
Animal studies by LifeCell indicate that XenoDerm tissue does not cause a
significant immune response when transplanted cross-species. Animal studies
conducted by unaffiliated laboratories have shown that XenoDerm tissue is
potentially as effective as AlloDerm tissue in treating full-thickness skin
loss.
LifeCell believes that, if successfully developed, the XenoDerm tissue
products would have the advantage of a potentially increased raw material supply
base and could facilitate distribution to certain international markets. See
"--Sources of Materials". The Company currently plans to begin clinical testing
of XenoDerm tissue products in 1997.
HEART VALVES. LifeCell is applying its universal tissue processing and
preservation technology to porcine heart valves intended for replacement
procedures. In 1994, LifeCell and Medtronic, Inc. ("Medtronic") entered into a
license and development agreement for the potential development and
commercialization of heart valves processed with LifeCell's technology. Since
that time, pursuant to the agreement, LifeCell and Medtronic have been engaged
in a development program for heart valves that is funded fully by Medtronic. See
"--Corporate Alliance".
5
<PAGE>
LifeCell's heart valves are based on its patented universal tissue processing
and preservation technology that the Company uses to process AlloDerm tissue
products. The Company processes heart valves harvested from pigs to remove the
cells that would be recognized by the body as foreign. By making the
transplanted heart valves non-immunogenic, LifeCell believes that the new valve
will last longer, become part of the body and perhaps last the patient's
lifetime.
Tissue heart valves on the market today have limited life spans of 10
to 18 years after transplantation as a result of progressive calcification.
Mechanical heart valves last longer but lack the blood flow dynamics of tissue
valves and require the patient to remain on anticoagulants for life to prevent
strokes. Human donor (allogeneic) valves are used in a limited number of the
procedures, but there is limited donor availability and, therefore, a limited
market.
Preliminary animal studies conducted by LifeCell have shown that the
LifeCell heart valves transplanted in the thoracic descending aorta become
populated with the recipient's own cells; I.E., they have not been rejected by
the recipient. Other animal studies conducted by LifeCell have shown that the
valves do not undergo significant calcification. Extensive FDA regulatory
involvement in both human and xenograft heart valves may significantly delay
product entry into this market. See "--Government Regulation".
VASCULAR CONDUITS. LifeCell is developing vascular conduit products for
arterial bypass as a treatment for atherosclerosis, a progressive, degenerative
disease characterized by a build-up of fats, cholesterol and other material
within the lining of arterial blood vessels located throughout the body. This
build-up is called plaque, and leads to reduced blood flow through the arteries,
and eventually, may result in serious arterial blockage that can cause tissue
damage and death.
Minimally invasive surgical devices are currently available for opening
blocked or occluded arteries, including balloon angioplasty to dilate
mechanically and thereby open the vessel, and atherectomy devices and lasers
that physically remove plaque from the vessel wall. These procedures, however,
are not recommended when the patient displays extensive deposits of
atherosclerotic plaque throughout the length of one or more vessels, which makes
it impractical to attempt the opening of the occluded arteries due to the
procedural time involved. In these cases, a more extreme and invasive surgical
procedure called arterial bypass is indicated, in which one or more of the
patient's own veins (usually the saphenous veins from the legs) are transplanted
to an arterial position to divert blood flow around the blockage. Arterial
bypass is also used when the blockage is in a critical location or when the
surgeon is unable to access the blockage safely.
Coronary bypass procedures, which involve replacement of vessels
supplying blood to the heart, typically use the patient's own veins or arteries.
The trauma endured from the vessel removal is often more extensive than that of
the bypass procedure itself. Even though immune response is not an issue with
these self-derived (autologous) vessels, long-term patency (greater than five
years) is limited due to eventual blockage from progressive wall thickening and
thrombosis.
Repeat arterial bypass procedures may be difficult due to depletion of
the available supply of autologous vessels. The use of synthetic arterial
substitutes has been attempted, but these devices occlude even more rapidly in
the coronary and below-knee positions, which require a small diameter (6
millimeter) graft. The synthetic conduit has been used more successfully in
above-the-knee peripheral procedures, but is still associated with infections,
leaking and blockage.
LifeCell currently is developing vascular conduit products using
allograft blood vessels and plans to extend the technology to xenografts. These
potential products utilize LifeCell's ability to process vascular tissue and
remove cells that would be recognized by the host as foreign and trigger an
immune response. Early preclinical studies conducted by LifeCell with its
vascular conduits show that they become re-populated with new host cells after
grafting and show no sign of rejection.
As part of the Company's agreements with Medtronic for the development
of heart valves, LifeCell granted Medtronic certain rights of first refusal to
evaluate technology and negotiate license and development agreements for
vascular conduit products utilizing LifeCell's technology. In December 1996,
LifeCell received a two-year
6
<PAGE>
Cooperative Agreement award from the U.S. Army Medical Research and
Material Command to support the development of vascular graft products.
BLOOD CELL PRESERVATION PRODUCTS
LifeCell is developing proprietary technology to extend the shelf life
of transfusable platelets, red blood cells and other mammalian cells. This
technology differs from the universal tissue graft applications in that cell
viability is crucial to successful processing.
THROMBOSOL PLATELET STORAGE SOLUTION. LifeCell is developing a
proprietary biochemical formulation called ThromboSol platelet storage solution
to protect transfusable platelets from damage at low temperatures. Platelets are
blood cells that control clotting. Untreated platelets are sensitive to low
temperatures and cannot be effectively refrigerated. Presently, platelets are
stored at room temperature and, due to the risk of microbial contamination, have
a limited shelf life of three to five days. LifeCell has shown in laboratory
tests that the addition of ThromboSol solution preserves the functional aspects
of refrigerated platelets for up to ten days and frozen platelets for more than
six months. LifeCell initiated toxicity studies for ThromboSol platelet storage
solution in late 1994 and began preclinical animal studies in 1995. LifeCell
intends to license this product to major pharmaceutical and other appropriate
companies.
The ThromboSol development program has been funded through a Phase I
and II SBIR contract with the United States Army. In April 1996, the Company
received additional contract funding of $613,000 for this program from the
United States Navy.
FREEZE-DRIED RED BLOOD CELLS. LifeCell previously has been funded by
the United States Navy to develop directly transfusable freeze-dried red blood
cells. The need for immediately available, screened blood units is of particular
importance to the United States Armed Services because a substantial number of
combat deaths have resulted from hemorrhaging due to the lack of availability of
on-site transfusable blood. In addition, freeze-dried red blood cells
potentially will allow for widespread autologous transfusion, thereby preventing
transfusion related complications, including disease transmission.
The fear of acquiring transmittable diseases such as AIDS and hepatitis
from donated blood units has created a growing market for blood recycling units,
preservation of autologous blood, blood cell growth stimulating factors, and
blood substitutes. Freeze-dried blood can eliminate the concern of disease
transmission by the patient donating his or her own blood to be freeze-dried
prior to the anticipated need for transfusable blood.
The Company is seeking additional funds from various government
granting agencies and potential corporate partners to continue this program and
intends to license this technology to third-parties at a later stage of
development.
CORPORATE ALLIANCE
In 1994, LifeCell entered into a license and development agreement with
Medtronic to develop jointly the Company's heart valve products. Pursuant to the
agreement, Medtronic paid LifeCell an initial $1.5 million license fee. The
agreement also provides that Medtronic will fund all costs of research and
development, including clinical trials, receive the exclusive right to market
any resulting commercial products and pay LifeCell royalties of up to $25
million on sales of products covered by the agreement. Medtronic may terminate
the agreement at any time if in its sole business judgment it deems the
development and commercialization of products thereunder not to be in its best
interests or otherwise to be imprudent. In such event, and if the agreement is
terminated under certain other circumstances, Medtronic has the option to
convert the $1.5 million license fee into shares of Common Stock, subject to
certain limitations, at the then current market price.
In 1994, Medtronic also made a $500,000 equity investment in LifeCell
by purchasing approximately 64,000 shares of Common Stock at $7.77 per share in
exchange for rights of first refusal to negotiate licenses to LifeCell universal
vascular conduit products.
7
<PAGE>
MARKETING
LifeCell currently markets AlloDerm grafts and cryopreserved allograft
skin to United States burn treatment centers and other potential customers
through its direct sales force. LifeCell has a sales and marketing staff
consisting of a vice president of sales and marketing, a director of
international sales and marketing, a national manager, a product manager, nine
field technical representatives, a clinical specialist, a customer service
representative, two marketing coordinators, and an international customer
service assistant. The field technical representatives and clinical specialists
are responsible for interacting with treatment physicians, primarily burn
surgeons and plastic surgeons at burn treatment centers, and educating them
regarding the use and anticipated benefit of AlloDerm tissue grafts. LifeCell
also participates in national and international conferences and trade shows for
burns and wound healing.
The Company has engaged specialty distributors to market and sell
AlloDerm tissue for plastic surgery indications. The Company has reached
agreement with 11 such companies and plans to add additional distributors to
cover the entire United States. The Company has nine field technical
representatives, who are responsible for promoting the use of AlloDerm tissue
products in plastic and reconstructive surgery and supporting regional
distributors of the product.
In June 1996, LifeCell engaged DENTSPLY International, Inc. (DENTSPLY)
to distribute AlloDerm grafts for periodontal surgery on a worldwide basis. In
March 1997, however, DENTSPLY advised LifeCell that it intends to discontinue
operations of the division with responsibility for distributing AlloDerm.
Accordingly, LifeCell expects that it will terminate the agreement with DENTSPLY
and in the near future will resume marketing AlloDerm for periodontal
applications through its direct sales force.
PROCESSING
LifeCell procures human skin and other tissues from unaffiliated tissue
banks. See "--Sources of Materials". LifeCell provides tissue banks and their
procurement agents with specific procurement protocols, which are required for
the optimum removal and transportation of tissues. Tissues are transported to
LifeCell in accordance with standard industry practices and are identified on
delivery to LifeCell with a unique identification number that allows tracing to
a specific donor. This unique identification number accompanies each processed
tissue to its destination. It then becomes the responsibility of the recipient
treatment center, hospital or surgeon to return a self-addressed patient
tracking card (included with all LifeCell tissues) to LifeCell for donor and
recipient tracking.
LifeCell begins aseptic processing of donor tissue within 12 days
post-mortem. Processing includes any required sizing and trimming, treatment to
remove cells from the dermal matrix, which is then preserved by proprietary
cryoprotection, packaging and freeze-drying. Microbiological and other quality
assurance testing is conducted before AlloDerm tissue products are released for
shipment to customers. Customers typically order the AlloDerm product on a
just-in-time basis. The product is shipped at ambient temperature by overnight
delivery services.
Cryopreserved allograft skin is processed by a standard industry
protocol and stored at LifeCell's premises until requisitioned by a customer.
Cryopreserved allograft skin is transported to the customer on dry ice by
overnight delivery.
SOURCES OF MATERIALS
LifeCell procures allograft skin from unaffiliated tissue banks.
LifeCell is expanding its current procurement of skin and other tissues to
include any of approximately 100 major national tissue banks, including
approximately 35 skin banks. Procurement of certain human organs and tissue for
transplantation is subject to the restrictions of the National Organ Transplant
Act ("NOTA"), which prohibits purchase and sale of human organs and related
tissue for "valuable consideration". See "--Government Regulation". LifeCell
pays a procurement fee to the tissue bank, which covers the cost of recovering
the tissue, conducting donor testing for communicable diseases, including AIDS
and hepatitis tests recommended by the Centers for Disease Control and
Prevention.
8
<PAGE>
Pursuant to contractual arrangements, LifeCell reimburses tissue banks for
recovering and delivering to LifeCell cadaveric skin suitable for
transplantation. In procuring such tissues, LifeCell competes with treatment
centers that use cadaveric skin for temporary wound dressings.
LifeCell has entered into allograft skin procurement service agreements
with certain tissue banks that, prior to these agreements, did not recover skin
from consented tissue donors. Pursuant to these agreements, LifeCell accepts
from these tissue banks all skin tissue that meets LifeCell's allograft skin
procurement specifications, the requirements of the FDA and the procedural
guidelines outlined by the American Association of Tissue Banks. Allograft skin
tissue that is procured in excess of that required to meet the demand for
AlloDerm tissue products is processed by conventional cryopreservation and
distributed to burn treatment centers and hospitals for use as a temporary or
transitional wound dressing. See "--Products--Temporary Wound Coverage
- --Cryopreserved Allograft Skin".
The Company has established what it believes to be adequate sources of
cadaveric skin at acceptable costs to satisfy the foreseeable demand for
AlloDerm tissue products. Although to date the Company has not experienced any
material difficulty in procuring adequate supplies of cadaveric skin, there can
be no assurance that the future availability of human skin will be sufficient to
meet LifeCell's demand for such materials. Any supply shortage of available
tissues in the future would have a material adverse effect on LifeCell's
business. Different grades or thicknesses of material are required for different
surgical uses. There can be no assurances that imbalances in demand will not
result in shortages of desired materials and simultaneous increases in
inventoried materials.
GOVERNMENT REGULATION
Government regulation, both domestic and foreign, is a significant
factor in the manufacture and marketing of LifeCell's current and developing
products. In the United States, the Company's currently marketed human skin
allograft and AlloDerm products are subject to regulation by the FDA. The United
States Food, Drug and Cosmetics Act (the "FDC Act"), the Public Health Service
Act (the "PHS Act") and other federal statutes and regulations govern or
influence the testing, manufacture, labeling, storage, record keeping, approval,
advertising and promotion of such products. Noncompliance with applicable
requirements can result in fines, injunctions, civil penalties, recall or
seizure of products, total or partial suspension of production, refusal of the
government to authorize the marketing of new products or to allow the Company to
enter into supply contracts and criminal prosecution.
In December 1993, the FDA published an interim rule regulating "banked
human tissue". The rule defines banked human tissue as any tissue derived from a
human body which is (i) intended for administration to another human for the
diagnosis, cure, mitigation, treatment or prevention of any condition or disease
and (ii) recovered, processed, stored or distributed by methods not intended to
change tissue function or characteristics. The FDA definition excludes, among
other things, tissue that currently is regulated as a human drug, biological
product or medical device and kidney, liver, heart, lung, pancreas or any other
vascularized human organ. Banked human tissue is regulated by the FDA in a
manner the agency has deemed necessary to protect the public health from the
transmission of HIV infection and hepatitis infection through transplantation of
tissue from donors with or at risk of these diseases. Under the FDA regulations,
all facilities engaged in the procurement, processing, storage or distribution
of human tissue intended for transplant are required to assure that certain
infectious disease testing and donor screening is performed and that records
documenting such testing for each tissue are available for inspection by the
FDA. The regulations also provide authority for the FDA to conduct inspections
of banked human tissue facilities and to detain, recall or destroy tissue for
which appropriate documentation is not available. Banked human tissue, however,
is not subject to premarket notification or approval by the FDA as are certain
drugs, biologicals and medical devices.
In December 1991, the Company first contacted the FDA regarding the
regulatory status of AlloDerm and was advised in May 1992 that the FDA had not
made a final determination on the status of intact processed human cadaver skin,
that the agency currently was studying the issue and that these products may at
some future time be subject to FDA regulation. The FDA sent the Company a copy
of the December 1993 publication of the FDA's banked human tissue regulations
shortly after its release of such regulations and inspected the Company for
compliance with those regulations in July 1994. For these reasons, the Company
believed that AlloDerm was covered by the FDA's definition of banked human
tissue and that the product would not be regulated as a medical device.
9
<PAGE>
In November 1995, following LifeCell's commercial introduction of
AlloDerm for periodontal applications, the Company received a letter from the
FDA, stating that it considered AlloDerm to be a "device" as defined by the FDC
Act, and that a 510(k) premarket notification was required to be submitted and
cleared by the FDA in order to market the product. Following several months of
correspondence and discussions with the FDA, the Company received a letter from
the agency dated September 17, 1996, to the effect that, after considering the
information and views that the Company submitted at a May 1996 meeting with
agency officials and in subsequent correspondence, the FDA agrees with the
Company's position that AlloDerm intended for use for replacement or repair of
damaged or inadequate integumental tissue, including gingival dermis, is banked
human tissue within the meaning of the interim final rule. Consequently,
AlloDerm is not subject to premarket notification or approval by the FDA and the
Company may continue to promote and sell AlloDerm for use in the treatment of
wounds, such as third-degree burns, in periodontal surgical procedures, such as
free-gingival grafting and guided tissue regeneration, and in plastic and
reconstructive surgery procedures, such as contracture release grafting and scar
revision. The agency also informed the Company that this decision applies only
to AlloDerm when it is intended for use in transplantation, and the regulatory
status of the product when it is promoted for other uses, such as a void filler
for soft tissue, for cosmetic augmentation or as a wound healing agent (the
"Additional Indications"), would need to be determined by the FDA on a case by
case basis.
While the Company's marketing efforts had not previously focused on the
Additional Indications, as a follow-up to its September 17 letter, the FDA, by
letter dated September 23, 1996, informed the Company that indications for
Additional Indications would have to be formally presented to the FDA to
determine if, with these indications, AlloDerm would continue to fall within the
scope of the interim rule for banked human tissue and thus not require premarket
clearance. The Company was asked to indicate what changes in advertisement and
promotion it would make for AlloDerm in response to the September 23, 1996
letter. The Company responded to the FDA letter in October 1996, and informed
the agency that the Company believes that the distinctions drawn regarding the
definition of transplantation and banked human tissue and between integumental
tissue and all other tissue in the September 17 opinion were fairly novel and
ones for which the Company would require clarification from the FDA as it goes
forward. The Company believes that AlloDerm, when used for augmentation and as a
void filler, still qualifies as banked human tissue. Similarly, the Company
advised the FDA that since almost every replacement or repair of damaged or
inadequate tissue involves a cosmetic aspect, the Company believes that many
cosmetic uses of AlloDerm are within the purview of banked human tissue.
Nevertheless, the Company informed the FDA that it intends to follow
the agency's decision and, until this matter is clarified on a case by case
basis, will not promote AlloDerm for the Additional Indications. The Company
also advised the FDA that it would present its arguments to the agency as to why
it believes that these uses fall within the definition of banked human tissue.
There can be no assurance that the FDA will not finally conclude that use of
AlloDerm for the Additional Indications should be regulated as a medical device
and require a 510(k) premarket notification or premarket approval ("PMA") for
AlloDerm for such indications. If the FDA were to conclude definitively that the
Company is required to obtain agency clearance of a 510(k) notification or
approval of a PMA for AlloDerm for the Additional Indications, the FDA may
require the Company to conduct laboratory testing and preclinical and clinical
studies of AlloDerm to support a marketing application. Testing, preparation of
necessary applications and processing of those applications by the FDA is
expensive and any required laboratory testing or preclinical or clinical studies
that the Company were required to conduct could take several years to complete.
There can be no assurance that any required testing could be completed
successfully, or that if successfully completed, would provide sufficient data
and information to enable the FDA to determine, on a timely basis, if at all,
that when AlloDerm is used for the Additional Indications, it is substantially
equivalent to a legally marketed predicate device or is safe and effective for
the Additional Indications and permit the product to be marketed for such uses.
Failure of the Company to receive any required FDA clearance or approval of
AlloDerm for the Additional Indications on a timely basis would preclude
promotion of AlloDerm for the Additional Indications and could have a material
adverse effect on the Company's business, financial condition and results of
operation. See "--Risk Factors--Regulatory Status of AlloDerm".
The FDA's banked human tissue regulation requires establishments
engaged in the procurement, processing, and distribution of human tissue to
conduct and maintain records of tissue donor screening procedures and blood
testing. In addition, tissue processing establishments are periodically
inspected by the FDA to ensure compliance with these requirements. If at any
time the FDA determines that a banked human tissue product is not
10
<PAGE>
procured, processed or distributed in accordance with these requirements (E.G.,
there is a question about the source of the tissue, the adequacy of the testing
or the adequacy of donor selection), the agency may order the
recall and destruction of the product. The failure of a tissue processing
establishment to adhere to the FDA's requirements could subject the
establishment and its principals to civil and criminal prosecution. LifeCell
believes that the Company's operations substantially comply with the
requirements of the FDA's interim rule.
LifeCell requires that the tissue banks supplying the Company with
tissue comply with the FDA's banked human tissue regulation. In addition, the
Company requires supplying tissue banks to comply with procedural guidelines
outlined by the American Association of Tissue Banks (the "AATB"). Since 1976,
the AATB has administered a voluntary accreditation system for skin and
orthopedic tissue banks. The AATB evaluates tissue banks for compliance with a
rigorous set of standards through site inspections and document review. The
AATB's standards apply to the procurement, processing, preservation, storage and
labeling of tissue and include requirements for disease screening through donor
testing and review of donor medical histories. Although the Company requires its
supplying tissue banks to comply with the FDA's requirements and the AATB's
standards, there can be no assurance that these tissue banks are in full
compliance with these requirements. The failure of a tissue bank to comply with
regulatory requirements with respect to tissue provided to the Company could
have a material adverse effect on the Company.
In its interim rule on banked human tissue, the FDA stated that it
would propose additional requirements for such products. Additional requirements
may include registration of tissue banking establishments with the FDA,
donor-recipient tracking and clinical evaluation of tissues that are determined
to have undergone other than "minimal processing". To date, the FDA has not
proposed additional requirements; however, if significant additional regulatory
requirements were to be established, the Company could incur significant
additional costs in order to comply with such requirements.
LifeCell's proposed human and xenograft heart valve products and its
proposed xenograft tissue transplantation products including XenoDerm tissue and
xenograft vascular conduits will be subject to regulation by the FDA as medical
devices, although the FDA has proposed classifying human heart valves as banked
human tissue. LifeCell's proposed blood cell additives, including ThromboSol
platelet storage solution, will be subject to regulation as biologics.
Accordingly, such products will require FDA premarket approval or clearance
prior to commercialization. To obtain FDA approval or clearance for these
products, the Company must submit proof of the safety and efficacy of these
products. In most cases, this entails extensive pre-clinical and clinical
testing. Such testing must be performed in accordance with the FDA's
regulations. The testing, preparation of necessary applications and processing
of those applications by the FDA is expensive and time consuming and will take
several years to complete. There is no assurance that the FDA will act favorably
or quickly in making such reviews, and significant difficulties or costs may be
encountered by the Company in its efforts to obtain the FDA approvals or
clearances that could delay or preclude the Company from marketing any product
it may develop. The FDA may also require post-market testing and surveillance to
monitor the effects of approved products, and may place conditions on approvals
that could restrict commercial applications of such products. Product marketing
approvals or clearances may be withdrawn if compliance with regulatory standards
is not maintained or if problems occur following initial marketing. In addition,
delays imposed by the governmental approval process may materially reduce the
period during which the Company may have the exclusive right to commercialize
patented products.
The FDA reviews medical devices for marketing approval or clearance
through two different procedures, the 510(k) premarket notification process and
the PMA process. LifeCell will need to pursue one of these routes with respect
to each of its proposed medical device products. The determination of which
process will be required for any particular product will depend in part upon how
the FDA has regulated similar products by the time LifeCell is ready to pursue
its own approvals or clearances.
Under the 510(k) premarket notification procedure, the applicant or
"sponsor" submits an application containing data that demonstrate the
"substantial equivalence" of the product to a device marketed prior to the
enactment of the Medical Device Amendments of 1976 or to a device legally
marketed thereafter pursuant to a 510(k). The FDA may require a 510(k) applicant
to submit additional, and possibly extensive, clinical data establishing the
safety and effectiveness of the product for each proposed medical use. Prior to
conducting the necessary clinical trials, an applicant may be required to submit
an investigational device ("IDE") protocol to the FDA for approval. An IDE
application typically contains data from laboratory and animal testing
demonstrating
11
<PAGE>
that the product is sufficiently safe for study in humans as well as a
description of the proposed study methods and protocol. Clinical studies must be
conducted according to a written protocol and pursuant to the approval and
oversight of one or more Institutional Review Boards. In addition, clinical
investigators must adhere to good clinical practices. The FDA may order the
temporary or permanent discontinuation of a clinical trial at any time for
non-compliance with its regulations, because of safety issues or for other
reasons. The collection of data and preparation of a 510(k) application can be
costly and time consuming, and a 510(k) applicant may not market the product
until a favorable decision is received from the FDA. The FDA review of a 510(k)
premarket notification can take anywhere from a few months to several years.
There can be no assurance that marketing clearance ultimately will be obtained
for any of LifeCell's products that are the subject of 510(k) premarket
notifications.
The PMA process is significantly more complex, costly and time
consuming than the 510(k) clearance procedure. To obtain premarket approval, the
applicant is required to submit extensive preclinical and clinical data to the
FDA. An IDE may be required to conduct the clinical trials. Upon completion and
analysis of clinical studies, the applicant assembles and submits a PMA
application setting forth the preclinical, clinical, manufacturing and other
data. Typically, the FDA will also inspect the manufacturing facility for
compliance with Good Manufacturing Practice ("GMP") regulations. The FDA review
and approval of a PMA can take several years. There can be no assurance that PMA
approvals will be obtained for any of LifeCell's proposed products.
With respect to LifeCell's proposed biological products, the Company or
its contracted designee must obtain both a product license and an establishment
license from the FDA prior to marketing. A product and license application
("PLA") and establishment license application ("ELA") must be submitted and
supported by extensive data, including preclinical and clinical data that
demonstrate that the manufactured product meets prescribed standards of safety
and efficacy. Before conducting the required clinical testing of a biological
product, an applicant must submit an investigational new drug ("IND")
application to the FDA. Similar to the IDE for testing of devices, the IND
application must contain preclinical data demonstrating the safety of the
product for human investigational use, information about the manufacturing
processes and procedures, and the proposed clinical protocol. Clinical trials of
biological products are typically conducted in three sequential phases, but may
overlap. Phase I trials test the product in a small number of healthy subjects,
primarily to determine its safety and tolerance at one or more doses. In Phase
II, in addition to safety, the efficacy, optimal dose and side effects of the
product are evaluated in a patient population somewhat larger than the Phase I
trial. Phase III involves further safety and efficacy testing on an expanded
patient population at geographically dispersed test sites. All clinical studies
must be conducted in accordance with FDA approved protocol and are subject to
the approval and monitoring of one or more Institutional Review Boards. In
addition, clinical investigators must adhere to good clinical practices.
Completion of all three phases of clinical studies may take several years, and
the FDA may temporarily or permanently suspend a clinical study at any time.
Upon completion and analysis of clinical trials, the applicant assembles and
submits a PLA and an ELA. The ELA contains a complete description of the
manufacturing process. Before the licenses can be granted, the Company or its
designee must undergo a successful establishment inspection. The FDA review and
approval of a biological product can take several years.
There can be no assurance that LifeCell will obtain the required approvals for
any of its proposed biological products.
All products marketed by LifeCell pursuant to the above-described
approvals and clearances will be subject to pervasive and continuing regulation
by the FDA. Products must be manufactured in registered establishments and must
be produced in accordance with GMP regulations. There are post-marketing
surveillance and reporting requirements. Manufacturing facilities and processes
are subject to periodic FDA inspection. Labeling and promotional activities are
also subject to FDA scrutiny and, in certain instances, by the Federal Trade
Commission. The export of devices and biologics is also subject to regulation
and may require prior FDA clearance. From time to time, the FDA may modify such
regulations and impose additional or different requirements. It is impossible to
predict how such revisions would affect the Company's operations. Failure to
comply with any applicable FDA requirements could result in civil and criminal
enforcement actions and penalties.
Sales of medical device and biological products outside the United
States are subject to foreign regulatory requirements that vary widely from
country to country. Approval of a product by comparable regulatory authorities
of foreign countries must be obtained prior to commercialization of the product
in those countries. The time required to obtain such foreign approval may be
longer or shorter than that required for FDA approval and there can be no
assurance that approvals would be obtained for any of the Company's products.
12
<PAGE>
In addition, NOTA prohibits the acquisition, receipt or transfer of certain
human organs, including skin and heart valves and vascular conduits for
"valuable consideration", but permits the payment of reasonable expenses
associated with the removal, transportation, processing, preservation, quality
control and storage of human tissue and skin. Assuming that NOTA applies to
LifeCell's products, it may be interpreted to limit the prices that LifeCell may
charge for processing and transporting such human tissue products. LifeCell
includes in its AlloDerm pricing structure certain of its educational costs
associated with the processing and transportation of human tissue. Although
LifeCell believes that recovery of educational costs is permitted under NOTA, a
future inability of LifeCell to pass these costs on to purchasers of its
products could adversely affect LifeCell's business and prospects. Assuming that
NOTA applies to LifeCell's products, LifeCell intends to comply with NOTA, but
there can be no assurance that the government will not adopt interpretations of
NOTA that would adversely affect LifeCell's pricing structure or otherwise call
into question one or more aspects of LifeCell's method of operation.
LifeCell is also subject to various federal, state and local laws,
regulations and recommendations relating to such matters as safe working
conditions, laboratory and manufacturing practices, and the use, handling and
disposal of hazardous or potentially hazardous substances used and produced in
connection with LifeCell's research and development work. See "--Environmental
Matters". Although LifeCell believes it is in compliance in all material
respects with these laws and regulations, there can be no assurance that the
Company will not incur significant additional costs to comply with environmental
laws or regulations in the future.
RESEARCH AND DEVELOPMENT
LifeCell currently uses funds received primarily through external
sources, including corporate alliances and government grants and contracts, to
fund the development of additional universal tissue products and products for
blood cell preservation.
LifeCell plans to continue to develop its non-AlloDerm technology
through an ongoing research and product development program. To date, its
research has been funded primarily through government SBIR grants, Department of
Defense (DOD) contracts and the proceeds from various offerings of its equity
securities. LifeCell's research and development costs in 1994, 1995 and 1996 for
all programs, including those programs funded through corporate and government
support, were approximately $2.1 million, $2.2 million and $1.6 million,
respectively. The development of LifeCell heart valves is currently being funded
by Medtronic. The 1996 funding of this program was approximately $546,000. See
"--Corporate Alliance".
The SBIR grant program provides funding for two phases of awards. Phase
I is to evaluate the scientific and technical merit and feasibility of an idea.
Awards are up to $100,000 with a period of performance normally not to exceed
six months. Phase II is to expand on the results of and pursue the development
of Phase I. Awards are up to $750,000, with a period of performance normally not
to exceed two years. To date, LifeCell has been awarded approximately $4.6
million through 14 approved SBIR program awards and Department of Defense
contracts.
In 1996, LifeCell received a two-year Phase II SBIR grant award from
the NSF in the amount of $300,000 to support the composite skin graft program, a
one-year U.S. Navy contract in the amount of approximately $613,000 to support
the ThromboSol program and a two-year Collaborative Agreement with the U.S. Army
in the amount of approximately $1,069,000 to support investigation of AlloDerm
grafts to repair dura mater, the membrane lining of the brain, the use of
AlloDerm grafts in conjunction with microskin grafting in burn wounds and the
development of vascular graft products.
LifeCell intends to continue to seek funding through the SBIR programs,
as well as to pursue additional government grant and contract programs.
Generally, LifeCell has the right to patent any technologies developed from
government grants and contract funding, subject to the United States
government's right to receive a royalty-free license for federal government use
and to require licensing to others in certain circumstances.
PATENTS, PROPRIETARY INFORMATION AND TRADEMARKS
LifeCell's ability to compete effectively with other companies is
materially dependent upon the proprietary nature of its technologies. LifeCell
relies primarily on patents and trade secrets to protect its technologies.
LifeCell currently has the exclusive right to eight patents through a license
agreement with the Board of Regents of the
13
<PAGE>
University of Texas System. In addition, LifeCell has
been issued three patents and has five pending United States patent
applications.
LifeCell has also applied for patent protection in several foreign
countries. Because of the differences in patent laws and laws concerning
proprietary rights, the extent of protection provided by United States patents
or proprietary rights owned by or licensed to LifeCell may differ from that of
their foreign counterparts.
LifeCell believes that it owns or has the right to use all knowledge
necessary to manufacture and market its current products and planned products
without infringing any existing patent or proprietary rights of others such that
it would be liable for damages or prevented from manufacturing or marketing its
products. No assurances may be given, however, that the Company's patents or
other proprietary rights may not be the subject of an infringement or other
claim that could invalidate to some extent its patents or other rights. Any
successful patent infringement claim relating to any patent could have a
material adverse effect on the Company. See "-- Risk Factors--Patents and
Proprietary Rights".
LifeCell may decide for business reasons to retain certain knowledge
that it considers proprietary as trade secrets. In that event, or if patent
protection is unattainable, LifeCell must rely upon trade secrets, know-how and
continuing technological innovation to maintain its competitive position.
Employees and consultants of LifeCell who have access to proprietary information
have signed confidentiality agreements. It is LifeCell's policy to require any
new employee to sign similar confidentiality agreements.
LifeCell has federal trademark or service mark registrations that it
currently uses for LifeCell(R) and LifeCell Process(R), which cover processing
and preserving tissue samples, and AlloDerm(R), which covers LifeCell's
commercial dermal skin graft product.
COMPETITION
UNIVERSAL TISSUE GRAFTS
LifeCell anticipates direct competition for AlloDerm tissue products
and all of its proposed transplantable tissue products, as well as indirect
competition from advances in therapeutic agents, such as growth factors now used
to enhance wound healing. LifeCell believes that therapeutic growth factors may
be used in conjunction with its proposed products and may potentially enhance
the products' efficacy. LifeCell is not aware of any person or entity currently
marketing transplantable tissue products with features similar to AlloDerm and
LifeCell's other proposed transplantable products. There can be no assurance,
however, that LifeCell will be able to compete effectively with other
commercially available products or that development of other technologies will
not detrimentally affect LifeCell's commercial opportunities or competitive
advantage.
ALLODERM TISSUE PRODUCTS--BURNS. LifeCell believes that the AlloDerm
process is the only technology that consistently and effectively eliminates the
targets of rejection and permits permanent transplantation of human dermal
tissue. Competitive commercial products are currently in clinical trials that
claim to provide permanent full-thickness wound coverage. In most cases, these
products contain a "dermal equivalent", which is usually a processed animal
collagen gel or a bioabsorbable synthetic material in which human cells that
produce collagen (fibroblasts) are usually seeded. The fibroblasts secrete
dermal-like proteins and are intended to support a split-skin graft. In
comparison to these products, LifeCell has focused its product development on
the extracellular matrix, and not the cell population of dermis.
Advanced Tissue Sciences, Inc. and Organogenesis, Inc. each has
developed or is developing such dermal equivalent products. In early 1997,
Advanced Tissue Sciences received a PMA from the FDA to market a temporary wound
covering. LifeCell does not believe that this product will directly compete with
AlloDerm, which is a permanent graft.
LifeCell believes that these "dermal equivalent products" lack
important dermal components and will encounter difficulty in adequately
anchoring the vital surface epithelial cells. LifeCell's primary objectives in
processing AlloDerm tissue include the preservation of important dermal
components, including a basement membrane complex. The Company believes this
structure not only is essential for sufficient anchoring of epidermal
14
<PAGE>
cells, but also determines the degree of differentiation of these cells, an
aspect that has direct bearing on the skin's vital water barrier function.
LifeCell has demonstrated by electron microscopy that its processing technology
has produced preserved dermis with an intact basement membrane complex. LifeCell
has further demonstrated that a human epidermal cell population (keratinocytes)
will attach and differentiate into the stratified layers typical of normal skin,
on both human and porcine processed dermis. The AlloDerm process also preserves
the basement membrane of the vascular channels and capillaries within the dermal
matrix. LifeCell has demonstrated in animal studies that these vascular channels
become repopulated with host cells that normally line blood vessels and
ultimately restore a normal blood supply to the tissue graft. LifeCell believes
this aspect of its technology is fundamental to the ability of the transplanted
tissue to engraft permanently (integrate) into host tissue and that it is its
principal competitive advantage.
Integra LifeSciences Corporation received a PMA in 1996 from the FDA to
market two-layer wound dressings that include a biosynthetic dermal equivalent
and a silicone membrane. Integra's product is currently restricted to treatment
of life-threatening burns in cases where autologous tissue is not available.
This treatment requires that the patient's autograft be applied in a subsequent
surgery approximately two weeks later.
LifeCell believes that AlloDerm grafts will effectively compete with
Integra's product in the treatment of burns based on superior product
performance and because AlloDerm grafts can be applied simultaneously with the
patient's autograft in a single procedure as opposed to an additional subsequent
procedure, thereby reducing surgical costs.
COMPOSITE SKIN GRAFT. Genzyme Tissue Repair has developed technology
for culturing autologous keratinocytes (epidermal) cells for commercial
distribution. LifeCell believes that these cultured epidermal cell sheets alone
are not optimum as a permanent skin replacement for full-thickness skin injury.
This product does not contain a dermal layer, and in some clinical cases this
type of treatment for a full-thickness wound has resulted in fragility with
severe blistering and loss of grafts. The fragile nature of the product usually
requires that it be hand-carried to the hospital. In some cases, this product
has been used by burn surgeons in conjunction with AlloDerm grafts in an attempt
to improve the quality of healing with these cultured cell sheets.
LifeCell believes that its composite skin product will compete
effectively with currently available cultured cell sheets because it will
contain a dermal layer, which should improve the take rate and reduce the
fragility currently associated with these products.
ALLODERM TISSUE PRODUCTS--PERIODONTAL SURGERY. AlloDerm grafts used in
free-gingival graft procedures compete with procedures using the patient's own
tissue, removed from the roof of the mouth or from another area of the patient's
skin, such as the leg, and freeze-dried allograft skin, procured from tissue
banks. LifeCell believes it competes with procedures using the patient's own
tissue by eliminating the need for a donor site and the resulting trauma. The
Company believes it competes with freeze-dried allograft skin because of
AlloDerm's higher biocompatability and reduced immune response.
AlloDerm grafts used as barrier membranes for guided tissue
regeneration compete with several commercial products, including "Gore-Tex",
manufactured by W.L. Gore & Associates, Inc. Gore-Tex is nonabsorbable and must
be removed by the periodontist several months following the initial surgery.
LifeCell believes that AlloDerm grafts compete with Gore-Tex by eliminating the
need for a second surgical procedure for removal of the membrane. The Company is
aware of other barrier membrane products that are absorbed by the body and,
therefore, do not have to be removed, including products manufactured by Guidor
and Integra LifeSciences Corporation. LifeCell believes that AlloDerm grafts
will compete with absorbable membrane products through more effective
performance and versatility of use.
ALLODERM TISSUE PRODUCTS--PLASTIC AND RECONSTRUCTIVE SURGERY. When used
during reconstructive surgery as a graft to release burn wound contractures,
AlloDerm competes with the patient's own tissue and potentially with the
products described above intended for burn wound grafting. For the repair and
replacement of damaged or inadequate integumental tissue, AlloDerm competes with
injectable collagen products, such as those manufactured by Collagen
Corporation, and bovine synthetic products such as Gore-Tex. LifeCell believes
that AlloDerm will compete with these products because of AlloDerm's high
biocompatibility and reduced immune response.
15
<PAGE>
CRYOPRESERVED ALLOGRAFT SKIN (TEMPORARY WOUND COVERAGE). LifeCell competes with
regional tissue banks for the distribution of cryopreserved allograft skin for
temporary wound coverage. The Company believes that it can compete successfully
with these tissue banks by offering customized products and services, such as
pre- meshing of the grafts, which save time in the operating room reducing
surgery costs.
Advanced Tissue Sciences, Inc. has received a PMA from the FDA for a
biosynthetic wound dressing consisting of a commercially available wound
dressing in which human neonatal fibroblasts are cultured and then covered with
a thin synthetic covering to prevent fluid loss. LifeCell believes that its
cryopreserved allograft skin product will compete successfully with this product
primarily because the application of cryopreserved allograft skin is considered
the clinically preferred procedure for temporary wound coverage.
HEART VALVES. Three current types of replacement heart valves are
commercially available, mechanical valves, chemically processed animal valves
and human allograft valves. Mechanical valves require the patient to be
maintained on lifelong anticoagulant therapy to prevent blood clotting and
subsequent complications of stroke. There also are published reports of sudden
catastrophic failure of these valves, resulting in patient death. Animal valves
calcify or harden over time and usually require replacement within ten to 18
years. Human allograft valves are in short supply. Major manufacturers and
suppliers of mechanical and animal heart valve products include Medtronic, St.
Jude Medical, Inc. and the Edwards Division of Baxter Healthcare Corporation.
Human tissue valves are procured and processed and distributed by Cryolife, Inc.
and non-profit tissue banks, including the American Red Cross.
LifeCell's preclinical data has indicated that its processed porcine
valve tissue undergoes reduced calcification compared to chemically processed
porcine valves and reduced immune response compared to fresh or cryopreserved
heart valve tissue. LifeCell believes that its processed heart valve, currently
under development with Medtronic, will minimize complications associated with
commercially available valves.
VASCULAR CONDUITS. Medical treatment for cardiovascular disease,
including atherosclerosis, is a highly competitive industry. Significant
technological progress has been made with respect to the development of
minimally invasive devices for dilation of blocked vessels and devices for
physically removing the plaque from the vessel wall. Additionally, drugs are
being developed to prevent or reverse atherosclerosis. Bypass surgery, however,
is generally performed when the patient displays extensive deposits of plaque
throughout the length of one or more vessels, when the blockage is in a critical
position or when the blockage site cannot be safely accessed.
The two current clinically preferred methods for coronary arterial
bypass procedure are transposing available arteries and using an autologous vein
from another area in the patient's body. The second procedure induces trauma to
the area of vein harvest and has shown evidence of failure or occlusion after
five to ten years. There are commercially available synthetic vascular conduit
substitutes, but these products also show evidence of occlusion and the
increased potential for leaking and infection. LifeCell believes that its
processing technology will reduce the causes and, accordingly, the potential for
vessel occlusion, leakage and infection.
BLOOD CELL PRESERVATION PRODUCTS
LifeCell currently is not aware of any product or developing product
that it anticipates will compete with the products it is developing for blood
cell preservation; however, technological competition in the blood banking field
is intense. Several companies with significantly greater financial resources
than LifeCell are developing blood substitute products. Additionally, several
commercially available blood recycling units are currently used in some surgical
procedures, and growth factors are being developed that are intended to increase
the body's capacity for producing blood cells. LifeCell believes that its
planned freeze-dried blood products and mammalian cells will successfully
compete with these technologies on the basis of cost and convenience.
ENVIRONMENTAL MATTERS
LifeCell's research and development and processing techniques generate
waste that is classified as hazardous by the United States Environmental
Protection Agency and the Texas Natural Resources Commission. LifeCell
segregates such waste and disposes of it through a licensed hazardous waste
transporter. Although LifeCell believes it is currently in compliance in all
material respects with applicable environmental regulations,
16
<PAGE>
its failure to comply fully with any such regulations could result in the
imposition of penalties, fines or sanctions that could have an adverse effect on
LifeCell's business.
EMPLOYEES
At March 26, 1997, the Company had 73 full-time and two part-time
employees of which 23 were employed in processing and support, 18 in sales and
marketing, 17 in research and development and 17 in administration and
accounting. As of March 26, 1997, the Company employed, full time, two persons
with M.D.
degrees and six persons with Ph.D. degrees.
RISK FACTORS
THE COMPANY'S EXPECTATIONS WITH RESPECT TO FUTURE RESULTS OF OPERATIONS
THAT MAY BE EMBODIED IN ORAL AND WRITTEN FORWARD-LOOKING STATEMENTS, INCLUDING
ANY FORWARD-LOOKING STATEMENTS THAT MAY BE CONTAINED IN THIS ANNUAL REPORT ON
FORM 10-K, ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT MUST BE CONSIDERED WHEN
EVALUATING THE LIKELIHOOD OF THE COMPANY'S REALIZATION OF SUCH EXPECTATIONS. THE
COMPANY'S ACTUAL RESULTS COULD DIFFER MATERIALLY. FACTORS THAT COULD CAUSE OR
CONTRIBUTE TO SUCH DIFFERENCES INCLUDE, BUT ARE NOT LIMITED TO, THOSE DISCUSSED
BELOW.
NO ASSURANCE OF ADDITIONAL NECESSARY CAPITAL
LifeCell expects to incur substantial expenses for AlloDerm marketing
and the Company's product development programs (including costs of clinical
studies), production, sales and marketing, product introduction, technical
seminars, support of ongoing administrative activities and research and
development activities, such as regulatory and quality assurance programs and
continuing applications for patent protection for the proprietary aspects of its
technology. The Company currently intends to fund these activities from its
existing cash resources, sales of products, and research and development funding
received from others. There can be no assurance that such sources of funds will
be sufficient to meet these future expenses. The Company's need for additional
financing will be principally dependent on the degree of market acceptance
achieved by the Company's products and the extent to which the Company can
achieve substantial growth in product sales during 1997 and 1998 as well as the
extent to which the Company may decide or may be required to use its own
resources, in addition to external funding, to expand its product development
efforts. There can be no assurance that the Company will be able to obtain any
such additional financing on acceptable terms.
HISTORY OF OPERATING LOSSES
The Company has incurred substantial losses since inception in January
1986, including losses of approximately $3.7 million, $3.9 million and $ 4.1
million for the years ended December 31, 1994, 1995, and 1996, respectively, and
had an accumulated deficit of approximately $29.3 million at December 31, 1996.
There can be no assurance that the Company will ever become profitable.
FDA REGULATORY STATUS OF ALLODERM
In December 1993, the FDA published an interim rule regulating "banked
human tissue". The rule defines banked human tissue as any tissue derived from a
human body which is (i) intended for administration to another human for the
diagnosis, cure, mitigation, treatment or prevention of any condition or disease
and (ii) recovered, processed, stored or distributed by methods not intended to
change tissue function or characteristics. The FDA definition excludes, among
other things, tissue that currently is regulated as a human drug, biological
product or medical device and kidney, liver, heart, lung, pancreas or any other
vascularized human organ. Banked human tissue is regulated by the FDA in a
manner the agency has deemed necessary to protect the public health from the
transmission of HIV infection and hepatitis infection through transplantation of
tissue from donors with or at risk of these diseases. Under the FDA regulations,
all facilities engaged in the procurement, processing, storage or distribution
of human tissue intended for transplant are required to assure that certain
infectious disease testing and donor screening is performed and that records
documenting such testing for each tissue are available for inspection by the
FDA. The regulations also provide authority for the FDA to conduct inspections
of banked human tissue facilities and to detain, recall or destroy tissue for
which appropriate documentation is not available. Banked human
17
<PAGE>
tissue, however, is not subject to premarket notification or approval by the FDA
as are certain drugs, biologicals and medical devices.
In December 1991, the Company first contacted the FDA regarding the
regulatory status of AlloDerm and was advised in May 1992 that the FDA had not
made a final determination on the status of intact processed human cadaver skin,
that the agency currently was studying the issue and that these products may at
some future time be subject to FDA regulation. The FDA sent the Company a copy
of the December 1993 publication of the FDA's banked human tissue regulations
shortly after its release of such regulations and inspected the Company for
compliance with those regulations in July 1994. For these reasons, the Company
believed that AlloDerm was covered by the FDA's definition of banked human
tissue and that the product would not be regulated as a medical device.
In November 1995, following LifeCell's commercial introduction of
AlloDerm for periodontal applications, the Company received a letter from the
FDA, stating that it considered AlloDerm to be a "device" as defined by the FDC
Act, and that a 510(k) premarket notification was required to be submitted and
cleared by the FDA in order to market the product. Following several months of
correspondence and discussions with the FDA, the Company received a letter from
the agency dated September 17, 1996, to the effect that, after considering the
information and views that the Company submitted at a May 1996 meeting with
agency officials and in subsequent correspondence, the FDA agrees with the
Company's position that AlloDerm intended for use for replacement or repair of
damaged or inadequate integumental tissue, including gingival dermis, is banked
human tissue within the meaning of the interim final rule. Consequently,
AlloDerm is not subject to premarket notification or approval by the FDA and the
Company may continue to promote and sell AlloDerm for use in the treatment of
wounds, such as third-degree burns, in periodontal surgical procedures, such as
free-gingival grafting and guided tissue regeneration, and in plastic and
reconstructive surgery procedures, such as contracture release grafting and scar
revision. The agency also informed the Company that this decision applies only
to AlloDerm when it is intended for use in transplantation, and the regulatory
status of the product when it is promoted for other uses, such as the Additional
Indications, would need to be determined by the FDA on a case by case basis. To
date, a minimal amount of LifeCell's aggregate product sales are attributable to
the Additional Indications.
While the Company's marketing efforts had not previously focused on the
Additional Indications, as a follow-up to its September 17 letter, the FDA, by
letter dated September 23, 1996, informed the Company that indications for
Additional Indications would have to be formally presented to the FDA to
determine if, with these indications, AlloDerm would continue to fall within the
scope of the interim rule for banked human tissue and thus not require premarket
clearance. The Company was asked to indicate what changes in advertisement and
promotion it would make for AlloDerm in response to the September 23, 1996
letter. The Company responded to the FDA letter in October 1996, and informed
the agency that the Company believes that the distinctions drawn regarding the
definition of transplantation and banked human tissue and between integumental
tissue and all other tissue in the September 17 opinion were fairly novel and
ones for which the Company would require clarification from the FDA as it goes
forward. The Company believes that AlloDerm, when used for augmentation and as a
void filler, still qualifies as banked human tissue. Similarly, the Company
advised the FDA that since almost every replacement or repair of damaged or
inadequate tissue involves a cosmetic aspect, the Company believes that many
cosmetic uses of AlloDerm are within the purview of banked human tissue.
Nevertheless, the Company informed the FDA that it intends to follow
the agency's decision and, until this matter is clarified on a case-by-case
basis, will not promote AlloDerm for the Additional Indications. The Company
also advised the FDA that it would present its arguments to the agency as to why
it believes that these uses fall within the definition of banked human tissue.
There can be no assurance that the FDA will not finally conclude that use of
AlloDerm for the Additional Indications should be regulated as a medical device
and require a 510(k) premarket notification or PMA for AlloDerm for such
indications. If the FDA were to conclude definitively that the Company is
required to obtain agency clearance of a 510(k) notification or approval of a
PMA for AlloDerm for the Additional Indications, the FDA may require the Company
to conduct laboratory testing and preclinical and clinical studies of AlloDerm
to support a marketing application. Testing, preparation of necessary
applications and processing of those applications by the FDA is expensive and
any required laboratory testing or preclinical or clinical studies that the
Company were required to conduct could take several years to complete. There can
be no assurance that any required testing could be completed successfully, or
that if successfully completed, would provide sufficient data and information to
enable the FDA to determine, on a timely basis, if at all, that when AlloDerm is
used for the
18
<PAGE>
Additional Indications, it is substantially equivalent to a legally marketed
predicate device or is safe and effective for the Additional Indications and
permit the product to be marketed for such uses. Failure of the Company to
receive any required FDA clearance or approval of AlloDerm for the Additional
Indications on a timely basis would preclude promotion of AlloDerm for the
Additional Indications and could have a material adverse effect on the Company's
business, financial condition and results of operation. See "--Government
Regulation--Proposed Products".
GOVERNMENT REGULATION--PROPOSED PRODUCTS
Many if not all of LifeCell's products under development will require
regulatory approval or clearance prior to commercialization. Human therapeutic
products are subject to rigorous preclinical and clinical testing as a condition
of approval by the FDA and by similar regulatory authorities in foreign
countries. The lengthy process of obtaining these approvals and clearances and
the ongoing process of compliance with applicable federal statutes and
regulations will require the expenditure of substantial resources, and there can
be no assurance that the FDA or foreign approvals will be obtained for any of
the Company's proposed products.
LifeCell's proposed human and xenograft heart valve products and its
proposed xenograft tissue transplantation products will be subject to regulation
as medical devices. The Company's proposed blood cell additives will be subject
to regulation as biologics. Such products require FDA premarket clearance prior
to commercialization in the United States. To obtain FDA approval for these
products, the Company must submit proof of their safety and efficacy. Testing,
preparation of necessary applications and processing of those applications by
the FDA is expensive and time consuming. There can be no assurance that the FDA
will act favorably or quickly in making such reviews, and significant
difficulties or costs may be encountered by the Company in its efforts to obtain
FDA clearances that could delay or preclude the Company from marketing any
product it may develop. The FDA may also place conditions on clearances that
could restrict commercial applications of such products. Product marketing
approvals or clearances may be withdrawn if compliance with regulatory standards
is not maintained or if problems occur following initial marketing. Delays
imposed by the governmental clearance process may materially reduce the period
during which the Company has the exclusive right to commercialize patented
products.
Products marketed by LifeCell pursuant to FDA or foreign approval will
be subject to pervasive and continuing regulation. In the United States, devices
and biologics must be manufactured in registered establishments and must be
produced in accordance with GMP regulations. Manufacturing facilities and
processes are subject to periodic FDA inspection. Labeling and promotional
activities are also subject to scrutiny by the FDA and, in certain instances, by
the Federal Trade Commission. The export of devices and biologics is also
subject to regulation and may require FDA approval. From time to time, the FDA
may modify such requirements, imposing additional or different requirements.
Failure to comply with any applicable FDA requirements could result in civil and
criminal enforcement actions and other penalties. In addition, there can be no
assurance that the various states and foreign countries in which LifeCell's
products are sold will not impose additional regulatory requirements or
marketing impediments.
NOTA prohibits the acquisition, receipt or transfer of certain human
organs, including skin, heart valves and vascular conduits, for "valuable
consideration". NOTA permits the payment of reasonable expenses associated with
the removal, transportation, processing, preservation, quality control and
storage of human tissue and skin. NOTA may be interpreted to limit the prices
that LifeCell may charge for processing and transporting its human tissue
products. This could result in limited revenues which could adversely affect
LifeCell's business and prospects.
DEPENDENCE ON KEY MANAGEMENT AND PERSONNEL
The success of LifeCell will be dependent largely on the efforts of
Paul M. Frison, Chairman of the Board, President and Chief Executive Officer of
the Company, and Stephen A. Livesey, M.D., Ph.D., Executive Vice President,
Chief Scientific Officer and a director of the Company. The loss of either
person's services would have a material adverse effect on LifeCell's business
and prospects. Dr. Livesey, a citizen of Australia, has received an extension of
an "H-1B" visa to work in the United States that currently expires in June 1997,
and he is in the process of applying for permanent residence status in the
United States. There can be no assurance that he will be able to
19
<PAGE>
obtain such status. Further, the success of LifeCell is also dependent upon its
ability to hire and retain suitable operating, marketing and technical
personnel. The competition for qualified personnel in the biomedical industry is
intense and, accordingly, there can be no assurance that LifeCell will be able
to hire or retain necessary personnel.
TECHNOLOGICAL CHANGE AND COMPETITION
The biomedical field is undergoing rapid and significant technological
change. LifeCell's success depends upon its ability to develop and commercialize
its technology. There are many companies and academic institutions that are
capable of developing products based on similar technology, and that have
developed and are capable of developing products based on other technologies,
which are or may be competitive with LifeCell's products. Many of those
companies and academic institutions are well-established, have substantially
greater financial and other resources than LifeCell and have established
reputations for success in the development, sale and service of products. These
companies and academic institutions may succeed in developing competing products
that are more effective than LifeCell's products or that receive government
approvals more quickly than LifeCell's products.
AVAILABILITY OF MATERIALS
The Company's business will be dependent on the availability of human
cadaveric skin and cardiovascular tissue to the extent that LifeCell is unable
successfully to develop products using animal tissue. A limited supply of
donated skin is available. Although the Company has established what it believes
to be an adequate source of cadaveric skin to satisfy the expected demand for
AlloDerm, there can be no assurance that the availability of human skin and
cardiovascular tissue will be sufficient to meet LifeCell's demand for such
materials.
UNCERTAINTY OF MARKET ACCEPTANCE
Achieving broad market acceptance for AlloDerm and LifeCell's proposed
products will require substantial additional marketing efforts. There can be no
assurance that AlloDerm or any of LifeCell's proposed products ultimately will
achieve widespread commercial acceptance.
PATENTS AND PROPRIETARY RIGHTS
LifeCell's ability to compete effectively with other companies is
materially dependent upon the proprietary nature of its technologies. LifeCell
relies primarily on patents and trade secrets to protect its technologies.
LifeCell currently has the exclusive right to eight patents through a license
agreement with the Board of Regents of the University of Texas System. In
addition, LifeCell has been issued three patents and has five pending United
States patent applications. There can be no assurance that LifeCell will obtain
any additional key patents or other protection, that the patents currently
applied for will be granted, that existing patents or proprietary rights owned
by or licensed to LifeCell will not be invalidated or that patents will provide
significant commercial benefits. The invalidation of key patents or proprietary
rights owned by or licensed to LifeCell could have a material adverse effect on
LifeCell and on its business prospects.
LifeCell believes that it owns or has the right to use all knowledge
necessary to manufacture and market its current products and planned products
without infringing any existing patent or proprietary rights of others such that
it would be liable for damages or prevented from manufacturing or marketing its
products. No assurances may be given, however, that the Company's patents or
other proprietary rights may not be the subject of an infringement or other
claim that could invalidate to some extent its patents or other rights. Any
successful patent infringement claim relating to any patent could have a
material adverse effect on the Company.
There can be no assurance that LifeCell will not be required to resort
to litigation to protect its patents or other proprietary rights or that the
Company may be the subject of patent litigation to defend its patents or other
rights against claims of infringement or other intellectual property claims.
Such litigation could result in substantial costs and diversion of resources and
could have a material adverse effect on the Company's financial condition and
results of operations.
20
<PAGE>
LifeCell has also applied for patent protection in several foreign
countries. Because of the differences in patent laws and laws concerning
proprietary rights, the extent of protection provided by United States patents
or proprietary rights owned by or licensed to LifeCell may differ from that of
their foreign counterparts.
LIMITED THIRD-PARTY REIMBURSEMENT
Generally, hospitals, physicians and other health care providers
purchase products, such as the products being sold or developed by LifeCell, for
use in providing care to their patients. These parties typically rely on
third-party payors, including Medicare, Medicaid, private health insurance and
managed care plans, to reimburse all or part of the costs of acquiring those
products and costs associated with the medical procedures performed with those
products. Cost control measures adopted by third-party payors in recent years
have had and may continue to have a significant effect on the purchasing
practices of many health care providers, generally causing them to be more
selective in the purchase of medical products. These and future changes in
third-party payor reimbursement practices regarding the procedures performed
with LifeCell's products may adversely affect LifeCell's business.
PRODUCT LIABILITY AND INSURANCE
The Company's business will expose it to potential product liability
risks which are inherent in the testing, manufacturing and marketing of medical
products. Although the Company has product liability insurance coverage with an
aggregate limit of $5 million, there can be no assurance that such insurance
will provide adequate coverage against potential liabilities or that adequate
product liability insurance will continue to be available in the future or that
it can be maintained on acceptable terms.
LIMITATION ON THE USE OF NET OPERATING LOSSES AND RESEARCH AND
DEVELOPMENT TAX CREDITS
As of December 31, 1996, LifeCell had accumulated net operating loss
("NOL") carryforwards for federal income tax purposes of approximately $26
million and research and development tax credits of approximately $385,000 since
its inception, and may continue to incur NOL carryforwards. United States tax
laws provide for an annual limitation on the use of NOL carryforwards following
certain ownership changes and also limit the time during which NOL and tax
credit carryforwards may be applied against future taxable income and tax
liabilities. Accordingly, LifeCell may not be able to take full advantage of its
NOL carryforwards and tax credits for federal income tax purposes.
DISPOSAL OF HAZARDOUS MATERIALS
LifeCell's research and development and processing techniques generate
waste that is classified as hazardous by the United States Environmental
Protection Agency and the Texas Natural Resources Commission. LifeCell
segregates such waste and disposes of it through a licensed hazardous waste
transporter. Although LifeCell believes it is currently in compliance in all
material respects with applicable environmental regulations, its failure to
comply fully with any such regulations could result in the imposition of
penalties, fines or sanctions that could have an adverse effect on LifeCell's
business.
ITEM 2. PROPERTIES
LifeCell leases approximately 20,000 square feet of laboratory, office
and warehouse space at its facilities in The Woodlands, Texas, under lease
agreements that expire in January 2001. The Company's monthly rental obligation
for its facilities is approximately $18,000.
ITEM 3. LEGAL PROCEEDINGS
None.
21
<PAGE>
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
PART II
ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER
MATTERS
MARKET FOR THE COMMON STOCK
The Company's Common Stock is listed on the Nasdaq SmallCap Market
under the symbol "LIFC". The table below sets forth the high and low sales
prices of the Common Stock for each quarter of 1995 and 1996, as reported by The
Nasdaq Stock Market. The quotations reflect inter-dealer prices, without retail
mark-down or commission, and may not represent actual transactions.
1995 1996
Price Range Price Range
----------------- ------------------
High Low High Low
----------------- ------------------
First Quarter $4 $1 5/8 $6 $2 1/4
Second Quarter 5 1/2 2 1/8 5 3 3/4
Third Quarter 4 3/4 3 3/8 5 7/8 3 5/8
Fourth Quarter 4 2 4 1/4 2 7/8
As of March 26, 1997, the last sales price per share of LifeCell's
Common Stock, as reported by The Nasdaq Stock Market, was $7.00.
At March 26, 1997, the Company's 6,754,761 shares of Common Stock
outstanding were held by approximately 250 stockholders of record and the
Company estimates that there are in excess of 1,500 beneficial owners. At March
26, 1977, the Company's 125,583 shares of Series B Preferred Stock outstanding
were held by 52 stockholders of record.
DIVIDEND POLICY
LifeCell has not paid a cash dividend to its holders of Common Stock
and does not anticipate paying cash dividends to the holders of its Common Stock
in the foreseeable future.
Pursuant to the terms of the Company's Series A Preferred Stock, on
December 6, 1996, the Company paid a per share dividend of $1.60 in shares of
Common Stock to the holders of the Series A Preferred Stock, on March 26, 1997,
the Company paid a per share dividend of $.50 in shares of its Common Stock to
such security holders, and on March 26, 1997, the Company paid a per share
dividend of $.25 in cash to such security holders.
Also on March 26, 1997, in accordance with the terms of the Series A Preferred
Stock, the Company redeemed all of the outstanding shares of the Series A
Preferred Stock through the conversion of such shares into shares of Common
Stock. Accordingly, no further dividends are payable in respect of the Series A
Preferred Stock.
On February 15, 1997, the Company paid a per share dividend of $1.17 in
shares of Series B Preferred Stock to the holders of Series B Preferred Stock.
The Series B Preferred Stock bears dividends at the annual rate of (i) $6.00
(subject to adjustment in certain events) and (ii) the per annum rate of
dividends per share paid, if applicable, by the Company, on the Common Stock.
The dividends may be paid, at the Company's option, in cash or shares of Series
B Preferred Stock or in a combination of cash and shares of Series B Preferred
Stock.
22
<PAGE>
The dividends will accrue and be paid quarterly. Under the General Corporation
Law of the State of Delaware, a corporation's board of directors may declare and
pay dividends only out of surplus or current net profits.
RECENT SALES OF UNREGISTERED SECURITIES
During November 1996, the Company completed a private placement of
124,157 shares of its Series B Preferred Stock and stock purchase warrants to
purchase an aggregate of 2,803,530 shares of Common Stock for a total purchase
price of $12,415,700. The Series B Preferred Stock and warrants were sold to
accredited investors. Each share of Series B Preferred Stock is convertible at
any time into approximately 32.26 shares of Common Stock, subject to adjustment
in certain events. The placement agent for the private placement received a
stock purchase warrant to purchase an aggregate of 354,734 shares of Common
Stock.
From January 1, 1996 through September 13, 1996, the Company issued a
total of 5,000 shares of Common Stock for an aggregate consideration of $14,375
to a director of the Company pursuant to the exercise of options granted under
the Company's non-employee director stock option plan. Also in 1996, the Company
issued a total of 247,000 shares of Common Stock for an aggregate consideration
of $765,700 to certain holders of the Company's Series A Preferred Stock
pursuant to the exercise of certain stock purchase warrants.
The Company considers the above-described securities to have been
offered and sold in transactions not involving a public offering and, therefore,
to be exempted from registration under Section 4(2) or Regulation D of the
Securities Act of 1933, as amended.
23
<PAGE>
ITEM 6. SELECTED FINANCIAL DATA
The following table sets forth certain selected financial data of
LifeCell for each of the years in the five-year period ended December 31, 1996,
derived from the Company's audited financial statements. This information should
be read in conjunction with "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and the Financial Statements and notes
thereto included elsewhere in this Annual Report on Form
10-K.
<TABLE>
<CAPTION>
Year Ended
December 31,
1992 1993 1994 1995 1996
--------- --------- -------- --------- -----------
OPERATIONS STATEMENT DATA:
Revenues:
<S> <C> <C> <C> <C> <C>
Product sales ............................. -- 20,737 93,940 742,238 2,012,205
Corporate alliance ........................ $ -- $ -- $ 358,331 $ 825,221 $ 546,461
Grants and contracts ...................... 239,102 377,057 364,334 239,116 386,904
--------- --------- -------- --------- -----------
Total revenues ......................... 239,102 397,794 816,615 1,806,575 2,945,570
--------- --------- -------- --------- -----------
Costs and expenses:
Cost of goods sold ........................ -- 207,398 515,500 925,174 1,281,353
Funded research and
development ............................... 239,102 377,057 722,675 1,064,337 933,365
Proprietary research and
development ............................... 1,354,941 1,718,799 1,363,176 1,105,427 654,821
General and administrative ................ 1,165,662 1,479,327 1,381,470 1,422,588 1,911,254
Selling and marketing ..................... 205,108 268,618 727,615 1,475,296 2,389,573
--------- --------- --------- --------- -----------
Total costs and expenses ............... 2,964,813 4,051,199 4,710,436 5,992,822 7,170,366
--------- --------- --------- --------- -----------
Loss from operations ......................... (2,725,711) (3,653,405) (3,893,821) (4,186,247) (4,224,796)
--------- --------- --------- --------- -----------
Interest income and other ................. 161,443 223,973 167,300 280,843 135,082
--------- --------- --------- --------- -----------
Net loss ..................................... $(2,564,268) (3,429,472) (3,726,521) (3,905,404) (4,089,714)
--------- --------- --------- --------- -----------
Loss per share(1) ............................ (0.70) (0.80) (0.90) (1.10) (1.14)
--------- --------- --------- --------- -----------
Shares used in computing loss per
share ........................................ 3,643,333 4,277,171 4,294,179 4,313,366 4,542,519
--------- --------- --------- --------- -----------
</TABLE>
<TABLE>
<CAPTION>
At December 31,
1992 1993 1994 1995 1996
--------- --------- -------- --------- -----------
BALANCE SHEET DATA:
<S> <C> <C> <C> <C> <C>
Cash and cash equivalents ........... $ 3,938,598 $ 426,104 $ 1,877,295 $ 3,015,332 $ 10,748,250
Short-term investments .............. 2,589,493 3,016,511 5,154,824 -- --
Working capital (deficit) ........... 6,770,195 3,433,008 6,613,304 2,888,048 10,884,779
Total assets ........................ 7,413,401 4,260,079 7,997,404 4,376,039 12,890,015
Long-term obligations ............... -- -- 1,500,000 1,500,000 1,500,000
Accumulated deficit ................. (13,189,203) (16,618,635) (20,678,402) (24,774,753) (29,310,934)
Total stockholders' equity .......... 7,152,253 4,045,661 5,743,127 2,093,906 10,197,104
</TABLE>
(1) Includes effect of accounting treatment of preferred stock of $0.03, $0.19
and $0.24 in 1994, 1995 and 1996, respectively.
24
<PAGE>
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
THE FOLLOWING DISCUSSION AND ANALYSIS SHOULD BE READ IN CONJUNCTION
WITH THE FINANCIAL STATEMENTS AND RELATED NOTES CONTAINED ELSEWHERE IN THIS
ANNUAL REPORT ON FORM 10-K.
GENERAL AND BACKGROUND
LifeCell was organized in 1986 and since inception has been financed
through the public and private sale of equity securities to individuals, venture
capital firms and corporations, product sales, its corporate alliance with
Medtronic and the receipt of government grants and contracts.
In December 1993, LifeCell began commercial distribution of AlloDerm
human dermal grafts. The initial AlloDerm product was used as a dermal
replacement in the grafting of third-degree burns. LifeCell commenced commercial
sales of AlloDerm for periodontal surgery in September 1995 and for plastic and
reconstructive surgery uses in June 1995. The Company reported total product
sales of approximately $94,000, $742,000 and $2,012,000 in 1994, 1995 and 1996,
respectively.
In 1994, LifeCell entered into an agreement with Medtronic pursuant to
which Medtronic agreed (subject to certain rights to terminate at Medtronic's
discretion) to fund the development of LifeCell's proprietary tissue processing
technology in the field of heart valves. Additionally, LifeCell's research and
development of blood cell products has been substantially funded through
government grants and contracts.
RESULTS OF OPERATIONS
YEARS ENDED DECEMBER 31, 1996 AND 1995
Total revenues for 1996 were approximately $2.9 million compared to
approximately $1.8 million for 1995. As a result of increased marketing
activities, expansion of distribution channels and expanded uses of the
Company's
AlloDerm product, product sales for the year increased $1.3 million from 1995.
Corporate alliance revenue decreased from $825,000 in 1995 to $546,000 in 1996
as a result of certain non-recurring revenue received by LifeCell in the first
quarter of 1995 under the Medtronic agreement and the timing of planned
activities performed by LifeCell related to the progress of the project. The
corporate alliance revenue is recorded based on the costs of the work performed
under the agreement. During 1996, the Company recognized $387,000 in revenue
from its government grants and contracts, or an increase of $148,000 over 1995,
as a result of additional governmental awards received during 1996 for the
Company's ThromboSol and keratinocyte development programs.
Total costs and expenses for 1996 were $7.2 million, an increase of
$1.2 million compared to the same period of the prior year principally as a
result of expanded sales and marketing activities for the Company's products and
costs related to such expanded activities. Cost of goods sold for 1996 were $1.3
million compared to $925,000 in the same period of 1995. This increase was due
to an increase in product sales and the shift from the development of AlloDerm
to processing, consistent with taking a product to market. The cost of funded
research and development declined from $1.1 million in 1995 to $933,000 in 1996
as a result of the timing of planned activities as well as the funding
available, as such costs are reimbursed by others. Proprietary research and
development expense decreased to $655,000 for the 1996 from $1.1 million in 1995
primarily due to the shift in the Company's focus from the development of
AlloDerm to processing. General and administrative expense increased to $1.9
million for the year ended December 31, 1996 from $1.4 million in the same
period of 1995 principally as a result of expanded administrative activities as
the Company increased its product sales and marketing activities as well as
certain administrative expenses recognized in conjunction with its 1996
financing activities and non-cash charges related to the reissuance of certain
stock options. Selling and marketing expenses increased to $2.4 million for 1996
from $1.5 million in 1995 primarily due to the addition of sales personnel and
promotional activities related to AlloDerm marketing and expanded distribution
activities.
Interest income and other decreased by $146,000 from 1995 to 1996 as a result of
the decrease in funds available for investment prior to the receipt of funds
from an equity financing in late 1996, as well as lower interest rates in 1996.
25
<PAGE>
YEARS ENDED DECEMBER 31, 1995 AND 1994
Total revenues for 1995 were $1.8 million compared to approximately
$817,000 for 1994. This increase was primarily due to increased product sales
and increased activities in the corporate alliance with Medtronic. Product sales
increased to $742,000 in 1995 from $94,000 in 1994, due to greater market
acceptance and additional sales efforts. The corporate alliance revenues
increased to $825,000 in 1995 from $358,000 in 1994 due to a full year of
activity in 1995 and increased heart valve development activities. In 1995,
revenues included amounts recorded from one Small Business Innovative Research
("SBIR") contract of approximately $239,000, compared to $364,000 from two SBIR
contracts in 1994. During 1995, research and development contracts and grants
revenue consisted of $239,000 pursuant to the second year of a 1993 award of a
Phase II $740,000 SBIR contract from the United States Army for the prolonged
storage of platelets. Interest income increased to $281,000 in 1995 from
$167,000 in 1994 due to an increase in average funds available for investment in
1995 as compared to 1994.
Cost of goods sold for product sales increased $409,000 while revenues
increased $648,000 during 1995 as compared to 1994. During 1994, the "start up"
phase of manufacturing was still underway and the Company had excess capacity.
This resulted in higher amounts of unabsorbed overhead costs in 1994 than in
1995.
Proprietary research and development expense decreased to $1.1 million
in 1995 from $1.4 million in 1994 primarily as a result of the transfer of
AlloDerm related activities from proprietary research and development to
processing (cost of goods sold). These costs previously were recorded in
research and development expense.
General and administrative expenses remained relatively consistent with
the prior year. Selling and marketing expenses increased to $1.5 million in 1995
from $728,000 in 1994 primarily due to the addition of sales personnel,
increased promotional activities related to AlloDerm marketing activities and
commercial introduction of the AlloDerm graft in the periodontal surgery market.
LIQUIDITY AND CAPITAL RESOURCES
Since its inception, LifeCell's principal sources of funds have been
equity offerings, product sales, the Medtronic corporate alliance, government
grants and contracts and interest on investments.
LifeCell primarily funds research and development activities for
products other than AlloDerm with external funds from its corporate alliance and
government grants. In April 1996, LifeCell was awarded a one-year $613,000
contract from the U.S. Navy related to the development of ThromboSol. In August
1996, LifeCell was awarded a two-year $300,000 National Science Foundation Phase
II grant related to its keratinocytes program. In December 1996, LifeCell was
awarded a two-year contract from the U.S. Army to support the development of
vascular graft products.
In 1994, LifeCell entered into agreements with Medtronic pursuant to
which Medtronic paid LifeCell a license fee of $1.5 million and agreed, subject
to certain rights to terminate at Medtronic's discretion, to fund the
development of LifeCell's proprietary tissue processing technology in the field
of heart valves. Through December 31, 1996, LifeCell has recognized
approximately $1.7 million in revenues for development funding, excluding the
initial license fee, for this program.
In January 1996, LifeCell borrowed $120,000 from a bank for working
capital purposes. The loan was secured by cash, required monthly payments of
$2,000, plus interest, matured December 31, 1996, and bore interest at a rate
equal to 6.05% per annum. In August 1996, LifeCell borrowed $250,000 from the
same bank for working capital purposes. This loan was secured by accounts and
other receivables, matured in December 1996, and bore interest at a rate equal
to prime plus .25% per annum. The notes were paid in full November 1996.
In November 1996, LifeCell received net proceeds of approximately $10.9
million pursuant to the private sale of shares of Series B Preferred Stock and
warrants exercisable for the purchase of Common Stock.
In June 1996, LifeCell engaged DENTSPLY to distribute AlloDerm grafts
for periodontal surgery on a worldwide basis. In March 1997, however, DENTSPLY
advised LifeCell that it intends to discontinue operations of the division with
responsibility for distributing AlloDerm. Accordingly, LifeCell expects that it
will terminate the
26
<PAGE>
agreement with DENTSPLY and in the near future will resume marketing AlloDerm
for periodontal applications through its direct sales force. While the Company
anticipates that the termination of the DENTSPLY agreement may have some impact
on revenues attributable to sales of AlloDerm for periodontal applications
during this transition, LifeCell believes that it will not materially affect the
Company's overall revenues attributable to AlloDerm sales.
LifeCell expects to incur substantial expenses for AlloDerm marketing
and the Company's product development programs (including costs of clinical
studies), production, sales and marketing, product introduction, technical
seminars, support of ongoing administrative activities and research and
development activities, such as regulatory and quality assurance programs and
continuing applications for patent protection for the proprietary aspects of its
technology. The Company currently intends to fund these activities from its
existing cash resources, sales of products, and research and development funding
received from others. There can be no assurance that such sources of funds will
be sufficient to meet these future expenses. The Company's need for additional
financing will be principally dependent on the degree of market acceptance
achieved by the Company's products and the extent to which the Company can
achieve substantial growth in product sales during 1997 and 1998 as well as the
extent to which the Company may decide or may be required to use its own
resources, in addition to external funding, to expand its product development
efforts. There can be no assurance that the Company will be able to obtain any
such additional financing on acceptable terms.
LifeCell has had losses since inception and therefore has not been
subject to federal income taxes. As of December 31, 1996, LifeCell had NOL and
research and development tax credit carryforwards for income tax purposes of
approximately $26 million and $385,000, respectively, available to reduce future
income tax and tax liabilities. Federal tax laws provide for a limitation on the
use of NOL and tax credit carryforwards following certain ownership changes that
could limit LifeCell's ability to use its NOL and tax credit carryforwards. A
recapitalization effected by LifeCell in 1992, the issuance of additional
capital stock pursuant to its initial public offering in 1992 and its sales of
equity securities in 1994 and 1996 may cause a "more than 50 percent change in
ownership" as defined in the applicable tax laws. Accordingly, LifeCell's
ability to use its NOL and tax credit carryforwards to reduce future taxable
income may be restricted.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The financial statements and supplementary financial information
required to be filed under this Item are presented commencing on page F-1 of
this Annual Report on Form 10-K, and are incorporated herein by reference.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
None.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The information required by this Item will be set forth in the
Registrant's Proxy Statement relating to the annual meeting of the Registrant's
stockholders scheduled to be held June 19, 1997, under the captions "Election of
Directors" and "Executive Compensation", and such information is incorporated
herein by reference.
27
<PAGE>
ITEM 11. EXECUTIVE COMPENSATION
The information required by this Item will be set forth in the
Registrant's Proxy Statement relating to the annual meeting of the Registrant's
stockholders scheduled to be held June 19, 1997, under the caption "Executive
Compensation", and such information is incorporated herein by reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The information required by this Item will be set forth in the
Registrant's Proxy Statement relating to the annual meeting of the Registrant's
stockholders scheduled to be held June 19, 1997, under the caption "Security
Ownership of Certain Beneficial Owners and Management", and such information is
incorporated herein by reference.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The information required by this Item will be set forth in the
Registrant's Proxy Statement relating to the annual meeting of the Registrant's
stockholders scheduled to be held June 19, 1997, under the caption "Executive
Compensation", and such information is incorporated herein by reference.
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
(A) DOCUMENTS INCLUDED IN THIS REPORT:
1. FINANCIAL STATEMENTS PAGE
----
Report of Independent Public Accountants........................... F-2
Balance Sheets as of December 31, 1995 and 1996.................... F-3
Statements of Operations for the years ended
December 31, 1994, 1995 and 1996................................... F-4
Statements of Stockholders' Equity for the
years ended December 31, 1995 and 1996............................. F-5
Statements of Cash Flows for the years ended
December 31, 1994, 1995 and 1996................................... F-6
Notes to Financial Statements...................................... F-7
(B) REPORTS ON FORM 8-K:
During the quarter ended December 31, 1996, the Company filed (i) on
November 27, 1996, a Current Report on Form 8-K dated as of November 18,
1996, to report the private placement of equity securities of the Company;
and (ii) on December 31, 1996, a Current Report on Form 8-K dated as of
December 27, 1996, at the request of The Nasdaq Stock Market. The latter
report included the Company's balance sheet as of November 30, 1996, and
was filed to evidence the Company's compliance with The Nasdaq Stock
Market's continuing listing requirements for SmallCap issuers
(C) EXHIBITS:
Exhibits designated by the symbol * are filed with this Annual Report
on Form 10-K. All exhibits not so designated are incorporated by
reference to a prior filing as indicated.
Exhibits designated by the symbol + are management contracts or
compensatory plans or arrangements that are required to be filed with
this report pursuant to this Item 14.
28
<PAGE>
EXHIBIT NO. DESCRIPTION
- ---------- -----------
LifeCell undertakes to furnish to any stockholder so requesting a copy
of any of the following exhibits upon payment to the Company of the reasonable
costs incurred by Company in furnishing any such exhibit.
3.1 Restated Certificate of Incorporation, as amended (incorporated by
reference to Exhibit 4.1 to the Registrant's Current Report on
Form 8-K dated November 18, 1996).
3.2 Amended and Restated By-laws (incorporated by reference to Exhibit
3.2 to the Registrant's Quarterly Report on Form 10-Q for the
period ended June 30, 1996).
4.1* Form of Series B Preferred Stock Certificate.
4.2* See Exhibit 10.21 -- Voting Agreement dated November 18, 1996,
among LifeCell Corporation and certain stockholders named therein.
10.1+ Employment Agreement and accompanying Confidentiality, Inventions
and Discoveries and Non- Competition Agreement dated January 28,
1992, by and between the Registrant and Paul M. Frison
(incorporated by reference to Exhibit 10.19 to Amendment No. 2 to
the Registrant's Registration Statement on Form S-1, Registration
No. 33-44969, filed with the Commission on February 10, 1992).
10.2+ Employment Agreement and accompanying Confidentiality, Inventions
and Discoveries and Non- Competition Agreement dated January 28,
1992, by and between the Registrant and Stephen A. Livesey
(incorporated by reference to Exhibit 10.20 to Amendment No. 2 to
the Registrant's Registration Statement on Form S-1, Registration
No. 33-44969, filed with the Commission on February 10, 1992).
10.3*+ LifeCell Corporation Second Amended and Restated 1992 Stock Option
Plan, as amended.
10.4*+ LifeCell Corporation Second Amended and Restated 1993 Non-Employee
Director Stock Option Plan, as amended.
10.5 Form of Confidentiality/Non-Compete Agreement (incorporated by
reference to Exhibit 10.28 to the Registrant's Registration
Statement on Form S-1, Registration No. 33-44969, filed with the
Commission on January 9, 1992).
10.6 Exclusive License Agreement dated June 6, 1986, between the
Registrant and The Board of Regents of The University of Texas
System (incorporated by reference to Exhibit 10.29 to the
Registrant's Registration Statement on Form S-1, Registration No.
33-44969, filed with the Commission on January 9, 1992).
10.7+ Amended and Restated Registration Rights Agreement dated February
26, 1992, by and between the Registration and the stockholders
named therein (incorporated by reference to Exhibit 10.40 to
Amendment No. 3 to the Registrant's Registration Statement on Form
S-1, Registration No. 33- 44969, filed with the Commission on
February 27, 1992).
10.8 Underwriter's Warrant Agreement dated March 6, 1992, between the
Registrant and Robert Todd Financial Corporation, and First
Amendment to Underwriter's Warrant Agreement dated January 26,
1993, between the Registrant and Robert Todd Financial Corporation
(incorporated by reference to Exhibit 10.18 to the Registrant's
Annual Report on Form 10-K for the fiscal year ended December 31,
1992).
29
<PAGE>
EXHIBIT NO. DESCRIPTION
- ---------- -----------
10.9 Lease Agreement dated December 10, 1986, between the Registrant
and The Woodlands Corporation, Modification and Ratification of
Lease Agreement dated April 11, 1988, between the Registration and
The Woodlands Corporation Modification and Ratification of Lease
dated August 1, 1992, between the Company and The Woodlands
Corporation and Modification, Extension and Ratification of Lease
dated March 5, 1993, between the Registrant and The Woodlands
Corporation, and Modification and Ratification of Lease Agreement
dated December 21, 1995, between the Company and The Woodlands
Office Equities--'95 Limited (incorporated by reference to Exhibit
10.1 to the Registrant's Quarterly Report on Form 10-Q for the
period ended March 31, 1996).
10.10 Lease Agreement dated September 1, 1988, between the Registrant
and The Woodlands Corporation, and Modification of Lease Agreement
dated March 5, 1993, between the Registrant and The Woodlands
Corporation (incorporated by reference to Exhibit 10.22 to the
Registrant's Annual Report on Form 10-K for the fiscal year ended
December 31, 1992).
10.11 Stock Purchase Warrant dated January 26, 1993, issued to Strategem
of Alabama, Inc. (incorporated by reference to Exhibit 10.25 to
the Registrant's Annual Report on Form 10-K for the fiscal year
ended December 31, 1992).
10.12 License and Development Agreement dated March 3, 1994, between the
Registrant and Medtronic, Inc. (incorporated by reference to
Exhibit 10.1 to the Registrant's Current Report on Form 8-K dated
March 3, 1994).
10.13 Investment Agreement dated March 3, 1994, between the Registrant
and Medtronic, Inc. (incorporated by reference to Exhibit 10.2 to
Registrant's Current Report on Form 8-K dated March 3, 1994).
10.14 Lease Agreement between LifeCell Corporation and Unichem, dated
August 1, 1994 (incorporated by reference to Exhibit 10.3 to the
Registrant's Quarterly Report on Form 10-Q for the period ended
September 30, 1994).
10.15* Securities Purchase Agreement dated November 18, 1996, between
LifeCell Corporation and the Investors named therein.
10.16* Voting Agreement dated November 18, 1996, among LifeCell
Corporation and certain stockholders named therein.
10.17* Registration Rights Agreement dated November 18, 1996, between
LifeCell Corporation and certain stockholders named therein.
10.18* Form of Stock Purchase Warrant dated November 18, 1996, issued to
each of the warrant holders named on Schedule 10.19 attached
thereto.
10.19* Stock Purchase Warrant dated November 18, 1996, issued to Gruntal
& Co., Incorporated.
11.1* Statement Regarding Computation of Per Share Earnings.
23.1* Consent of Arthur Andersen LLP.
27.1* Financial Data Schedule.
30
<PAGE>
GLOSSARY
THE FOLLOWING GLOSSARY IS INTENDED TO PROVIDE THE READER WITH AN
EXPLANATION OF CERTAIN TECHNICAL TERMS USED IN CERTAIN SECTIONS OF THIS ANNUAL
REPORT ON FORM 10-K:
ALLOGRAFT......................... Graft derived from one individual and
transplanted to another of the same species
(E.G., human to human).
ANCHORING FIBRIL.................. A specialized collagen thread that attaches
to both epidermal cells of skin and to the
dermal basement membrane complex, bonding
them together.
ASEPTIC PROCESSING................ Processing in a sterile work environment
using special procedures to keep the tissue
free from exposure to infectious material.
AUTOGRAFT......................... Graft derived from one part of an
individual's body and transplanted to
another location in the same individual.
BASEMENT MEMBRANE
COMPLEX.......................... A highly specialized surface structure of
dermis that separates and anchors a layer
of epithelial cells to the underlying
dermis.
CALCIFICATION..................... Abnormal deposition of calcium salts within
a tissue, leading to hardening.
CELL CULTURE...................... The maintenance and growth of living cells
outside of the body, typically in glass or
plastic containers containing nutrients and
other supportive substances.
CHEILOPLASTY...................... Surgical lip augmentation.
CLINICAL TRIAL.................... An evaluation or experiment to test safety
and therapeutic value of a device or
substance in humans.
COLLAGEN.......................... A specialized group of proteins which form
fibers and comprise the structural support
for numerous tissues of the body (including
dermis, blood vessels, heart valves,
ligaments, and tendons).
CONTRACTURE RELEASE............... A surgical procedure to remove scar tissue
that is preventing free movement of
muscles, tendons or joints.
CORONARY BYPASS................... A surgically established shunt of blood
flow from the aorta (main artery) to the
blood vessels of the heart (coronary
arteries), bypassing an obstruction in the
coronary artery.
CRYOPRESERVATION.................. The preservation of a biological cell or
tissue by the use of freezing and low
temperature storage.
CRYOPROTECTION.................... The use of chemical substances that reduce
ice crystal damage associated with
freezing.
DERMIS............................ The inner layer of skin, composed of
extracellular protein matrix, collagen and
fibroblasts, which provides strength and
durability.
DIFFERENTIATION................... The developmental process whereby an
immature primary cell divides and acquires
properties required for its specialized
function.
ELA............................... Establishment License Application; filed
with the FDA Center for Biologic Evaluation
and Research to obtain approval to
manufacture a biological product at a
facility.
ENDOTHELIAL CELLS................. Thin flattened cells that line body
cavities, including the inside surface of
blood vessels.
31
<PAGE>
EPIDERMIS......................... The outermost superficial layer of skin
composed of epithelial cells
(keratinocytes) and pigment cells, which
overlies the dermis and is responsible for
water barrier function and pigmentation.
EPITHELIAL CELLS.................. Sheets of cells that cover exposed surfaces
of the body (including skin) and serve
especially to close and protect other parts
of the body.
EXTRACELLULAR MATRIX.............. A proteinaceous substance of lattice,
secreted by cells, which forms connective
tissue and serves as structural support for
certain tissues or organs of the body. (See
Dermis).
FIBROBLAST........................ A cell that secretes collagen and other
proteins involved in the formation of
connective tissue.
FREEZE-DRY........................ To dry a sample in a frozen state under
high vacuum especially for preservation.
FULL-THICKNESS WOUND.............. A skin injury that results in the loss of
all skin components, including epidermis
and dermis (E.G., third-degree burn).
GLABELLAR CONTOURING.............. A surgical procedure to restore the smooth
appearance of the forehead between the
eyebrows by filling in the depression
created by frown lines.
GRAFT............................. To surgically bond tissues that are
normally separate, or the tissue used in a
grafting procedure.
HEMORRHAGE........................ To undergo heavy or uncontrolled bleeding.
HOMOLOGOUS CELLS.................. Cells from another person which, when
transplanted, can be recognized by the body
as foreign and thus provoke an immune
response.
IDE APPLICATION................... Investigational Device Exemption allows a
company to conduct clinical studies with an
investigational medical device.
IMMUNE RESPONSE................... An inflammatory reaction of the body's
immune cells to a transplanted tissue or
organ, leading to its destruction.
IMMUNOSUPPRESSIVE................. That which suppresses the body's natural
immune response, preventing the destruction
or rejection of a transplanted tissue or
organ.
IND............................... An Investigational New Drug application
(IND) is usually the first step in the
process of obtaining FDA approval to
commercially distribute a new drug. Under
an IND, a sponsor can use the drug with
human subjects during and in connection
with clinical investigations.
The clinical trials generally
consist of three Phases.
Phase I, involves the study of a
drug's safety in a small number of
normal healthy volunteers.
Phase II, involves the assessment
of a drug's effectiveness
(efficacy) in a larger group of
volunteer patients with the
condition for which the drug is
directed.
Phase III, involves close
monitoring of a larger number of
patients with the condition for
which the drug is directed in order
to ascertain the drug's
effectiveness and to identify any
adverse reactions.
IN-VITRO.......................... A biological process conducted outside of
the body, as in a laboratory flask.
KERATINOCYTE...................... Primary epithelial cells of the skin which
have the ability to differentiate to
full-thickness when associated with a dermal
basement membrane complex.
32
<PAGE>
MOLECULAR DISTILLATION DRY......... To dry a sample containing unstable
frozen water under conditions of vacuum
and temperature such that ice
crystallization and subsequent damage to
the sample does not occur.
NASAL SEPTAL DEFECT............... An imperfection of the membrane inside the
nose that separates the nostrils.
NDA............................... A New Drug Approval application is an
application to the FDA for approval to
market a drug.
ORTHOPEDIC........................ Pertaining to the restoration of function
following injury to, and the correction of
deformities of, the skeletal system, its
joints and associated structures.
PERIPHERAL BYPASS................. An arterial bypass procedure in an area away
from the heart, usually in a limb.
PLA............................... A Product License Application (PLA) is an
application to the FDA for approval to
market a biological product.
PMA............................... A Pre-market Approval Application (PMA) is
an application to the FDA for approval to
market a medical device for human
therapeutic use.
PORCINE........................... Derived from pigs.
PRECLINICAL TRIALS................ Trials related to experimentation to test
safety and therapeutic value of a device or
product in living animals, prior to testing
in humans.
PREMARKET APPROVAL................ An approved premarket approval application
(PMA) is required for new types of Class III
medical devices prior to commercialization.
REJECTION......................... Destruction of a transplanted tissue or
organ by the host's immune cells.
RHINOPLASTY....................... Plastic surgical operation on the nose.
RHYTIDECTOMY...................... Removal of skin to eliminate wrinkles.
SAPHENOUS VEIN.................... Either of the two chief superficial veins of
the legs, commonly used for coronary bypass
procedures.
SPLIT-SKIN GRAFT.................. Skin containing both epidermis and dermis
which is excised from healthy sites and
transplanted to a full-thickness wound on
some other area of the body.
TAKE RATE......................... The percentage of the total graft area in
which the graft has adhered and
vascularized.
THIRD-DEGREE BURN................. Full-thickness injury of the skin, with loss
of both the epidermal and dermal components.
VASCULAR CONDUIT.................. A tubular structure through which blood
flows (i.e., blood vessel, artery or vein).
VENOUS STASIS ULCERS.............. Skin ulcers resulting from the slowing or
stoppage of normal blood flow because of
deteriorating valves in the veins.
XENOGRAFT......................... A tissue graft derived from one species and
transplanted to a different species (e.g.,
animal to human).
510(K) (REVIEW)................... A process which enables a manufacturer to
demonstrate to the FDA that a proposed
product is "substantially equivalent" to
another product that was in commercial
distribution in the United States before May
28, 1976, or has subsequently been cleared
33
<PAGE>
INDEX TO FINANCIAL STATEMENTS
Page
----
AUDITED FINANCIAL STATEMENTS
Report of Independent Public Accountants ................................. F-2
Balance Sheets as of December 31, 1995 and 1996 .......................... F-3
Statements of Operations for the years ended
December 31, 1994, 1995 and 1996 ................................... F-4
Statements of Stockholders' Equity for the years
ended December 31, 1994, 1995 and 1996 ............................. F-5
Statements of Cash Flows for the years ended
December 31, 1994, 1995 and 1996 ................................... F-6
Notes to Financial Statements ............................................ F-7
F-1
<PAGE>
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
To LifeCell Corporation:
We have audited the accompanying balance sheets of LifeCell Corporation
(a Delaware corporation) as of December 31, 1995 and 1996, and the related
statements of operations, stockholders' equity and cash flows for each of the
three years in the period ended December 31, 1996. These financial statements
are the responsibility of the Company's management. Our responsibility is to
express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present
fairly, in all material respects, the financial position of LifeCell Corporation
as of December 31, 1995 and 1996, and the results of its operations and its cash
flows for each of the three years in the period ended December 31, 1996, in
conformity with generally accepted accounting principles.
ARTHUR ANDERSEN LLP
Houston, Texas
March 26, 1997
F-2
<PAGE>
LIFECELL CORPORATION
BALANCE SHEETS
<TABLE>
<CAPTION>
December 31,
------------------------------------
1995 1996
------------ ------------
<S> <C> <C>
A S S E T S
CURRENT ASSETS
Cash and cash equivalents .......................................... $ 3,015,332 $ 10,748,250
Accounts and other receivables ..................................... 251,509 436,839
Inventories ........................................................ 351,502 839,821
Prepayments and other .............................................. 51,838 52,780
------------ ------------
Total current assets .......................................... 3,670,181 12,077,690
FURNITURE AND EQUIPMENT, net ........................................... 415,563 478,098
INTANGIBLE ASSETS, net ................................................. 290,295 334,227
------------ ------------
Total assets .................................................. $ 4,376,039 $ 12,890,015
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable ................................................... $ 384,780 $ 514,848
Accrued liabilities ................................................ 218,351 539,271
Deferred revenues .................................................. 179,002 138,792
------------ ------------
Total current liabilities ..................................... 782,133 1,192,911
DEFERRED CREDIT ......................................................... 1,500,000 1,500,000
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Series A preferred stock, $.001 par value, 300,000 shares
authorized, 264,500 and 260,000 issued and outstanding
including accrued dividends of $70,533 and $86,667 .................... 5,496,793 5,291,473
Series B preferred stock, $.001 par value, 182,205 shares
authorized, none and 124,157 issued and outstanding
and accrued dividends of none and 1,426 shares......................... -- 126
Undesignated preferred stock, $.001 par value, 1,517,795
shares authorized, none issued and outstanding .......................... -- --
Common stock, $.001 par value, 12,500,000 and 25,000,000
shares authorized, respectively, 4,403,658 and
4,899,944 shares issued and outstanding, respectively ................. 4,404 4,900
Warrants outstanding to purchase 574,066 and 3,378,264
shares of Common Stock, respectively .................................. 226,560 423,218
Additional paid in capital .............................................. 21,160,808 33,788,321
Unearned portion of restricted stock compensation & warrants ............ (19,906) --
Accumulated deficit ..................................................... (24,774,753) (29,310,934)
------------ ------------
Total stockholders' equity ......................................... 2,093,906 10,197,104
------------ ------------
Total liabilities and stockholders' equity ......................... $ 4,376,039 $ 12,890,015
============ ============
</TABLE>
The accompanying notes are an integral part of these financial statements.
F-3
<PAGE>
LIFECELL CORPORATION
STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
For the Year Ended December 31,
-------------------------------------------------------
1994 1995 1996
----------- ----------- -----------
<S> <C> <C> <C>
REVENUES
Product sales ............................... $ 93,940 $ 742,238 $ 2,012,205
Corporate alliance .......................... 358,331 825,221 546,461
Grants and contracts ........................ 364,344 239,116 386,904
----------- ----------- -----------
Total revenues ......................... 816,615 1,806,575 2,945,570
----------- ----------- -----------
COSTS AND EXPENSES
Cost of goods sold .......................... 515,500 925,174 1,281,353
Funded research and development ............. 722,675 1,064,337 933,365
Proprietary research and development ........ 1,363,176 1,105,427 654,821
General and administrative .................. 1,381,470 1,422,588 1,911,254
Selling and marketing ....................... 727,615 1,475,296 2,389,573
----------- ----------- -----------
Total costs and expenses ............... 4,710,436 5,992,822 7,170,366
----------- ----------- -----------
LOSS FROM OPERATIONS ............................. (3,893,821) (4,186,247) (4,224,796)
----------- ----------- -----------
Interest income ............................. 167,300 280,843 135,082
----------- ----------- -----------
NET LOSS ......................................... $(3,726,521) $(3,905,404) $(4,089,714)
=========== =========== ===========
Loss per share before effect of preferred
dividends, accretion of preferred stock
and warrant exercises ....................... $ (0.87) $ (0.91) $ (0.90)
Effect of preferred dividends, accretion of
preferred stock and warrant exercises ....... $ (0.03) $ (0.19) $ (0.24)
----------- ----------- -----------
LOSS PER SHARE ................................... $ (0.90) $ (1.10) $ (1.14)
=========== =========== ===========
SHARES USED IN COMPUTING LOSS PER SHARE .......... 4,294,179 4,313,366 4,542,519
=========== =========== ===========
</TABLE>
The accompanying notes are an integral part of these financial statements.
F-4
<PAGE>
LIFECELL CORPORATION
STATEMENTS OF STOCKHOLDERS' EQUITY
<TABLE>
<CAPTION>
Series A Series B Class I
Preferred Stock Preferred Stock Common Stock Common Stock
----------------------- -------------- ------------------ --------------------
Shares Amount Shares Amount Shares Amount Shares Amount
-------- ----------- ------- ---- --------- ------ ---------- -------
<S> <C> <C> <C> <C> <C> <C> <C>
Balance at December 31, 1993 .................. -- $ -- -- $-- 1,473,359 $1,473 2,803,812 $ 2,804
Class I common converted to common ............ -- -- -- -- 2,803,812 2,804 (2,803,812) (2,804)
Purchase of common stock ...................... -- -- -- -- -- -- -- --
Issuance for cash ($7.77 per share) ........... -- -- -- -- 20,421 21 -- --
Issuance of Series A preferred stock and
warrants for cash ........................ 264,500 4,877,995 -- -- -- -- -- --
Warrant issued to purchase common stock ....... -- -- -- -- -- -- -- --
Earned portion of restricted stock compensation -- -- -- -- -- -- -- --
Earned portion of warrants .................... -- -- -- -- -- -- -- --
Dividends accrued on preferred stock .......... -- 333,246 -- -- -- -- -- --
Accretion of preferred stock .................. -- 68,668 -- -- -- -- -- --
Expiration of warrants ........................ -- -- -- -- -- -- -- --
Net Loss ...................................... -- -- -- -- -- -- -- --
-------- ----------- ------- ---- --------- ------ ---------- -------
Balance at December 31, 1994 .................. 264,500 $ 5,279,909 -- $-- 4,297,592 $4,298 -- $ --
Warrant issued to purchase common stock ....... -- -- -- -- -- -- -- --
Stock options exercised ....................... -- -- -- -- 1,000 1 -- --
Warrants exercised ............................ -- -- -- -- 1,250 1 -- --
Issuance of common stock as dividends on
Series A Preferred stock ................. -- (317,400) -- -- 103,816 104 -- --
Earned portion of restricted stock compensation -- -- -- -- -- -- -- --
Earned portion of warrants .................... -- -- -- -- -- -- -- --
Dividends accrued on preferred stock .......... -- 190,947 -- -- -- -- -- --
Accretion of preferred stock .................. -- 343,337 -- -- -- -- -- --
Net Loss ...................................... -- -- -- -- -- -- -- --
-------- ----------- ------- ---- --------- ------ ---------- -------
Balance at December 31, 1995 .................. 264,500 $ 5,496,793 -- $-- 4,403,658 $4,404 -- $ --
Stock options exercised ....................... -- -- -- -- 6,062 6 -- --
Warrants exercised ............................ -- -- -- -- 339,066 339 -- --
Expiration of warrants ........................ -- -- -- -- -- -- -- --
Conversion of preferred stock ................. (4,500) (90,000) -- -- 30,104 30 -- --
Issuance of common stock as dividends on
Series A Preferred stock ................. -- (415,920) -- -- 121,054 121 -- --
Earned portion of restricted stock compensation -- -- -- -- -- -- -- --
Issuance of stock options for services ........ -- -- -- -- -- -- -- --
Issuance of Series B preferred stock and
common stock warrants for cash .............. -- -- 124,157 124 -- -- -- --
Dividends accrued on preferred stock .......... -- 300,600 -- 2 -- -- -- --
Net Loss ...................................... -- -- -- -- -- -- -- --
-------- ----------- ------- ---- --------- ------ ---------- -------
Balance at December 31, 1996 .................. 260,000 $ 5,291,473 124,157 $126 4,899,944 $4,900 -- $ --
======== =========== ======= ==== ========= ====== ========== =======
</TABLE>
<TABLE>
<CAPTION>
Warrants Unearned
to Purchase Portion of
Common Stock Restricted Stock Additional
------------------------- Compensation Paid In
Shares Amount and Warrants Capital
---------- ----------- --------- ------------
<S> <C> <C> <C> <C>
Balance at December 31, 1993 .................. 165,933 $ 116,260 $(529,942) $ 21,073,701
Class I common converted to common ............ -- -- -- --
Purchase of common stock ...................... -- -- -- --
Issuance for cash ($7.77 per share) ........... -- -- -- 174,341
Issuance of Series A preferred stock and
warrants for cash ........................ 264,500 105,800 -- --
Warrant issued to purchase common stock ....... 90,816 5,000 -- --
Earned portion of restricted stock compensation -- -- 238,872 --
Earned portion of warrants .................... -- -- 21,958 --
Dividends accrued on preferred stock .......... -- -- -- --
Accretion of preferred stock .................. -- -- -- (68,668)
Expiration of warrants ........................ (5,933) -- -- --
Net Loss ...................................... -- -- -- --
---------- ----------- --------- ------------
Balance at December 31, 1994 .................. 515,316 $ 227,060 $(269,112) $ 21,179,374
Warrant issued to purchase common stock ....... 60,000 -- -- --
Stock options exercised ....................... -- -- -- 2,999
Warrants exercised ............................ (1,250) (500) -- 4,574
Issuance of common stock as dividends on
Series A Preferred stock ................. -- -- -- 317,198
Earned portion of restricted stock compensation -- -- 238,872 --
Earned portion of warrants .................... -- -- 10,334 --
Dividends accrued on preferred stock .......... -- -- -- --
Accretion of preferred stock .................. -- -- -- (343,337)
Net Loss ...................................... -- -- -- --
---------- ----------- --------- ------------
Balance at December 31, 1995 .................. 574,066 $ 226,560 $ (19,906) $ 21,160,808
Stock options exercised ....................... -- -- -- 17,274
Warrants exercised ............................ (339,066) (104,300) -- 1,155,617
Expiration of warrants ........................ (15,000) (6,000) -- 6,000
Conversion of preferred stock ................. -- -- -- 89,970
Issuance of common stock as dividends on
Series A Preferred stock ................. -- -- -- 409,700
Earned portion of restricted stock compensation -- -- 19,906 --
Issuance of stock options for services......... -- -- -- 150,000
Issuance of Series B preferred stock and
common stock warrants for cash .............. 3,158,264 306,958 -- 10,653,087
Dividends accrued on preferred stock .......... -- -- -- 145,865
Net Loss ...................................... -- -- -- --
---------- ----------- --------- ------------
Balance at December 31, 1996 .................. 3,378,264 $ 423,218 $ -- $ 33,788,321
========== =========== ========= ============
</TABLE>
<TABLE>
<CAPTION>
Total
Treasury Accumulated Stockholders'
Stock Deficit Equity
--------- ------------ ------------
<S> <C> <C> <C> <C> <C>
Balance at December 31, 1993 .................. $ -- $(16,618,635) $ 4,045,661
Class I common converted to common ............ -- -- --
Purchase of common stock ...................... (307,755) -- (307,755)
Issuance for cash ($7.77 per share) ........... 307,755 -- 482,117
Issuance of Series A preferred stock and
warrants for cash ........................ -- -- 4,983,795
Warrant issued to purchase common stock ....... -- -- 5,000
Earned portion of restricted stock compensation -- -- 238,872
Earned portion of warrants .................... -- -- 21,958
Dividends accrued on preferred stock .......... -- (333,246) --
Accretion of preferred stock .................. -- -- --
Expiration of warrants ........................ -- -- --
Net Loss ...................................... -- (3,726,521) (3,726,521)
--------- ------------ ------------
Balance at December 31, 1994 .................. $ -- $(20,678,402) $ 5,743,127
Warrant issued to purchase common stock ....... -- -- --
Stock options exercised ....................... -- -- 3,000
Warrants exercised ............................ -- -- 4,075
Issuance of common stock as dividends on
Series A Preferred stock ................. -- -- (98)
Earned portion of restricted stock compensation -- -- 238,872
Earned portion of warrants .................... -- -- 10,334
Dividends accrued on preferred stock .......... -- (190,947) --
Accretion of preferred stock .................. -- -- --
Net Loss ...................................... -- (3,905,404) (3,905,404)
--------- ------------ ------------
Balance at December 31, 1995 .................. $ -- $(24,774,753) $ 2,093,906
Stock options exercised ....................... -- -- 17,280
Warrants exercised ............................ -- -- 1,051,656
Expiration of warrants ........................ -- -- --
Conversion of preferred stock ................. -- -- --
Issuance of common stock as dividends on
Series A Preferred stock ................. -- -- (6,099)
Earned portion of restricted stock compensation -- -- 19,906
Issuance of stock options for services......... -- -- 150,000
Issuance of Series B preferred stock and
common stock warrants for cash .............. -- -- 10,960,169
Dividends accrued on preferred stock .......... -- (446,467) --
Net Loss ...................................... -- (4,089,714) (4,089,714)
--------- ------------ ------------
Balance at December 31, 1996 .................. $ -- $(29,310,934) $ 10,197,104
========= ============ ============
</TABLE>
The accompanying notes are an integral part of these financial statements.
F-5
<PAGE>
LIFECELL CORPORATION
STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
For the Year Ended December 31,
1994 1995 1996
------------ ------------ ------------
CASH FLOWS FROM OPERATING ACTIVITIES
<S> <C> <C> <C>
Net Loss ....................................................... $ (3,726,521) $ (3,905,404) $ (4,089,714)
Adjustments to reconcile net loss to net cash
used in operating activities--
Depreciation and amortization ............................. 107,351 138,518 229,237
Stock and warrant compensation expense .................... 260,830 249,206 169,906
Change in assets and liabilities --
(Increase) in accounts and other receivables ................. (67,237) (87,014) (185,330)
Increase in inventories ...................................... (54,834) (243,720) (488,319)
(Increase) decrease in prepayment and other .................. (8,580) 11,347 (942)
Increase in accounts payable and accrued liabilities ......... 270,219 118,494 450,988
Increase (decrease) in deferred revenues and credit .......... 1,769,640 (90,638) (40,210)
------------ ------------ ------------
Total adjustments .............................................. 2,277,389 96,193 135,330
------------ ------------ ------------
Net cash used in operating activities ................ (1,449,132) (3,809,211) (3,954,384)
------------ ------------ ------------
CASH FLOWS FROM INVESTING ACTIVITIES
Capital expenditures ........................................... (90,509) (190,199) (278,673)
Intangible assets .............................................. (34,012) (24,354) (57,032)
Short-term investments ......................................... (2,138,313) 5,154,824 --
------------ ------------ ------------
Net cash provided by (used in) investing activities .. (2,262,834) 4,940,271 (335,705)
------------ ------------ ------------
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of stock and warrants ................... 5,163,157 6,977 12,029,105
Proceeds from issuance of notes payable ........................ -- -- 370,000
Dividends paid ................................................. -- -- (6,098)
Payments of notes payable ...................................... -- -- (370,000)
------------ ------------ ------------
Net cash provided by (used in) financing activities .. 5,163,157 6,977 12,023,007
------------ ------------ ------------
NET INCREASE IN CASH AND CASH EQUIVALENTS ........................... 1,451,191 1,138,037 7,732,918
CASH AND CASH EQUIVALENTS AT BEGINNING
OF YEAR ........................................................... 426,104 1,877,295 3,015,332
------------ ------------ ------------
CASH AND CASH EQUIVALENTS AT END OF YEAR ............................ $ 1,877,295 $ 3,015,332 $ 10,748,250
============ ============ ============
SUPPLEMENTAL DISCLOSURES OF CASH FLOW
INFORMATION:
Cash paid during the year for interest ......................... $ - $ - $ 13,766
SUPPLEMENTAL SCHEDULE OF NONCASH
FINANCING ACTIVITIES:
During 1995 and 1996 , the Company issued common
stock as payment for dividends in the amount of
$317,400 and $415,920, respectively
</TABLE>
The accompanying notes are an integral part of these financial statements.
F-6
<PAGE>
LIFECELL CORPORATION
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 1996
1. ORGANIZATION:
LifeCell Corporation, a Delaware corporation (LifeCell or the Company),
is engaged in the research, development and commercialization of transplantable
tissue and transfusable blood products. The Company was incorporated on January
6, 1992 for the purpose of merging with its predecessor entity, which was formed
in 1986. LifeCell commercially introduced its first transplantable tissue
product, AlloDerm(R), during December 1993. Sales of AlloDerm to date have not
been sufficient to fund the Company's operations, and the Company expects
continued operating losses during 1997. The future operating results of the
Company will be principally dependent on the market acceptance of its current
and future products, competition from other products or technologies, protection
of the Company's proprietary technology, and access to funding as required.
Accordingly, there can be no assurance of the Company's future success. See
"Risk Factors" and "Management's Discussion and Analysis of Financial Condition
and Results of Operations" elsewhere herein.
2. ACCOUNTING POLICIES:
CASH AND CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS
The Company considers all highly liquid investments purchased with an
original maturity of three months or less to be cash equivalents. Investments
that the Company intends to hold to maturity are classified as either current or
non-current assets based on the maturity date of the security. As of December
31, 1995 and 1996, the Company held $3,009,376 and $10,638,981, respectively, of
interest bearing money market accounts and A1/P1 commercial paper which were
classified as "held to maturity" securities. The carrying basis of these
investments approximated fair value and amortized cost. The securities held at
December 31, 1996 matured prior to March 31, 1997.
INVENTORIES
Inventories are stated at the lower of cost or market, cost being
determined on a first-in, first-out (FIFO) basis.
FURNITURE AND EQUIPMENT
Furniture and equipment are stated at cost. Maintenance and repairs that
do not improve or extend the life of the assets are expensed as incurred.
Expenditures for renewals and betterments are capitalized. The cost of assets
retired and the related accumulated depreciation are removed from the accounts
and any gain or loss is included in the results of operations.
Depreciation of furniture and equipment is provided on the straight-line
method based on the estimated useful lives of the assets of five years.
Leasehold improvements are depreciated over the life of the lease.
INTANGIBLE ASSETS
Intangible assets primarily consist of the costs of obtaining patents
for the proprietary technology owned by or licensed to the Company. These costs
are being amortized over the lesser of the legal (generally 17 years) or
economic life of the patent. Accumulated amortization at December 31, 1995 and
1996, amounted to $39,933 and $53,033, respectively.
F-7
<PAGE>
REVENUE RECOGNITION
Product sales are recognized as revenue when the product is shipped to
fill customer orders. Revenues from corporate alliances and from government
grants and contracts are recognized as the work is performed unless the Company
has continuing performance obligations, in which case revenue is recognized upon
the satisfaction of such obligations. Revenue received, but not yet earned, is
classified as deferred revenue.
RESEARCH AND DEVELOPMENT COSTS
Research and development costs are expensed when incurred. The Company
performs research funded by others, including research funded through the
corporate alliance with Medtronic (see Note 8), as well as its own independent
proprietary research, development and clinical testing of its products.
Externally funded research consists of direct costs associated with specific
projects as well as an allocation of overhead associated with administering
these activities.
LOSS PER SHARE
Loss per share has been computed by dividing net loss, which has been
increased for periodic accretion and imputed and stated dividends on outstanding
Preferred Stock and the discount offered on warrant exercises induced during
1996, by the weighted average number of shares of Common Stock outstanding
during the periods. In all applicable years, all Common Stock equivalents,
including the Series A Preferred Stock and the Series B Preferred Stock, were
antidilutive and, accordingly, were not included in the computation.
In March 1997, the Financial Accounting Standards Board issued Statement
of Financial Accounting Standards No. 128, "Earnings Per Share." Statement 128
establishes standards for computing and presenting earnings per share (EPS).
This statement simplifies the standards for computing earnings per share
previously found in APB Opinion No. 15, EARNINGS PER SHARE, and makes them
comparable to international EPS standards. The statement also retroactively
revises the presentation of earnings per share in the financial statements. The
Company will adopt this Standard for the year ended December 31, 1997, and has
not currently quantified the effect of applying the new Standard.
STOCK-BASED COMPENSATION
The Company accounts for employee stock-based compensation pursuant to
the provisions of Accounting Principles Board Opinion No. 25. Compensation
expense for stock options issued to employees and directors is generally
recorded at the intrinsic value (the discount, if any, of the option price from
the market price of the Common Stock under option) of the option at the date of
grant. Subsequent changes in the market price of the underlying stock do not
affect the accounting treatment of the option. Options granted to others are
accounted for under the provisions of Statement of Financial Accounting
Standards No. 123, which requires that the option be recorded at its estimated
fair value using option-pricing formulas used in the financial markets.
USE OF ESTIMATES
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
F-8
<PAGE>
3. INVENTORIES:
Inventories consist of products in various stages produced for sale and
includes the costs of raw materials, labor, and overhead.
A summary of inventories is as follows:
1995 1996
-------- --------
Raw Materials ................ $ 29,171 $ 52,738
Work-In-Process .............. 107,988 437,221
Finished Goods ............... 214,343 349,862
-------- --------
$351,502 $839,821
======== ========
4. FURNITURE AND EQUIPMENT:
A summary of furniture and equipment is as follows:
1995 1996
---------- ----------
Office furniture and fixtures .............. $ 57,636 $ 61,130
Machinery and equipment .................... 1,097,480 1,342,243
Leasehold improvements ..................... 189,877 220,293
---------- ----------
1,344,993 1,623,666
Less -
Accumulated depreciation and amortization 929,430 1,145,568
---------- ----------
Net furniture and equipment .......... $ 415,563 $ 478,098
========== ==========
5. CAPITAL STOCK:
AUTHORIZED CAPITAL STOCK
As of December 31, 1996, the authorized capital of the Company consisted
of 25,000,000 shares of Common Stock, $.001 par value, and 2,000,000 shares of
Preferred Stock, $.001 par value, of which 300,000 shares were designated as
Series A Convertible Preferred Stock and 182,205 shares were designated as
Series B Preferred Stock. As of December 31, 1996, there were 4,899,944 shares
of Common Stock, 260,000 shares of Series A Convertible Preferred Stock and
124,157 shares of Series B Preferred Stock outstanding. During March 1997, all
outstanding shares of Series A Convertible Preferred Stock and a portion of the
accrued dividends were converted into 1,772,433 shares of Common Stock.
SERIES A PREFERRED STOCK
During November 1994, the Company issued 264,500 shares of Series A
Convertible Preferred Stock (Series A Preferred Stock) and warrants to acquire
264,500 shares of Common Stock for gross proceeds of approximately $5.3 million
in a private placement. Each share of Series A Preferred Stock was convertible
at any time at the option of the holder into 6.69 shares of Common Stock. During
1996, 4,500 shares of Series A Preferred Stock were converted into 30,104 shares
of Common Stock. The Series A Preferred Stock had a liquidation preference of
$20 per share, or $5,200,000 as of December 31, 1996.
The Series A Preferred Stock bore dividends at annual rates of $1.20,
$1.60, and $2.00 per share for each of the first, second and third years,
respectively, after the date of original issuance. Dividends were payable in
cash, Common Stock, or any combination of cash and Common Stock at the Company's
discretion. The Series A Preferred Stock had no ordinary voting rights. While
the preferred shares were outstanding or any dividends were owed thereon, the
Company could not declare or pay cash dividends on its Common Stock. During 1995
and 1996, respectively, the Company paid $317,400 and $415,920 in accrued
dividends on the Series A Preferred Stock by issuing 103,816 shares and 121,054
shares of Common Stock.
F-9
<PAGE>
The preferred stock was automatically convertible into Common Stock on
November 9, 1997 and could be redeemed sooner by the Company if, after November
9, 1995, the closing bid price of the Company's Common Stock averaged or
exceeded $5.17 per share for 20 consecutive days. Pursuant to such provisions,
during February 1997, the Company called for redemption all outstanding shares
of Series A Preferred Stock. During March 1997 the Company issued 1,739,128
shares of Common Stock to redeem the Series A Preferred Stock and paid a cash
dividend of $65,000 and issued an additional 33,305 shares of Common Stock for
dividends accrued through the date of redemption.
The carrying amount of the Series A Preferred Stock was increased for
accrued and unpaid stated dividends plus periodic accretion, using the effective
interest method, such that the carrying amount equaled the redemption amount on
November 9, 1995. In November 1994, the Series A Preferred Stock was also
increased by imputed dividends resulting from the increasing dividend rates.
SERIES B PREFERRED STOCK
During November 1996, the Company issued 124,157 shares of Series B
Preferred Stock (Series B Preferred Stock) and warrants to acquire 2,803,530
shares of Common Stock for gross proceeds of approximately $12.4 million in a
private placement. Each share of Series B Preferred Stock is initially
convertible at any time at the option of the holder into approximately 32.26
shares of Common Stock (or 4,005,064 shares of Common Stock at December 31,
1996), subject to adjustment for dilutive issuances of securities. The Series B
Preferred Stock has a liquidation preference of $100 per share, or $12,415,700
as of December 31, 1996, and shares ratable in any residual assets after payment
of such liquidation preference.
The Series B Preferred Stock bears cumulative dividends, payable
quarterly, for five years at the greater of the annual rate of $6.00 per share
or the rate of any dividends paid on the Series A Preferred Stock (effectively
$10 per share until the Series A Preferred Stock was redeemed in March 1997).
Dividends may be paid in cash, in additional shares of Series B Preferred Stock
based on the stated value of $100 per share, or any combination of cash and
Series B Preferred Stock at the Company's option. On all matters for which the
Company's stockholders are entitled to vote, each share of Series B Preferred
Stock will entitle the holder to one vote for each share of Common Stock into
which the share of Series B Preferred Stock is then convertible. Additionally,
the holders of Series B Preferred Stock have the right to elect up to three
directors to the Board of Directors of the Company. While the preferred shares
are outstanding or any dividends are owned thereon, the Company may not declare
or pay cash dividends on its Common Stock. During 1996 the Company declared
accrued dividends on the Series B Preferred Stock of $145,867 payable through
the issuance of 1,426 additional shares of Series B Preferred Stock on February
15, 1997.
The preferred stock will be automatically converted into Common Stock if
(i) the closing price of the Company's Common Stock averages or exceeds $9.30
per share for 30 consecutive trading days and (ii) the Company conducts an
underwritten public offering of newly issued Common Stock with gross proceeds,
net of underwriting discounts and commissions, exceeding $20 million.
Additionally, the preferred stock will be automatically converted into Common
Stock if the Company conducts an underwritten public offering of newly issued
Common Stock with gross proceeds, net of underwriting discounts and commissions,
exceeding $20 million and the price per share in such offering equals or exceeds
$9.30.
COMMON STOCK
During February 1994, all previously outstanding shares of Class I
Common Stock were automatically converted into 2,803,812 shares of Common Stock
and the Class I Common Stock was eliminated during June 1995.
During 1995 and 1996, respectively, the Company issued 103,816 shares
and 121,054 shares of Common Stock as payment of accrued dividends on Series A
Preferred Stock. Additionally, during 1996, the Company induced the exercise of
warrants by temporarily lowering exercise prices and issued 339,066 shares of
Common Stock at a weighted average price of $3.10 upon exercise of certain
warrants.
F-10
<PAGE>
During March 1997, the Company issued 1,739,128 shares of Common Stock
to redeem all outstanding shares of the Series A Preferred Stock and paid a cash
dividend of $65,000 and issued an additional 33,305 shares of Common Stock for
dividends accrued through the date of redemption.
During 1994, the Company purchased 43,965 shares of Common Stock from
several employees, including officers and directors, for the purpose of
satisfying their income tax liabilities for shares and options previously
granted under a deferred compensation arrangement. These treasury shares were
subsequently reissued during 1994.
In 1992, the Company adopted a Restricted Stock Plan and issued 241,372
shares of Common Stock to employees, a director and a consultant of the Company
for $.001 per share. The restricted stock vested over a four year period.
Deferred compensation expense totaling $965,000 was expensed over the vesting
period of the grants. The non-cash charge related to these stock grants was
$239,000 for 1994 and 1995 and $20,000 for 1996.
OPTIONS
The Company's 1992 Stock Option Plan, as amended (1992 Plan), provides
for the grant of options to purchase up to 1,000,000 shares of Common Stock.
Granted options generally become exercisable over a four year period, 25 percent
per year beginning on the first anniversary of the date of grant. To the extent
not exercised, options generally expire on the tenth anniversary of the date of
grant, except for employees who own more than 10 percent of all the voting
shares of the Company, in which event the expiration date is the fifth
anniversary of the date of grant. All options granted under the plan have
exercise prices equal to the fair market value at the dates of grant.
The 1993 Non-Employee Director Stock Option Plan (Director Plan) was
adopted in 1993 and amended during 1996. A total of 750,000 shares of Common
Stock are available for grant under the Director Plan. Upon amendment of the
Director Plan in 1996, options to purchase 50,000 shares of Common Stock were
granted to each then-current non-employee director of the Company at an exercise
price equal to the fair market value of a share of Common Stock on the date of
the Director Plan. Options to purchase 25,000 shares of Common Stock will be
granted to newly elected directors at an exercise price equal to the fair market
value of a share of Common Stock on such election date. The provisions of the
Director Plan provide for an annual grant of an option to purchase 10,000 shares
of Common Stock to each non-employee director. Options under the Director Plan
generally vest one year after date of grant and expire after 10 years.
F-11
<PAGE>
A summary of stock option activity is as follows:
<TABLE>
<CAPTION>
1992 Stock Option Plan Director Plan
--------------------- ---------------------
Weighted- Weighted
Avg. exercise Avg. Exercise
Options Price ($) Options Price ($)
---------- ------- ---------- -------
<S> <C> <C> <C> <C>
Balance at December 31, 1993 ............ 224,593 9.06 40,000 11.00
Granted ............................ 192,819 2.87 10,000 3.00
Exercised .......................... -- -- -- --
Forfeited .......................... (2,650) 7.68 -- --
---------- ----------
Balance at December 31, 1994 ............ 414,762 6.19 50,000 9.40
---------- ----------
Granted ............................ 266,350 2.46 10,000 2.75
Exercised .......................... (1,000) 3.00 -- --
Forfeited .......................... (225,917) 8.97 -- --
---------- ----------
Balance at December 31, 1995 ............ 454,195 2.63 60,000 8.29
---------- ----------
Granted ............................ 558,000 3.80 240,000 3.07
Exercised .......................... (1,062) 2.74 (5,000) 2.88
Forfeited .......................... (42,313) 3.18 -- --
Reissue ............................ -- -- (220,000) 4.14
---------- ----------
Balance at December 31, 1996 ............ 968,820 3.28 75,000 4.11
========== ==========
Exercisable at December 31, 1994 ........ 57,606 9.11 40,000 11.00
Exercisable at December 31, 1995 ........ 158,330 2.61 50,000 9.40
Exercisable at December 31, 1996 ........ 255,429 2.61 15,000 8.29
</TABLE>
At December 31, 1996, 28,718 and 670,000 options were available for
future grant under the 1992 Plan and the Director Plan, respectively. The
exercise prices of options outstanding under the 1992 Plan and the Director Plan
at December 31, 1996 range from $0.07 to $4.375 and $2.75 to $11.00,
respectively. The weighted average contractual life of options outstanding at
December 31, 1996 was 9.1 years for the 1992 Plan and 7.8 years for the Director
Plan.
In addition to the amounts set forth in the table above, during 1996,
the Company granted options to purchase 220,000 shares of Common Stock to
directors who resigned upon the closing of the sale of the Series B Preferred
Stock in exchange for options previously granted under the Director Plan. These
options have provisions identical to the options previously granted under the
Director Plan, including exercise prices and vesting periods. The weighted
average exercise price of the options granted was $4.14. The weighted average
remaining contractual life of the grants was 8.8 years as of December 31, 1996.
The Company expensed $150,000, which was the difference between the market price
and the option price on the date of the grant, during 1996 related to this
reissuance.
In October 1995, the Financial Accounting Standards Board issued SFAS
No. 123 "Accounting for Stock-Based Compensation" which, if fully adopted,
requires the Company to record stock-based compensation at fair value. The
Company has adopted the disclosure requirements of SFAS No. 123 and has elected
to record employee compensation expense in accordance with Accounting Principles
Board Opinion (APB) No. 25.
The Company accounts for its employee stock-based compensation plans
under APB No. 25 and its related interpretations. Accordingly, deferred
compensation expense is recorded for stock options based on the excess of the
market value of the common stock on the date the options were granted over the
aggregate exercise price of the options. This deferred compensation is amortized
over the vesting period of each option. As the exercise price of options granted
under the 1992 Plan and the Director Plan has been equal to or greater than the
market price of the Company's stock on the date of grant, no compensation
expense related to these plans has been recorded. Had compensation expense for
its 1992 Plan and Director Plan been determined consistent with SFAS No. 123,
the Company's net loss and loss per share would have been increased to the
following pro forma amounts:
F-12
<PAGE>
1995 1996
---- ----
Net Loss: As reported $3,905,404 $4,089,714
Pro forma $3,940,041 $5,372,049
Loss Per Share: As reported $1.10 $1.14
Pro forma $1.10 $1.42
Because the Statement 123 method of accounting has not been applied to
options granted prior to January 1, 1995, the resulting pro forma compensation
cost may not be representative of that to be expected in future years.
Under the provisions of SFAS No. 123, the weighted average fair value of
options granted in 1995 and 1996 was $1.88 and $3.21, respectively, under the
1992 Plan. The weighted average fair value of options granted in 1995 and 1996
was $2.21 and $2.40, respectively, under the Director Plan. The fair value of
each option grant is estimated on the date of grant using the Black-Scholes
option pricing model with the following weighted average assumptions used for
grants in 1995 and 1996, respectively: a weighted average risk-free interest
rate of 6 percent for both years; no expected dividend yields for both years;
expected lives of 3 years for both years and expected volatility between 96 and
100 percent.
The stock options issued to retiring directors in 1996 had a weighted
average fair value of $2.57. The fair values of such options are estimated on
the date of grant using Black-Scholes option price model with the following
assumptions used: a weighted average risk-free interest rate of 6 percent,
expected lives of 3 to 5 years, expected volatility of 99 percent and no
expected dividends.
During 1995, options to purchase 225,917 shares of Common Stock at
exercise prices of $9.00 and $14.50 were canceled and reissued at substantially
the same terms, but with an exercise price equal to the then current market
price of $2.50.
WARRANTS
As of December 31, 1996, warrants to acquire a total of 3,378,264 shares
of Common Stock were outstanding as set forth below.
During 1996, the Company issued warrants to acquire 2,803,530 shares of
Common Stock in conjunction with the sale of the Series B Preferred Stock (the
1996 Warrants). The 1996 Warrants are exercisable at an exercise price of $4.13
per share. The warrants expire on the fifth anniversary of the date of grant,
are callable if the average closing price of the Company's Common Stock for 30
trading days equals or exceeds three times the then-exercise price, and allow
cashless exercise. The warrants also have provisions for adjustment of the
exercise price and number of shares for below-exercise price issuance of
securities.
Additionally, the Company issued a warrant to acquire 354,734 shares of
Common Stock to the placement agent for the Series B Preferred Stock (Agent
Warrant). The Agent Warrant is exercisable at an exercise price of $4.50 per
share. The warrant expires on the fifth anniversary of the date of grant and
allows cashless exercise. The warrant also has provisions for adjustment of the
exercise price and number of shares for below-exercise price issuance of
securities.
In connection with the sale of the Series A Preferred Stock, the Company
issued warrants to acquire 264,500 shares of Common Stock at exercise prices of
$3.26 per share during the first year and $3.54 per share during the second
year. Additionally, the placement agent was issued a warrant to purchase 90,816
shares of Common Stock at $6.00 per share. A total of 339,066 warrants were
exercised during 1996 through inducement of exercise by lowering the exercise
price to $3.10 per share. The difference between the market price on the date of
inducement and the induced exercise price has been deducted from net income to
determine loss per Common share. A total of 15,000 warrants expired unexercised.
As of December 31, 1996, additional warrants to acquire 100,000 shares
of Common Stock were outstanding with exercise prices ranging from $2.50 to
$11.05. Such warrants expire during periods ranging from December 31,
F-13
<PAGE>
1997 to December 13, 2000. Additionally, as of December 31, 1996, warrants to
acquire 120,000 shares of Common Stock were outstanding but expired unexercised
on February 27, 1997.
6. EMPLOYEE BENEFIT PLANS:
The Company maintains a retirement savings plan as described in Section
401(k) of the Internal Revenue Code of 1986. The Company may, at its discretion,
contribute amounts not to exceed each employee's contribution. During January
1996 and January 1997, the Company made total contributions of $5,292 and $8,187
to the plan for a partial matching of employee contributions during 1995 and
1996, respectively.
During 1996, the Company established an Employee Stock Purchase Plan to
allow for the purchase of the Company's Common Stock on the open market using
employee and any employer matching contributions. During 1996, the Company
contributed $1,328 to this plan.
7. FEDERAL INCOME TAXES:
The Company has not made any income tax payments since inception. As of
December 31, 1996, the Company has a net operating loss (NOL) carryforward for
federal income tax purposes of approximately $26 million, subject to the
limitations described below, expiring as follows:
YEAR EXPIRES
2001.................................. $ 500,000
2002.................................. 1,500,000
2003.................................. 2,800,000
2004.................................. 2,200,000
2005.................................. 1,700,000
2006.................................. 1,400,000
2007.................................. 2,400,000
2008.................................. 3,000,000
2009.................................. 2,500,000
2010.................................. 4,000,000
2011.................................. 4,000,000
-----------
$26,000,000
===========
Additionally, the Company has approximately $385,000 of research and
development tax credit carryforwards which will expire in varying amounts
commencing in 2001. The Company's ability to utilize its tax loss and credit
carryforwards to reduce future taxable income may be limited by either the prior
expiration of such loss or credit or by the occurrence of a "change in
ownership," as such term is defined by federal income tax laws and regulations.
A change in ownership may occur upon the sale of additional equity securities by
the Company, conversion of existing shares of Series B Preferred Stock or by
sales of stock by existing stockholders. In the event of a change in ownership,
the amount of the tax loss and credit carryforwards that may be utilized to
offset taxable income in any year may be limited and result in the payment of
federal income taxes that otherwise would be offset by such tax losses or
credits.
For financial reporting purposes, a valuation allowance of $9,897,000
has been recorded as of December 31, 1996 to fully offset the deferred tax asset
related to these carryforwards. The principal components of the deferred tax
asset as of December 31, 1995 and 1996, assuming a 34% federal tax rate, are as
follows:
F-14
<PAGE>
1995 1996
---------- ----------
Temporary differences:
Deferred revenue ........................ 582,000 510,000
Restricted stock compensation............ (196,000) 154,000
Uniform capitalization of
inventory costs ...................... 160,000 37,000
Other items ............................. 66,000 (29,000)
---------- ----------
Total temporary differences ............. 612,000 672,000
Federal tax losses and credits
not currently utilizable ............. 7,845,000 9,225,000
---------- ----------
Total deferred tax assets ................... 8,457,000 9,897,000
Less valuation allowance ................ (8,457,000) (9,897,000)
---------- ----------
Net deferred tax asset ...................... -- --
========== ==========
The net increase in the deferred tax valuation allowance for 1995 and
1996 was $1,691,000, and $1,440,000, respectively. Other than the net operating
loss and tax credit carryforwards, there is no significant difference between
the statutory federal income tax rate and the Company's effective tax rate
during 1994, 1995 and 1996.
8. COLLABORATIONS AND CORPORATE ALLIANCES
MEDTRONIC CARDIOVASCULAR COLLABORATION
During March 1994, the Company entered into a collaboration with
Medtronic, Inc. (Medtronic) for the development and commercialization of
universal tissue heart valves engineered with LifeCell's proprietary technology.
Medtronic paid the Company an initial licensing fee of $1,500,000, agreed to
fund development of heart valve products, and acquired $500,000 of the Company's
Common Stock at a price of $7.77 per share. Medtronic is obligated to pay
royalties, up to a maximum of $25,000,000, on any product sales . Medtronic was
also granted a right of first refusal to evaluate technology and negotiate
license and development agreements for vascular conduit products utilizing the
Company's technology. In the event Medtronic terminates funding of the heart
valve program, Medtronic may convert its initial $1.5 million license fee into
newly issued shares of the Company's Common Stock at the then-current market
price. Accordingly, the Company has deferred recognition of the initial license
fee and recorded a $1.5 million deferred credit in the accompanying balance
sheet. Medtronic also has the right, subject to certain restrictions, to
purchase additional shares of the Company's Common Stock, to have the Company
register the resale of any Common Stock acquired from it, and to appoint one
member of the Board of Directors of the company through March 1999.
OTHER PRODUCT SALES ARRANGEMENTS
The Company has negotiated other distribution or sales collaboration
arrangements with various parties with exclusive regional or international
territories under each agreement. The agreements generally provide that the
distributor must meet certain performance measures or the agreement may be
terminated by the Company. The markets served by these arrangements include
plastic and reconstructive surgery.
9. COMMITMENTS AND CONTINGENCIES:
EXTERNAL FUNDING FOR RESEARCH
Certain of the Company's research programs have been funded by Small
Business Innovation Research (SBIR) grants and other direct federal government
funding contracts. The grants and contracts generally obligate the Company to
perform specified research activities in return for such funding, and the
utilization of funds under the grants is subject to audit by the appropriate
governmental agencies. At December 31, 1996, the Company had received $138,792
of deferred revenue, including advance payments from a corporate alliance, for
research to be
F-15
<PAGE>
conducted during 1997. Additionally, as of December 31, 1996, the Company has
unfunded awards totaling $1,597,000 for research that is expected to occur and
be funded during 1997 and 1998.
EXCLUSIVE LICENSE AGREEMENT
The Company has an exclusive license agreement with the Board of Regents
of the University of Texas System (Board) to technology and patents related to
the analysis or preservation of certain cells or tissues. The Company is
required to pay the Board royalties on net sales of products encompassing the
licensed technologies. For the periods ended December 31, 1994, 1995 and 1996 no
significant royalties were paid under the agreement.
LEASES
The Company leases approximately 20,000 square feet for office and
laboratory space. The future minimum lease payments under noncancelable lease
terms in excess of one year as of December 31, 1996 were as follows:
1997................................... $ 218,028
1998................................... 221,320
1999................................... 221,320
2000................................... 221,320
2001................................... 18,443
---------
Total........................ $ 900,431
==========
10. TRANSACTIONS WITH RELATED PARTIES:
The Company leases office space from an affiliate of a stockholder of
the Company. The Company paid rent expense of approximately $139,000, $129,000
and $142,000 during 1994, 1995, and 1996 respectively, related to this lease.
The Company paid consulting fees and expenses to an affiliate of a
stockholder and a former director of the Company, totaling approximately
$96,000, $91,000 and $80,000 during the years ended December 31, 1994, 1995 and
1996 respectively, pursuant to a consultant agreement.
As of December 31, 1996, the Company has notes receivable totaling
$95,060 from participants, two of whom are directors of the Company, in a
previous deferred compensation plan. Such notes represent loans of federal
income tax amounts payable by the individuals as a result of grants under the
plan.
F-16
<PAGE>
11. QUARTERLY FINANCIAL DATA (UNAUDITED)
The following table presents summary unaudited financial data for the
years ended December 31, 1995 and 1996. The Company believes that this
information reflects all adjustments, consisting of only normal recurring items,
considered necessary for a fair presentation of the quarterly financial
information presented. The operating results for any quarterly period are not
necessarily indicative of the results that may be expected for future periods.
First Second Third Fourth
Quarter Quarter Quarter Quarter
------- ------- ------- -------
(In thousands except per share amounts)
1995
Product Sales ............ $ 98 $ 130 $ 251 $ 263
Total Revenues ........... $ 430 $ 399 $ 514 $ 464
Gross Margin ............. $ (5) $ (52) $ (7) $ (119)
Net loss ................. $(958) $(1,016) $ (867) $(1,064)
Loss per share ........... $(0.27) $ (0.29) $ (0.25) $ (0.29)
1996
Product Sales ............ $ 421 $ 429 $ 561 $ 602
Total Revenues ........... $ 576 $ 678 $ 816 $ 876
Gross Margin ............. $ 149 $ 157 $ 205 $ 220
Net loss ................. $(949) $ (909) $(1,023) $(1,209)
Loss per share ........... $(0.25) $ (0.24) $ (0.33) $ (0.32)
F-17
<PAGE>
SIGNATURES
In accordance with Section 13 or 15(d) of the Securities Exchange Act of
1934, the registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
LIFECELL CORPORATION
(Registrant)
By: /s/ PAUL M. FRISON
Paul M. Frison,
President and Chief Executive
Officer and Chairman of the
Board of Directors
Dated: March 26, 1997.
In accordance with the Securities Exchange Act of 1934, this report has
been signed by the following persons on behalf of the registrant and in the
capacities and on the dates indicated:
SIGNATURE TITLE DATE
/S/ PAUL M. FRISON Chairman of the Board, March 26, 1997
(Paul M. Frison) President and Chief
Executive Officer (Principal
Executive Officer)
/S/ J. DONALD PAYNE Vice President, Secretary March 26, 1997
(J. Donald Payne) and Chief Financial Officer
(Principal Financial and
Accounting Officer)
/S/ MICHAEL E. CAHR Director March 26, 1997
(Michael E. Cahr)
/S/ JAMES G. FOSTER Director March 26, 1997
(James G. Foster)
/S/ LORI KOFFMAN Director March 26, 1997
(Lori Koffman)
/S/ STEPHEN A. LIVESEY Director March 26, 1997
(Stephen A. Livesey)
/S/ K. FLYNN MCDONALD Director March 26, 1997
(K. Flynn McDonald)
EXHIBIT 4.1
INCORPORATED UNDER THE
LAWS OF THE STATE OF DELAWARE
NUMBER SHARES
______________ LIFECELL (R) ______________
| | | |
| | | |
|____________| |____________|
THIS CERTIFICATE IS TRANSFERABLE IN CUSIP 531927-50-7
NEW YORK, NEW YORK, CLEVELAND, OHIO SEE REVERSE FOR CERTAIN DEFINITIONS
OR HOUSTON, TEXAS
LIFECELL CORPORATION
SERIES B PREFERRED STOCK
- --------------------------------------------------------------------------------
THIS CERTIFIES THAT
SPECIMEN
is the owner of
- --------------------------------------------------------------------------------
FULLY PAID AND NON-ASSESSABLE SHARES OF SERIES B
PREFFERED STOCK, PAR VALUE $.001 PER SHARE, OF
LifeCell Corporate transferable on the books of the Corporation by the holder
hereof in person or by duly authorized authorized attorney upon surrender of
this certificate properly endorsed. This certificate is not valid until
countersigned by the Transfer Agent and registered by the Registrar.
Witness the facsimile seal of the Corporation and the facsimile
signatures of its duly authorized Officers.
<TABLE>
<CAPTION>
<S> <C>
Dated: [LIFECELL CORPORATION] Countersigned and Registered:
[ CORPORATE SEAL ] KEYCORP SHAREHOLDER SERVICES, INC.
SPECIMEN Transfer Agent and Registrar
PAUL M. FRISON JUDITH H. COLYN By SPECIMEN
President Assistant Secretary Authorized Signature
</TABLE>
- --------------------------------------------------------------------------------
<PAGE>
LIFECELL CORPORATION
THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE LAW, AND
NO INTEREST THEREIN MAY BE SOLD OR OTHERWISE TRANSFERED IN THE ABSENCE OF SUCH
REGISTRATION AND QUALIFICATION WITHOUT AN OPINION OF LEGAL COUNSEL FOR THE
HOLDER THAT SUCH REGISTRATION AND QUALIFICATION ARE NOT REQUIRED, WHICH OPINION
AND COUNSEL SHALL BE REASONABLY SATISFACTORY TO THE THE CORPORATION.
THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE CERTAIN TRANFER AND
VOTING REGISTRATIONS PURSUANT TO A SECURITIES PURCHASE AGREEMENT AND A VOTING
AGREEMENT AMONG THE CORPORATION AND CERTAIN OF THE CORPORATION'S STOCKHOLDERS.
COPIES OF SUCH SECURITIES PURCHASE AGREEMENT AND SUCH VOTING AGREEMENT WILL BE
FURNISHED WITHOUT CHARGE BY THE CORPORATION TO THE HOLDER HEREOF UPON WRITTEN
REQUEST.
THE CORPORATION WILL FURNISH WITHOUT CHARGE TO EACH STOCKHOLDER WHO SO
REQUESTS THE POWERS, DESIGNATIONS, PREFERENCES AND RELATIVES, PARTICIPATING,
OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OR SERIES THEREOF WHICH
THE CORPORTATION IS AUTHORIZED TO ISSUE AND THE QUALIFICATIONS, LIMITATIONS OR
RESTRICTIONS OF SUCH PREFERENCES AND/OR RIGHTS. ANY SUCH REQUEST SHOULD BE
ADDRESSED TO THE CORPORATION AT ITS PRICIPAL PLACE OF BUSINESS OR TO THE
TRANSFER AGENT.
The following abbreviations, when used in the inscription on the face of
this certificate, shall be construed as though they were written out in full
according to applicable laws or regulations:
<TABLE>
<CAPTION>
<S> <C>
TEN COM --as tenants in common UNIF GIFT MIN ACT--________Custodian_________
TEN ENT --as tenants by the entireties (CUST) (MINOR)
JT TEN --as joint tenants with right of under Uniform Gifts to Minors Act
survivorship and not as tenants
in common _________________________________
(STATE)
Additional abbreviations may also be used though not in the above list.
For Value Recieved,____________________________________hereby sell, assign and transfer unto
PLEASE INSERT SOCIAL SECURITY OR OTHER
IDENTIFYING NUMBER OF ASSIGNEE
[_____________________________________]__________________________________________________________________________________
_________________________________________________________________________________________________________________________
(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESSS, INCLUDING ZIP OR POSTAL CODE, OF ASSIGNEE)
_________________________________________________________________________________________________________________________
___________________________________________________________________________________________________________________Shares
of the Series B Preffered Stock represented by the within certificate, and do hereby irreevocably constitute and appoint
_________________________________________________________________________________________________________________Attorney
to transfer the said shares on the books of the within named Corporation with full power of substitution in the premises.
Dated,_______________________________
X__________________________________________________________
NOTICE: THE SIGNATURE(S) TO
THIS ASSIGMENT MUST CORRESPOND
WITH THE NAME(S) AS WRITTEN UPON
THE FACE OF THE CERTIFICATE IN
EVERY PARTICULAR, WITHOUT ALTERATION
OR ENLARGMENT OR ANY CHANGE WHATEVER. X__________________________________________________________
ALL GUARANTEES MUST BE MADE BY A FINACIAL INSTITUTION (SUCH
AS A BLANK OR BROKER) WHICH IS A PARTICIPANT IN THE SECURITIES
TRANSFER AGENTS MEDALLION PROGRAM ("STAMP"), THE NEW YORK
STOCK EXCHANGE, INC. MEDALLION SIGNATURE PROGRAM ("MSP"), OR
THE STOCK EXCHANGES MEDALLION PROGRAM ("SEMP") AND MUST NOT BE
DATED. GUARTANTEES BY A NOTARY PUBLIC ARE NOT ACCEPTABLE.
</TABLE>
EXHIBIT 10.3
LIFECELL CORPORATION
SECOND AMENDED AND RESTATED 1992 STOCK OPTION PLAN
SEPTEMBER 19, 1994
1. PURPOSE. This Second Amended and Restated 1992 Stock Option Plan (this
"Plan") of LifeCell Corporation, a Delaware corporation (the "Company"), is
adopted for the benefit of certain individuals who have substantial
responsibility for the Company's management and growth, and is intended to
advance the interests of the Company by providing these individuals with
additional incentive by increasing their proprietary interest in the success of
the Company and thereby encouraging them to remain in its employ or affiliation.
2. ADMINISTRATION. This Plan shall be administered by a committee to be
appointed by the Board of Directors of the Company (the "Committee"), which
Committee shall consist of not less than two members of the Board of Directors,
who for a period of at least one year prior to being appointed to the Committee
and at all times during service on the Committee shall not have been granted or
awarded equity securities of the Company pursuant to this Plan or any other plan
of the Company (other than pursuant to a plan of the Company that would not
cause such Committee member to lose his status as a disinterested person as
defined in Rule 16b- 3(c)(2)(i) of the Securities Exchange Act of 1934, as
amended (the "Securities Exchange Act")). The Board of Directors of the Company
shall have the power from time to time to add or remove members of the
Committee, and to fill vacancies thereon arising by resignation, death, removal,
or otherwise. Meetings shall be held at such times and places as shall be
determined by the Committee. A majority of the members of the Committee shall
constitute a quorum for the transaction of business, and the vote of a majority
of those members present at any meeting shall decide any question brought before
that meeting. No member of the Committee shall be liable for any act or omission
of any other member of the Committee or for any act or omission on his own part,
including but not limited to the exercise of any power or discretion given to
him under this Plan, except those resulting from his own gross negligence or
willful misconduct. All questions of interpretation and application of this
Plan, or as to options granted hereunder (the "Options"), shall be subject to
the determination, which shall be final and binding, of a majority of the whole
Committee. When appropriate, this Plan shall be administered in order to qualify
certain of the Options granted hereunder as "incentive stock options" described
in Section 422 of the Internal Revenue Code of 1986, as amended.
3. OPTION SHARES. The stock subject to the Options and other provisions of
this Plan shall be shares of the Company's Common Stock, $.001 par value (the
"Common Stock"). The total amount of Common Stock with respect to which Options
may be granted shall not exceed in the aggregate 530,254 shares, PROVIDED that
the class and aggregate number of shares which may be subject to the Options
granted hereunder shall be subject to adjustment in accordance with the
provisions of Paragraph 17 hereof. Such shares may be treasury shares or
authorized but unissued shares.
<PAGE>
In the event that any outstanding Option for any reason shall expire or
terminate by reason of the death or severance of employment of the optionee, the
surrender of any such Option, or any other cause, the shares of Common Stock
allocable to the unexercised portion of such Option may again be subject to an
Option under this Plan.
4. AUTHORITY TO GRANT OPTIONS. The Committee may grant the following
options from time to time to such eligible individuals of the Company as it
shall from time to time determine:
(a) "Incentive Stock Options". The Committee may grant to an
eligible employee an Option, or Options, to buy a stated number of shares
of Common Stock under the terms and conditions of this Plan, so that the
Option will be an "incentive stock option" within the meaning of Section
422 of the Internal Revenue Code of 1986, as amended.
(b) "Non-incentive Stock Options". The Committee may grant to an
eligible individual an Option, or Options, to buy a stated number of
shares of Common Stock under the terms and conditions of this Plan, even
though such Option or Options would not constitute an "incentive stock
option" within the meaning of Section 422 of the Internal Revenue Code of
1986, as amended.
Each option granted shall be approved by the Committee. Subject only to
any applicable limitations set forth in this Plan, the number of shares of
Common Stock to be covered by an Option shall be as determined by the Committee.
5. ELIGIBILITY. The individuals who shall be eligible to receive incentive
stock options under this Plan shall be such full-time key employees, including
officers and directors if they are employees, of the Company, or of any parent
or subsidiary corporation, as the Committee shall determine from time to time,
PROVIDED, that no such employee who owns stock possessing more than ten percent
of the total combined voting power of all classes of stock of the corporation
employing the employee or of its parent or subsidiary corporation shall be
eligible to receive an incentive stock option unless at the time that it is
granted the option price is at least 110% of the fair market value of Common
Stock at the time the Option is granted and the Option by its own terms is not
exercisable after the expiration of five years from the date such Option is
granted.
For the purposes of the preceding paragraph, an employee will be
considered as owning the stock owned, directly or indirectly, by or for his
brothers and sisters (whether by the whole or half blood), spouse, ancestors,
and lineal descendants; and stock owned, directly or indirectly, by or for a
corporation, partnership, estate or trust will be considered as being owned
proportionately by or for its shareholders, partners or beneficiaries. Except as
otherwise provided, for all purposes of this Plan the term "parent corporation"
shall mean any corporation (other than the Company) in an unbroken chain of
corporations ending with the Company if, on the date of grant of the Option in
question, each of the corporations other than the Company owns stock possessing
50% or more of the total combined voting power of all classes of stock
-2-
<PAGE>
in one of the other corporations in such chain; and the term "subsidiary
corporation" shall mean any corporation in an unbroken chain of corporations
beginning with the Company if, on the date of grant of the Option in question,
each of the corporations, other than the last corporation in the chain, owns
stock possessing 50% or more of the total combined voting power of all classes
of stock in one of the other corporations in such chain.
The individuals who shall be eligible to receive non-incentive stock
options shall be such individuals as the Committee shall determine from time to
time.
No individual shall be eligible to receive an Option under this Plan while
the individual is a member of the Committee.
6. OPTION PRICE. The price at which shares may be purchased pursuant to an
Option, whether it is an incentive stock option or a non-incentive stock option,
shall be not less than the fair market value of the shares of Common Stock on
the date such Option is granted and the Committee in its discretion may provide
that the price at which shares may be so purchased shall be more than such fair
market value. In the case of any employee described in Paragraph 5 who owns
stock possessing more than ten percent of the total combined voting power of all
classes of stock of the corporation employing the employee or of its parent or
subsidiary corporation (described in Paragraph 5), the option price at which
shares may be so purchased pursuant to any Option which is an incentive stock
option granted hereunder shall be not less than 110% of the fair market value of
the Common Stock on the date such Option is granted.
7. DURATION OF OPTIONS. No Option which is an incentive stock option shall
be exercisable after the expiration of ten years from the date such Option is
granted; and the Committee in its discretion may provide that such Option shall
be exercisable throughout such ten-year period or during any lesser period of
time commencing on or after the date of grant of such Option and ending upon or
before the expiration of such ten-year period. In the case of any employee who
owns stock possessing more than ten percent of the total combined voting power
of all classes of stock of the corporation employing the employee or of its
parent or subsidiary corporation (described in Paragraph 5), no Option which is
an incentive stock option shall be exercisable after the expiration of five
years from the date such Option is granted. No Option which is a non-incentive
stock option shall be exercisable after the expiration of ten years from the
date such Option is granted; and the Committee in its discretion may provide
that such Option shall be exercisable throughout such ten-year period or during
any lesser period of time commencing on or after the date of grant of such
Option and ending upon or before the expiration of such ten-year period.
8. MAXIMUM VALUE OF STOCK SUBJECT TO OPTIONS WHICH ARE INCENTIVE STOCK
OPTIONS. Notwithstanding any other provisions of this Plan to the contrary, the
aggregate fair market value (determined as of the date the Option is granted) of
the stock with respect to which incentive stock options are exercisable for the
first time by the optionee in any calendar year (under this Plan and any other
incentive stock option plan(s) of the Company and any parent and subsidiary
corporation(s) thereof) shall not exceed $100,000.
-3-
<PAGE>
9. AMOUNT EXERCISABLE. Each Option may be exercised, so long as it is
valid and outstanding, from time to time in part or as a whole, in such manner
and subject to such conditions as the Committee in its discretion may provide in
the option agreement. However, the Committee in its absolute discretion may
accelerate the time at which any outstanding Option may be exercised.
10. EXERCISE OF OPTIONS. Options shall be exercised by the delivery of
written notice to the Company setting forth the number of shares with respect to
which the Option is to be exercised, together with: (i) cash, certified check,
bank draft, or postal or express money order payable to the order of the Company
for an amount equal to the option price of such shares, (ii) Common Stock at the
fair market value on the date of exercise, or (iii) any other form of payment
which is acceptable to the Committee, and specifying the address to which the
certificates for such shares are to be mailed. As promptly as practicable after
receipt of such written notification and payment, the Company shall deliver to
the optionee certificates for the number of shares with respect to which such
Option has been so exercised, issued in the optionee's name; provided that such
delivery shall be deemed effected for all purposes when a stock transfer agent
of the Company shall have deposited such certificates in the United States mail,
addressed to the optionee, at the address specified pursuant to this Paragraph
10.
11. TAX WITHHOLDING. The Company shall be entitled to deduct from other
compensation payable to each employee any sums required by federal, state or
local tax law to be withheld with respect to the grant or exercise of an Option.
In the alternative, the Company may require the employee (or other individual
exercising the Option) to pay the sum directly to the Company. If the employee
(or other individual exercising the Option) is required to pay the sum directly,
payment in cash or by check of such sums for taxes shall be delivered within ten
days after the date of exercise. The Company shall have no obligation upon
exercise of any Option until payment has been received, unless withholding (or
offset against a cash payment) as of or prior to the date of exercise is
sufficient to cover all sums due with respect to that exercise. The Company
shall not be obligated to advise an employee of the existence of the tax or the
amount which the employer corporation will be required to withhold.
12. TRANSFERABILITY OF OPTIONS. Options shall not be transferable by the
optionee otherwise than by will or under the laws of descent and distribution.
13. TERMINATION OF EMPLOYMENT OR AFFILIATION OR DEATH OF OPTIONEE. Except
as may be otherwise expressly provided herein, Options shall terminate on the
earlier of the date of the expiration of the Option or one day less than three
months after the date of the severance, upon severance of the employment or
affiliation relationship between the Company and the optionee for any reason,
for or without cause, other than death. Whether authorized leave of absence, or
absence on military or government service, shall constitute severance of the
employment or affiliation relationship between the Company and the optionee
shall be determined by the Committee at the time thereof. In the event of the
death of the holder of an Option while in the employ or affiliation of the
Company and before the date of expiration of such Option, such Option shall
terminate on the earlier of such date of expiration or six months following the
date of such death. After the death of the optionee, his executors,
administrators
-4-
<PAGE>
or any person or persons to whom his Option may be transferred by will or by the
laws of descent and distribution, shall have the right, at any time prior to
such termination, to exercise the Option, in whole (subject to the provisions of
Paragraph 8 hereof, but without regard to any limitations set forth in or
imposed pursuant to Paragraph 9 hereof) or in part. An employment or affiliation
relationship between the Company and the optionee shall be deemed to exist
during any period in which the optionee is employed by or affiliated with the
Company, by any parent or subsidiary corporation, by a corporation issuing or
assuming a common stock option in a transaction to which Section 424(a) of the
Internal Revenue Code of 1986, as amended, applies, or by a parent or subsidiary
corporation of such corporation issuing or assuming a stock option (and for this
purpose, the phrase "corporation issuing or assuming a stock option" shall be
substituted for the word "Company" in the definitions of parent and subsidiary
corporations specified in Paragraph 5 of this Plan, and the parent-subsidiary
relationship shall be determined at the time of the corporate action described
in Section 424(a)).
14. REQUIREMENTS OF LAW. The Company shall not be required to sell or
issue any shares under any Option if the issuance of such shares shall
constitute a violation by the optionee or the Company of any provisions of any
law or regulation of any governmental authority. Each Option granted under this
Plan shall be subject to the requirements that, if at any time the Board of
Directors of the Company or the Committee shall determine that the listing,
registration or qualification of the shares subject thereto upon any securities
exchange or under any state or federal law of the United States or of any other
country or governmental subdivision thereof, or the consent or approval of any
governmental regulatory body, or investment or other representations, are
necessary or desirable in connection with the issue or purchase of shares
subject thereto, no such Option may be exercised in whole or in part unless such
listing, registration, qualification, consent, approval or representations shall
have been effected or obtained free of any conditions not acceptable to the
Board of Directors. Any determination in this connection by the Committee shall
be final, binding and conclusive. In the event the shares issuable on exercise
of an Option are not registered under the Securities Act of 1933, as amended,
(the "Securities Act") the Company may imprint on the certificate for such
shares the following legend or any other legend which counsel for the Company
considered necessary or advisable to comply with the Securities Act:
"The shares of stock represented by this certificate have not been
registered under the Securities Act of 1933 or under the securities laws
of any state and may not be sold or transferred except upon such
registration or upon receipt by the Corporation of an opinion of counsel
satisfactory to the Corporation, in form and substance satisfactory to the
Corporation, that registration is not required for such sale or transfer."
The Company may, but shall in no event be obligated to, register any securities
covered hereby pursuant to the Securities Act (as now in effect or as hereafter
amended) and, in the event any shares are so registered, the Company may remove
any legend on certificates representing such shares. The Company shall not be
obligated to take any other affirmative action in order to cause the exercise of
an Option or the issuance of shares pursuant thereto to comply with any law or
regulation or any governmental authority.
-5-
<PAGE>
15. NO RIGHTS AS STOCKHOLDER. No optionee shall have rights as a
stockholder with respect to shares covered by his Option until the date of
issuance of a stock certificate for such shares; and, except as otherwise
provided in Paragraph 17 hereof, no adjustment for dividends, or otherwise,
shall be made if the record date therefor is prior to the date of issuance of
such certificate.
16. EMPLOYMENT OR AFFILIATION OBLIGATION. The granting of any Option shall
not impose upon the Company any obligation to employ or affiliate with or
continue to employ or affiliate with any optionee; and the right of the Company
to terminate the employment or affiliation of any officer, employee or other
individual shall not be diminished or affected by reason of the fact that an
Option has been granted to him.
17. CHANGES IN THE COMPANY'S CAPITAL STRUCTURE. The existence of
outstanding Options shall not affect in any way the right or power of the
Company or its stockholders to make or authorize any or all adjustments,
recapitalizations, reorganizations or other changes in the Company's capital
structure or its business, or any merger or consolidation of the Company, or any
issue of bonds, debentures, preferred or prior preference stock ahead of or
affecting the Common Stock or the rights thereof, or the dissolution or
liquidation of the Company, or any sale or transfer of all or any part of its
assets or business, or any other corporate act or proceeding, whether of a
similar character or otherwise.
If the Company shall effect a subdivision or consolidation of shares or
other capital readjustment, the payment of a stock dividend, or other increase
or reduction of the number of shares of Common Stock outstanding, without
receiving compensation therefor in money, services or property, then (a) the
number, class and per share price of shares of stock subject to outstanding
Options hereunder shall be appropriately adjusted in such a manner as to entitle
an optionee to receive upon exercise of an Option, for the same aggregate cash
consideration, the same total number and class or classes of shares as he would
have received had he exercised his Option in full immediately prior to the event
requiring the adjustment, disregarding any fractional shares; and (b) the number
and class of shares then reserved for issuance under this Plan shall be adjusted
by substituting for the total number and class of shares of stock then reserved
for the number and class or classes of shares of stock that would have been
received by the owner of an equal number of outstanding shares of Common Stock
as the result of the event requiring the adjustment, disregarding any fractional
shares.
If the Company merges or consolidates with another corporation, whether or
not the Company is a surviving corporation, or if the Company is liquidated or
sells or otherwise disposes of substantially all its assets while unexercised
Options remain outstanding under this Plan, or if any "person" (as that term is
used in Section 13(d) and 14(d)(2) of the Securities Exchange Act) is or becomes
the beneficial owner, directly or indirectly, of securities of the Company
representing greater than 50% of the combined voting power of the Company's then
outstanding securities, (i) subject to the provisions of clause (iii) below,
after the effective date of such merger, consolidation, liquidation, sale or
other disposition, or change in beneficial ownership, as the case may be, each
holder of an outstanding Option shall be entitled, upon exercise of such Option,
to receive, in lieu of shares of Common Stock, the number and class
-6-
<PAGE>
or classes of shares of such stock or other securities or property to which such
holder would have been entitled if, immediately prior to such merger,
consolidation, liquidation, sale or other disposition, or change in beneficial
ownership, such holder had been the holder of record of a number of shares of
Common Stock equal to the number of shares as to which such Option may be
exercised; (ii) the Board of Directors may waive any limitations set forth in or
imposed pursuant hereto so that all Options, from and after a date prior to the
effective date of such merger, consolidation, liquidation, sale or other
disposition, or change in beneficial ownership, as the case may be, specified by
the Board of Directors, shall be exercisable in full; and (iii) all outstanding
Options may be canceled by the Board of Directors as of the effective date of
any such merger, consolidation, liquidation, sale or other disposition or change
in beneficial ownership.
Except as hereinbefore expressly provided, the issue by the Company of
shares of stock of any class, or securities convertible into shares of stock of
any class, for cash or property, or for labor or services either upon direct
sale or upon the exercise of rights or warrants to subscribe therefor, or upon
conversion of shares or obligations of the Company convertible into such shares
or other securities, shall not affect, and no adjustment by reason thereof shall
be made with respect to, the number or price of shares of Common Stock then
subject to outstanding Options.
18. SUBSTITUTION OPTIONS. Options may be granted under this Plan from time
to time in substitution for stock options held by employees of other
corporations who are about to become employees of the Company, or whose employer
is about to become a parent or subsidiary corporation, conditioned in the case
of an incentive stock option upon the employee becoming an employee as the
result of a merger or consolidation of the Company with another corporation, or
the acquisition by the Company of substantially all the assets of another
corporation, or the acquisition by the Company of at least 50% of the issued and
outstanding stock of another corporation as the result of which it becomes a
subsidiary of the Company. The terms and conditions of the substitute Options so
granted may vary from the terms and conditions set forth in this Plan to such
extent as the Board of Directors of the Company at the time of grant may deem
appropriate to conform, in whole or in part, to the provisions of the stock
options in substitution for which they are granted, but with respect to stock
options which are incentive stock options, no such variation shall be such as to
affect the status of any such substitute option as an "incentive stock option"
under Section 422 of the Internal Revenue Code of 1986, as amended.
19. AMENDMENT OR TERMINATION OF PLAN. The Board of Directors may modify,
revise or terminate this Plan at any time and from time to time, PROVIDED that
without the further approval of the holders of at least a majority of the
outstanding shares of voting stock, or if the provisions of the corporate
charter, by-laws or applicable state law prescribe a greater degree of
stockholder approval for this action, without the degree of stockholder approval
thus required, the Board of Directors may not (a) increase the aggregate number
of shares which may be issued under Options granted pursuant to the provisions
of this Plan; (b) materially increase the benefits accruing to participants
under this Plan; (c) change the class of employees eligible to receive incentive
stock options; or (d) materially modify the requirements as to eligibility for
-7-
<PAGE>
participation in this Plan, PROVIDED, FURTHER, that the Board shall have the
power to make such changes in this Plan and in the regulations and
administrative provisions hereunder or in any outstanding Option as in the
opinion of counsel for the Company may be necessary or appropriate from time to
time to enable any Option granted pursuant to this Plan to qualify as incentive
stock options under Section 422 of the Internal Revenue Code of 1986, as
amended, and the regulations which may be issued thereunder as in existence from
time to time. All Options granted under this Plan shall be subject to the terms
and provisions of this Plan and any amendment, modification or revision of this
Plan shall be deemed to amend, modify or revise all Options outstanding under
this Plan at the time of such amendment, modification or revision. In the event
this Plan is terminated by action of the Board of Directors, all Options
outstanding under this Plan may be terminated.
20. WRITTEN AGREEMENT. Each Option granted hereunder shall be embodied in
a written option agreement, which shall be subject to the terms and conditions
prescribed above, and shall be signed by the optionee and by the appropriate
officer of the Company for and in the name and on behalf of the Company. Such an
option agreement shall contain such other provisions as the Committee in its
discretion shall deem advisable.
21. INDEMNIFICATION OF THE COMMITTEE AND THE BOARD OF DIRECTORS. The
Company will, to the fullest extent permitted by law, indemnify, defend and hold
harmless any person who at any time is a party or is threatened to be made a
party to any threatened, pending or completed action, suit or proceeding
(whether civil, criminal, administrative or investigative) in any way relating
to or arising out of this Plan or any Option or Options granted hereunder by
reason of the fact that such person is or was at any time a director of the
Company or a member of the Committee against judgments, fines, penalties,
settlements and reasonable expenses (including attorneys' fees) actually
incurred by such person in connection with such action, suit or proceeding. This
right of indemnification will inure to the benefit of the heirs, executors and
administrators of each such person and is in addition to all other rights to
which such person may be entitled by virtue of the by-laws of the Company or as
a matter of law, contract or otherwise.
22. EFFECTIVE DATE OF PLAN. This Plan shall become effective and shall be
deemed to have been adopted on January 17, 1992, if within one year of that date
it shall have been approved by the holders of at least a majority of the
outstanding shares of voting stock of the Company voting in person or by proxy
at a duly held stockholders' meeting, or if the provisions of the corporate
charter, by-laws or applicable state law prescribe a greater degree of
stockholder approval for this action, the approval by the holders of that
percentage, at a duly held meeting of stockholders. No Options shall be granted
pursuant to this Plan after January 16, 2002.
-8-
<PAGE>
FIRST AMENDMENT
TO
LIFECELL CORPORATION
SECOND AMENDED AND RESTATED 1992 STOCK OPTION PLAN
ADOPTED BY THE BOARD OF DIRECTORS MARCH 15, 1996
AND
BY THE STOCKHOLDERS MAY 20, 1996
1. Paragraph 3 of the LifeCell Corporation Second Amended and Restated
1992 Stock Option Plan is hereby deleted in its entirety and replaced by the
following:
3. OPTION SHARES. The stock subject to the Options and other
provisions of this Plan shall be shares of the Company's Common Stock,
$.001 par value (the "Common Stock"). The total amount of Common Stock
with respect to which Options may be granted shall not exceed in the
aggregate 1,000,000, PROVIDED that the class and aggregate number of
shares which may be subject to the Options granted hereunder shall be
subject to adjustment in accordance with the provisions of Paragraph 17
hereof. Such shares may be treasury shares or authorized but unissued
shares.
In the event that any outstanding Option for any reason shall expire
or terminate by reason of the death or severance of employment of the
optionee, the surrender of any such Option, or any other cause, the shares
of Common Stock allocable to the unexercised portion of such Option may
again be subject to an Option under this Plan.
2. Except as expressly amended by this First Amendment, the LifeCell
Corporation Second Amended and Restated 1992 Stock Option Plan shall continue in
full force and effect in accordance with its terms.
<PAGE>
SECOND AMENDMENT
TO
LIFECELL CORPORATION
SECOND AMENDED AND RESTATED
1992 STOCK OPTION PLAN
ADOPTED BY THE BOARD OF DIRECTORS FEBRUARY 10, 1997
1. The first sentence of Paragraph 2 of the LifeCell Corporation Second
Amended and Restated 1992 Stock Option Plan, as amended by the First Amendment
to LifeCell Corporation Second Amended and Restated 1992 Stock Option Plan
adopted by the Board of Directors on March 15, 1996 and the stockholders of
LifeCell Corporation on June 20, 1996 (the "First Amendment"), is hereby deleted
in its entirety and replaced by the following:
This Plan shall be administered by a committee to be appointed by the
Board of Directors of the Company (the "Committee"), which Committee shall
consist of not less than two members of the Board of Directors and shall
be comprised solely of members of the Board of Directors who qualify as
non-employee directors as defined in Rule 16b-3(b)(3) of the Securities
Exchange Act of 1934, as amended (the "Securities Exchange Act").
2. Except as expressly amended by the First Amendment and this Second
Amendment, the LifeCell Corporation Second Amended and Restated 1992 Stock
Option Plan shall continue in full force and effect in accordance with its
terms.
EXHIBIT 10.4
LIFECELL CORPORATION
SECOND AMENDED AND RESTATED 1993
NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN
MARCH 15, 1996
1. PURPOSE.
This Second Amended and Restated 1993 Non-Employee Director Stock Option
Plan (this "Plan") of LifeCell Corporation, a Delaware corporation (the
"Company"), is adopted, subject to stockholder approval, for the benefit of the
directors of the Company who at the time of their service are not employees of
the Company or any of its subsidiaries ("Non-Employee Directors"), and is
intended to advance the interests of the Company by providing the Non-Employee
Directors with additional incentive to serve the Company by increasing their
proprietary interest in the success of the Company.
2. ADMINISTRATION.
This Plan shall be administered by a committee to be appointed by the
Board of Directors of the Company (the "Committee"), the members of which shall
consist of not less than two members of the Board of Directors. For the purposes
of this Plan, a majority of the members of the Committee shall constitute a
quorum for the transaction of business, and the vote of a majority of those
members present at any meeting shall decide any question brought before that
meeting. No member of the Committee shall be liable for any act or omission of
any other member of the Committee or for any act or omission on his own part,
including (without limitation) the exercise of any power or discretion given to
him under this Plan, except those resulting from his own gross negligence or
willful misconduct. All questions of interpretation and application of this
Plan, or as to options granted hereunder (the "Options"), shall be subject to
the determination, which shall be final and binding, of a majority of the whole
Committee. Notwithstanding the above, the selection of Non-Employee Directors to
whom Options are to be granted, the number of shares subject to any Option, the
exercise price of any Option and the term of any Option shall be as hereinafter
provided and the Committee shall have no discretion as to such matters.
3. OPTION SHARES.
The stock subject to the Options and other provisions of this Plan shall
be shares of the Company's Common Stock, $.001 par value per share (or such
other par value as may be designated by act of the Company's stockholders, the
"Common Stock"). The total amount of Common Stock with respect to which Options
may be granted shall not exceed 750,000 shares in the aggregate; PROVIDED, that
the class and aggregate number of shares which may be subject to the Options
granted hereunder shall be subject to adjustment in accordance with the
provisions of Section of this Plan. Such shares may be treasury shares or
authorized but unissued shares.
If any outstanding Option for any reason shall expire or terminate by
reason of the death of the
<PAGE>
optionee or the fact that the optionee ceases to be a director, the surrender of
any such Option, or any other cause, the shares of Common Stock allocable to the
unexercised portion of such Option may again be subject to an Option under this
Plan.
4. GRANT OF OPTIONS.
(a) DIRECTORS ON THE EFFECTIVE DATE OF THIS PLAN.
(i) Subject to the provisions of Section hereof, there shall be
granted to each person who is a Non-Employee Director upon the effective
date of this Plan an Option to purchase 50,000 shares of Common Stock at a
per share Option Price equal to the fair market value (as defined in
Subsection (c) below) of a share of Common Stock on such date.
(ii) For so long as this Plan is in effect and shares are available
for the grant of Options hereunder, on June 1 of each year beginning June
1, 1996, there shall be granted to each person who is a Non-Employee
Director on the effective date of this Plan and on such June 1 an Option
to purchase 10,000 shares of Common Stock at a per share Option Price
equal to the fair market value of a share of the Company's Common Stock on
such date (such number of shares being subject to the adjustments provided
in Section of this Plan).
(b) DIRECTORS ELECTED AFTER THE EFFECTIVE DATE OF THIS PLAN.
(i) Subject to the provisions of Section , for so long as this Plan
is in effect and shares are available for the grant of Options hereunder,
each person who shall become a Non-Employee Director after the effective
date of this Plan shall be granted, on the date of his election, an Option
to purchase 25,000 shares of Common Stock at a per share Option Price
equal to the fair market value of a share of Common Stock on such date
(such number of shares being subject to the adjustments provided in
Section of this Plan).
(ii) For so long as this Plan is in effect and shares are available
for the grant of Options hereunder, on June 1 of each year beginning June
1, 1996 there shall be granted to each person who shall become a
Non-Employee Director after the effective date of this Plan and is a
Non-Employee Director on such June 1 an Option to purchase 10,000 shares
of Common Stock at a per share Option Price equal to the fair market value
of a share of Common Stock on such date (such number of shares being
subject to the adjustments provided in Section of this Plan).
(c) FAIR MARKET VALUE. For purposes of this Section , the "fair market
value" of a share of Common Stock as of any particular date shall mean (i) if
the Common Stock is listed or admitted to trading on any securities exchange or
on the National Association of Securities Dealers (the "NASD") Automated
Quotation System ("Nasdaq") National Market, the closing price on such day on
the principal
-2-
<PAGE>
securities exchange or on the Nasdaq National Market on which the Common Stock
is traded or quoted, or if such day is not a trading day for such securities
exchange or the Nasdaq National Market, the closing price on the first preceding
day that was a trading day, (ii) if the Common Stock is not then listed or
admitted to trading on any securities exchange or on the Nasdaq National Market,
the closing bid price on such day as reported by the NASD, or if no such price
is reported by the NASD for such day, the closing bid price as reported by the
NASD on the first preceding day for which such price is available, and (iii) if
the Common Stock is not then listed or admitted to trading on any securities
exchange or on the Nasdaq National Market and no such closing bid price is
reported by the NASD, as determined by another reputable quotation source
selected by the Committee in good faith.
5. DURATION OF OPTIONS.
Each Option granted under this Plan shall be exercisable for a term of
nine years from the date such Option first becomes exercisable pursuant to
Section hereof, subject to earlier termination as provided in Section of this
Plan.
6. AMOUNT EXERCISABLE.
Each Option granted under this Plan may be exercised in whole or in part
at any time commencing one year after the grant thereof.
7. EXERCISE OF OPTIONS.
An optionee may exercise his Option by delivering to the Company a written
notice stating (a) that such optionee wishes to exercise such Option on the date
such notice is so delivered, (b) the number of shares of stock with respect to
which such Option is to be exercised and (c) the address to which the
certificate representing such shares of stock should be mailed. To be effective,
such written notice shall be accompanied by payment of the Option Price of each
of such shares of stock. Each such payment shall be made by cash, cashier's
check or bank draft drawn on a national banking association or postal or express
money order, payable to the order of the Company in United States dollars.
As promptly as practicable after the receipt by the Company of (a) such
written notice from the optionee and (b) payment, in the form required by the
foregoing provisions of this Section , of the Option Price of the shares of
stock with respect to which such Option is to be exercised, a certificate
representing the number of shares of stock with respect to which such Option has
been so exercised registered in the name of such optionee, shall be delivered to
such optionee, provided that such delivery shall be considered to have been made
when such certificate shall have been mailed, postage prepaid, to such optionee
at the address specified for such purpose in such written notice from the
optionee to the Company.
-3-
<PAGE>
8. TRANSFERABILITY OF OPTIONS.
Options shall not be transferable by the optionee otherwise than by will
or under the laws of descent and distribution.
9. TERMINATION.
Except as may be otherwise expressly provided in this Plan, each Option,
to the extent it shall not have been exercised previously, shall terminate on
the earlier of the following:
(a) On the last day of the three-month period commencing on the date
on which the optionee ceases to be a member of the Company's Board of
Directors, for any reason other than the death or permanent disability of
the optionee, during which period the optionee shall be entitled to
exercise all Options held by the optionee on the date on which the
optionee ceased to be a member of the Company's Board of Directors which
could have been exercised on such date;
(b) On the last day of the six-month period commencing on the date
of the optionee's death while serving as a member of the Company's Board
of Directors, during which period the executor or administrator of the
optionee's estate or the person or persons to whom the optionee's Option
shall have been transferred by will or the laws of descent or
distribution, shall be entitled to exercise all Options in respect of the
number of shares that the optionee would have been entitled to purchase
had the optionee exercised such Options on the date of his death; or
(c) Ten years after the date of grant of such Option.
10. REQUIREMENTS OF LAW.
The Company shall not be required to sell or issue any shares under any
Option if the issuance of such shares shall constitute a violation by the
optionee or the Company of any provisions of any law or regulation of any
governmental authority. Each Option granted under this Plan shall be subject to
the requirements that, if at any time the Board of Directors of the Company or
the Committee shall determine that the listing, registration or qualification of
the shares subject thereto upon any securities exchange or under any state or
federal law of the United States or of any other country or governmental
subdivision thereof, or the consent or approval of any governmental regulatory
body, or investment or other representations, are necessary or desirable in
connection with the issue or purchase of shares subject thereto, no such Option
may be exercised in whole or in part unless such listing, registration,
qualification, consent, approval or representation shall have been effected or
obtained free of any conditions not acceptable to the Board of Directors. Any
determination in this connection by the Committee shall be final, binding and
conclusive. If the shares issuable on exercise of an Option are not registered
under the Securities Act of 1933, as amended (the "Securities Act"), the Company
may imprint on the certificate for such shares the following legend or any other
legend which counsel for the Company considers necessary or advisable to comply
with the Securities Act:
-4-
<PAGE>
THE SHARES OF STOCK REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933 OR UNDER THE SECURITIES LAWS
OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED EXCEPT UPON SUCH
REGISTRATION OR UPON RECEIPT BY THE CORPORATION OF AN OPINION OF COUNSEL
SATISFACTORY TO THE CORPORATION, IN FORM AND SUBSTANCE SATISFACTORY TO THE
CORPORATION, THAT REGISTRATION IS NOT REQUIRED FOR SUCH SALE OR TRANSFER.
The Company may, but shall in no event be obligated to, register any securities
covered hereby pursuant to the Securities Act (as now in effect or as hereafter
amended) and, if any shares are so registered, the Company may remove any legend
on certificates representing such shares. The Company shall not be obligated to
take any other affirmative action to cause the exercise of an Option or the
issuance of shares pursuant thereto to comply with any law or regulation of any
governmental authority.
11. NO RIGHTS AS STOCKHOLDER.
No optionee shall have rights as a stockholder with respect to shares
covered by his Option until the date of issuance of a stock certificate for such
shares; and, except as otherwise provided in Section hereof, no adjustment for
dividends, or otherwise, shall be made if the record date therefor is prior to
the date of issuance of such certificate.
12. CHANGES IN THE COMPANY'S CAPITAL STRUCTURE.
The existence of outstanding Options shall not affect in any way the right
or power of the Company or its stockholders to make or authorize any or all
adjustments, recapitalizations, reorganizations or other changes in the
Company's capital structure or its business, or any merger or consolidation of
the Company, or any issue of bonds, debentures, preferred or prior preference
stock ahead of or affecting the Common Stock or the rights thereof, or the
dissolution or liquidation of the Company, or any sale or transfer of all or any
part of its assets or business, or any other corporate act or proceeding,
whether of a similar character or otherwise.
If the Company shall effect a subdivision or consolidation of shares or
other capital readjustment, the payment of a stock dividend or other increase or
reduction of the number of shares of Common Stock outstanding, without receiving
compensation therefor in money, services or property, then (a) the number, class
and per share price of shares of stock subject to outstanding Options hereunder
shall be appropriately adjusted in such a manner as to entitle an optionee to
receive upon exercise of an Option, for the same aggregate cash consideration,
the same total number and class or classes of shares as he would have received
had he exercised his Option in full immediately prior to the event requiring the
adjustment; and (b) the number and class of shares then reserved for issuance
under this Plan and the number of shares to be subject to the grants to be made
pursuant to Subsections (a)(ii), (b)(i) and (b)(ii) shall be adjusted by
substituting for the total number and class of shares of stock then reserved or
subject to grant the number and class or classes of shares of stock that would
have been received by the owner of an equal number of outstanding shares of
Common Stock as the result of the event requiring the adjustment, disregarding
any fractional shares.
If the Company merges or consolidates with another corporation, whether or
not the Company
-5-
<PAGE>
is a surviving corporation, or if the Company is liquidated or sells or
otherwise disposes of substantially all its assets while unexercised Options
remain outstanding under this Plan, or if any "person" (as that term is used in
Section 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended
(the "Securities Exchange Act")) is or becomes the beneficial owner, directly or
indirectly, of securities of the Company representing greater than 50% of the
combined voting power of the Company's then outstanding securities, after the
effective date of such merger, consolidation, liquidation, sale or other
disposition, as the case may be, each holder of an outstanding Option shall be
entitled, upon exercise of such Option, to receive, in lieu of shares of Common
Stock, the number and class or classes of shares of such stock or other
securities or property to which such holder would have been entitled if,
immediately prior to such merger, consolidation, liquidation, sale or other
disposition, such holder had been the holder of record of a number of shares of
Common Stock equal to the number of shares as to which such Option may be
exercised.
Except as otherwise expressly provided in this Plan, the issue by the
Company of shares of stock of any class, or securities convertible into shares
of stock of any class, for cash or property, or for labor or services either
upon direct sale or upon the exercise of rights or warrants to subscribe
therefor, or upon conversion of shares or obligations of the Company convertible
into such shares or other securities, shall not affect, and no adjustment by
reason thereof shall be made with respect to, the number or price of shares of
Common Stock then subject to outstanding Options.
13. AMENDMENT OR TERMINATION OF PLAN.
The Board of Directors may modify, revise or terminate this Plan at any
time and from time to time; PROVIDED, HOWEVER, that without the further approval
of the holders of at least a majority of the outstanding shares of voting stock,
or if the provisions of the corporate charter, bylaws or applicable state law
prescribes a greater degree of stockholder approval for this action, without the
degree of stockholder approval thus required, the Board of Directors may not (a)
materially increase the benefits accruing to participants under this Plan; (b)
materially increase the number of shares of Common Stock which may be issued
under this Plan; or (c) materially modify the requirements as to eligibility for
participation in this Plan, unless, in each such case, the Board of Directors of
the Company shall have obtained an opinion of legal counsel to the effect that
stockholder approval of the amendment is not required (x) by law, (y) by the
rules and regulations of, or any agreement with, the National Association of
Securities Dealers, Inc. or (z) to make available to the optionee with respect
to any option granted under this Plan, the benefits of Rule 16b-3 of the Rules
and Regulations under the Securities Exchange Act, or any similar or successor
rule. In addition, this Plan may not be amended more than once every six months
with respect to the plan provisions referred to in Rule 16b-3(c)(2)(ii)(A) of
the Rules and Regulations under the Securities Exchange Act other than to
comport with changes in the Internal Revenue Code of 1986, as amended, the
Employee Retirement Income Security Act of 1974, as amended, or the rules
thereunder. All Options granted under this Plan shall be subject to the terms
and provisions of this Plan and any amendment, modification or revision of this
Plan shall be deemed to amend, modify or revise all Options outstanding under
this Plan at the time of such amendment, modification or revision. If this Plan
is terminated by action of the Board of Directors, all outstanding Options may
be terminated.
-6-
<PAGE>
14. WRITTEN AGREEMENT.
Each Option granted hereunder shall be embodied in a written option
agreement, which shall be subject to the terms and conditions prescribed above,
and shall be signed by the optionee and by the appropriate officer of the
Company for and in the name and on behalf of the Company. Such an option
agreement shall contain such other provisions as the Committee in its discretion
shall deem advisable.
15. INDEMNIFICATION OF COMMITTEE AND BOARD OF DIRECTORS.
The Company shall, to the fullest extent permitted by law, indemnify,
defend and hold harmless any person who at any time is a party or is threatened
to be made a party to any threatened, pending or completed action, suit or
proceeding (whether civil, criminal, administrative or investigative) in any way
relating to or arising out of this Plan or any Option or Options granted
hereunder by reason of the fact that such person is or was at any time a
director of the Company or a member of the Committee against judgments, fines,
penalties, settlements and reasonable expenses (including attorneys' fees)
actually incurred by such person in connection with such action, suit or
proceeding. This right of indemnification shall inure to the benefit of the
heirs, executors and administrators of each such person and is in addition to
all other rights to which such person may be entitled by virtue of the by-laws
of the Company or as a matter of law, contract or otherwise.
16. EFFECTIVE DATE OF PLAN.
This Plan restates and integrates, and also amends, the LifeCell
Corporation 1993 Non-Employee Director Stock Option Plan originally adopted
effective July 22, 1993, as amended.
This Plan shall become effective, subject to stockholder approval, on
March 15, 1996. This Plan, and all Options granted under this Plan on or after
March 15, 1996, and prior to stockholder approval, shall be void and of no
further force and effect unless this Plan shall have been approved by the
requisite vote of the stockholders entitled to vote at a meeting of the
stockholders of the Company called for such purpose prior to March 15, 1997.
No Option shall be granted pursuant to this Plan on or after July 22,
2003.
-7-
<PAGE>
FIRST AMENDMENT
TO
LIFECELL CORPORATION
SECOND AMENDED AND RESTATED
1993 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN
ADOPTED BY THE BOARD OF DIRECTORS ON FEBRUARY 10, 1997
1. The first sentence of Paragraph 2 of the LifeCell Corporation 1993
Non-Employee Director Stock Option Plan, as amended, is hereby deleted in its
entirety and replaced by the following:
This Plan shall be administered by a committee to be appointed by the
Board of Directors of the Company (the "Committee"), which Committee shall
consist of not less than two members of the Board of Directors and shall
be comprised solely of members of the Board of Directors who qualify as
non-employee directors as defined in Rule 16b-3(d)(1) of the Securities
Exchange Act of 1934, as amended (the "Securities Exchange Act").
2. Except as expressly amended by this First Amendment, the LifeCell
Corporation Second Amended and Restated 1993 Non-Employee Director Stock Option
Plan, as amended, shall continue in full force and effect in accordance with its
terms.
EXHIBIT 10.15
- ------------------------------------------------------------------------------
LIFECELL CORPORATION
SECURITIES PURCHASE AGREEMENT
SERIES B PREFERRED STOCK
AND
WARRANTS
- ------------------------------------------------------------------------------
NOVEMBER 18, 1996
<PAGE>
LIST OF SCHEDULES
Schedule 1 Investors; Securities Purchased; Purchase Price
Schedule 3.2 Capital Stock
Schedule 3.4 Conflicts
Schedule 3.5 Litigation
Schedule 3.10 Taxes
Schedule 3.11 Material Adverse Effect
Schedule 3.12 Title
Schedule 3.13 Proprietary Rights
Schedule 3.14 Contracts
Schedule 3.15 Indebtedness
Schedule 3.16 Compliance with Law
Schedule 3.18 Insurance
Schedule 3.21 Related Party Transactions
Schedule 4.9 Principal Office or Domicile
Schedule 6.1 Use of Proceeds
LIST OF EXHIBITS
Exhibit A Form of Warrant
Exhibit B Form of Certificate of Designation
Exhibit C Form of Voting Agreement
Exhibit D Form of Registration Rights Agreement
Exhibit E Form of Opinion of Counsel
<PAGE>
SECURITIES PURCHASE AGREEMENT, dated as of November 18, 1996 (this
"AGREEMENT"), by and among LIFECELL CORPORATION, a Delaware corporation (the
"COMPANY"), and those persons whose names are set forth on SCHEDULE 1 annexed
hereto (each, an "INVESTOR" and collectively, the "INVESTORS").
R E C I T A L S:
WHEREAS, the Company wishes to issue and sell to the Investors,
and the Investors wish to purchase from the Company, for an aggregate purchase
price of $12,415,700 (the "PURCHASE PRICE"), (a) an aggregate of 124,157 shares
of the Series B Preferred Stock, and (b) warrants, in the form of EXHIBIT A
attached hereto and made a part hereof (the "WARRANTS"; together with the Series
B Preferred Stock, the "SECURITIES"), to purchase 2,803,530 shares of the
Company's common stock, par value $.001 per share ("COMMON STOCK"), subject to
and upon the terms and conditions hereinafter set forth. Capitalized terms not
otherwise defined herein are defined in Section 12.
AGREEMENTS;
NOW, THEREFORE, in consideration of the foregoing and of the
respective covenants and undertakings hereunder and for other good and valuable
consideration, the receipt and adequacy of which are hereby acknowledged, the
Company and the Investors agree as follows:
1. SECURITIES.
1.1 PURCHASE. The Company hereby agrees to sell to the Investors,
and the Investors hereby agree to purchase from the Company, the Series B
Preferred Stock and the Warrants for an aggregate purchase price equal to the
Purchase Price. At the closing of the separate purchases and sales of shares of
the Series B Preferred Stock and the Warrants to each Investor (the "CLOSING"),
the Company shall issue, sell and deliver to each Investor, and each Investor,
severally and not jointly, shall purchase from the Company, the number of shares
of the Series B Preferred Stock and Warrants set forth opposite the name of such
Investor listed on SCHEDULE 1, for the PRO RATA portion of the Purchase Price
set forth opposite the name of such Investor on such SCHEDULE 1. The Purchase
Price shall be paid by the Investors to the Company at the Closing in
immediately available funds by wire transfer or by delivery of bank cashier's
checks or certified checks or by such other form as approved by the Company.
1.2 CERTIFICATE OF DESIGNATION. In connection with the issuance of
shares of the Series B Preferred Stock, the Company will designate, authorize
and create the Series B Preferred Stock, which will have the designations,
powers, preferences and rights and the qualifications, limitations or
restrictions thereof set forth in the Certificate of Designation (the
"CERTIFICATE OF DESIGNATION") with respect to such series in the form of EXHIBIT
B attached hereto and made a part hereof.
<PAGE>
2. CLOSING.
2.1 PLACE AND TIME. The Closing shall take place at the offices of
Kirkland & Ellis, 200 East Randolph Drive, Chicago, Illinois 60601 at 11:00 a.m.
(Chicago time) November 18, 1996 following the satisfaction of the conditions
set forth in this Agreement or at such other place, date and time as the Company
and the Investors may agree in writing.
2.2 DELIVERIES.
(a) COMPANY. At the Closing, upon receipt by the Company from
the Investors of the Purchase Price, the Company shall deliver to each Investor
(i) a certificate representing the number of shares of the Series B Preferred
Stock set forth opposite such Investor's name on SCHEDULE 1, duly registered in
the name of such Investor, (ii) a Warrant duly registered in the name of such
Investor, representing the right to purchase in the aggregate the number of
shares of Common Stock set forth opposite such Investor's name on such SCHEDULE
1 and (iii) all other documents, instruments and writings required by this
Agreement to be delivered by the Company at the Closing.
(b) INVESTORS. At the Closing, each Investor shall deliver to
the Company (i) by wire transfer of immediately available funds or bank
cashier's or certified check payable to the order of the Company in the amount
of the Purchase Price set forth opposite such Investor's name on SCHEDULE 1, and
(ii) all other documents, instruments and writings required by this Agreement to
be delivered by such Investor at the Closing.
3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company
represents and warrants to and agrees with the Investors that:
3.1 ORGANIZATION AND QUALIFICATION. The Company is a corporation
duly organized, validly existing and in good standing under the laws of the
State of Delaware and has all requisite corporate power and authority to own its
assets, carry on its business and carry out the transactions contemplated by
this Agreement. The Company is qualified to do business in each of the
jurisdictions in which the character of its assets or the nature of its
activities makes such qualification in such jurisdictions necessary, except
where the failure to so qualify would not have a Material Adverse Effect (as
defined in Section 3.8 hereof). The Company has no subsidiaries and does not own
of record or beneficially any securities of any corporation or any instrument or
investment in any partnership, association, corporation, fund or business
entity.
3.2 CAPITAL STOCK. Subject to the valid filing of the Certificate
of Designation with the Secretary of State of Delaware, the authorized capital
stock of the Company immediately following the Closing will consist of
25,000,000 shares of Common Stock and 2,000,000 shares of preferred stock, par
value $.001 per share ("PREFERRED STOCK"), of which 300,000 shares are
designated as shares of the Company's Series A Preferred Stock, par value $.001
per share ("SERIES A PREFERRED STOCK"), and 182,205 shares are designated as
shares of the Series B Preferred Stock. Immediately following the Closing, there
will be (a) 4,778,890 fully paid and non-assessable shares of Common Stock duly
issued and outstanding and additional shares of Common Stock duly authorized and
reserved for issuance (including (i) 1,761,139 shares of Common Stock duly
2
<PAGE>
authorized and reserved for issuance upon conversion of the Series A Preferred
Stock, (ii) 4,005,062 shares of Common Stock duly authorized and reserved for
issuance upon conversion of the Series B Preferred Stock, (iii) 3,613,264 shares
of Common Stock duly authorized and reserved for issuance upon exercise of those
outstanding options and warrants (excluding employee and director stock options)
set forth on SCHEDULE 3.2 - CAPITAL STOCK annexed hereto, (iv) 1,750,000 shares
of Common Stock duly authorized and reserved for issuance pursuant to options
granted or which may be granted under the Company's Second Amended and Restated
1992 Stock Option Plan and Second Amended and Restated 1993 Non-Employee
Director Option Plan, (v) such number of shares of Common Stock as may be
necessary, from time to time, for issuance to Medtronic, Inc. pursuant to that
certain Investment Agreement, dated March 3, 1994, between the Company and
Medtronic, Inc. and (vi) such number of shares of Common Stock as may be issued,
from time to time, as dividends on the Preferred Stock; (b)260,000 fully paid
and non-assessable shares of the Series A Preferred Stock duly issued and
outstanding, registered to those holders of the Series A Preferred Stock set
forth on SCHEDULE 3.2 - CAPITAL STOCK; and (c) 124,157 fully paid and
non-assessable shares of the Series B Preferred Stock duly issued and
outstanding, registered to the Investors as set forth on SCHEDULE 1.
Upon the Closing, except as disclosed in this Section 3.2, no
other capital stock of the Company will be outstanding or authorized or reserved
for issuance. Except as disclosed on SCHEDULE 3.2 - CAPITAL STOCK, or as
otherwise provided for in or contemplated by this Agreement, there are no
preemptive rights or rights of first refusal to purchase any shares of the
Series B Preferred Stock. The Company has not violated any applicable federal or
state securities laws in connection with the offer, sale or issuance of any of
its capital stock, and, assuming the accuracy of the representations and
warranties set forth in Section 4, the offer, sale and issuance of the Series B
Preferred Stock and the Warrants hereunder do not require registration under the
Securities Act of 1933, as amended (the "SECURITIES ACT"), or registration or
qualification under any applicable state securities laws other than such
registration or qualification which the Company has obtained as of the Closing
and which is disclosed on SCHEDULE 3.2 - CAPITAL STOCK. Other than as set forth
on SCHEDULE 3.2 - CAPITAL STOCK, there are no options, warrants or rights to
purchase any Common Stock, the Company has not authorized the issuance of any
Common Stock, and there is no instrument or security convertible into or
exchangeable for, or which entitles the holder thereof to purchase, any security
of the Company.
3.3 AUTHORIZATION. The Company has taken all action necessary to
authorize the issuance of the Securities and the execution and delivery of (a)
this Agreement, (b) that certain Voting Agreement, dated as of the date hereof
(the "VOTING AGREEMENT"), by and among the Company and the Investors, in the
form of EXHIBIT C attached hereto and made a part hereof, (c) that certain
Registration Rights Agreement, dated as of the date hereof (the "REGISTRATION
RIGHTS AGREEMENT"), by and among the Company and the Investors, in the form of
EXHIBIT D attached hereto and made a part hereof, and (d) the Warrants
(collectively, the "TRANSACTION DOCUMENTS"). The Transaction Documents, when
duly and validly executed and delivered by the Company, will thereafter
constitute the legal, valid and binding obligations of the Company, enforceable
in accordance with their respective terms, except as such enforceability may be
limited by or subject to any bankruptcy, insolvency, reorganization, moratorium
or similar laws affecting the enforcement of creditors' rights generally, and
subject to general principles of equity.
3
<PAGE>
3.4. NO CONFLICT. Except as set forth in SCHEDULE 3.4 - CONFLICTS,
neither the execution and delivery of the Transaction Documents nor the
fulfillment of the terms thereof will (a) conflict with or constitute a breach
of, or a default under or give any third party the right to modify, terminate or
accelerate any obligation under, (i) the Company's Restated Certificate of
Incorporation, as amended (the "CERTIFICATE OF INCORPORATION"), (ii) the
Company's Amended and Restated By-Laws (the "BY-LAWS"), (iii) any material
agreement to which the Company is a party or by which the Company is bound, or
(iv) any provision of law or any order of any court or governmental agency or
authority entered in any proceeding to which the Company was or is now a party
or by which the Company is bound or (b) result in the creation of any lien,
charge or encumbrance on any of the business, assets or properties of the
Company.
3.5 LITIGATION, ETC. Except as disclosed on SCHEDULE 3.5 -
LITIGATION annexed hereto, there are no actions, suits, proceedings or
investigations pending or, to the knowledge of the Company, threatened against
the Company or which relate to the Company before any court or before any
administrative agency or administrative officer, nor is there any litigation
pending or, to the knowledge of the Company, threatened against the Company or
against the principal executive officers of the Company by reason of employment
agreements, confidentiality agreements, noncompetition agreements or other
agreements or arrangements. Except as set forth on SCHEDULE 3.5 - LITIGATION,
neither the Company nor any of its assets is subject to any judicial or
administrative order, judgment or decree. Except as set forth on SCHEDULE 3.5 -
LITIGATION, the Company has no knowledge of any existing violations by the
Company or the principal executive officers of the Company of federal, state or
local laws, regulations or orders.
3.6 GOVERNMENTAL AUTHORIZATIONS . Except for the filing of the
Certificate of Designation with the Secretary of the State of Delaware and
filings pursuant to federal and state securities and blue sky laws (which
securities or blue sky law filings have been made, or are not required to be
made, prior to the Closing), no approval or authorization of, or registration,
qualification or filing with, any state regulatory body or any federal, state or
municipal governmental authority in the United States or in any foreign country
is required in connection with the execution, delivery or performance by the
Company of the Transaction Documents or the issuance of the Securities or the
performance by the Company of its obligations under the Certificate of
Designation.
3.7 FURNISHING OF DOCUMENTS. The Company has furnished to the
Investors a copy of the Company's Final Confidential Private Placement
Memorandum, dated October 29,1996 and a Supplement thereto dated November __,
1996 (together, the "MEMORANDUM"), together with such information and
documentation as the Investors have deemed necessary or appropriate to verify
and confirm the accuracy and completeness of the information set forth in the
Memorandum.
3.8 FULL DISCLOSURE. Neither (x) the Memorandum nor (y) the
representations and warranties of the Company contained in this Section 3
contains any untrue statement of a material fact or omits to state a material
fact necessary to make the statements contained therein, in the light of the
circumstances under which they were made, not misleading. There is no fact known
to the Company which the Company has not disclosed to the Investors which has
had or, to the knowledge of the Company, could reasonably be expected to have a
Material Adverse Effect (as defined below). A "MATERIAL ADVERSE EFFECT" shall
mean any fact, event or occurrence or reasonably anticipated future event or
occurrence which (a) involves an aggregate of $100,000 or more or (b) could be
expected
4
<PAGE>
to materially adversely effect (i) the business, assets, prospects, profits or
condition (financial or otherwise) of the Company or (ii) the Company's ability
to perform its obligations under the Transaction Documents or the Certificate of
Designation.
3.9 FINANCIAL STATEMENTS. The Company has delivered to the
Investors (a) an audited balance sheet of the Company as of December 31, 1995,
and the related income statements for the fiscal year then ended (the "ANNUAL
FINANCIAL STATEMENTS"), (b) an unaudited balance sheet of the Company as of June
30, 1996 and the related income statement for the fiscal quarter then ended (the
"QUARTERLY FINANCIAL STATEMENTS"); and (c) a balance sheet of the Company as of
August 31, 1996 (the "AUGUST BALANCE SHEET"; together with the Annual Financial
Statements and the Quarterly Financial Statements, the "FINANCIAL STATEMENTS")
and the related statement of income for the month then ended. The Financial
Statements (a) present fairly the financial condition of the Company as of their
respective dates and, as applicable, the results of operations for their
respective periods (subject to, in the case of the Quarterly Financial
Statements and the August Balance Sheet, year-end adjustments), (b) were
prepared in accordance with the books and records of the Company in accordance
with generally accepted accounting principles ("GAAP") consistently applied and
(c) are true, correct and complete in all material respects. The Company hereby
specifically confirms that there have been no changes during the periods covered
in the Financial Statements in the Company's accounting principles and practices
except as disclosed in the Financial Statements and there have been no changes
in the Company's accounting principles and practices since the August Balance
Sheet.
3.10 TAXES. Except as set forth on SCHEDULE 3.10 - TAXES annexed
hereto, the Company has filed or caused to be filed on a timely basis all Tax
Returns (as defined below) that are or were required to be filed by or with
respect to it pursuant to the laws, regulations or administrative requirements
of each governmental agency or authority with taxing power over it or its
assets; the Company has paid, or has made adequate provision for the payment of,
all Taxes (as defined below) that have or may have become due and no Tax Returns
referred to above have been audited by any governmental agency or authority; the
Company has not given or been requested to give waivers or extensions (or is or
would be subject to a waiver or extension given by any other entity) of any
statute of limitations relating to the payment of Taxes by the Company or for
which the Company may be liable; the Company has received no notice of any
proposed tax assessment against the Company. All Taxes that the Company is or
was required by law to withhold or collect have been duly withheld or collected
and, to the extent required, have been paid to the proper governmental agency or
authority or other person; there is no claim, audit, action, suit, proceeding,
or investigation with respect to Taxes due or claimed to be due from the Company
or any Tax Return filed or required to be filed by the Company pending or, to
the Company's knowledge, threatened against or with respect to the Company; to
the knowledge of the Company, no Tax Return of the Company is being examined by
the Internal Revenue Service (the "IRS") or any other governmental agency or
authority, and no property of the Company which serves as the basis for the
imposition of Taxes has been appraised, examined or reassessed by any taxing
authority since the filing of the last Tax Return relating to the payment of
such Taxes; the Company is not party to a tax sharing agreement; the Company has
not made an election under Section 341(f) of the Internal Revenue Code of 1986,
as amended (the "CODE"); to the knowledge of the Company, the Company is not
liable for the taxes of another person in any material amount under (a) Treas.
Reg. Section 1.1502-6 (or any comparable provisions of state, federal, local or
foreign law), (b) as a transferee or successor, (c) by contract or
5
<PAGE>
indemnity or (d) otherwise; and the Company has disclosed on its federal income
Tax Returns any position taken for which substantial authority (within the
meaning of Code Sec. 6662(d)(2)(B)(i)) did not exist at the time such return was
filed by the Company. For the purposes hereof, (a) "TAX RETURNS" shall mean any
return, report, information return or other document (including any related or
supporting information) filed or required to be filed with any governmental
agency or authority in connection with the determination, assessment or
collection of any Taxes or the administration of any laws, regulations or
administrative requirements relating to any Taxes; and (b) "TAXES" shall mean
all taxes, duties, charges, fees, levies, interest, penalties, additions to tax
or other assessments, including, but not limited to, foreign, federal, state and
local income, excise, employment, property, sales, use, occupation, value added
and franchise taxes and customs duties, imposed by any governmental agency or
authority and any payments with respect thereto required under any tax-sharing
agreement.
3.11 NO MATERIAL ADVERSE CHANGE. Since the date of the Annual
Financial Statements, except as set forth on SCHEDULE 3.11 - MATERIAL ADVERSE
EFFECT annexed hereto, there has not been any occurrence which could have a
Material Adverse Effect (including without limitation the (a) entering into of
any transaction (whether or not in the Company's ordinary course of business);
(b) damage to, or destruction or loss of, physical property (whether or not
covered by insurance); (c) borrowing or agreement to borrow by the Company or
change in the contingent obligations of the Company by way of guaranty,
endorsement, indemnity, warranty, or otherwise or grant of a mortgage or
security interest in any properties of the Company; (d) payment of any
obligation or liability other than current liabilities paid in the ordinary
course of business; or (e) sale, assignment, transfer, or encumbrance of any
tangible or intangible asset of the Company (except in the ordinary course of
business) or the unauthorized discourse of any proprietary or confidential
information on the Company.)
3.12 TITLE TO PROPERTIES; ENCUMBRANCES. The Company owns no real
property, and has good and valid title to all other properties (personal and
mixed, tangible and intangible) that it purports to own and a valid leasehold
interest in all properties that it has leased. The Company is in compliance with
all leases to which it is a party. The properties owned or leased by the Company
are sufficient for the operation of the business of the Company as now conducted
and as proposed to be conducted. Except as set forth on SCHEDULE 3.12 - TITLE
annexed hereto, all properties and assets owned by the Company are owned free
and clear of all encumbrances, except for security interests incurred in
connection with the purchase of its property or assets (such security being
limited to the property or assets so acquired and securing the purchase price
therefor).
3.13 PROPRIETARY RIGHTS. Except as set forth on SCHEDULE 3.13 -
PROPRIETARY RIGHTS annexed hereto, to the best knowledge of the Company, the
Company owns or possesses, or has adequate and enforceable licenses or other
rights to use and license for all purposes, all Proprietary Rights (as defined
below) necessary for its business as now conducted and as proposed to be
conducted without any conflict with or infringement of the rights of others.
SCHEDULE 3.13-PROPRIETARY RIGHTS sets forth a true, complete and correct list of
the Company's Proprietary Rights. Except as set forth on SCHEDULE 3.13 -
PROPRIETARY RIGHTS, no claim has been asserted or, to the knowledge of the
Company, threatened, by any person regarding the use or licensing of any of the
Company's Proprietary Rights by the Company or challenging or questioning the
validity, enforceability or effectiveness of any licenses or agreements
(including, without limitation,
6
<PAGE>
assignments) relating to Proprietary Rights or asserting any rights in such
Proprietary Rights. To the best knowledge of the Company, other than as set
forth on SCHEDULE 3.13 - PROPRIETARY RIGHTS, the use by the Company of its
Proprietary Rights does not violate or infringe, and has not in the past
violated or infringed, the rights of any person. Except as set forth on SCHEDULE
3.13 - PROPRIETARY RIGHTS, no claims have been asserted by the Company against
any other person claiming infringement of the Company's Proprietary Rights.
Except as set forth on SCHEDULE 3.13 - PROPRIETARY RIGHTS, the Company is not
aware of any third parties who are infringing or violating any of the Company's
Proprietary Rights. Neither the Company nor, to the knowledge of the Company,
any other person is in default under any license or other agreement relating to
the Company's Proprietary Rights (including without limitation, assignments),
and all such licenses and agreements are valid, enforceable and in full force
and effect. All inventors of patents and patent applications of the Company are
or have been employees of the Company and have executed or agreed to execute an
assignment of Proprietary Rights with respect to any such Proprietary Rights,
and the Company has no obligation to pay any royalties with respect to the use
of any such Proprietary Rights, except as set forth on SCHEDULE 3.13 -
PROPRIETARY RIGHTS. SCHEDULE 3.13 - PROPRIETARY RIGHTS annexed hereto sets forth
a list of those assignments of any Proprietary Rights of the Company which have
been executed. As used in this Section 3.13, "PROPRIETARY RIGHTS" means all
patents, patent applications, patent disclosures and inventions (whether or not
patentable and whether or not reduced to practice), patent licenses, trademarks,
trade names, trade secrets, service marks, brand marks, brand names, internet
domain names, copyrights, copyright applications, inventions, mask works,
technologies, know-how, formulae, processes, computer software, names and
likenesses owned by the Company or pursuant to which the Company has a valid and
enforceable license to use.
3.14 CONTRACTS. SCHEDULE 3.13 - PROPRIETARY RIGHTS, SCHEDULE 3.14 -
CONTRACTS annexed hereto and SCHEDULE 3.21 - RELATED PARTY TRANSACTIONS annexed
hereto set forth a true, complete and correct list of all material contracts,
agreements, commitments, obligations and licenses to which the Company is a
party ("COMPANY CONTRACTS"). For purposes hereof, a Company Contract is
"material" if it is a Contract (or series of related Contracts) that (a)
obligates the Company to pay in excess of $50,000 per annum or pursuant to which
the Company would receive in excess of $50,000 per annum or (b) is not
cancelable within sixty (60) days' notice by the Company without premium or
penalty. All of the Company Contracts are valid and binding and in full force
and effect; other than as set forth on SCHEDULE 3.14 - CONTRACTS, there are no
existing defaults (or events which, with notice or lapse of time or both, would
constitute a default) by the Company, or to the Company's knowledge, by any
other party, thereunder. The Company has provided the Investors' counsel with
copies of all of the Company Contracts identified on SCHEDULE 3.13 - PROPRIETARY
RIGHTS, SCHEDULE 3.14 - CONTRACTS and SCHEDULE 3.21 - RELATED PARTY
TRANSACTIONS, as such Company Contracts are in effect as of the date of the
Closing.
3.15 INDEBTEDNESS. As of the date hereof, except as set forth on
SCHEDULE 3.15-INDEBTEDNESS, the Company has no indebtedness or liabilities of
any nature (matured or unmatured, fixed or contingent, direct or indirect, as
guarantor or in any other capacity) which are not set forth in the Financial
Statements and all reserves established by the Company and set forth in the
Financial Statements are adequate for the purposes for which they were
established.
3.16 REQUIRED APPROVALS; COMPLIANCE WITH LAW. Other than (a) the
valid adoption by the Board of Directors of resolutions (i) embodied in the
Certificate of Designation, and (ii)
7
<PAGE>
authorizing the execution and delivery by the Company of the Transaction
Documents (and the consummation of the transactions contemplated hereby and
thereby, and the performance by the Company of its obligations hereunder and
thereunder), (b) the consent of the majority of the holders of shares of the
Series A Preferred Stock to the authorization and issuance of shares of the
Series B Preferred Stock, and (c) the waiver by certain stockholders of the
Company of those registration rights set forth on Schedule 5.1 to the
Registration Rights Agreement ("CONFLICTING REGISTRATION RIGHTS"), and (d) the
required consent of the holders of Conflicting Registration Rights to certain
amendments to such Conflicting Registration Rights, no approval or consent is
required by law or by the Certificate of Incorporation or By-Laws or by any
indenture, agreement or other instrument to which the Company is a party or is
otherwise bound or to which its assets are subject, or by any indebtedness of
the Company, in connection with the issuance and sale of the Securities to the
Investors pursuant to this Agreement and the performance by the Company of its
obligations under the Transaction Documents and the Certificate of Designation.
Other than as set forth on SCHEDULE 3.16 - COMPLIANCE WITH LAW annexed hereto,
the Company is in compliance in all material respects with all laws (including
without limitation the United States Food, Drug and Cosmetics Act, as amended,
and the United States Public Health Service Act, as amended), rules, regulations
and other requirements of all governmental bodies, domestic and foreign, having
jurisdiction over the Company including, without limitation, the United States
Food and Drug Administration.
3.17 ENVIRONMENTAL PROTECTION.
(a) COMPLIANCE. The Company is in compliance in all material
respects with all limitations, restrictions, conditions, standards,
prohibitions, requirements, obligations, schedules and timetables contained in
any Applicable Environmental Laws (as defined below), or in any judicial and
administrative orders, determinations, decrees or judgments issued, entered,
promulgated or approved thereunder or in connection therewith. The Company is
not aware of, and has not received notice of, any past, present or future
events, conditions, circumstances, activities, practices, incidents, actions or
plans which would reasonably be expected to interfere with or prevent continued
compliance, or which may give rise to any common law or legal liability, or
otherwise form the basis of any claim, action, suit, proceedings, hearing or
investigation, based on or related to the manufacture, processing, distribution,
use, treatment, storage, disposal, transport, or handling, or the emission,
discharge, release or threatened release into the environment, of any Hazardous
Material (as defined below).
(b) HAZARDOUS MATERIAL. No Hazardous Material has been
incorporated in, used on, stored on or under, released from, treated on,
transported to or from, or disposed of on or from any property leased by the
Company during the period of the Company's lease(s) (or, to the knowledge of the
Company, any prior period), such that, under Applicable Environmental Laws, (i)
any such Hazardous Material would be required to be removed, cleaned-up or
remediated before the property could be altered, renovated, demolished or
transferred, or (ii) the owner or lessee of the property could be subjected to
liability for the removal, clean-up or remediation of such Hazardous Material;
and the Company has not received any notification from any Governmental Bodies
or other third parties relating to Hazardous Material on or affecting any
property owned or leased by the Company or relating to any potential or known
liability under Applicable Environmental Laws arising from the ownership or
leasing of any property.
8
<PAGE>
(c) DEFINITIONS. For the purposes of this Agreement,
"APPLICABLE ENVIRONMENTAL LAWS" shall mean the Comprehensive Environmental
Response, Compensation and Liability Act, 42 U.S.C. ss.ss. 6901 et seq.
("CERCLA"), Resource Conservation and Recovery Act, 42 U.S.C. ss.ss. 6901 et
seq. ("RCRA"), the Federal Waste Pollution Control Act, 33 U.S.C. ss. ss. 1261
et seq., the Clean Air Act, 42 U.S.C. ss. ss. 7401 et seq., any similar
provisions of state or local law in the countries and jurisdictions where the
properties of the Company are located and where the Company conducts its
business and the regulations thereunder and any other local, state and/or
federal laws or regulations that govern (i) the existence, cleanup and/or
remediation of contamination on property; (ii) the protection of the environment
from spilled, deposited or otherwise emplaced contamination; (iii) the control
of hazardous wastes; or (iv) the use, generation, transport, handling,
treatment, storage, disposal, removal or recovery of Hazardous Material,
including building materials. For the purposes of this Agreement, "HAZARDOUS
MATERIAL" shall mean any substance which as of the date of this Agreement shall
be identified as "hazardous" or "toxic" or otherwise regulated under CERCLA or
RCRA or which has been determined by any agency or court to be a hazardous or
toxic substance under Applicable Environmental Law.
3.18 INSURANCE. The Company has insured by reputable insurers its
assets that are of an insurable character against risks of liability (including
product liability), casualty, and fire in adequate and customary amounts for
similarly situated companies in similar businesses. SCHEDULE 3.18 - INSURANCE
annexed hereto sets forth a true, complete and correct list of the Company's
insurance policies, including policy limits and deductibles. The Company's
insurance coverage is customary for well insured corporations of similar size
engaged in similar lines of business. Except as set forth on SCHEDULE 3.18 -
INSURANCE, the Company does not have any self-insurance or co-insurance
programs, and the reserves set forth on the August Balance Sheet are adequate to
cover all anticipated liabilities with respect to any such self-insurance or
co-insurance programs. There are no material claims, actions, suits or
proceedings arising out of or based upon any of such policies of insurance and,
to the knowledge of the Company, no basis for any such material claim, action,
suit or proceeding exists.
3.19 ERISA.
(a) COMPANY BENEFIT PLAN AND BENEFIT ARRANGEMENT DEFINITIONS.
The Company has previously delivered or made available to the Investors true and
complete copies of: (i) all plan texts and agreements relating to each of the
Company's benefit plan and benefit arrangements ("PLANS"); (ii) annual reports
(Forms 5500) and periodic reports, if any, with respect to each plan for the
last five years; (iii) the most recent actuarial valuation reports and financial
statements for the last five years and the most recent determination letter
received from the IRS with respect to the Company's Profit Sharing Plan; and
(iv) the most recent summary plan description, each summary of material
modifications thereto and the most recent employee handbook of the Company.
(b) COMPLIANCE, LITIGATION. With respect to each Plan: (i) the
Company has timely made all payments due from it to date, and all amounts
properly accrued to date as liabilities of the Company which have not been paid
have been properly recorded on the books of the Company if required by GAAP;
(ii) the Company has complied in all material respects with, and each such Plan
conforms in all material respects to, all applicable laws and regulations,
including, without limitation, the Employee Retirement Income Security Act of
1974, as amended ("ERISA"), and the
9
<PAGE>
Code, and each such plan or arrangement that is intended to be "qualified"
within the meaning of Section 401(a) or 403(a) of the Code has been determined
by the IRS to be qualified; and (iii) there are no actions, suits, claims or
audits pending (other than routine claims for benefits) or, to the Company's
knowledge, threatened, with respect to any Plan or against the assets of any
Plan. The Company has made all contributions in respect of its 1995 fiscal year
on account of each Plan (including, without limitation, unfunded pension
liabilities and profit sharing liabilities), whether or not such contributions
have come due as of the date of this Agreement. As of the date of this
Agreement, there is no unfunded past service cost in respect of any Plan.
(c) PENSION PLANS. No Plan that is a "pension plan" (as
defined in Section 3(2) of ERISA) that is or was subject to Title IV of ERISA
has been terminated or merged; no proceeding has been initiated to terminate any
such Plan; no "reportable event" within the meaning of Section 4043(b) of ERISA
has occurred or is expected to occur (other than as a result of this
transaction); neither the Company nor any Plan fiduciary (as defined in Section
3(21) of ERISA) with respect to any Plan, has engaged in any transaction or
acted or failed to act in a manner that violates Section 404 or 406 of ERISA or
engaged in any prohibited transaction (as defined in Section 4975(c)(1) of the
Code) for which there exists neither a statutory or regulatory exemption or for
which an exemption has not been obtained; and the Company has not incurred any
liability, whether to the Pension Benefit Guaranty Corporation or otherwise,
except for required premium payments, which payments have been made when due. No
event has occurred, and there exists no condition or set of circumstances which
presents a risk of the partial termination of any such Plan.
(d) FUNDING DEFICIENCY. No such Plan has incurred an
"accumulated funding deficiency" (as defined in Section 302 of ERISA and Section
412 of the Code), whether or not waived.
(e) TRIGGERING EVENTS. The consummation of the transactions
contemplated by this Agreement by itself and without consideration of subsequent
events will not (i) entitle any current or former employee of the Company to
severance pay, unemployment compensation or any similar payment, or (ii)
accelerate the time of payment or vesting, or increase the amount of any
compensation due to any such employee or former employee.
(f) MULTIPLE EMPLOYER PLAN. No Plan is a "multiple employer
plan," within the meaning of the Code or ERISA or the regulations promulgated
thereunder, or a "multi-employer plan" as defined in Section 4001(a)(3) of
ERISA, and the Company has not made any contributions to or participated in any
"multiple employer plan" or "multi-employer plan."
3.20 NO BROKER OR FINDER. Other than Gruntal & Co., Incorporated,
the Company has engaged no broker or finder in connection with this Agreement or
the transactions contemplated hereby.
3.21 RELATED PARTY TRANSACTIONS. SCHEDULE 3.21 - RELATED PARTY
TRANSACTIONS contains a list of all Contracts (including summaries of any oral
Contracts) between the Company and any employee, officer or director of the
Company, any existing holder of five percent (5%) or more of the outstanding
shares of Common Stock, or any Affiliate or immediate family member of any of
the foregoing (any of the foregoing, a "RELATED PARTY"). Except as disclosed in
the Memorandum or
10
<PAGE>
on SCHEDULE 3.21 - RELATED PARTY TRANSACTIONS, no Related Party is indebted to
the Company, and the Company is not indebted and is not committed to make loans
or extend or guarantee credit to any Related Party. Except as disclosed on
SCHEDULE 3.21 - RELATED PARTY TRANSACTIONS, no Related Party is interested,
directly or indirectly, in any Contract with the Company except by reason of
such Related Party's ownership interest in the Company. Except as disclosed on
SCHEDULE 3.21 - RELATED PARTY TRANSACTIONS, no Related Party or party to this
Agreement is presently, directly or indirectly through such party's affiliation
with any other person, a party to any transaction with the Company providing for
the furnishing of services by, or rental of real or personal property from, or
otherwise requiring cash payments to, any such person pursuant to a Contract.
3.22 SMALL BUSINESS MATTERS
(a) REPRESENTATIONS.
(i) The information set forth in the United States Small
Business Administration ("SBA") Forms 480, 652 and Part A of Form 1031 regarding
the Company and its Affiliates is accurate and complete. Copies of such forms
shall have been completed and executed by the Company and delivered to each
Investor that has advised the Company that it is licensed as a "small business
investment company" by the SBA (each, a "SBIC INVESTOR") at the Closing.
(ii) The proceeds from the sale of the Securities will be used
by the Company as set forth on SCHEDULE 6.1 - USE OF PROCEEDS annexed hereto. No
portion of such proceeds will be used (A) to provide capital to a corporation
licensed under the Small Business Investment Act of 1958, as amended (the
"SBIA"), (B) to acquire farm land, (C) to fund production of a single item or
defined limited number of items, generally over a defined production period,
with such production constituting the majority of the activities of the Company
(examples include motion pictures and electric generating plants), or (D) for
any purpose contrary to the public interest (including, but not limited to,
activities which are in violation of law) or inconsistent with free competitive
enterprise, in each case, within the meaning of 13 C.F.R. ss. 107.720.
(iii) The Company's primary business activity does not
involve, directly or indirectly, providing funds to others, the purchase or
discounting of debt obligations, factoring or long-term leasing of equipment
with no provision for maintenance or repair; and the Company is not classified
under Major Group 65 (Real Estate) of the SIC Manual. The assets of the
Company's business will not be reduced or consumed, generally without
replacement, as the life of the business progresses; and the nature of the
Company's business does not require that a stream of cash payments be made to
the financing sources of the Company's business, on a basis associated with the
continuing sale of assets (examples of such businesses would include real estate
development projects and oil and gas wells). (SEE 13 C.F.R. 107.720)
(iv) The proceeds from the sale of the Securities will not be
used substantially for a foreign operation; and at the time of the Closing or
within one year thereafter, no more than 49% of the employees or tangible assets
of the Company will be located outside the United States. This clause (iv) does
not prohibit such proceeds from being used to acquire foreign materials and
equipment or foreign property rights for use or sale in the United States.
11
<PAGE>
(v) If the Company breaches the representation contained in
clauses (ii), (iii) or (iv) of this subsection 3.22 (a) in any material respect,
then in addition to all other remedies available to each SBIC Investor, each
SBIC Investor may demand that the Company immediately repurchase all Securities
purchased by each SBIC Investor hereunder at original cost.
(b) REGULATORY COMPLIANCE COOPERATION.
(i) In the event that a SBIC Investor determines that it has a
Regulatory Problem (as defined in clause (iv) below), the Company and each
Investor agree to use commercially reasonable efforts to take all such actions
as are reasonably requested by the SBIC Investor in order (A) to effectuate and
facilitate any transfer by the SBIC Investor of any Capital Stock of the Company
then held by the SBIC Investor to any person designated by the SBIC Investor (B)
to permit the SBIC Investor (or any member of its Group) to exchange all or any
portion of the voting Capital Stock of the Company then held by such person on a
share-for-share basis for shares of a class of non-voting Capital Stock of the
Company, which non-voting Capital Stock shall be identical in all respects to
such voting Capital Stock, except that such new Capital Stock shall be
non-voting and shall be convertible into voting Capital Stock on such reasonable
(and substantially equivalent terms to the Capital Stock now held) as are
requested by the SBIC Investor in light of regulatory considerations then
prevailing, and (C) to continue and preserve the respective allocation of the
voting interests with respect to the Company provided for in this Agreement
and/or arising out of the SBIC Investor's ownership of the voting Capital Stock
of the Company. Any such transferee shall agree to be bound by the terms of this
Agreement. Such actions may include, but shall not necessarily be limited to:
(A) entering into such additional agreements as are reasonably
requested by the SBIC Investor to permit any person(s) designated
by the SBIC Investor to exercise any voting power which is
relinquished by the SBIC Investor upon any exchange of voting
Capital Stock for non-voting Capital Stock of the Company; and
(B) entering into such additional agreements, adopting such
amendments to the Certificate of Incorporation and By-Laws of the
Company and taking such additional actions as are reasonably
requested by the SBIC Investor in order to effectuate the intent
of the foregoing.
If the SBIC Investor elects to transfer Capital Stock of the Company to a
Regulated Holder (as defined below) in order to avoid a Regulatory Problem, the
Company shall enter into such agreements with such Regulated Holder as it may
reasonably request in order to assist such Regulated Holder in complying with
applicable laws, rules and regulations to which it is subject. Such agreements
may include restrictions on the redemption, repurchase or retirement of Capital
Stock of the Company that would result or be reasonably expected to result in
such Regulated Holder holding more voting securities or total securities (equity
and debt) than it is permitted to hold under such regulations.
(ii) In the event the SBIC Investor has the right to acquire
any of the Company's Capital Stock (as the result of Section 5 hereof or
otherwise), at the SBIC Investor's request the Company will offer to sell to the
SBIC Investor non-voting Capital Stock (or, if the Company is not the proposed
seller, will arrange for the exchange of any voting Capital Stock for
12
<PAGE>
non-voting Capital Stock immediately prior to or simultaneous with such sale) on
the same terms as would have existed had the SBIC Investor acquired the Capital
Stock so offered and immediately requested its exchange for non-voting Capital
Stock pursuant to clause (i) above.
(iii) In the event that any subsidiary of the Company ever
offers to sell any of its Capital Stock to the SBIC Investor, then the Company
will cause such subsidiary to enter into agreements with the SBIC Investor
substantially similar to this subsection (b) and subsection (c) below.
(iv) The Company shall grant to any subsequent holder of
Capital Stock originally acquired by the SBIC Investor (a "SUBSEQUENT
PURCHASER"), upon such person's request, the same rights granted to the SBIC
Investor pursuant to this subsection (b) and subsection (c) below.
(c) INFORMATION RIGHTS AND RELATED COVENANTS.
(i) Within 75 days after the Closing, upon request of a SBIC
Investor and the furnishing by such SBIC Investor of an appropriate form
therefor, the Company shall provide to such SBIC Investor a certificate of its
chief financial officer (A) verifying (and describing in reasonable detail) the
use of the proceeds of the SBIC Investor's financing hereunder and (B)
certifying compliance by the Company with the provisions of this Agreement. In
addition to any other rights granted hereunder, the Company shall provide each
SBIC Investor, any Affiliate of each SBIC Investor and the SBA access to its
books and records for the purpose of verifying the use of the proceeds of such
person's financing and for all other purposes required by the SBA.
(ii) Upon request of a SBIC Investor and the furnishing by
such SBIC Investor of an appropriate form therefor, after the end of each fiscal
year (but in any event prior to February 28 of each year), the Company shall
provide such SBIC Investor with a written assessment, in form and substance
satisfactory to each SBIC Investor, of the economic impact of each SBIC
Investor's financing under this Agreement, specifying the full-time equivalent
jobs created or retained, the impact of the financing on the Company's business
in terms of expanded revenue and taxes and other appropriate economic benefits,
including, but not limited to, technology development or commercialization,
minority business development, urban or rural business development, expansion of
exports and assistance to manufacturing firms.
(iii) Upon the request of a SBIC Investor, any Affiliate of a
SBIC Investor or any Subsequent Purchaser, the Company will furnish to such
person all information reasonably requested by it in order for it to prepare and
file SBA Form 468 and any other information requested or required by any
governmental agency asserting jurisdiction over such person.
(iv) For a period of one year following the date hereof,
neither the Company nor any subsidiaries thereof will change its business
activity such that the Company would be unable to make the representations
contained in clauses (ii), (iii) or (iv) of Section 3.22(a) and accordingly be
ineligible to receive financial assistance from a "small business investment
company" under the SBIA and the regulations thereunder (within the meanings of
13 C.F.R. 107.720 and 107.760(b)). If the Company breaches this covenant, then,
in addition to all other remedies available
13
<PAGE>
to a SBIC Investor, a SBIC Investor may demand that the Company immediately
repurchase all Securities acquired by a SBIC Investor at original cost.
(v) The Company will at all times comply with the
non-discrimination requirements of 13 C.F.R., Parts 112, 113 and 117.
3.23 EMPLOYEES. The Company is not aware that any executive or key
employee of the Company or any group of employees of the Company has any plans
to terminate employment with the Company.
4. REPRESENTATIONS AND WARRANTIES OF THE INVESTORS. The parties hereto
acknowledge that each Investor (a) is making representations and warranties in
this Agreement only with respect to such Investor and (b) shall be liable only
for representations and warranties made with respect to such Investor and not
for any representations and warranties made with respect to any other Investor.
Therefore, giving effect to the provisions set forth in the immediately
preceding sentence, each of the Investors, severally and not jointly, hereby
represents and warrants to the Company as follows:
4.1 AUTHORITY, EXECUTION AND DELIVERY. Such Investor, if a
corporation, partnership or trust, has taken all corporate and other action or
taken all action under applicable partnership and other agreements and
applicable laws, as the case may be, necessary to authorize the execution and
delivery of the Transaction Documents to which it is a party. Such Investor, if
a corporation, has all necessary corporate power and authority to execute and
deliver the Transaction Documents to which it is a party and to perform all of
the terms and conditions herein and therein which are required to be performed
by such Investor. Such Investor, if a partnership, trust or an individual, has
all necessary power and authority, to execute and deliver the Transaction
Documents to which it is a party and to perform all of the terms and conditions
herein and therein which are required to be performed by such Investor. The
Transaction Documents to which such Investor is a party have been duly and
validly executed and delivered by such Investor and constitute the legal, valid
and binding obligations of such Investor, enforceable in accordance with their
respective terms, except as such enforceability may be limited by or subject to
any bankruptcy, insolvency, reorganization, moratorium or similar laws affecting
the enforcement of creditors' rights generally, and subject to general
principles of equity.
4.2 NO CONFLICT OR VIOLATION. Neither the execution and delivery
of the Transaction Documents to which such Investor is a party nor the
fulfillment of the terms hereof or thereof will conflict with or constitute a
breach of, or a default under, the organization documents of such Investor (if
the Investor is a corporation, partnership, trust or other entity) or any other
material Contract to which such Investor is a party or by which such Investor is
bound, or result in the creation of any lien, charge or encumbrance on any of
the business, assets or property of such Investor. The execution and delivery of
this Agreement and the purchase of the Securities by such Investor will not
violate any laws, rules, decisions or orders to which such Investor is subject.
4.3 INVESTMENT REPRESENTATIONS. The Investor is acquiring the
Securities for the Investor's own account, for investment, and not with a view
to, or for sale in connection with, the distribution thereof or of any interest
therein, in violation of state or federal law. The Investor is an accredited
investor as such term is defined in Rule 501(a) promulgated under the Securities
Act. The Investor has adequate net worth and means of providing for its current
needs and contingencies and
14
<PAGE>
is able to sustain a complete loss of the investment in the Securities and has
no need for liquidity in such investment. The Investor, itself or through its
officers, employees or agents, has sufficient knowledge and experience in
financial and business matters to be capable of evaluating the merits and risks
of an investment such as an investment in the Securities, and the Investor,
either alone or through its officers, employees or agents, has evaluated the
merits and risks of the investment in the Securities.
4.4 TRANSFERS.
(a) GENERAL. The Investors understand that the Securities have
not been registered under the Securities Act, and that the Securities may not be
sold, transferred, assigned or otherwise disposed of (any of the foregoing, a
"TRANSFER") except pursuant to (x) an effective registration statement under the
Securities Act, or (y) an available exemption from registration under the
Securities Act permitting such disposition of securities and, if requested by
the Company, an opinion of counsel, which opinion of counsel shall be reasonably
satisfactory to counsel for the Company, that an exemption from such
registration is available. In the event any of the Investors desires to Transfer
any of the Securities or any interest therein (other than pursuant to an
effective registration statement under the Securities Act or a sale pursuant to
Rule 144 promulgated under the Securities Act, including Rule 144(k) or any
successor thereto (any of the foregoing, a "PUBLIC SALE"); such Investor must
give the Company prior written notice of such proposed Transfer including the
name and address of the proposed transferee. Prior to any such proposed Transfer
(other than in a Public Sale), and as a condition thereto, such Investor will
deliver to the Company (i) an investment covenant signed by the proposed
transferee, (ii) an agreement by such transferee to the restrictive investment
legend set forth in Section 4.5 hereof on the certificate or certificates
representing the Securities acquired by such transferee, and (iii) an agreement
by the transferee to be subject to this Section 4.4, the Voting Agreement and
the Registration Rights Agreement to the same extent as if such transferee were
originally a signatory to this Agreement, the Voting Agreement and the
Registration Rights Agreement. Except as restricted hereby, the Securities may
be transferred by any Investor in whole or in part at any time or from time to
time. Any Transfer of the Securities attempted contrary to the provisions of
this Agreement, or any levy of execution, attachment or other process attempted
upon the Securities, shall be null and void and without effect.
(b) CERTAIN PERMITTED TRANSFERS.
(i) MEMBERS OF GROUP. Notwithstanding any provisions to the
contrary contained in subsection (a) above, (i) in the case of a Transfer by an
Investor to a member of such Investor's Group, no opinion of counsel shall be
necessary, provided that the transferee agrees in writing to be subject to this
Section 4.4, the Voting Agreement and the Registration Rights Agreement to the
same extent as if such transferee were originally a signatory to this Agreement,
the Voting Agreement and the Registration Rights Agreement, and (ii) in the case
of any Investor that is a partnership, no opinion of counsel shall be necessary
for a Transfer by such Investor to a partner of such Investor, or a retired
partner of such Investor who retires after the date hereof or the estate of any
Investor, or the estate of any such partner or retired partner if, with respect
to such Transfer by a partnership, such Transfer is made in accordance with the
partnership agreement of such partnership, and the transferee agrees in writing
to be subject to the terms of this Section 4.4, the Voting Agreement and the
Registration Rights Agreement to the same extent as if such transferee
15
<PAGE>
were originally a signatory to this Agreement, the Voting Agreement and the
Registration Rights Agreement.
(ii) METHOD OF TRANSFER. Upon surrender of any certificate
representing the Securities to the Company or at the office of its stock
transfer agent, if any, with assignment documentation duly executed and, upon
compliance with the foregoing provisions, the Company shall, without charge,
execute and deliver a new certificate representing such Securities in the name
of the assignee named in such instrument of assignment, and the old certificate
representing such Securities shall promptly be canceled.
4.5 LEGEND. So long as the Securities received by the Investors
remain subject to the restrictions set forth in this Agreement, each instrument
or certificate representing any of the Securities shall bear a legend
substantially as follows:
THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY
APPLICABLE STATE LAW, AND NO INTEREST THEREIN MAY BE SOLD OR
OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION, WITHOUT
AN OPINION OF LEGAL COUNSEL FOR THE HOLDER THAT SUCH REGISTRATION
IS NOT REQUIRED, WHICH OPINION OF COUNSEL SHALL BE REASONABLY
SATISFACTORY TO THE ISSUER OF SUCH SECURITIES (THE "COMPANY"). THE
SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN
TRANSFER AND VOTING RESTRICTIONS PURSUANT TO A SECURITIES PURCHASE
AGREEMENT AND A VOTING AGREEMENT EACH DATED AS OF NOVEMBER 18,
1996, AMONG THE COMPANY AND CERTAIN OF THE COMPANY'S STOCKHOLDERS.
COPIES OF SUCH SECURITIES PURCHASE AGREEMENT AND SUCH VOTING
AGREEMENT WILL BE FURNISHED WITHOUT CHARGE BY THE COMPANY TO THE
HOLDER HEREOF UPON WRITTEN REQUEST.
The Company and any transfer agent acting on behalf of the Company may maintain
on the Company's register for the Securities appropriate "stop transfer"
notations with respect to the securities.
4.6 INFORMATION REGARDING COMPANY. The Investor has received from
the Company a copy of the Memorandum and is aware of the risks related to an
investment in the Securities. The Investor has obtained such further information
and has had the opportunity to make any further investigation and inquiry
concerning the Company as it has deemed necessary in order to verify and update
the information contained in the Memorandum. All such questions have been
answered to the full satisfaction of the Investor. The Investor further
acknowledges that there can be
16
<PAGE>
no assurance that the Company will be successful in the implementation of its
business and that a total loss of the investment in the Securities is possible.
4.7 NO BROKER OR FINDER. The Investor has engaged no broker or
finder in connection with this Agreement or the transactions contemplated
hereby.
4.8 PRINCIPAL OFFICE OR DOMICILE. The principal office of the
Investor (if the Investor is a corporation, partnership, trust or other entity)
or domicile of the Investor (if the Investor is an individual) is set forth on
SCHEDULE 4.8 - DOMICILE annexed hereto.
5. RIGHT OF FIRST REFUSAL.
5.1 FIRST OFFER.
(a) So long as any shares of the Series B Preferred Stock are
outstanding, if the Company proposes to issue any shares of Common Stock or any
security convertible into or exchangeable for shares of Common Stock, or any
unit of securities which includes shares of Common Stock or any security
convertible into or exchangeable or exercisable for shares of Common Stock (in
the case of securities convertible into or exchangeable or exercisable for
shares of Common Stock, whether or not so convertible or exchangeable or
exercisable only upon payment of additional consideration), in each case in
connection with a financing by the Company, subject to Section 5.5 hereof (an
"OFFERING"), then the Company shall prior thereto or simultaneously therewith
offer to each Investor a percentage of the securities being issued in the
Offering (the "OFFERING SECURITIES") equal to such Investor's then percentage
ownership of the aggregate of the Underlying Common Stock and the Common Stock
(such Investor's "PERCENTAGE SHARE"). Such offer shall be made by written notice
setting forth the quantity and description of the security proposed to be
issued, the price to be received in exchange therefor and the proposed date,
time and place of the closing of the Offering (the "OFFERING NOTICE"). The
Offering Notice shall be delivered by hand or by first-class, certified or
overnight mail, postage prepaid, or by telecopier, by the Company to each
Investor.
(b) Each such Investor shall thereupon be entitled, for a period
ending thirty (30) days after the date of the Offering Notice (the "ELECTION
PERIOD"), to elect to purchase, at the price and upon the terms set forth in the
Offering Notice, all or a portion of such Investor's Percentage Share of the
Offering Securities by notice to the Company during the Election Period.
(c) Each Investor electing to purchase its Percentage Share of the
Offering Securities pursuant to this Section 5.1 (a "PARTICIPATING INVESTOR")
shall, concurrently with the closing of any such Offering, deliver to the
Company an official bank or certified check for the appropriate amount to the
Company by hand delivery or by first-class, certified or overnight mail, postage
prepaid addressed to the Company's principal office (or at such other place as
the Company may designate at least ten (10) days prior to the closing of such
Offering); and simultaneously therewith the Company shall issue and deliver to
each Participating Investor certificates representing the Offering Securities
being purchased by such Participating Investor. The Company covenants and agrees
that all Offering Securities will, upon issuance and payment therefor, be duly
and validly issued and outstanding, fully paid and non-assessable and free from
all taxes, liens, and charges with respect to the issue thereof.
17
<PAGE>
5.2 OVERSUBSCRIPTION AS TO OTHER INVESTORS. If any Investor has
not elected to purchase all of such Investor's Percentage Share of the Offering
Securities pursuant to Section 5.1 (such Investor, the "NONPARTICIPATING
INVESTOR"), the Company shall so advise the Participating Investors by providing
them with written notice, transmitted as aforesaid within five (5) days after
the expiration of the Election Period. Each Participating Investor shall
thereupon for a period of seven (7) days from the date of such notice be
entitled to elect to purchase all or a portion of the Nonparticipating
Investors' Percentage Share of the Offering Securities (the "AVAILABLE OFFERING
SECURITIES"); PROVIDED, HOWEVER, that to the extent that more than one
Participating Investor desires to purchase a portion of the Available Offering
Securities which exceeds such Participating Investor's pro rata share of the
Available Offering Securities (based on the Underlying Common Stock owned by all
Participating Investors) (the "ADJUSTED PRO RATA SHARE"), the amount of such
Available Offering Securities which each such Participating Investor shall be
entitled to purchase shall be reduced to such Participating Investor's Adjusted
Pro Rata Share. The rights granted by this Section 5.2 shall be exercisable in
the manner described in Section 5.1. Any Offering Securities not so purchased
may be sold at the closing of any Offering to Persons other than Investors for
the price and upon the terms set forth in the Offering Notice.
5.3 OVERSUBSCRIPTION AS TO OTHER PERSONS. In addition to the
rights granted under Section 5.2, if any holder of capital stock of the Company
who is entitled to exercise rights comparable to those granted to the Investors
under Section 5.1 does not exercise such rights in connection with any such
Offering, in whole, after being notified of the availability of such rights, the
Company shall so advise the Participating Investors by providing them with
written notice, transmitted as aforesaid within five (5) days after the first to
occur of (i) being advised of the failure of such other holders to exercise such
rights or (ii) the expiration of any period in which such rights could have been
exercised. Each Participating Investor shall thereupon for a period of seven (7)
days from the date of such notice be entitled to elect to purchase some or all
of the Offering Securities which could have been purchased by such other holders
who did not exercise such rights; PROVIDED, HOWEVER, that to the extent that
more than one of such Participating Investors exercising its rights granted
under this Section 5.3 desires to purchase Offering Securities exceeding such
Participating Investor's pro rata share (based on the aggregate number of
securities held by all Participating Investors exercising their purchase rights
under this Section 5.3) ("EXCESS ADDITIONAL SECURITIES"), the amount of such
Excess Additional Securities which each such Participating Investor shall be
entitled to purchase shall be reduced PRO RATA in accordance with that
proportion as the number of securities held by such Investor then bears to the
total number of securities then held by all such Investors desiring to purchase
Excess Additional Securities pursuant to this Section 5.3. The rights granted by
this Section 5.3 shall be exercisable in the manner described in Section 5.1.
Any securities not so purchased may be sold at the closing of any Offering to
Persons other than Investors who are entitled to purchase securities in the
Offering for the price and upon the terms set forth in the notice first sent
pursuant to said Section 5.1.
5.4 NO FRACTIONS. Notwithstanding the foregoing provisions, any
purchase of securities pursuant to Sections 5.1, 5.2 or 5.3 may be made by a
Participating Investor only of full shares or units and not of fractions of
shares or units, any fraction to be rounded up to the nearest whole shares or
unit and a Non-Participating Investor shall not be entitled to exercise any
rights pursuant to such Sections from and after the date on which it becomes a
Non-Participating Investor.
18
<PAGE>
5.5 NON-APPLICABILITY. The foregoing provisions of this Section 5
shall not apply to (a) Common Stock issued in an offering registered under the
Securities Act or to the public through a broker, dealer or market maker
pursuant to the provisions of Rule 144 adopted under the Securities Act, (b)
Common Stock issued by the Company as a dividend on Preferred Stock or upon any
subdivision or split-up of the outstanding shares of any capital stock of the
Company or any recapitalization thereof, or upon conversion of any shares of
Preferred Stock, (c) Common Stock issued pursuant to any option or warrants or
other rights that are outstanding as of the Closing identified on SCHEDULE 3.2 -
CAPITAL STOCK, (d) Common Stock of the Company issued in connection with a
Board-approved acquisition of a business by the Company as a result of which the
Company owns in excess of 50% of the voting power of such business, (e) Common
Stock issued to employees, officers, consultants, directors or vendors of the
Company or pursuant to any Board-approved employee, officer, consultant or
director benefit plan including, without limitation, any Board- approved stock
option plan, and (f) Common Stock issued to (1) banks, savings and loan
associations, equipment lessors or similar lending institutions in connection
with such entities providing Board-approved credit facilities or equipment
financings to the Company or (2) any party to any technology transfer agreement,
distribution agreement, marketing agreement or any other agreement similar
thereto, with the Company, as approved by the Board.
6. COVENANTS OF THE COMPANY. So long as at least 25% of the Underlying
Common Stock remains outstanding or, if earlier, until the sixth anniversary of
the date of the Closing:
6.1 USE OF PROCEEDS. The proceeds of the sale of the Series B
Preferred Stock to be purchased pursuant to this Agreement shall be used solely
as set forth on SCHEDULE 6.1 - USE OF PROCEEDS.
6.2 RESERVATION OF SHARES. The Company shall reserve and keep
available out of its authorized but unissued Common Stock the number of shares
of Common Stock required for issuance upon (a) the conversion of all of the
Series B Preferred Stock and (b) the exercise of the Warrants (including in each
case, any additional shares of Common Stock that may become so issuable by
reason of the operation of anti-dilution provisions contained in the Certificate
of Designation or the Warrants, respectively).
6.3 CORPORATE EXISTENCE; COMPLIANCE WITH LAW. The Company will
maintain, preserve and renew its corporate existence and all material permits
necessary to the conduct of the business of the Company as currently conducted
and will comply, in all material respects, with all applicable statutes, rules,
regulations and orders of all governmental bodies with respect to the conduct of
its business and the ownership of its properties.
6.4 ENVIRONMENTAL MATTERS. The Company shall not discharge, place,
release, spill or dispose of any Hazardous Materials or any other pollutants or
effluents upon any properties leased by the Company or elsewhere (including, but
not limited to, underground injection of such substances) other than in
compliance with the Applicable Environmental Laws and the Company shall not
discharge into the air any emission which would require a permit under the Clean
Air Act or its state counterparts or any other Environmental Laws unless any and
all such permit(s) are obtained prior to any discharge.
19
<PAGE>
6.5 SMALL BUSINESS STOCK. The Company will take all actions
reasonably necessary to ensure that the Underlying Common Stock shall constitute
small business stock within the meaning of Section 1202(c) of the Code, and will
make all filings required under Section 1202(d)(1)(C) of the Code and any
related Treasury Regulations in connection therewith.
6.6 OPERATING COMPANY. The Company shall take all actions
necessary to allow it to continue to constitute an Operating Company (as defined
below), or otherwise not to cause any of the underlying assets of the Company or
any of its subsidiaries to be deemed Plan Assets (as defined below) with respect
to any qualified pension plan investor in the Company. For the purposes hereof,
(a) "OPERATING COMPANY" shall mean an "operating company" within the meaning of
Department of Labor Regulation ss.2510.3-101(c) or successor rule or regulation,
as from time to time amended and in effect, and (b) "PLAN ASSETS" shall mean
"plan assets" within the meaning of Department of Labor Regulation
ss.2510.3-101(c) or successor rule or regulation, as from time to time amended
and in effect.
6.7 EMPLOYMENT AND NON-COMPETITION AGREEMENTS. The Company shall
not, without the prior consent of the majority of the Company's Board of
Directors, amend any of (i) the Employment Agreement dated January 28, 1992
between the Company and Paul M. Frison, (ii) the Confidentiality, Inventions and
Discoveries and Non-Competition Agreement dated as of January 28, 1992 between
the Company and Mr. Frison, (iii) the Employment Agreement dated January 28,
1992 between the Company and Stephen A. Livesey, and (iv) the Confidentiality,
Inventions and Discoveries and Non-Competition Agreement dated January 28, 1992
between the Company and Dr. Livesey, and shall enforce each of the foregoing
agreements to the fullest extent permitted by law.
6.8 FINANCIAL AND OTHER INFORMATION. The Company shall provide the
following information to each Investor holding at least 30% of the Underlying
Common Stock as of the Closing (so long as such Investor holds any Underlying
Common Stock):
(a) ANNUAL STATEMENTS. As soon as practicable and in any event
within 100 calendar days after the close of each fiscal year of the Company,
copies of (A) the balance sheet of the Company as of the end of such fiscal
year, (B) statements of operations of the Company for such fiscal year, and (C)
statements of changes in cash flows of the Company for such fiscal year, setting
forth in each case in comparative form the corresponding figures of the previous
annual period and the most recent Budget (as defined in clause (d) below), all
in reasonable detail, prepared in accordance with generally accepted accounting
principles ("GAAP") consistently applied throughout the periods involved and
audited and reported on (except for the comparison to the most recent Budget),
by Arthur Andersen LLP or another firm of independent certified public
accountants of recognized national standing.
(b) QUARTERLY STATEMENTS. As soon as practicable, and in any
event within 55 calendar days after the end of each of the first three fiscal
quarters of the Company, copies of an unaudited balance sheet of the Company as
at the end of each such fiscal quarter and unaudited statements of operations,
and changes in cash flows for such fiscal quarter, setting forth in each case in
comparative form corresponding figures for the preceding year's respective
fiscal quarter and for the Budget, all in reasonable detail and (except for
corresponding figures for the Budget) in the form
20
<PAGE>
in which the Company currently provides such information to its stockholders,
prepared in accordance with GAAP consistently applied throughout the period
involved and certified as being correct and complete and fairly presenting the
results of operations of the Company for the quarter indicated, subject to
year-end audit adjustment, by the principal financial officer of the Company and
in the form in which the Company currently provides such information to its
directors.
(c) MONTHLY STATEMENTS. For each calendar month, as soon as
practicable and in any event within 30 calendar days after the close of each
such month, copies of (A)(1) the balance sheet of the Company as of the end of
such month, (2) statements of operations of the Company for such month, and (3)
statements of changes in cash flows of the Company for such month setting forth
in each case in comparative form the corresponding figures for the preceding
month and for the Budget, for the year to date and for the comparable periods in
the preceding year, all in reasonable detail and in the form in which the
Company currently provides such information to its directors, prepared in
accordance with generally accepted accounting principles consistently applied
throughout the periods involved and certified as being correct and complete and
fairly presenting the results of operations of the Company for the month
indicated, subject to year-end audit adjustment, by the principal financial
officer of the Company and (B) a certificate of the principal financial officer
of the Company giving a narrative analysis of operations and trends in the
business of the Company during such month and in the form in which the Company
currently provides such information to its directors.
(d) BUDGET. As soon as practicable and in any event no later
than the end of each fiscal year of the Company, a proposed annual operating
budget for the Company for the succeeding fiscal year, containing forecasts of
profit and loss and cash flow with monthly and quarterly breakdowns and
management's reasonably estimated projections of indebtedness and commitments
for the succeeding fiscal year (the "BUDGET").
(e) MISCELLANEOUS DOCUMENTS. Promptly upon, and in any event
within ten (10) calendar days after transmission thereof, a copy of all reports,
proxy statements, financial statements, management letters and other materials
(A) delivered or sent by the Company to its stockholders, (B) filed by the
Company with the Securities and Exchange Commission or with any securities
exchange on which any of the securities are then listed, and copies of all press
releases and other statements made available generally by the Company to the
public concerning material developments in the Company's and the subsidiaries'
businesses; or (C) given to the Company by its independent accountants (and not
otherwise contained in materials provided hereunder) to the extent such
information concerns significant aspects of the Company.
If for any period the Company shall have any subsidiary or subsidiaries whose
accounts are consolidated with those of the Company, then the financial
statements delivered for such period pursuant to the foregoing clauses (i) and
(ii) shall be the consolidated and consolidating financial statements of the
Company and all such consolidated subsidiaries and, if the financial statements
of such subsidiary or subsidiaries are not consolidated with those of the
Company, separate financial statements for such subsidiary or subsidiaries shall
be provided.
(f) ENVIRONMENTAL MATTERS. Written notification as to any pending
or threatened claim, demand or action by any governmental agency or authority or
other Person relating
21
<PAGE>
to any Hazardous Materials affecting any properties leased by the Company of
which it has knowledge promptly after the receipt of such knowledge.
(g) LITIGATION. Written notification as to any material
pending or threatened claim, demand or action by any governmental agency or
authority or other Person promptly after the receipt of such knowledge.
(h) BUSINESS RECORDS. During normal business hours, (a) all
business records of the Company for inspection, and (b) the officers, employees
and public accountants of the Company for discussions concerning the business,
affairs and finances of the Company.
6.9 PROTECTIVE PROVISIONS. So long as the Company is required to
deliver financial and other information to certain Investors pursuant to Section
6.8 hereof, the Company shall not select a lead managing underwriter for a
public offering of Common Stock or other securities convertible into Common
Stock without the prior approval of the Board of Directors of the Company which
approval shall include the approval of a majority of the Investor Directors (as
defined in the Voting Agreement).
6.10LIVESEY KEY-MAN LIFE INSURANCE. As soon as reasonably
practicable after the Closing, the Company shall cause the death benefit of the
Key Man Policy (as defined in Section 7.9) on the life of Dr. Livesey to be
increased from $1.0 million to $3.0 million (or, alternatively the Company shall
obtain an additional such policy with a death benefit of $2.0 million), naming
the Company as sole beneficiary, from an insurer reasonably acceptable to the
holders of a majority of the Series B Preferred Stock.
7. CONDITIONS TO OBLIGATIONS OF THE INVESTORS. The Investors'
obligation to purchase the Securities shall be subject to the satisfaction of
the following conditions, any of which may be waived in writing:
7.1 DELIVERY OF SECURITIES. The Company shall have delivered to
each Investor the number of Securities set forth opposite such Investor's name
on SCHEDULE 1.
7.2 REPRESENTATIONS AND WARRANTIES TRUE AT CLOSING: NON-OCCURRENCE
OF DEFAULT. The representations and warranties contained in Section 3 hereof
shall be true immediately prior to the Closing, there shall exist no condition,
event or fact constituting (or which, with notice or passage of time or both
would constitute) a default in the observance of any of the Company's
undertakings or covenants hereunder or pursuant to the Certificate of
Designation, and all conditions precedent to the Closing to be performed by the
Company shall have been complied with; and the Chief Executive Officer and the
Chief Financial Officer of the Company shall deliver to the Investors at the
Closing a certificate to such effect, executed by them.
7.3 CORPORATE PROCEEDINGS. All corporate and other proceedings
required to be taken in connection with the transactions contemplated hereby and
by the Certificate of Designation (including, without limitation, the valid
adoption and filing of the Certificate of Designation, the consent of the
majority of the holders of the Series A Preferred Stock to the authorization and
issuance of the Series B Preferred Stock and the waivers of holders of
Conflicting Registration
22
<PAGE>
Rights), and all documents incident hereto and thereto, shall be satisfactory in
form and substance to the Investors, and the Investors shall have received all
such counterpart originals or certified or other copies of such documents as
they shall reasonably request.
7.4 CERTIFICATE OF DESIGNATION. The Board shall have adopted the
resolutions embodied in the Certificate of Designation; and the Certificate of
Designation shall have been filed with the Secretary of State of the State of
Delaware, and its terms shall have become effective, and the Investors shall
have received a copy of the Certificate of Designation, certified by the
Secretary of State of the State of Delaware. The Certificate of Designation
shall be in full force and effect as of the Closing and shall not have been
amended or modified.
7.5 GOOD STANDING CERTIFICATES. The Investors shall have received
(a) a copy of the Certificate of Incorporation certified as a recent date by the
Secretary of State of Delaware, and (b) certificates of the Secretary of State
of the State of Delaware with respect to the Company, and of each state in which
the Company is qualified to do business as a foreign corporation as of a recent
date showing the Company to be validly existing or qualified as a foreign
corporation in its states of existence and qualification, as the case may be,
and in good standing.
7.6 SECRETARY'S CERTIFICATE. The Investors shall have received a
Certificate of the Secretary of the Company certifying that (a) no document has
been filed relating to or affecting the Certificate of Incorporation of the
Company after the date of the Certificate of the Secretary of the State of
Delaware furnished pursuant to Section 7.4 except the Certificate of
Designation, (b) attached to the Certificate is a true and complete copy of
By-Laws of the Company, as in full force and effect at the Closing Date and (c)
the names and true signatures of each officer of the Company who has been
authorized to execute and deliver this Agreement and any other document to be
delivered by the Company at the Closing.
7.7 VOTING AGREEMENT. The Company and the Investors shall have
entered into the Voting Agreement, in the form of EXHIBIT C, and a copy of the
signed Voting Agreement shall have been delivered to the Investors.
7.8 REGISTRATION RIGHTS AGREEMENT. The Company and the Investors
shall have entered into the Registration Rights Agreement, in the form of
EXHIBIT D, and a copy of the signed Registration Rights Agreement shall have
been delivered to the Investors.
7.9 KEY-MAN LIFE INSURANCE. The Company shall have obtained key
man life insurance policies (the "KEY-MAN POLICIES") on the lives of Mr. Frison
and Dr. Livesey with death benefits of $1.0 million and $1.0 million,
respectively, each naming the Company as the sole beneficiary, from an insurer
of recognized responsibility; and upon completion of the Closing, the Key-Man
Policies shall be effective, in full force and unencumbered, and all premiums,
fees or charges which are due thereon shall have been paid.
7.10 OPINION OF COUNSEL. The Investors shall have received from
Fulbright & Jaworski L.L.P., counsel to the Company, an opinion of counsel
substantially in the form of EXHIBIT E attached hereto and made a part hereof.
23
<PAGE>
7.11 SMALL BUSINESS ADMINISTRATION FORMS. Each SBIC Investor shall
have received SBA Forms 480, 652 and Part A of Form 1031 properly completed and
executed from the Company.
7.12 LITIGATION. No action or proceeding shall be pending or, to
the knowledge of the Company, threatened, by or before any person, court or
other governmental body to restrain or prohibit or to recover damages in respect
of the consummation of any or all of the transactions contemplated by the
Transaction Documents, nor shall there be any other action or proceeding pending
or threatened which action, or other proceeding in the reasonable opinion of the
Investors, may result in a decision, ruling, or finding that individually or in
the aggregate has or may reasonably be expected to have a Material Adverse
Effect or a material adverse effect on (a) the validity or enforceability of
this Agreement, or (b) the Company's ability to perform its obligations under
this Agreement.
7.13 APPROVALS AND CONSENTS. All licenses, authorizations,
consents, orders and regulatory approvals of governmental bodies necessary in
the good faith judgment of the Investors for the consummation of any or all of
the transactions contemplated hereby shall have been obtained on terms
satisfactory to the Investors and shall be in full force and effect; and
consents or waivers from parties other than governmental bodies that are
required in connection with the consummation of any or all of the transactions
contemplated hereby shall have been obtained on terms satisfactory to the
Investors and shall be in full force and effect and signed copies thereof shall
have been delivered to the Investors.
7.14 COMPLIANCE EVIDENCE. The Investors shall have received such
certificates, opinions, documents and information as they may reasonably request
in order to establish satisfaction of the conditions set forth in this Section
7.
7.15 PROCEEDINGS SATISFACTORY. All certificates, opinions and
other documents to be delivered by the Company and all other matters to be
accomplished prior to or at the Closing shall be satisfactory in the reasonable
judgment of the Investors and their counsel.
7.16 DUE DILIGENCE SATISFACTORY. The Investors shall have
completed due diligence satisfactory to them with respect to the Company
including, without limitation, due diligence relating to regulatory compliance
and the Company's Proprietary Rights.
8. CONDITIONS TO OBLIGATIONS OF COMPANY. The Company's obligation to
issue the Securities shall be subject to the satisfaction of the following
conditions, any of which may be waived in writing:
8.1 DELIVERY OF PURCHASE PRICE. Each Investor shall have delivered
to the Company that portion of the Purchase Price set forth opposite such
Investor's name on SCHEDULE 1 annexed hereto.
8.2 REPRESENTATIONS AND WARRANTIES TRUE AT CLOSING; NON-OCCURRENCE
OF DEFAULT. The representations and warranties contained in Section 4 hereof
shall be true upon completion of the Closing, there shall exist no condition,
event or fact constituting, or which, with notice or passage of time or both
would constitute, a default in the observance of any of such Investor's
undertakings
24
<PAGE>
hereunder, and all conditions precedent to the Closing to be performed by the
Investors shall have been complied with.
8.3 PROCEEDINGS AND DOCUMENTS. All legal and corporate proceedings
in connection with the transactions contemplated by this Agreement shall be in
form and substance reasonably satisfactory to the Company and its counsel, and
the Company shall have received all such counterpart originals or certified or
other copies of such documents and proceedings in connection with such
transactions as the Company reasonably requests.
9. INDEMNIFICATION. The Company shall indemnify and hold harmless each
Investor, its directors, partners, any member of its Group and each other person
which controls (within the meaning of the Securities Act) such Investor or any
of its directors or partners (any of the foregoing, a "COVERED PERSON") of,
against and from any losses, claims, damages, liabilities or expenses ("LOSSES")
insofar as such Losses (or actions in respect thereof) arise out of or are based
upon (a) the falsity or incorrectness as of the Closing of any representation or
warranty of the Company contained in or made pursuant to Section 3 hereof, (b) a
default in the observance of any of the Company's undertakings or covenants
under any Transaction Document or pursuant to the Certificate of Designation,
(c) any action, claim or proceeding, asserted or unasserted, by any stockholder
or creditor of the Company, or (d) the use, generation, storage, release,
threatened release, discharge, disposal, transport, handling, treatment,
removal, recovery or presence of Hazardous Materials on, under or about any
properties leased by the Company by any person during the period that the
Company was the tenant of any properties leased by the Company or which occurred
prior to such time and was otherwise actually known by, or should have been
known by, the Company. The obligation of the Company to indemnify each Covered
Person shall specifically cover and include, without limitation, all fines and
penalties imposed by federal, state or local authorities, costs of removing or
neutralizing the Hazardous Materials, injury to the property adjoining any
properties leased by the Company, injury to persons living or working on or
about any properties leased by the Company or adjoining or otherwise affecting
any such property, and all other indirect or consequential damages incurred by
each Covered Person. The Company shall also pay all attorney's and accountant's
fees and costs and court costs incurred by any Covered Person in enforcing the
indemnification provided for herein. Notwithstanding the foregoing, the Company
expressly agrees and acknowledges that the right of indemnification granted to
each Covered Person herein shall not be deemed to be the exclusive remedy
available to such Covered Person for any of the matters described herein.
10. EXPENSES. The Company agrees, in the event the transactions
contemplated hereby are consummated, to pay, and save the Investors harmless
against liability for the payment of, (a) their reasonable out-of-pocket costs,
accounting fees, and legal fees arising in connection with the negotiation,
execution and Closing of the transactions contemplated hereby, including without
limitation (i) expenses relating to the Investors' due diligence investigation
with respect to the transactions contemplated hereby and (ii) expenses of
counsel for the Investors, (b) stamp and other transfer taxes which may be
payable in respect of the execution and delivery of this Agreement or the
issuance of the Securities and the Common Stock issuable on conversion or
exercise thereof, and (c) fees and expenses (including, without limitation,
reasonable attorneys' fees) incurred in respect of the enforcement by the
Investors or the holders of the Securities of the rights granted to the
Investors or the holders of the Securities under the Transaction Documents or
the Certificate of Designation.
25
<PAGE>
11. CONFIDENTIALITY. No Investor shall disclose any Confidential
Information (as defined below); provided that, notwithstanding the foregoing, no
Investor shall be prohibited from disclosing to any Person information that (i)
is obtainable from a third party who is not obligated to maintain such
information's confidentiality, (ii) is or becomes generally available to the
public other than as a result of a breach by an Investor of its obligations
under this Section 11 or has been published in a form generally available to the
public, (iii) is lawfully in such Investor's possession prior to it being
disclosed to such Investor through the Memorandum or otherwise by the Company,
or (iv) an Investor is legally compelled to disclose. For purposes of this
Section 11, the term "CONFIDENTIAL INFORMATION" means information that is not
generally known to the public and that is developed or obtained by the Company
in connection with its business which is contained in the Memorandum or provided
to any Investor pursuant to the provisions of Sections 4.6 and 6.8 of this
Agreement.
12. CERTAIN DEFINITIONS.
"AFFILIATE" has the meaning set forth in Section 405 of the
Securities Act.
"CAPITAL STOCK" means, with respect to any person, such person's
capital stock or any options, warrants or other securities which are directly or
indirectly convertible into, or exercisable or exchangeable for, such person's
capital stock (whether or not such derivative securities are issued by the
Company). Whenever a reference herein to "CAPITAL STOCK" refers to any
derivative securities, the rights of the SBIC Investor shall apply to such
derivative securities and all underlying securities directly or indirectly
issuable upon conversion, exchange or exercise of such derivative securities.
"CIBC-WG" means CIBC Wood Gundy Ventures, Inc.
"GROUP" shall mean as to (i) an Investor that is a limited
partnership, such Investor with any and all of the limited partnerships now
existing or hereafter arising that are Affiliates, in whole or in part, of one
or more general partners or of one or more general partners of a general partner
of such Investor and any predecessor or successor partnership and any limited
and general partners of any such partnership; (ii) an Investor that is a trust,
such Investor together with any of the beneficiaries, settlors or grantors now
existing or hereafter arising of, or any person under common control with, such
Investor and (iii) as to any other type of Investor, such Investor, together
with the Affiliates of such Investor.
"PERSON" means an individual, a partnership, a corporation,
limited liability company, an association, a joint stock company, a trust, a
joint venture, an unincorporated organization and a governmental entity or any
department, agency or political subdivision thereof.
"REGULATED HOLDER" means any holder of the Company's Capital Stock
that is (or that is a subsidiary of a bank holding company that is) subject to
the various provisions of Regulation Y of the Board of Governors of the Federal
Reserve Systems, 12 C.F.R., Part 225 (or any successor to Regulation Y);
"REGULATORY PROBLEM" means (A) any set of facts or circumstances
wherein it has been asserted by any governmental regulatory agency (or the SBIC
Investor or any Subsequent
26
<PAGE>
Purchaser reasonably believes that there is a significant risk of such
assertion) that such person (or any bank holding company that controls such
person) is not entitled to hold, or exercise any material right with respect to,
all or any portion of the Capital Stock of the Company which such person holds
or (B) when such person and its Affiliates would own, control or have power
(including voting rights) over a greater quantity of Capital Stock of the
Company than is permitted under any law or regulation or any requirement of any
governmental authority applicable to such person or to which such person is
subject.
"SALE" means a sale of all or substantially all of the Company's
assets or a sale of all or substantially all of the Company's outstanding
capital stock (whether by merger, recapitalization, consolidation,
reorganization, combination or otherwise).
"UNDERLYING COMMON STOCK" means (i) the Common Stock issued or
issuable upon conversion of the Series B Preferred Stock or upon exercise of the
Warrants and (ii) any Common Stock issued or issuable with respect to the
securities referred to in clause (i) above by way of stock dividend or stock
split or in connection with a combination of shares, recapitalization, merger,
consolidation or other reorganization. For purposes of this Agreement, any
Person who holds Series B Preferred Stock or any Warrants shall be deemed to the
holder of the Underlying Common Stock obtainable upon conversion of the Series B
Preferred or exercise of the Warrants in connection with the transfer thereof or
otherwise regardless of any restriction or limitation on the conversion of the
Series B Preferred to exercise of the Warrants, such Underlying Common Stock
shall be deemed to be in existence and such person shall be entitled to exercise
the rights of a holder of Underlying Common Stock hereunder. As to any
particular shares of Underlying Common Stock, such shares shall cease to be
Underlying Common Stock when they have been (a) effectively registered under the
Securities Act and disposed of in accordance with the registration statement
covering them, (b) distributed to the public through a broker, dealer or market
maker pursuant to Rule 144 under the Securities Act (or any similar provision
the in force) or (c) repurchased by the Company.
"VECTOR" means Vector Later-Stage Equity Fund, L.P.
13. MISCELLANEOUS.
13.1 GOVERNING LAW; JURISDICTION. THIS AGREEMENT SHALL BE GOVERNED
BY AND CONSTRUED IN ACCORDANCE WITH THE DOMESTIC LAWS OF THE STATE OF NEW YORK
APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED IN THAT STATE WITHOUT GIVING
EFFECT TO ANY CHOICE OR CONFLICT OF LAW PROVISION OR RULE (WHETHER IN THE STATE
OF NEW YORK OR ANY OTHER JURISDICTION) THAT WOULD CAUSE THE APPLICATION OF THE
LAWS OF ANY JURISDICTION OTHER THE STATE OF NEW YORK. THE PARTIES HERETO CONSENT
TO THE JURISDICTION OF THE STATE OF NEW YORK OR STATE OR FEDERAL COURTS LOCATED
THEREIN FOR ALL DISPUTES ARISING UNDER THIS AGREEMENT.
13.2 SURVIVAL. All representations, warranties and covenants
contained in this Agreement or in any Exhibit or Schedule annexed hereto or
certificate delivered in connection herewith shall survive the execution and
delivery of this Agreement and the Closing and any investigation at any time
made by the Investors or on their behalf and shall continue for a period of four
(4) years following the Closing; PROVIDED, HOWEVER, that all representations,
warranties and
27
<PAGE>
covenants relating to Taxes and environmental matters shall survive until the
expiration of the applicable statute of limitations relating thereto.
13.3 NOTICES. All notices, certificates or other communications
hereunder shall be in writing, addressed as follows, and shall be effective (a)
upon receipt if delivered personally or by telecopy (followed by telephonic
confirmation of receipt), (b) three (3) business days after the date of postmark
by the U.S. Postal Service when mailed, by registered or certified mail, return
receipt requested, postage prepaid, or (c) the next business day following
delivery to a reputable overnight courier service:
If to the Company, to:
LifeCell Corporation
3606 Research Forest Drive
The Woodlands, Texas 77381
Attention: President
Tel. No.: (713) 367-5368
Fax No.: (713) 363-3360
with a copy to:
Fulbright & Jaworski L.L.P.
1301 McKinney, Suite 5100
Houston, Texas 77010-3095
Attention: Robert E. Wilson, Esq.
Tel. No.: (713) 651-5151
Fax No.: (713) 651-5246
If to any Investor, to the address set forth opposite the name of such Investor
on SCHEDULE 4.9 annexed hereto with a copy to Kirkland & Ellis, 200 East
Randolph Drive, Chicago, Illinois 60601, Attention: Wendy L. Chronister, Esq..
Any party hereto may, by notice given hereunder, designate any further or
different addresses to which subsequent notice, certificates or other
communications shall be sent, which notice shall be deemed given when received.
13.4UNDERSTANDING AMONG THE INVESTORS. The determination of each
Investor to purchase the Securities pursuant to this Agreement has been made by
such Investor independent of any other Investor and independent of any
statements or opinions as to the advisability of such purchase or as to the
business, assets, prospects, profits or condition (financial or otherwise) of
the Company which may have been made or given by any other Investor or by any
agent or employee of any other Investor. In addition, it is acknowledged by each
Investor that no other Investor has acted as an agent of such Investor in
connection with making its investment hereunder and that no other Investor shall
be acting as an agent of such Investor in connection with monitoring its
investment hereunder.
28
<PAGE>
13.5 BINDING EFFECT. The provisions of this Agreement shall bind
and inure to the benefit of the parties hereto and their respective heirs,
successors and permitted assigns.
13.6 NO WAIVER. No failure on the part of the Company or the
Investors in exercising any right, power or privilege granted hereunder shall
operate as a waiver thereof or of any other right, power or privilege, nor shall
any single or partial exercise of such right, power or privilege preclude any
other or further exercise thereof or of any other right, power or privilege.
13.7 ENTIRE AGREEMENT. This Agreement, together with the other
Transaction Documents and the Certificate of Designation, sets forth the entire
agreement among the parties hereto with respect to the subject matter hereof,
and supersedes any prior oral or written agreement among the parties.
13.8 HEADINGS. The headings of this Agreement are solely for the
convenience of the parties and shall not serve to limit or otherwise affect the
interpretation or effect of any terms or provisions hereof.
13.9 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed to be an original, but all of which
together shall constitute one and the same document.
13.10 SEVERABILITY. In the event that any court or any
governmental authority or agency declares all or any part of any Section of this
Agreement to be unlawful or invalid, such unlawfulness or invalidity shall not
serve to invalidate any other Section of this Agreement, and in the event that
only a portion of any Section is so declared to be unlawful or invalid, such
unlawfulness or invalidity shall not serve to invalidate the balance of such
Section.
13.11 FURTHER ASSURANCES. Each party shall cooperate and take such
action as may be reasonably requested by another party in order to carry out the
provisions and purposes of this Agreement and the transactions contemplated
hereby.
13.12 AMENDMENTS AND WAIVERS. This Agreement may be amended,
modified and supplemented, and compliance with any term, covenant, agreement or
condition contained herein may be waived either generally or in particular
instances, and either retroactively or prospectively, only by a written
instrument executed by (a) the Company and (b) holders of at least a majority of
the Underlying Common Stock. No course of dealing between or among any persons
having any interest in this Agreement will be deemed effective to modify, amend
or discharge any part of this Agreement or any rights or obligations of any
person under or by reason of this Agreement.
* * * * *
29
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this
Agreement on the date first above written, in the case of corporations by their
respective officers thereunto duly authorized.
LIFECELL CORPORATION
By: PAUL M. FRISON
Name Paul M. Frison
Title Chairman of the Board,
President and Chief Executive
Officer
VECTOR LATER-STAGE EQUITY FUND,
L.P.
By: [SIGNATURE ILLEGIBLE]
Name:
Title: PRESIDENT
CIBC WOOD GUNDY VENTURES, INC.
By: LORI KOFFMAN
Name: Lori Koffman
Title: Managing Director
30
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 6th day of November, 1996.
/s/ STEPHEN LIVESEY
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Stephen Livesey
3606 Research Forest Dr.
The Woodlands, TX 77381 ###-##-#### 250 5,645 $ 25,000
==================================== ================ ============== ============ =============
</TABLE>
31
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/s/ CHRISTOPHER C. KRAFT, JR.
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Christopher C. Kraft, Jr.
Smith Barney Inc. KEO P/S Cust.
14919 Village Elm St.
Houston, TX 77062 ###-##-#### 250 175 $ 25,000
==================================== ================ ============== ============ =============
</TABLE>
32
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/s/ P. WILLIAM CURRERI, M.D.
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
P. William Curreri, M.D.
217 Berwyn Dr. W. #222
Mobile, AL 36608 ###-##-#### 400 280 $ 40,000
==================================== ================ ============== ============ =============
</TABLE>
33
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ DAVID SAKS
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
David Saks
2 Knollwood Road
Woodcliff Lake, NJ 07675 ###-##-#### 500 11,290 $ 50,000
==================================== ================ ============== ============ =============
</TABLE>
34
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ WILLIAM J. MCCLUSKEY
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
William J. McCluskey
25 Wisconsin St.
Long Beach, NY 11561 ###-##-#### 186 4,200 $ 18,600
==================================== ================ ============== ============ =============
</TABLE>
35
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
The Woodlands Venture Capital Company
By: /s/ DON E. ROOSE, JR.
(Signature)
Don E. Roose, Jr.
Vice President and Controller
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================= ============= ============ =============
<S> <C> <C> <C> <C>
The Woodlands Venture
Capital Company 74-2177794 2,500 $ 250,000
==================================== ================= ============= ============ =============
</TABLE>
36
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ JOHN S. BAI
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
John S. Bai
30 W. 61st - 27A
New York, NY 10023 ###-##-#### 70 49 $ 21,700
==================================== ================ ============== ============ =============
</TABLE>
37
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ ROBERT WEINSTEIN
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Robert Weinstein
155 W. 68th St., 24C
New York, NY 10023 ###-##-#### 155 3,500 $ 15,500
==================================== ================ ============== ============ =============
</TABLE>
38
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/JAMES C. GALE /s/ JUDITH S. HASELTON
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
FEDERAL SERIES B NUMBER OF
EMPLOYER I.D. OR PREFERRED WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY STOCK SHARES INVESTMENT
NUMBER PURCHASED
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
James C. Gale & Judith S.
Haselton
315 W. 106 St., Apt. 4A ###-##-####
New York, New York 10025 ###-##-#### 1,550 35,000 $ 155,000
================================== ================ =============== =========== ==============
</TABLE>
39
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/JAMES C. GALE, TRUSTEE
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
FEDERAL SERIES B NUMBER OF
EMPLOYER I.D. OR PREFERRED WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY STOCK SHARES INVESTMENT
NUMBER PURCHASED
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
James C. Gale, Trustee F/B/O
Ariana J. Gale
315 W. 106 St., Apt. 4A
New York, New York 10025 13-6882735 620 14,000 $ 62,000
================================== ================ =============== =========== ==============
</TABLE>
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/s/ JOHN CIRRITO
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
John Cirrito
29 Rambling Drive
Scotch Plains, NJ 07076 ###-##-#### 250 5645 $ 25,000
==================================== ================ ============== ============ =============
</TABLE>
40
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ B. MICHAEL PISANI
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
B. Michael Pisani
44 Lake Rd.
Short Hills, NJ 07078 ###-##-#### 775 17,500 $ 77,500
==================================== ================ ============== ============ =============
</TABLE>
41
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/s/ JOHN LATSHAW
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
John Latshaw
5049 Wornall #2C
Kansas City, MO 64112 ###-##-#### 930 21,000 $ 93,000
==================================== ================ ============== ============ =============
</TABLE>
42
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ EVAN KLEINBERG
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Evan Kleinberg, IRA
Gruntal & Co. Custodian
3 Centennial Rd.
Livingston, NJ 07039 ###-##-#### 155 3,500 $ 15,500
==================================== ================ ============== ============ =============
</TABLE>
43
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ DOUGLAS KLEINBERG
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Douglas Kleinberg
200 E. 94th St., Apt. 126
New York, NY 10128 ###-##-#### 248 5,600 $ 24,800
==================================== ================ ============== ============ =============
</TABLE>
44
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ DANIEL KLEINBERG /s/ ELAINE KLEINBERG
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Daniel & Elaine Kleinberg
3 Centennial Rd.
Livingston, NJ 07039 ###-##-#### 263.50 5,950 $ 26,350
==================================== ================ ============== ============ =============
</TABLE>
45
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ ALLAN BOORSTEIN
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Chinook Equities
147 E. 48th St.
New York, NY 10017 13-3226477 500 11,290 $ 50,000
==================================== ================ ============== ============ =============
</TABLE>
46
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/s/ BARRY RICHTER
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Barry Richter
Tideway
Sandspoint, NY 11050 ###-##-#### 250 5,645 $ 25,000
==================================== ================ ============== ============ =============
</TABLE>
47
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ STEPHEN G. WEISS
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Stephen G. Weiss
115 Ravinoaks Ln.
Highland Park, IL 60035 ###-##-#### 330 7,451 $ 33,000
==================================== ================ ============== ============ =============
</TABLE>
48
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ JOSEPH BATTIPAGLIA
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Joseph Battipaglia
77 Water Street (10th Fl.)
New York, NY 10005 ###-##-#### 150 3,387 $ 15,000
==================================== ================ ============== ============ =============
</TABLE>
49
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ WILLIAM J. STRAZZULLO
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
William J. Strazzullo
750 Columbus Ave., 4C
New York, NY 10025 ###-##-#### 800 1,806 $ 8,000
==================================== ================ ============== ============ =============
</TABLE>
50
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ ROBERT SABLOWSKY
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Robert Sablowsky
150 East 69th Street, 16th Fl.
New York, NY 10021 ###-##-#### 465 10,500 $ 46,500
==================================== ================ ============== ============ =============
</TABLE>
51
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/s/ JOHN D. GOLDBERG
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
John D. Goldberg
2500 E. Hallandale Beach Blvd.
Suite 500
Hallandale, FL 33009 ###-##-#### 310 7,000 $ 31,000
==================================== ================ ============== ============ =============
</TABLE>
52
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ JOSEPH A. RUSSO
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Joseph A. Russo
3 Midwood Ave.
Verona, NJ 07044 ###-##-#### 50 35 $ 15,500
==================================== ================ ============== ============ =============
</TABLE>
53
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 31st day of October, 1996.
/s/ MICHAEL GIRONTA
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Michael Gironta
89 Rigewood Ave.
Glen Ridge, NJ 07028 ###-##-#### 1,000 22,581 $ 100,000
==================================== ================ ============== ============ =============
</TABLE>
54
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ DONNA GREENBERG
/s/ CHARLES C. GREENBERG
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Charles & Donna Greenberg
JTWROS
503 Pinehurst Court
Roslyn, NY 11576 ###-##-#### 1,500 33,870 $ 150,000
==================================== ================ ============== ============ =============
</TABLE>
55
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ RICHARD L. SERRANO
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Richard L. Serrano
64 Brighton Ave.
Bloomfield, NJ 07003 ###-##-#### 46.5 1,050 $ 4,650
==================================== ================ ============== ============ =============
</TABLE>
56
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ DAVID HARRIS /s/ MARY JANE HARRIS
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
David and Mary Jane Harris
JTWROS
174 Pacific St., Apt. 2A
Brooklyn, NY 11201 ###-##-#### 200 4,516 $ 20,000
==================================== ================ ============== ============ =============
</TABLE>
57
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ PAUL B. ANKIN /s/ LOIS F. ANKIN
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Paul B. Ankin and Lois F. Ankin
as joint tenants w/r/o/s
4233 W. Grove
Skokie, IL 60076 ###-##-#### $ 25,000
==================================== ================ ============== ============ =============
</TABLE>
58
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ JEROME SCHACHTER
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Jerome Schachter
2926 Leanne Ct.
Northbrook, IL 60062 ###-##-#### 500 11,290 $ 50,000
==================================== ================ ============== ============ =============
</TABLE>
59
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ LISA B. TUCKERMAN
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
S.B.S.F. Biotechnology
Partners, L.P.
c/o Lisa Tuckerman
Spears Benick Salomon & Farrell
45 Rockefeller Plaza
New York, NY 10111 13-386-8438 1,000 22,580 $ 100,000
==================================== ================ ============== ============ =============
</TABLE>
60
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/s/ MARK RICE
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Namax Corp. (Attn: Mark Rice)
666 Dundee Rd., Suite 1801
Northbrook, IL 60062 36-393-4918 2,100 45,161 $ 200,000
==================================== ================ ============== ============ =============
</TABLE>
61
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 11th day of November, 1996.
/s/ DON A. SANDERS
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Don A. Sanders
3100 Texas Commerce Tower
Houston, TX 77002 ###-##-#### 620 14,000 $ 62,000
==================================== ================ ============== ============ =============
</TABLE>
62
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 2nd day of November, 1996.
/s/ RONALD KOENIG
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Ronald Koenig
114 No. Village Way
Jupiter, FL 33458 ###-##-#### 310 7,000 $ 31,000
==================================== ================ ============== ============ =============
</TABLE>
63
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ ROBERT M. ADAMS
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Robert M. Adams
P. O. Box 998
Plandome, NJ 11030 ###-##-#### 1,550 35,000 $ 155,000
==================================== ================ ============== ============ =============
</TABLE>
64
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/s/ EDWARD A. KERBS
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Edward A. Kerbs
8 South Cherry Ln.
Rumson, NJ 07760 ###-##-#### 310 7,000 $ 31,000
==================================== ================ ============== ============ =============
</TABLE>
65
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ BERNARD B. SALZMAN
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Bernard B. Salzman IRA
Gruntal & Co., Inc., Custodian
20 S. Charles Street
Baltimore, MD 21201 ###-##-#### 55.8 1,260 $ 5,580
==================================== ================ ============== ============ =============
</TABLE>
66
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/s/ MICHAEL H. RICHMOND
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Michael H. Richmond
20 E. Wedgewood Glen
The Woodlands, TX 77381 ###-##-#### 400 9,032 $ 40,000
==================================== ================ ============== ============ =============
</TABLE>
67
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 2nd day of November, 1996.
/s/ MICHAEL E. CAHR
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Michael E. Cahr
1051 Saxony Dr.
Highland Park, IL 60035 ###-##-#### 500 11,290 $ 50,000
==================================== ================ ============== ============ =============
</TABLE>
68
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
By: Technology Funding, Inc.
Managing General Partner
BY: /s/ THOMAS J. TOY
(Signature)
Thomas J. Toy, Vice President
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Technology Funding Medical
Partners I, L.P.
2000 Alameda de Las Pulgas
San Mateo, CA 94403 94-3166762 2,500 56,451 $ 250,000
==================================== ================ ============== ============ =============
</TABLE>
69
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 6th day of November, 1996.
/s/ MICHAEL J. KOBLITZ
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Michael J. Koblitz
12 Downey Dr.
Tenafly, NJ 07670 ###-##-#### 50 1,129 $ 5,000
==================================== ================ ============== ============ =============
</TABLE>
70
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 6th day of November, 1996.
/s/ FRED GREENBERG
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Pharmaceutical & Medical
Technology Fund
300 Park Ave. 13-3603142 3,000 67,741 $ 300,000
New York, NY 10022
Stragegic Healthcare Fund
300 Park Ave.
New York, NH 10022 N/A 1,000 22,580 $ 100,000
==================================== ================ ============== ============ =============
</TABLE>
71
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ LISA B. TUCKERMAN
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
S.B.S.F. Biotechnology Fund, L.P.
c/o Lisa Tuckerman
Spears Benzak Salomon & Farrell
45 Rockefeller Plaza
New York, NY 10111 13-3523468 9,000 203,225 $ 900,000
==================================== ================ ============== ============ =============
</TABLE>
72
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/s/ JEFFREY KEELER
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Jeffrey Keeler
577 W. 50th Street
Miami Beach, FL 33140 ###-##-#### 86.8 1,960 $ 8,680
==================================== ================ ============== ============ =============
</TABLE>
73
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/s/ JONATHAN GREENWALD, GENERAL PARTNER
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Harbour Court L.P. II 13-391-5074 250 5,645 $ 25,000
==================================== ================ ============== ============ =============
</TABLE>
74
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/s/ MICHAEL J. KOBLITZ
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Marcus J. Koblitz
Lauren J. Koblitz
12 Downey Dr. ###-##-#### 25 $ 2,500
Tenafly, NJ 07670 ###-##-#### 25 $ 2,500
==================================== ================ ============== ============ =============
</TABLE>
75
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/s/ SHELDON DROBNY
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Sheldon Drobny
95 Revere Drive, Suite A
Northbrook, IL 60062 ###-##-#### 500 11,290 $ 50,000
==================================== ================ ============== ============ =============
</TABLE>
76
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/s/ PERRY H. BACON
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Perry H. Bacon
5300 Mission Woods Rd.
Shawnee Mission, KS 66205 ###-##-#### 620 14,000 $ 62,000
==================================== ================ ============== ============ =============
</TABLE>
77
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/s/ JAMES J. PELTS
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
James J. Pelts
29 E. Madison St., Suite 1505
Chicago, IL 60602 ###-##-#### 500 11,290 $ 50,000
==================================== ================ ============== ============ =============
</TABLE>
78
<PAGE>
[SECURITIES PURCHASE AGREEMENT]
SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/s/ ROBERT WEINSTEIN
(Signature)
<TABLE>
<CAPTION>
NUMBER OF
SHARES OF
SERIES B
FEDERAL PREFERRED NUMBER OF
EMPLOYER I.D. OR STOCK WARRANT TOTAL
NAME AND ADDRESS SOCIAL SECURITY PURCHASED SHARES INVESTMENT
NUMBER
==================================== ================ ============== ============ =============
<S> <C> <C> <C> <C>
Robert Weinstein
155 W. 68th St., 24C
New York, NY 10023 ###-##-#### 20 1,400 $ 6,200
==================================== ================ ============== ============ =============
</TABLE>
79
<PAGE>
SCHEDULE 1
INVESTORS; SECURITIES PURCHASED; PURCHASE PRICE
Shares Warrant Purchase
Purchased Shares Price
- --------------------------------------------------------------------------------
CIBC Wood Gundy Ventures, Inc. ............ 44,800 1,011,612 $4,480,000
The Woodlands Venture Capital Company ..... 2,500 56,451 250,000
P. William Curreri, M.D ................... 400 9,032 40,000
Christopher C. Kraft, Jr., Smith .......... 250 5,645 25,000
Barney Inc. KEO P/S Custodian Acct:
721-66059-10-022
Michael H. Richmond ....................... 400 9,032 40,000
Stephen Livesey ........................... 250 5,645 25,000
Michael E. Cahr ........................... 500 11,290 50,000
Technology Funding Medical ................ 2,500 56,451 250,000
Partners I, L.P. ..........................
Vector Later-Stage Equity Fund, L.P. ...... 40,000 903,225 4,000,000
William J. McCluskey ...................... 186 4,200 18,600
David Saks ................................ 500 11,290 50,000
Joseph Battipaglia ........................ 150 3,387 15,000
S.B.S.F. Biotechnology Partners, L.P. ..... 1,000 22,580 100,000
S.B.S.F. Biotechnology Fund, L.P. ......... 9,000 203,225 900,000
Jerome Schachter .......................... 500 11,290 50,000
Paul B. Ankin and Lois F. Ankin, .......... 250 5,645 25,000
JTWROS
David and Mary Jane Harris, ............... 200 4,516 20,000
JTWROS
Richard L. Serrano ........................ 50 1,129 5,000
80
<PAGE>
Shares Warrant Purchase
Purchased Shares Price
- --------------------------------------------------------------------------------
Charles and Donna Greenberg, ............... 1,500 33,870 150,000
JTWROS
Michael Gironta ............................ 1,000 22,580 100,000
Joseph A. Russo ............................ 155 3,500 15,500
John D. Goldberg ........................... 310 7,000 31,000
Robert Sablowsky ........................... 465 10,500 46,500
William J. Strazzullo ...................... 80 1,806 8,000
Stephen G. Weiss ........................... 330 7,451 33,000
Barry Richter .............................. 250 5,645 25,000
Chinook Equities, Inc. ..................... 500 11,290 50,000
Daniel and Elaine Kleinberg, JTWROS ........ 267 6,029 26,700
Douglas Kleinberg .......................... 248 5,600 24,800
Evan Kleinberg IRA, Gruntal & Co., ......... 155 3,500 15,500
Inc., Custodian Dated July 19, 1996
John Latshaw ............................... 930 21,000 93,000
B. Michael Pisani .......................... 775 17,500 77,500
John Cirrito ............................... 250 5,645 25,000
James C. Gale, Trustee F/B/O Ariana ........ 620 14,000 62,000
J. Gale The James C. Gale Trust,
dated November 21, 1986
James C. Gale and Judith S. Haselton ....... 1,550 35,000 155,000
JTWROS
John S. Bai ................................ 217 4,900 21,700
Ronald Koenig .............................. 310 7,000 31,000
Robert M. Adams ............................ 1,550 35,000 155,000
Edward A. Kerbs ............................ 310 7,000 31,000
81
<PAGE>
Shares Warrant Purchase
Purchased Shares Price
- --------------------------------------------------------------------------------
Bernard B. Salzman IRA, Gruntal & ........... 55 1,241 5,500
Co., Inc., Custodian Dated May 14,
1982 Acct: 215-67321-1-3-231
Don A. Sanders .............................. 620 14,000 62,000
Jeffrey Keeler .............................. 87 1,964 8,700
Harbour Court L.P., II ...................... 250 5,645 25,000
Namax Corp. ................................. 2,000 45,161 200,000
Sheldon Drobny .............................. 500 11,290 50,000
Perry H. Bacon .............................. 620 14,000 62,000
James J. Pelts .............................. 500 11,290 50,000
Robert Weinstein ............................ 217 4,900 21,700
The Marcus L. Koblitz Trust, Michael ........ 25 564 2,500
J. Koblitz, Trustee Est. April 14, 1992
The Lauren J. Koblitz Trust, Michael ........ 25 564 2,500
J. Koblitz, Trustee Est. April 14, 1992
Pharmaceutical & Medical Technology ......... 3,000 67,741 300,000
Fund
Strategic Healthcare Fund ................... 1,000 22,580 100,000
Michael J. Koblitz .......................... 50 1,129 5,000
------- --------- ----------
TOTAL .................. 124,157 2,803,530 12,415,700
======= ========= ==========
82
<PAGE>
SCHEDULE 3.2
CAPITAL STOCK
OUTSTANDING OPTIONS
Pursuant to certain Non-Statutory Stock Options granted on November 4,
1996, P. William Curreri, Christopher C. Kraft, Jr. and Martin P. Sutter
have the right to purchase an aggregate of 225,000 shares of common stock,
par value $.001 per share (the "Common Stock"), of LifeCell Corporation
(the "Company").
1,000,000 shares of Common Stock are reserved for issuance under the
Company's Second Amended and Restated 1992 Stock Option Plan, as amended.
As of November 18, 1996, options to purchase 998,945 shares have been
granted pursuant to such plan and are outstanding.
750,000 shares of Common Stock are reserved for issuance under the
Company's Second Amended and Restated 1993 Non-Employee Director Stock
Option Plan. As of November 18, 1996, options to purchase 90,000 shares
have been granted pursuant to such plan and are outstanding.
OUTSTANDING WARRANTS
As of November 18, 1996, the persons or entities listed below hold
warrants to purchase the number of shares of Common Stock set forth
opposite their name.
Robert Todd Financial Corporation 120,000
Strategem of Alabama, Inc. 5,000
Thomas James Associates 20,000
The Renaissance Group Limited 75,000
Donald P. Callan, D.D.S. 10,000
Gruntal & Co. Incorporated 354,734
As of November 18, 1996, the holders of the Company's Series B Preferred
Stock, par value $.001 per share (the "Series B Preferred Stock"), hold
warrants to purchase an aggregate of 2,803,530 shares of Common Stock.
HOLDERS OF SERIES A PREFERRED STOCK
Allstate Insurance Company
Medtronic, Inc.
The Woodlands Venture Capital Company
Technology Funding Partners III, L.P.
P. William Curreri, M.D.
Gil Fuqua, Jr.
83
<PAGE>
Smith Barney, Inc., Custodian of the Christopher C. Kraft, Jr.
Keogh Profit Sharing Plan
Robert E. Garrison II
Martin P. Sutter
David R. Sincox
CONVERTIBLE INSTRUMENTS AND RIGHTS
The Series A Preferred Stock, of which 260,000 shares are outstanding as
of November 18, 1996, is convertible into an aggregate of 1,761,139 shares
of Common Stock, subject to adjustment upon certain events, including the
issuance of Common Stock as a dividend with respect to the outstanding
Common Stock, subdivisions, splits or combinations of Common Stock, or the
issuance of any shares of capital stock by reclassification of Common
Stock.
The Series B Preferred Stock, of which 124,157 shares are outstanding as
of November 18, 1996, is convertible into an aggregate of 4,005,052 shares
of Common Stock, subject to adjustment as described in the Certificate of
Designation of the Series B Preferred Stock. Additionally, any dividends
on the Series B Preferred Stock paid in shares of Series B Preferred Stock
will be convertible into shares of Common Stock.
Pursuant to the License and Development Agreement dated March 3, 1994,
between the Company and Medtronic, Inc. ("Medtronic"), Medtronic paid the
Company a $1.5 million licensing fee. If such agreement is terminated
under certain circumstances, including Medtronic's right to terminate at
any time if in its sole business judgment it deems the development and
commercialization of products thereunder not to be in its best interests
or otherwise imprudent, Medtronic has the option the convert the $1.5
million licensing fee into shares of Common Stock, at the then current
market price, unless immediately following such conversion the number of
shares received upon such conversion together with all other shares of
Common Stock held by Medtronic would exceed 19% of the then issued and
outstanding shares of Common Stock, in which case LifeCell shall pay cash
or issue a promissory note or deliver a combination of the two to
Medtronic in an amount equal to the difference between the $1.5 million
and the value of the number of shares of Common Stock actually issued to
Medtronic pursuant to such conversion. In addition, if immediately
following such conversion the number of shares of Common Stock issued in
connection with such conversion together with the number of shares of
Common Stock then held by Medtronic equal less than 5% of the then issued
and outstanding shares of Common Stock, Medtronic shall have the option to
purchase from LifeCell in cash on the date on such conversion a number of
shares of Common Stock such that the aggregate number of shares of Common
Stock held by Medtronic shall equal up to but no more than 5% of the then
issued and outstanding shares of Common Stock. The price at which
Medtronic may purchase such additional shares would be equal to the
arithmetic average of the market price for the Common Stock for the 20
trading days immediately preceding such date.
84
<PAGE>
DIVIDEND SHARES
Holders of the Series A Preferred Stock are entitled to receive, when, as
and if declared by the Board of Directors, out of the funds of the Company
legally available therefor, an annual dividend of $1.60 per share for the
year ended November 9, 1996, and $2.00 per share for the year ended
November 9, 1997, which may be paid in shares of Common Stock. The number
of shares to be issued will be based upon the then current market price of
the Common Stock.
BLUE SKY REGISTRATIONS/QUALIFICATIONS
The filing of a Form M-11 with the Department of Law of the State of New
York.
85
<PAGE>
SCHEDULE 3.4
CONFLICTS
The consent of the holders of the Series A Preferred Stock is required to
authorize, create and issue the Series B Preferred Stock.
The waiver of certain holders of capital stock of the Company of certain
registration rights of such holders under an Amended and Restated Registration
Rights Agreement, dated February 26, 1992, by and among the Company and such
holders (the "Prior Registration Rights Agreement") and certain amendments to
the Prior Registration Rights Agreement are required to avoid a conflict
resulting from the Company's execution and delivery of the Registration Rights
Agreement.
The waiver of Medtronic, Inc. of certain registration rights it has under an
Investment Agreement dated March 3, 1994, between the Company and Medtronic,
Inc. and certain amendments to such Investment Agreement are required to avoid a
conflict resulting from the Company's execution and delivery of the Registration
Rights Agreement.
Section 10.2(c) of the Distribution Agreement dated June 1, 1996, between the
Company and DENTSPLY International, Inc. ("DENTSPLY"), allows DENTSPLY to
terminate such Distribution Agreement if the Company comes under the ownership
or control, directly or indirectly, of any person other than persons having
ownership or control of the Company at the date such Distribution Agreement was
executed.
The Company has been advised by the Nasdaq Stock Market that the issuance of the
Series B Preferred Stock may violate Rule 4310(c)(21) of the Rules of The Nasdaq
Stock Market. The Company disagrees with this interpretation and currently is
discussing this issue with the Nasdaq Stock Market.
86
<PAGE>
SCHEDULE 3.5
Litigation
None.
87
<PAGE>
SCHEDULE 3.10
TAXES
None.
88
<PAGE>
SCHEDULE 3.11
MATERIAL ADVERSE EFFECT
None other than as disclosed under "Risk Factors", "Management's Discussion and
Analysis of Financial Condition and Results of Operation" and otherwise in the
Confidential Private Placement Memorandum dated October 29, 1996 of the Company
(the "Memorandum").
89
<PAGE>
SCHEDULE 3.12
TITLE
Pursuant to a Security Agreement - Pledge of Certificate of Deposit and
Assignment of Deposit Account dated January 3, 1996, between the Company and
Texas Commerce Bank National Association ("TCB"), Certificate of Deposit No.
0039001256 is pledged to secure the obligations of the Company under the Term
Installment Note dated January 3, 1996, in the original principal amount of
$120,000, payable by the Company to TCB (the "Installment Note").
The Company granted TCB a security interest in its tangible personal property,
accounts and other receivables to secure the Company's obligations under the
Term Promissory Note dated October 8, 1996, in the original principal amount of
$250,000, payable by the Company to TCB (the "Term Note").
Liens for taxes or assessments or other governmental charges or levies to the
extent not yet due and payable.
Mechanics and materialmen liens or encumbrances for construction in progress to
the extent not perfected by filing, recording, giving of notice or other
appropriate action in the relevant jurisdiction.
Workmen, repairmen, warehousemen, carriers, lessors and operators liens or
encumbrances arising in the ordinary course of business to the extent not
perfected by filing, recording, giving of notice or other appropriate action in
the relevant jurisdiction.
90
<PAGE>
SCHEDULE 3.13
PROPRIETARY RIGHTS
See ANNEX 3.13 attached hereto.
The Company has federal trademark and service mark registrations for LifeCell,
LifeCell Process and AlloDerm.
Pursuant to a Non-Exclusive License Agreement dated September 1, 1996, between
Competitive Technologies, Inc. ("CTI") and the Company, the Company was granted
a non-exclusive license to (i) U.S. Patent No. 4,810,299, issued January 31,
1989 and entitled "Body Implants of Extracellular Matrix and Means and Methods
of Making and Using Such Implants, invented by Klaus Brendel and Raymond C.
Duhamel, and (ii) Japan Patent No. 1842777, the foreign counterpart to the
patent referred to in clause (i) above. The Company is obligated to pay
royalties pursuant to such agreement.
The Company is obligated to pay royalties pursuant to the terms of the Exclusive
License Agreement dated June 6, 1986, by and between the Board of Regents of the
University of Texas System and the Company.
Pursuant to a License and Development Agreement with Medtronic, Inc., the
Company granted an irrevocable, worldwide, exclusive license to Medtronic, Inc.
for certain patents and know-how relating to homograft and heterograft heart
valve bioprostheses. Pursuant to such License Agreement, Medtronic paid the
Company a $1.5 million licensing fee, agreed to fund the development of heart
valve products using the Company's technology, and agreed to pay total
cumulative royalties of up to $25 million in respect of any sales of any
products developed and sold using the Company's patented technologies. On the
same date, the Company also entered into an Investment Agreement with Medtronic
pursuant to which the Company granted Medtronic certain rights of first refusal
to evaluate technology and negotiate a license and development agreement for
vascular conduit products using the Company's technology.
The distribution agreements set forth in Schedule 3.14 are incorporated herein
by reference thereto.
Page 1 of Schedule 3.13
<PAGE>
ANNEX 3.13
THE LIFECELL PATENT PORTFOLIO
March 25, 1997
<TABLE>
<CAPTION>
DOCKET NUMBER SERIAL FILING DATE PATENT NUMBER ISSUE DATE OFFICIAL TITLE/
(AWD/UT) COUNTRY NUMBER [DESCRIP. TITLE]
- --------- ------------- -------- ----------- ------------ ----------- -----------------------------------
<S> <C> <C> <C> <C> <C> <C>
UTSH:022 United States 525,626 08-23-83 4,510,169 04-09-85 Method and Apparatus for
UTHSC/HOU:0 Cryopreparing Biological Tissue for
22 Australia 31666/84 08-07-84 583477 08-25-89 Ultrastructural Analysis.
[ABANDONED Canada 460,541 08-08-84 1,239,289 07-19-88 ALL CASES ABANDONED BY NON-
PAYMENT OF MAINTENANCE FEES
Canada-1 547,938 09-25-87
*European 84305391.9 08-08-84
Patent
Convention
*France
*Great Britain
*West Germany
*Sweden
*Switzerland/
Liechtenstein
175807/84 08-23-84
Japan
United States
ABANDONED
UTSH:032 8/9/88 038,038 04/13/87 Quick Release Flange
</TABLE>
Page 2 of Schedule 3.13
<PAGE>
<TABLE>
<S> <C>
UTSH:040 Apparatus and Method for
UTHSC/HOU:0 United States 777,083 09-17-85 Cryopreparing Biological Tissue
40
[continuation ABANDONED
of 041 which 1/31/87 777,083 09-17-85 [Sample Chamber]
is a CIP
of 022]
United States 767,855 11-30-84 4,567,847 02-04-86 Apparatus and Method for
UTSH:041 Cryopreparing Biological Tissue for
UTHSC/HOU:0 Australia 49963/85 11-15-85 Ultrastructural Analysis
41
[CIP of 022] Canada 495,267 11-13-85 1,239,290 07-12-88 [Generic Apparatus]
[ABANDONED Canada-1 547,937 09-25-87 1,301,465 05-26-92 ALL CASES ABANDONED BY NON-
PAYMENT OF MAINTENANCE FEES
*European 85308760.9 12-02-85
Patent Convention
*Austria
*Belgium
*France
*Great Britain
*West Germany
*Italy
*Luxembourg
*Netherlands
*Sweden
*Switzerland/
Liechtenstein
Japan 275080/85 11-30-85
</TABLE>
Page 3 of Schedule 3.13
<PAGE>
<TABLE>
<S> <C>
UTSH:044 United States 676,856 11-30-84 4,619,257 10-28-86 Apparatus and Method for
UTHSC/HOU:044 Cryopreparing Corneal Tissue for
[CIP of 022] Surgical Procedures
[Corneal Tissue Method]
UTSH:051 United States 770,772 08-29-85 4,676,070 06-30-87
UTHSC/HOU:051 Apparatus and Method for
[continuation of Cryopreparing Biological Tissue
041 which is a for Ultrastructural Analysis
CIP of 022]
[Generic Tissue Method]
Preparation of Biological Tissue for
UTSH:052 Ultrastructural Analysis
UTHSC/HOU:052 [INACTIVE]
[Omnibus application]
UTSH:065
UTHSC/HOU:065 [INACTIVE]
UTSH:082 United 939,701 12-03-86 4,707,998 11-24-87 Apparatus and Method for Ultrarapid
UTHSC/HOU:0 States Cooling of Biological Sample [Cryo
82 Slammer]
[ABANDONED
</TABLE>
Page 4 of Schedule 3.13
<PAGE>
<TABLE>
<S> <C>
UTSH:089 United 926,985 11-04-86 4,799,361 1-24-89 Apparatus and Method for
UTHSC/HOU:0 States Cryopreparing Biological Tissue for
89 80664/87 11-04-87 ABANDONED Ultrastructural Analysis
[CIP OF 051] Australia [Second Generic Sample]
551010 11-04-87 1,239,291 7-19-88
Canada
87309774.5 11-04-87 ABANDONED
*European
Patent
Convention
*Austria
*Belgium
*France
*Germany
*Greece
*Italy
*Luxembourg
*Netherlands
*Spain
*Sweden
*Switzerland/
Liechtenstein
*Great Britain
Japan 278994/87 11-04-87 ABANDONED
</TABLE>
Page 5 of Schedule 3.13
<PAGE>
<TABLE>
<S> <C>
UTSH:091 United 942,172 12-16-86 4,742,690 5-10-88 Apparatus and Method for
UTHSC/HOU:0 States Cryopreparing Biological Tissue for
91 87118696.1 12-16-87 ABANDONED Ultrastructural Analysis
[CIP of 040 *European [Sample Holder]
which is a Patent
continuation Convention ALL CASES ABANDONED BY NON-
of 041 which PAYMENT OF MAINTENANCE FEES
is a CIP of *Austria
022] *Belgium
*France
[ABANDONED] *Germany
*Greece
*Italy
*Luxembourg
*Netherlands
*Spain
*Sweden
*Switzerland/
Liechtenstein
*United Kingdom
UTSH:095 [INACTIVE]
UTHSC/HOU:0
95
UTSH:096 Apparatus and Method for
[CIP of Cryopreparing Biological tissue for
UTSH:091 et United Ultrastructural Analysis
seq.] States 038,840 04-13-87 4,745,771 5-24-88 [Sample Holder]
[ABANDONED]
</TABLE>
Page 6 of Schedule 3.13
<PAGE>
<TABLE>
<S> <C>
UTSH:097 United States 102,395 09-29-87 4,807,442 02-28-89 Cryo-Slamming Apparatus and Method for
for Ultrarapid Cooling of Biological Samples
[ABANDONED]
Australia 23559/88 10-07-88 616,687 03-03-92 [Cryo-Slammer]
Canada 579683 10-07-88 1,311,620 12-22-92
*European 88309764.4 10-18-88 364,633 ALL CASES ABANDONED BY NON-
Patent PAYMENT OF MAINTENANCE FEES
Convention
*Austria
*Belgium
*France
*W. Germany
*Greece
*Italy
*Luxembourg
*Netherlands
*Spain
*Sweden
*Switzerland/
Liechtenstein
*United 272883/88 10-28-88
Kingdom
Japan
</TABLE>
Page 7 of Schedule 3.13
<PAGE>
<TABLE>
<S> <C>
UTSH:113 United 284,989 12-15-88 5,044,165 09-03-91 Improved Cryo-Slammer
[CIP of States
UTSH:097]
Australia 31516 3-20-89 627,718 01-12-93
Canada 284,989 12-15-88 1,320,646 07-27-93
*European 284,989 12-15-88 373,738
Patent
Convention
*Austria
*Belgium
*France
*West
Germany
*Italy
*Luxembourg
*Netherlands
*Sweden
*Switzerland/
Liechtenstein 098624/89 4-8-89
*United
UTSH:113 Kingdom
[CIP of
UTSH:097] Japan
UTSH:116 United 217,561 7-11-88 4,865,871 9-12-89 Method for Cryopreparing Biological
States Tissue
[Cryoprotectant]
UTSH:117 United 230,768 8-9-88 5,024,830 06-18-91 Apparatus and Method for
[Divisional States Cryopreparing Biological Tissue for
of UTSH:089] Ultrastructural Analysis
[Generic Method]
UTSH:120 United 343,882 4-13-89 D323,895 02-11-92 Design Patent for CF-100 Cryo
States Slammer
</TABLE>
Page 8 of Schedule 3.13
<PAGE>
<TABLE>
<S> <C>
United Molecular Distillation Dryer
UTSH:129 States 395,028 8-17-89 4,964,280 10-23-90 (Apparatus for distillation drying)
UTSH:141 United 492,724 3-13-90 5,154,007 10-13-92 Molecular Distillation Dryer
[Divisional States
of UTSH:129]
LIFD:027 United 581,584 9-12-90 ABANDONED Method for Cryopreparation and Dry
States (CIP LIFD:031) Stabilization of Vaccines and Viruses
LIFD:028 United INACTIVE Cryopreparation of Collagen Based
States Transplantable Tissue
LIFD:029 United INACTIVE Cryopreparation of Biological Tissue
States Using Mid-Range Drying
United Preservation of Biological Heart Valves
LIFD:030 States INACTIVE in the Dry State
LIFD:031 United 709,504 06-03-91 ABANDONED
[CIP of States (FWC
LIFD:027] LIFD:045)
</TABLE>
Page 9 of Schedule 3.13
<PAGE>
<TABLE>
<S> <C>
Australia 83797/91 09-10-91 Method for Cryopreparation & Dry
650045 09/27/94 Stabilization of Vaccines and Viruses
Australia 67405/94 07-13-94 [Nebulizing]
Canada 2,051,092 09-10-91
*European 91115480.5 09-12-91
Patent 047549
Convention
*Austria
*Belgium
*Denmark
*France
*Germany
*Greece
*Italy
*Luxembourg
*Netherlands
*Spain
*Sweden
*Switzerland
*United
Kingdom 91/233340 09-12-91
Japan
LIFD:037 ABANDONED
(CIP of United (CIP is Method for Processing Collagen-Based
LIFD:031) States 835,138 2-12-92 LIFD:038) Tissues for Transplantation
</TABLE>
Page 10 of Schedule 3.13
<PAGE>
<TABLE>
<S> <C>
LIFD:038 United
(CIP of States 08/004,752 02-02-93 5,336,616 08/09/94 Method for Processing and Preserving
LIFD:037) Collagen-Based Tissues for
Australia 32934/93 02-10-93 668703 09/09/96 Transplantation
[Generic Method]
Canada
93102264.4 2/12/93
*European 0564786
Patent
Convention
*Austria
*Belgium
*Denmark
*France
*Germany
*Greece
*Ireland
*Italy
*Luxembourg
*Monaco
*Netherlands
*Portugal
*Spain
*Sweden
*Switzerland/
Liechtenstein
*United
Kingdom
Japan
LIFD:045 United 08/018,357 02-16-93 5,364,756 11-15-94 Method for Cryopreparation & Dry
(FWC of States Stabilization of Vaccines and Viruses
LIFD:031) [Nebulizing]
</TABLE>
Page 11 of Schedule 3.13
<PAGE>
<TABLE>
<S> <C>
LIFD:050 United 08/227,264 04-13-94 Method for Processing and Preserving
(Con. of States Collagen-Based Tissue for
LIFD:038) Transplantation
LIFD:051 United To be prepared Method for Processing and Preserving
C-I-P of States Collagen-Based Tissue for
LIFD:050 Transplantation
LIFD:052 United 08/326,036 10-19-94 Prolonged Preservation of Blood
States Platelets (Thrombosol)
PCT US95/1332 10/19/95 WO96/13158
40
LIFD:054 United 08/291,340 08-17-94 Apparatus for Cryopreserving a
DIV of States Suspension of Biological Material
LIFD:045
LIFD:061PZ1 United 60/002,882 08/25/95 Reconstituted Skin
States
LIFD:064 United 08/600343 02/13/96 Prolonged Preservation of Blood
CIP of States Platelets (Cytokines)
LIFD:052
LIFD065
CIP of United Prolonged Preservation of Blood
LIFD:052 States 08/600,816 02/13/96 Platelets (Taxol)
</TABLE>
Page 13 of Schedule 3.13
<PAGE>
SCHEDULE 3.14
CONTRACTS
The contracts, agreements, commitments, obligations and licenses referred to in
Schedules 3.2, 3.12, 3.13, 3.18 and 3.21 are incorporated herein by reference
thereto.
Agreement dated September 1, 1996, between the Company and Medidas.
Distribution Agreement dated October 1, 1996, by and between the Company and
Boracchia & Associates.
Distribution Agreement dated October 1, 1996, by and between the Company and
Cosmetic Surgery Suppliers, Inc.
Distribution Agreement dated June 1, 1996, by and between DENTSPLY
International, Inc. and the Company.
Distribution Agreement dated April 1, 1996, by and between the Company and
Implant Specialties Ltd., Inc.
Distribution Agreement dated May 1, 1996, by and between the Company and Life
Lines Medical, Inc.
Distribution Agreement dated October 1, 1996, by and between the Company and
Martell Medical Products, Inc.
Distribution Agreement dated July 1, 1996, by and between the Company and OR
Specialties, Inc.
Distribution Agreement dated August 1, 1996, by and between the Company and
Quantum Medical.
Distribution Agreement dated February 7, 1996, by and between the Company and
Sun Medical Inc.
Page 1 of Schedule 3.14
<PAGE>
Distribution Agreement dated April 1, 1996, by and between the Company and Tech
Medical Services, Inc.
Distribution Agreement dated April 1, 1996, by and between the Company and Vista
Medical Systems, Inc.
Agreement dated effective April 4, 1996, between the Company and Medlink Europe
B.V.
Employment Agreement and accompanying Confidentiality, Inventions and
Discoveries and Non-Competition Agreement dated January 28, 1992, by and between
the Company and Paul M.
Frison.
Employment Agreement and accompanying Confidentiality, Inventions and
Discoveries and Non-Competition Agreement dated January 28, 1992, by and between
the Company and Stephen A. Livesey.
Sub-lease Agreement dated August 1, 1994, by and between the Company and The
Western Company of North America (predecessor to B.J. Services).
Small Business Innovative Research Contract dated August 15, 1996, between the
Company and National Science Foundation.
Small Business Innovative Research Contract dated April 16, 1996, between the
Company and the Department of Defense U.S. Navy.
Amended and Restated Registration Rights Agreement, dated February 26, 1992, by
and among the Company and the holders of capital stock of the Company identified
therein.
Underwriter's Warrant Agreement, dated March 6, 1992, between the Company and
Robert Todd Financial Corporation, as amended by First Amendment to
Underwriter's Warrant Agreement, dated January 26, 1993, between the Company and
Robert Todd Financial Corporation (the "Underwriter's Warrant Agreement").
Subscription Agreement, dated November 1994, executed by each of the
Subscriber's named therein (the "Series A Subscription Agreement").
Page 2 of Schedule 3.14
<PAGE>
DEFAULTS
The Company has not provided notice to Robert Todd Financial Corporation of
certain price and share adjustments under the terms of the Underwriter's Warrant
Agreement.
Page 3 of Schedule 3.14
<PAGE>
SCHEDULE 3.15
INDEBTEDNESS
$100,000.00, plus accrued interest, under the Installment Note.
$250,000.00, plus accrued interest, under the Term Note.
$698,422.15 in trade payables.
$416,000.00 in accrued and unpaid dividends on the Series A Preferred Stock as
of November 9, 1996.
$120,793.66 in other payables.
<PAGE>
SCHEDULE 3.16
COMPLIANCE WITH LAW
None.
<PAGE>
SCHEDULE 3.18
INSURANCE
See ANNEX 3.18 attached hereto.
<PAGE>
LifeCell Corporation
3606 Research Forest Drive
The Woodlands, Texas 77381
ANNEX 3.18
SCHEDULE OF INSURANCE
[GRAPHIC OMMITTED]
[GRAPHIC DEPICTING COVERAGE, LIMITS, EXPIRATION, COMPANY, POLICY NO., COMMENTS,
AND PREMIUM. THE COVERAGES ARE PRETAINING TO PROPERTY INSURANCE, GENERAL
LIABILITY, BUSINESS AUTOMOBILE, DIRECTORS AND OFFICERS, KEYMEN, CARGO, WORKERS'
COMPENSATION, BONDED EMPLOYEES AND HEALTH.]
Page 2 of Schedule 3.18
<PAGE>
SCHEDULE 3.21
RELATED PARTY TRANSACTIONS
The Contracts between the Company and any Related Party referred to in Schedules
3.2, 3.13, 3.14 and 3.18 are incorporated herein by reference thereto.
See "Certain Transactions" on page 50 of the Memorandum.
Pursuant to a Letter of Agreement dated September 15, 1996, the Company engaged
NRS Communications Inc. ("NRS"), of which Leslie Summers-Schwartz, wife of Randy
Schwartz, Vice President Sales and Marketing of the Company, is a principal. NRS
is engaged through December 15, 1996 for a fee of $3,800 to complete a one-time
public relations project.
<PAGE>
SCHEDULE 4.8
PRINCIPAL OFFICE OR DOMICILE
Vector Later-Stage Equity Fund, L.P. Charles and Donna Greenberg
1751 Lake Cook Road, Suite 350 503 Pinehurst Court
Deerfield, Illinois 60015 Roslyn, NY 11576
CIBC Wood Gundy Ventures, Inc. Michael Gironta
425 Lexington Avenue 89 Ridgewood Avenue
New York, New York 10017 Glen Ridge, NJ 07028
The Woodlands Venture Capital Company Joseph A. Russo
2201 Timberloch Place 3 Midwood Avenue
The Woodlands, TX 77380 Verona, NJ 07044
SBSF Biotechnology Fund, L.P. John D. Goldberg
c/o Lisa Tuckerman 2500 East Hallandale Beach Blvd.
Spears Benzak Salomon & Farrell Suite 500
45 Rockefeller Plaza -- 33rd Floor Hallandale, FL 33009-4838
New York, NY 10111
Robert Sablowsky
SBSF Biotechnology Partners, L.P. 150 East 69th Street, 16A
c/o Lisa Tuckerman New York, NY 10021
Spears Benzak Salomon & Farrell
45 Rockefeller Plaza -- 33rd Floor William J. Strazzullo
New York, NY 10111 750 Columbus Avenue, 4C
New York, NY 10025
Jerome Schachter
2926 Leanne Court Joseph Battipaglia
Northbrook, IL 60062 77 Water Street (10th Floor)
New York, NY 10005
Paul B. Ankin and Lois F. Ankin,
as joint tenants Stephen G. Weiss
4233 W. Grove 115 Ravin Oaks Lane
Skokie, IL 60076 Highland Park, IL 60035
David and Mary Jane Harris Barry Richter
174 Pacific Street, Apt. 2A Tideway
Brooklyn, NY 11201 Sandspoint, NY 11050
Richard L. Serrano
64 Brighton Avenue
Bloomfield, NJ 07003
35
<PAGE>
Chinook Equities, Inc. William J. McCluskey
147 East 48th Street 25 Wisconsin Street
New York, NY 10017 Long Beach, NY 11561
Daniel and Elaine Kleinberg
3 Centennial Road
Livingston, NJ 07039
Douglas Kleinberg
200 East 95th Street, Apt. 126
New York, NY 10128
Evan Kleinberg IRA
Gruntal & Co. Custodian
3 Centennial Road
Livingston, NJ 07039
John Latshaw
5049 Wornall #2C
Kansas City, MO 64112
B. Michael Pisani
44 Lake Road
Short Hills, NJ 07078
John Cirrito
29 Rambling Drive
Scotch Plains, NJ 07076
James C. Gale, Trustee F/B/O Ariana J. Gale
315 W. 106th Street, Apt. 4A
New York, NY 10025
James C. Gale and Judith S. Haselton
315 West 106th Street, Apt. 4A
New York, NY 10025
Robert Weinstein
155 West 68th Street, 24C
New York, NY 10023
John S. Bai
30 West 61st, 27A
New York, NY 10023
36
<PAGE>
David F. Saks Bernard B. Salzman IRA,
2 Knollcliff Road Gruntal & Co., Inc., Custodian
Woodcliff Lake, NJ 07675 20 S. Charles Street
Baltimore, MD 21201
P. William Curreri, M.D.
217 Berwyn Drive, W. #222 Don A. Sanders
Mobile, Alabama 36608 3100 Texas Commerce Tower
Houston, TX 77002
Christopher C. Kraft, Jr.
Smith Barney Inc. KEO P/S Custodian Jeffrey Keeler
14919 Village Elm Street 577 W. 50th Street
Houston, TX 77062 Miami Beach, FL 33140
Michael H. Richmond Harbour Court L.P., II
20 E. Wedgewood Glen 253 W. 73rd St., Apt. 6D
The Woodlands, TX 77381 New York, NY 10023
Attention: Jonathan Greenwald
Stephen Livesey
3606 Research Forest Drive Namax Corp.
The Woodlands, TX 77381 666 Dundee Road, Suite 1801
Northbrook, IL 60062
Michael E. Cahr Attention: Mark Rice, President
1051 Saxony Drive
Highland Park, IL 60035 Sheldon Drobny
95 Revere Drive, Suite A
Technology Funding Medical Partners I, L.P. Northbrook, IL 60062
2000 Alameda de las Pulgas
San Mateo, CA 94403 Perry H. Bacon
5300 Mission Woods Road
Ronald Koenig Shawnee Mission, KS 66205
114 No. Village Way
Jupiter, Florida 33458 James J. Pelts
29 East Madison Street, Suite 1505
Robert M. Adams Chicago, IL 60602
P.O. Box 998
Plandome, NY 11030 The Marcus L. Koblitz Trust
Michael J. Koblitz, Trustee
Edward A. Kerbs 12 Downey Drive
8 South Cherry Lane Tenafly, NJ 07670
Rumson, NJ 07760
The Lauren J. Koblitz Trust,
Michael J. Koblitz, Trustee
12 Downey Drive
Tenafly, NJ 07670
37
<PAGE>
Pharmaceutical & Medical Technology Fund
300 Park Avenue
New York, NY 10022
Strategic Healthcare Fund
300 Park Avenue
New York, NY 10022
Michael J. Koblitz
12 Downey Drive
Tenafly, NJ 07670
38
<PAGE>
SCHEDULE 6.1
USE OF PROCEEDS
See "Use of Proceeds" on page 12 of the Memorandum.
<PAGE>
EXHIBIT A
This Warrant was originally issued on November 18, 1996, and such issuance
was not registered under the Securities Act of 1933, as amended. The
transfer of this Warrant and the securities obtainable upon exercise
thereof is subject to the conditions on transfer specified in the
Securities Purchase Agreement, dated as of November 18, 1996 (as amended
and modified from time to time), between the issuer hereof (the "COMPANY")
and the initial holder hereof, and the Company reserves the right to refuse
the transfer of such security until such conditions have been fulfilled
with respect to such transfer. Upon written request, a copy of such
conditions shall be furnished by the Company to the holder hereof without
charge.
LIFECELL CORPORATION
STOCK PURCHASE WARRANT
Date of Issuance: November 18, 1996 Certificate No. BW-___
FOR VALUE RECEIVED, LIFECELL Corporation, a Delaware corporation
(the "COMPANY"), hereby grants to _________________________________________ or
its registered assigns (the "REGISTERED HOLDER") the right to purchase from the
Company __________ shares of the Company's Common Stock, par value $.001 per
share ("COMMON STOCK"), at a price per share of $4.13 (as adjusted from time to
time hereunder, the "EXERCISE PRICE"). This Warrant is one of several warrants
(collectively, the "WARRANTS") issued by the Company to certain investors
pursuant to the Securities Purchase Agreement, dated as of November 18, 1996
(the "PURCHASE AGREEMENT"). Certain capitalized terms used herein are defined in
Section 5 hereof. The amount and kind of securities obtainable pursuant to the
rights granted hereunder and the purchase price for such securities are subject
to adjustment pursuant to the provisions contained in this Warrant.
This Warrant is subject to the following provisions:
Section 1. EXERCISE OF WARRANT.
1A. EXERCISE PERIOD. Subject to the provisions of Paragraph 1B, the
Registered Holder may exercise, in whole or in part (but not as to a fractional
share of Common Stock), the purchase rights represented by this Warrant at any
time and from time to time after the Date of Issuance to and including the fifth
anniversary thereof (the "EXERCISE PERIOD"). The Company shall give the
Registered Holder written notice of the expiration of the rights hereunder at
least 30 days but not more than 90 days prior to the end of the Exercise Period.
In the event the Company fails to give the Registered
<PAGE>
Holder such notice, the Exercise Period shall continue until and terminate on
the thirtieth calendar day following the day the Company gives such notice.
1B. MANDATORY EXERCISE. Notwithstanding the provisions of Paragraph
1A, during the period commencing with the second anniversary of the Date of
Issuance through the Exercise Period (the "MANDATORY EXERCISE PERIOD"), upon
written notice from the Company evidencing that the Current Market Price equals
or exceeds an amount equal to three times the then Exercise Price (the
"MANDATORY EXERCISE NOTICE"), the Registered Holder shall exercise all (but not
as to any fractional share of Common Stock) of the purchase rights represented
by this Warrant; provided that, notwithstanding the foregoing, the Registered
Holder shall have no obligation pursuant to this Paragraph 1B to exercise any
portion of the purchase rights represented by this Warrant on any date if on
such date or at any time during the 30 consecutive trading day period ending
immediately prior to such date the Common Stock is not listed or admitted to
trading on any national securities exchange and is not traded over the counter
and reported by Nasdaq or any comparable system. for purposes of this paragraph,
"CURRENT MARKET PRICE" means, at any date during the Mandatory Exercise Period,
the average of the daily closing price per share of Common Stock for the 30
consecutive trading day period during the Mandatory Exercise Period ending on
the trading day immediately before such date ( as adjusted for any stock
dividend, split, combination or reclassification that took effect during such 30
trading day period). The closing price for each day shall be the last reported
sale price on the principal national securities exchange on which Common Stock
is listed or admitted to trading or if not listed or admitted to trading on any
national securities exchange, as reported by Nasdaq, if such security is traded
over the counter and quoted in the Nasdaq National Market or Nasdaq Small Cap
Market, or if such equity security is so traded, but not so quoted, the closing
bid price of Common Stock as reported by Nasdaq or any comparable system. The
Registered Holder shall be required to exercise pursuant to Paragraph 1C all of
the then unexercised purchase rights represented by this Warrant no earlier than
the 30th day following the Registered Holder's receipt of the Mandatory Exercise
Notice.
1C. EXERCISE PROCEDURE.
(i) This Warrant shall be deemed to have been exercised at
such time when the Company has received all of the following items (the
"EXERCISE TIME"):
(a) a completed Exercise Agreement, as described in
Paragraph 1D, executed by the Person exercising all or part of the
purchase rights represented by this Warrant (the "PURCHASER");
(b) this Warrant;
3
<PAGE>
(c) if this Warrant is not registered in the name of the
Purchaser, an Assignment or Assignments in the form set forth in
EXHIBIT I hereto evidencing the assignment of this Warrant to the
Purchaser, in which case the Registered Holder shall have complied
with the provisions set forth in Section 7 hereof; and
(d) either (1) a check payable to the Company in an
amount equal to the product of the Exercise Price multiplied by the
number of shares of Common Stock being purchased upon such exercise
(the "AGGREGATE EXERCISE PRICE"), (2) the surrender to the Company
of debt or equity securities of the Company or any of its
wholly-owned Subsidiaries having a Market Price equal to the
Aggregate Exercise Price of the shares of Common Stock being
purchased upon such exercise (provided that for purposes of this
subparagraph 1C(i)(d), the Market Price of any note or other debt
security or any preferred stock shall be deemed to be equal to the
aggregate outstanding principal amount or liquidation value thereof
plus all accrued and unpaid interest thereon or accrued or declared
and unpaid dividends thereon) or (3) a written notice to the Company
that the Purchaser is exercising this Warrant (or a portion thereof)
by authorizing the Company to withhold from issuance a number of
shares of Common Stock issuable upon such exercise of this Warrant
which when multiplied by the Market Price of the Common Stock is
equal to the Aggregate Exercise Price (and such withheld shares
shall no longer be issuable under this Warrant).
(ii) Certificates for shares of Common Stock purchased upon
exercise of this Warrant shall be delivered by the Company to the Purchaser as
soon as practicable but in any event within ten business days after the date of
the Exercise Time. Unless this Warrant has expired or all of the purchase rights
represented hereby have been exercised, the Company shall prepare a new Warrant,
substantially identical hereto, representing the rights formerly represented by
this Warrant which have not expired or been exercised and shall within such
ten-day period, deliver such new Warrant to the Person designated for delivery
in the Exercise Agreement.
(iii) The shares of Common Stock issuable upon the exercise of
this Warrant shall be deemed to have been issued to the Purchaser at the
Exercise Time, and the Purchaser shall be deemed for all purposes to have become
record holder of such shares of Common Stock at the Exercise Time.
(iv) The issuance of certificates for shares of Common Stock
issued upon exercise of this Warrant shall be made without charge to the
Registered Holder for any issuance tax in respect thereof or other cost incurred
by the Company in connection with such exercise and the related issuance of
shares of Common Stock. Each share of Common Stock issuable upon exercise of
this Warrant shall, upon payment of the Exercise Price therefor, be fully paid
and nonassessable and free from all liens and
4
<PAGE>
charges with respect to the issuance thereof.
(v) The Company shall not close its books against the transfer
of this Warrant or of any share of Common Stock issued or issuable upon the
exercise of this Warrant in any manner which interferes with the timely exercise
of this Warrant. The Company shall from time to time take all such action as may
be necessary to assure that the part value per share of the unissued Common
Stock acquirable upon exercise of this Warrant is at all times equal to or less
than the Exercise Price then in effect.
(vi) The Company shall assist and cooperate with the
Registered Holder or the Purchaser, as the case may be, in connection with any
governmental filings or any governmental approvals required to be made or
obtained by the Registered Holder or the Purchaser, as the case may be, prior to
or in connection with any exercise of this Warrant (including, without
limitation, making any filings required to be made by the Company).
(vii) Notwithstanding any other provision hereof, if an
exercise of any portion of this Warrant is to be made in connection with a
registered public offering or the sale of the Company, such exercise may, at the
election of the holder hereof, be conditioned upon the consummation of the
public offering or sale of the Company in which case such exercise shall not be
deemed to be effective until the consummation of such transaction.
(viii) The Company shall at all times reserve and keep
available out of its authorized but unissued shares of Common Stock solely for
the purpose of issuance upon the exercise of the Warrants, such number of shares
of Common Stock issuable upon the exercise of all outstanding Warrants. All
shares of Common Stock which are so issuable shall, when issued, be duly and
validly issued, fully paid and nonassessable and free from all taxes, liens and
charges. The Company shall take all such actions as may be necessary to assure
that all such shares of Common Stock may be so issued without violation of any
applicable law or governmental regulation or any requirements of any domestic or
foreign securities exchange upon which shares of Common Stock may be listed
(except for official notice of issuance which shall be immediately delivered by
the Company upon each such issuance) including without limitation, the Nasdaq
National Market or the Nasdaq Small Cap Market (as the case may be). The Company
shall not take any action which would cause the number of authorized but
unissued shares of Common Stock to be less than the number of such shares
required to be reserved hereunder for issuance upon exercise of the Warrants.
1D. EXERCISE AGREEMENT. Upon any exercise of this Warrant, the
Exercise Agreement shall be substantially in the form set forth in EXHIBIT II
hereto, except that if the shares of Common Stock are not to be issued in the
name of
5
<PAGE>
the Person in whose name this Warrant is registered, the Exercise Agreement
shall also state the name of the Person to whom the certificates for the shares
of Common Stock are to be issued, and if the number of shares of Common Stock to
be issued does not include all shares of Common Stock purchasable hereunder, it
shall also state the name of the Person to whom a new Warrant for the
unexercised portion of the rights hereunder is to be delivered. Such Exercise
Agreement shall be dated the actual date of execution thereof.
1E. FRACTIONAL SHARES. If a fractional share of Common Stock would,
but for the provisions of Paragraph 1A and Paragraph 1B, as the case may be, be
issuable upon exercise of the rights represented by this Warrant, the Company
shall, within ten business days after the date of the Exercise Time, deliver to
the Purchaser a check payable to the Purchaser in lieu of such fractional share
in an amount equal to the difference between the Market Price of such fractional
share as of the date of the Exercise Time and the Exercise Price of such
fractional share.
Section 2. ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF SHARES. In
order to prevent dilution of the rights granted under this Warrant, the Exercise
Price shall be subject to adjustment from time to time as provided in this
Section 2, and the number of shares of Common Stock obtainable upon exercise of
this Warrant shall be subject to adjustment from time to time as provided in
this Section 2.
2A. ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF SHARES UPON ISSUANCE
OF COMMON STOCK.
(i) If and whenever on or after the Date of Issuance of this
Warrant the Company issues or sells, or in accordance with paragraph 2B is
deemed to have issued or sold, any shares of Common Stock (other than the
Excluded Stock) for a consideration per share less than the Exercise Price in
effect immediately prior to such time, then immediately upon such issue or sale
the Exercise Price shall be reduced to the Exercise Price determined by dividing
(A) the sum of (y) the product derived by multiplying
the Exercise Price in effect immediately prior to such issue or sale and the
number of shares of Common Stock Deemed Outstanding immediately prior to such
issue or sale plus (z) the consideration, if any, received by the Company upon
such issue or sale, by
(B) the number of shares of Common Stock Deemed
Outstanding immediately after such issue or sale.
(ii) Upon each such adjustment of the Exercise Price
hereunder, the number of shares of Warrant Stock acquirable upon exercise of
this Warrant shall be adjusted to the number of shares determined by multiplying
the Exercise Price in effect immediately prior to such adjustment by the number
of shares of Warrant Stock
6
<PAGE>
acquirable upon exercise of this Warrant immediately prior to such adjustment
and dividing the product thereof by the Exercise Price resulting from such
adjustment.
(iii) For purposes of this Section 2, "EXCLUDED STOCK" means
(1) Common Stock issued or reserved for issuance by the Company as a dividend on
Preferred Stock or upon any subdivision or split-up of the outstanding shares of
any shares of capital stock of the Company or any recapitalization thereof, or
upon conversion of any shares of Preferred Stock, (2) Common Stock issuable
pursuant to any portion or warrants or other rights that are outstanding on the
date of Issuance identified on SCHEDULE 3-2 - CAPITAL STOCK to the Purchase
Agreement, (3) Common Stock of the Company issued or issuable in connection with
a Board-approved acquisition of a business by the Company as a result of which
the Company owns in excess of 50% of the voting power of such business, (4)
Common Stock issued or issuable to employees, officers, consultants, directors
or vendors of the Company or pursuant to any Board-approved employee, officer,
consultant or director benefit plan, including without limitation any
Board-approved stock option plan, and (5) Common Stock issued or issuable to (x)
banks, savings and loan associations, equipment lessors or similar lending
institutions in connection with such entities providing Board-approved credit
facilities or equipment financings to the company or (y) any party to any
technology transfer agreement, distribution agreement, marketing agreement or
any other agreement similar thereto, with the Company, as approved by the Board.
2B. EFFECT ON EXERCISE PRICE OF CERTAIN EVENTS. For purposes of
determining the adjusted Exercise Price under Paragraph 2A, the following shall
be applicable:
(i) ISSUANCE OF RIGHTS OR OPTIONS. If the company in any
manner grants or sells any Options and the price per share for which Common
Stock is issuable upon the exercise of such Options, or upon conversion or
exchange of any Convertible Securities issuable upon exercise of such Options,
is less than the Exercise Price in effect immediately prior to the time of the
granting the sale of such Options, then the total maximum number of shares of
Common Stock issuable upon the exercise of such Options, or upon conversion or
exchange of the total maximum amount of such Convertible Securities issuable
upon the exercise of such Options, shall be deemed to be outstanding and to have
ben issued and sold by the Company at such time for such price per share. For
purposes of this paragraph, the "PRICE PER SHARE FOR WHICH COMMON STOCK IS
ISSUABLE UPON EXERCISE OF SUCH OPTIONS OR UPON CONVERSION OR EXCHANGE OF SUCH
CONVERTIBLE SECURITIES" is determined by dividing (A) the result of (i) the
total amount, if any, received or receivable by the Company as consideration for
the granting or sale of such Options, plus (ii) the minimum aggregate amount of
additional consideration payable to the Company upon the exercise of all such
Option, plus (iii) in the case of such Options which are exercisable into
Convertible Securities, the minimum aggregate amount of additional
consideration, if any, payable to the Company upon the issuance or sale of such
Convertible Securities and the conversation
7
<PAGE>
or exchange thereof, by (B) the total maximum number of shares of Common Stock
issuable upon exercise of such Options or upon the conversion or exchange of all
such Convertible Securities issuable upon the exercise of such Options. No
further adjustment of the Exercise Price shall be made upon the actual issuance
of such Common Stock or of such Convertible securities upon the exercise of such
Options or upon the actual issuance of such Common Stock upon conversion or
exchange of such Convertible Securities.
(ii) ISSUANCE OF CONVERTIBLE SECURITIES. If the Company in any
manner issues or sells any Convertible Securities and the price per share for
which Common Stock is issuable upon conversion or exchange thereof is less than
the Exercise Price in effect immediately prior to the time of such issue or
sale, then the maximum number of shares of Common Stock issuable upon conversion
or exchange of such Convertible Securities shall be deemed to be outstanding and
to have been issued and sold by the Company for such price per share. For the
purposes of this paragraph, the "PRICE PER SHARE FOR WHICH COMMON STOCK IS
ISSUABLE UPON CONVERSION OR EXCHANGE THEREOF" is determined by dividing (A) the
result of (i) the total amount received or receivable by the Company as
consideration for the issue or sale of such Convertible Securities, plus (ii)
the minimum aggregate amount of additional consideration, if any, payable to the
Company upon the conversation or exchange thereof, by (B) the total maximum
number of shares of Common Stock issuable upon the conversion or exchange of all
such Convertible Securities. No further adjustment of the Exercise Price shall
be made upon the actual issue of such Common Stock upon conversion or exchange
of such Convertible Securities, and if any such issue or sale of such
Convertible Securities is made upon exercise of any Options for which
adjustments of the Exercise Price had been or are to be made pursuant to other
provisions of this Paragraph 2B, no further adjustment of the Exercise Price
shall be made by reason of such issue or sale.
(iii) CHANGE IN OPTION PRICE OR CONVERSION RATE. If the
purchase price provided for in any Options, the additional consideration, if
any, payable upon the issue, conversion or exchange of any Convertible
Securities, or the rate at which any Convertible Securities are convertible into
or exchangeable for Common Stock changes at any time, the Exercise Price in
effect at the time of such change shall be adjusted immediately to the Exercise
Price which would have been in effect at such time had such Options or
Convertible Securities still outstanding provided for such changed purchase
price, additional consideration or changed conversion rate, as the case may be,
at the time initially granted, issued or sold and the number of shares of
Warrant Stock shall be correspondingly adjusted; provided that if such
adjustment would result in an increase of the Exercise Price then in effect,
such adjustment shall not be effective until 30 days after written notice
thereof has been given by the Company to all holders of the Warrants. For
purposes of this Paragraph 2B, if the terms of any Option or Convertible
Security which was outstanding as of the date of issuance of this Warrant are
changed in the manner described in the immediately preceding sentence,
8
<PAGE>
then such Option or Convertible Security and the Common Stock deemed issuable
upon exercise, conversation or exchange thereof shall be deemed to have been
issued as of the date of such change; provided that no such change shall at any
time cause the Exercise Price hereunder to be increased.
(iv) TREATMENT OF EXPIRED OPTIONS AND UNEXERCISED CONVERTIBLE
SECURITIES. Upon the expiration of any Option or the termination of any right to
convert or exchange any Convertible Securities without the exercise of such
Option or right, the Exercise Price then in effect and the number of shares of
Warrant Stock acquirable hereunder shall be adjusted immediately to the Exercise
Price and the number of shares which would have ben in effect at the time of
such expiration or termination had such Option or Convertible Securities to the
extent outstanding immediately prior to such expiration or termination, never
been issued; provided that if such expiration or termination would result in an
increase in the Exercise Price then in effect, such increase shall no be
effective until 30 days after written notice thereof has been given to all
holders of the Warrants. For purposes of this Paragraph 2B, the expiration or
termination of any Option or Convertible Security which was d as of the date of
issuance f this Warrant shall not cause the Exercise Price hereunder to be
adjusted unless, and only to the extent that, a change in the terms of such
Option or Convertible Security caused it to be deemed t have been issued after
the date of issuance of this Warrant.
(v) CALCULATION OF CONSIDERATION RECEIVED. If any Common
Stock, Options or Convertible Securities are issued or sold or deemed to have
been issued or sold for cash, the consideration received therefor shall be
deemed to be the gross amount (net of any underwriter, placement agent or broker
discounts and commissions) received by the Company therefor. In case any Common
Stock, Options or Convertible Securities are issued or sold for a consideration
other than cash, the amount of the consideration other than cash received by the
Company shall be the fair value of such consideration, except where such
consideration consists of securities, in which case the amount of consideration
received by the Company shall be the Market Price thereof as of the date of
receipt. In case any Common Stock, Options or Convertible Securities are issued
to the owners of the non-surviving entity in connection with any merger in which
the Company is the surviving entity the amount of consideration therefor shall
be deemed to be the fair value of such portion of the net assets and business of
the non-surviving entity as is attributable to such Common Stock, Options or
Convertible Securities, as the case may be. The fair value of any consideration
other than cash or securities shall be determined jointly by the Company and the
Registered Holders of the Warrants representing a majority of the shares of the
Warrant Stock obtainable upon exercise of such Warrants. If such parties are
unable to reach agreement within a reasonable period of time, such fair value
shall be determined by an appraiser jointly selected by the Company and the
Registered Holders of the Warrants representing a majority of the shares of
Warrant Stock obtainable upon exercise of such Warrants.
9
<PAGE>
The determination of such appraiser shall be final and binding on the Company
and the Registered Holders of such Warrants, and the fees and expenses of such
appraiser shall be paid by the Company.
(vi) INTEGRATED TRANSACTIONS. In case any Option is issued in
connection with the issue or sale of other securities of the Company, together
comprising one integrated transaction in which no specific consideration is
allocated to such Options by the parties thereto, the Options shall be deemed to
have been issued without consideration.
(vii) TREASURY SHARES. The number of shares of Common Stock
outstanding at any given time does not include shares owned or held by or for
the account of the Company or any subsidiary, and the disposition of any shares
so owned or held shall be considered an issue or sale of Common Stock.
(viii)RECORD DATE. If the Company takes a record of the
holders of Common Stock for the purpose of entitling them (A) to receive a
dividend or other distribution payable in Common Stock, Options or in
Convertible Securities of (B) to subscribe for or purchase Common Stock, Options
or Convertible Securities, then such record date shall be deemed to be the date
of the issue or sale of the shares of Common Stock deemed to have been issued or
sold upon the declaration of such dividend or the making of such other
distribution or the date of the granting of such right of subscription or
purchase, as the case may be.
2C. SUBDIVISION OR COMBINATION OF COMMON STOCK. If the Company at
any time subdivides (by any stock split, stock dividend, recapitalization or
otherwise) one or more classes of its outstanding shares of Common Stock into a
greater number of shares, the Exercise Price in effect immediately prior to such
subdivision shall be proportionately reduced and the number of shares of Warrant
Stock obtainable upon exercise of this Warrant shall be proportionately
increased. If the Company at any time combines (by reverse stock split or
otherwise) one or more classes of its outstanding shares of Common Stock into a
smaller number of shares, the Exercise Price in effect immediately prior to such
combination shall be proportionately increased and the number of shares of
Warrant Stock obtainable upon exercise of this Warrant shall be proportionately
decreased.
2D. REORGANIZATION, RECLASSIFICATION, CONSOLIDATION, MERGER OR SALE.
Any recapitalization, reorganization, reclassification, consolidation, merger,
sale of all or substantially all of the Company's assets or other transaction,
which in each case is effective in such a way that the holders of Common Stock
are entitled to receive (either directly or upon subsequent liquidation) stock,
securities or assets with respect to or in exchange for Common Stock is referred
to herein as "ORGANIC CHANGE". Prior to the consummation of any Organic Change,
the Company shall make appropriate provision
10
<PAGE>
(in form and substance satisfactory to the Registered Holders of the Warrants
representing a majority of the shares of Warrant Stock obtainable upon exercise
of all Warrants then outstanding) to insure that each of the Registered Holders
of the Warrants shall thereafter have the right to acquire and receive, in lieu
of or addition to (as the case may be) the shares of Warrant Stock immediately
theretofore acquirable and receivable upon the exercise of such holder's
Warrant, such shares of stock, securities or assets as may be issued or payable
with respect to or in exchange for the number of shares of Warrant Stock
immediately theretofore acquirable and receivable upon exercise of such holder's
Warrant had such Organic Change not taken place. In any such case, the Company
shall make appropriate provision (in form and substance satisfactory to the
Registered Holders of the Warrants representing a majority of the shares of
Warrant Stock obtainable upon exercise of all of the Warrants then outstanding)
with respect to such Registered Holders' rights and interests to insure that the
provisions of this Section 2 and Sections 3 and 4 hereof shall thereafter be
applicable to the Warrants (including, in the case of any such consolidation,
merger or sale in which the successor entity or purchasing entity is other than
the Company and in which the value for the Common Stock reflected by the terms
of such consolidation, merger or sale is less than the Base Price in effect
immediately prior to such consolidation, merger or sale, an immediate adjustment
of the Exercise Price to the product of such Exercise Price immediately prior to
such consolidation, merger or sale multiplied by the ratio of such value of the
Common Stock divided by the Base Price in effect immediately prior to such
consolidation, merger or sale and a corresponding immediate adjustment in the
number of shares of Warrant Stock acquirable and receivable upon exercise of the
Warrants). The Company shall not effect any such consolidation, merger or sale,
unless prior to the consummation thereof, the successor entity (if other than
the Company) resulting from consolidation or merger or the entity purchasing
such assets assumes by written instrument (in form and substance satisfactory to
the Registered Holders of the Warrants representing a majority of the Warrant
Stock obtainable upon exercise of all of the Warrants then outstanding), the
obligation to deliver to each such Registered Holder such shares of stock,
securities or assets as, in accordance with the foregoing provisions, such
Registered Holder may be entitled to acquire.
2E. CERTAIN EVENTS. If any event occurs of the type contemplated by
the provisions of Section 2A but not expressly provided for by such provisions,
then the Exercise Price and the number of shares of Warrant Stock obtainable
upon exercise of this Warrant shall be adjusted by the Corporation's Board of
Directors in good faith so as to protect the rights of the holders of the
Warrants; provided that no such adjustment shall increase the Exercise Price or
decrease the number of shares of Warrant Stock obtainable as otherwise
determined pursuant to this Section 2.
2F. NOTICES.
11
<PAGE>
(i) Immediately upon any adjustment of the Exercise Price, the
Company shall give written notice thereof to the Registered Holder, setting
forth in reasonable detail and certifying the calculation of such adjustment.
(ii) The Company shall give written notice to the Registered
Holder at least 20 days prior to the date on which the Company closes its books
or takes a record (A) with respect to any dividend or distribution upon shares
of Common Stock, (B) with respect to any pro rata subscription offer to holders
of Common Stock or (C) for determining rights to vote with respect to any
Organic Change, dissolution or liquidation.
(iii) The Company shall also give written notice to the
Registered Holders at least 20 days prior to the date on which any Organic
Change, dissolution or liquidation shall take place.
Section 3. LIQUIDATING DIVIDENDS. If the Company declares or pays a
dividend upon shares of Common Stock payable otherwise than in cash out of
earnings or earned surplus (determined in accordance with generally accepted
accounting principles, consistently applied) except for a stock dividend payable
in shares of Common Stock (a "LIQUIDATING DIVIDEND"), then the Company shall pay
to the Registered Holder at the time of payment thereof the Liquidating Dividend
which would have been paid to the Registered Holder on the Warrant Stock had
this Warrant been fully exercised immediately prior to the date on which a
record is taken for such Liquidating Dividend, or, if no record is taken, the
date as of which the record holders of Common Stock entitled to such dividends
are to be determined.
Section 4. PURCHASE RIGHTS. If at any time the Company grants,
issues or sells any Options, Convertible Securities or warrants, securities or
other like property pro rate to the record holders of any class of Common Stock
(the "PURCHASE RIGHTS"), then the Registered Holder shall be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate
Purchase Rights which such Registered Holder could have acquired if such
Registered Holder had held the number of shares of Common Stock acquirable upon
complete exercise of this Warrant immediately before the date on which a record
is taken for the grant, issuance or sale of such Purchase Rights, or, if no such
record is taken, the date as of which the record holders of Common Stock are to
be determined for the grant, issue or sale of such Purchase Rights.
Section 5. DEFINITIONS. The following terms have meanings set forth
below:
"BOARD" means the Company's Board of Directors.
"COMMON STOCK" means the Company's Common Stock, $0.001 par value,
and
12
<PAGE>
except for purposes of the shares obtainable upon exercise of this Warrant,
any capital stock of any class of the Company hereafter authorized which is not
limited to a fixed sum or percentage of par or stated value in respect to the
rights of the holders thereof to participate in dividends or in the distribution
of assets upon any liquidation, dissolution or winding up of the Company.
"COMMON STOCK DEEMED OUTSTANDING" means, at any given time, the
number of shares of Common Stock actually outstanding at such time, plus the
number of shares of Common Stock deemed to be outstanding pursuant to paragraphs
2B(i) and 2B(ii) hereof regardless of whether the Options or Convertible
Securities are actually exercisable or convertible at such time.
"CONVERTIBLE SECURITIES" means any stock or securities (directly or
indirectly) convertible into or exchangeable for Common Stock.
"MARKET PRICE" means as to any security the average of the closing
prices of such security's sales on all domestic or foreign securities exchanges
on which such security may at the time be listed, or, if there have been no
sales on any such exchange on any day, the average of the highest bid and lowest
asked prices on all such exchanges at the end of such day, or, if on any day
such security is not so listed, the average of the representative bid and asked
prices quoted in the Nasdaq National Market or Nasdaq Small Cap Market, as of
4:00 P.M., New York time, on such day, or, if on any day such security is not
quoted in the Nasdaq National Market or the Nasdaq Small Cap Market (as
applicable), the average of the highest bid and lowest asked prices on such day
in the domestic over-the-counter market as reported by the National Quotation
Bureau, Incorporated, or any similar successor organization, in each such case
averaged over a period of 30 days consisting of the day as of which "MARKET
PRICE" is being determined and the 29 consecutive business days prior to such
day; provided that if such security is listed on any domestic securities
exchange the term "BUSINESS DAYS" as used in this sentence means business days
on which such exchange is open for trading. If at any time such security is not
listed on any domestic securities exchange or quoted in the Nasdaq National
Market System or the Nasdaq Small Cap Market or the domestic over-the-counter
market, the "MARKET PRICE" shall be the fair value thereof determined jointly by
the Company and the Registered Holders of Warrants representing a majority of
the Common Stock purchasable upon exercise of all the Warrants then outstanding,
provided that if such parties are unable to reach agreement within a reasonable
period of time, such fair value shall be determined by an appraiser jointly
selected by the Company and the Registered Holders of the Warrants representing
a majority of the shares of Common Stock purchasable upon exercise of all the
Warrants then outstanding. The determination of such appraiser shall be final
and binding on the Company and the Registered Holders of the Warrants, and the
fees and expenses of such appraiser shall be paid by the Company.
13
<PAGE>
"OPTION" means any rights to subscribe for or purchase Common Stock
or Convertible Securities.
"PERSON" means an individual, a partnership, a joint venture, a
corporation, a limited liability company, a trust, an unincorporated
organization and a government or any department or agency thereof.
"WARRANT STOCK" means Common Stock; provided that if there is a
change such that the securities issuable upon exercise of the Warrants are
issued by an entity other than the Company or there is a change in the type or
class of securities so issuable, then the term "WARRANT STOCK" shall mean one
share of the security issuable upon exercise of the Warrants if such security is
issuable in shares, or shall mean the smallest unit in which such security is
issuable if such security is not issuable in shares.
Other capitalized terms used in this Warrant but not defined herein
shall have the meanings set forth in the Purchase Agreement.
Section 6. NO VOTING RIGHTS; LIMITATIONS OF LIABILITY. This Warrant
shall not entitle the holder hereof to any voting rights or other rights as a
stockholder of the Company. No provision hereof, in the absence of affirmative
action by the Registered Holder to purchase Common Stock, and no enumeration
herein of the rights or privileges of the Registered Holder shall give rise to
any liability of such holder for the Exercise Price of Common Stock acquirable
by exercise hereof or as a stockholder of the Company.
Section 7. WARRANT TRANSFERABLE. Subject to the transfer conditions
referred to in the legend endorsed hereon, this Warrant and all rights hereunder
are transferable, in whole or in part, without charge to the Registered Holder,
upon surrender of this Warrant with a properly executed Assignment (in the form
of EXHIBIT I hereto) at the principal office of the Company.
Section 8. WARRANT EXCHANGEABLE FOR DIFFERENT DENOMINATIONS. This
Warrant is exchangeable, upon the surrender hereof by the Registered Holder at
the principal office of the Company, for new Warrants of like tenor representing
in the aggregate the purchase rights hereunder, and each of such new Warrants
shall represent such portion of such rights as is designated by the Registered
Holder at the time of such surrender. The date the Company initially issues this
Warrant shall be deemed to be the "DATE OF ISSUANCE" hereof regardless of the
number of times new certificates representing the unexpired and unexercised
rights formerly represented by this Warrant shall be issued. All Warrants
representing portions of the rights hereunder are referred to herein as the
"WARRANTS."
14
<PAGE>
Section 9. REPLACEMENT. Upon receipt of evidence reasonably
satisfactory to the Company (an affidavit of the Registered Holder shall be
satisfactory) of the ownership and the loss, theft, destruction or mutilation of
any certificate evidencing this Warrant, and in the case of any such loss, theft
or destruction, upon receipt of indemnity reasonably satisfactory to the Company
(provided that if the holder is a financial institution or other institutional
investor its own agreement shall be satisfactory), or in the case of any such
mutilation upon surrender of such certificate of like kind representing the same
rights represented by such loss, stolen, destroyed or mutilated certificate and
dated the date of such loss, stolen, destroyed or mutilated certificate.
Section 10. NOTICES. Except as otherwise expressly provided herein, all
notices referred to in this Warrant shall be in writing and shall be delivered
personally, sent by reputable overnight courier service (charges prepaid) or
sent by registered or certified mail, return receipt requested, postage prepaid
and shall b deemed to have been given when so delivered, sent or deposited in
the U.S. Mail (i) to the Company, at its principal executive offices and (ii) to
the Registered Holder of this Warrant, at such holder's address as it appears in
the records of the Company (unless otherwise indicated by any such holder).
Section 11. AMENDMENT AND WAIVER. Except as otherwise provided
herein, the provisions of the Warrants may be amended and the Company may take
any action herein prohibited, or omit to perform any act herein required to be
performed by it, only if the Company has obtained the written consent of the
Registered Holders of Warrants representing a majority of the shares of Common
Stock obtainable upon exercise of all of the Warrants then outstanding; provided
that no such action may change the Exercise Price of the Warrants or the number
of shares or class of stock obtainable upon exercise of each Warrant without the
written consent of the Registered Holders of Warrants representing at least 80%
of the shares of Common Stock obtainable upon exercise of the Warrants then
outstanding.
Section 12. DESCRIPTIVE HEADINGS; GOVERNING LAW. The descriptive
headings of the several Sections and paragraphs of this Warrant are inserted for
convenience only and do not constitute a part of this Warrant. The corporation
laws of the State of Delaware shall govern all issues concerning the rights of
the Company and all rights of the Company's stockholders relative to the
Company. All other questions concerning the construction, validity, enforcement
and interpretation of this Warrant shall be governed by the internal law of the
State of New York, without giving effect to any choice of law or conflict of law
provision or rule (whether of the State of New York or any other jurisdictions)
that would cause the application of the laws of any jurisdictions other than the
State of New York.
* * * * * *
15
<PAGE>
IN WITNESS WHEREOF, the Company has caused this Warrant to be signed
by its duly authorized officer and to be dated the Date of Issuance.
LIFECELL CORPORATION
By
Paul M. Frison
President and Chief Executive Officer
16
<PAGE>
EXHIBIT I
ASSIGNMENT
FOR VALUE RECEIVED,________________ hereby sells, assigns and
transfers all of the rights of the undersigned under the attached Warrant
(Certificate No. BW-______) with respect to the number of shares of the Common
Stock covered thereby set forth below, unto:
NAMES OF ASSIGNEE ADDRESS NO. OF SHARES
Signature
Witness
17
<PAGE>
EXHIBIT B
LIFECELL CORPORATION
CERTIFICATE OF DESIGNATION
OF SERIES B PREFERRED STOCK
Pursuant to Section 151 of the
General Corporation Law of the State of Delaware
LifeCell Corporation (the "Corporation"), a corporation organized
and existing under and by virtue of the General Corporation Law of the State of
Delaware, does hereby certify:
FIRST: That the Board of Directors of the Corporation, pursuant to a
unanimous consent of the Board of Directors dated as of November 6, 1996, duly
adopted the following resolution:
RESOLVED, that pursuant to the authority expressly granted to and
vested in the Board of Directors of the Corporation by the provisions of the
Restated Certificate of Incorporation of the Corporation, out of the authorized
but unissued shares of Preferred Stock of the Corporation this Board of
Directors hereby creates a series of the Preferred Stock, par value $.001 per
share (the "Preferred Stock"), of the Corporation, and this Board of Directors
hereby fixes the powers, designations, preferences and relative, participating,
optional or other special rights of the shares of such series, and the
qualifications, limitations or restrictions thereof (in addition to the powers,
designations, preferences and relative, participating, optional or other special
rights, and the qualifications, limitations or restrictions thereof, set forth
in the Restated Certificate of Incorporation of the Corporation which are
applicable to Preferred Stock of all series) as follows:
1. DESIGNATION. The designation of the series shall be "Series B
Preferred Stock" (the "Series B Preferred Stock").
2. NUMBER. The number of shares constituting the Series B Preferred
Stock shall be 182,205.
18
<PAGE>
3. VOTING RIGHTS.
(a) GENERAL. Each share of Series B Preferred Stock shall
entitle the holder thereof to one vote for each share of Common Stock, $.001 par
value per share, of the Corporation (the "Common Stock"), into which such share
of Series B Preferred Stock is convertible on the record date for such vote on
all matters submitted to a vote of the stockholders of the Corporation.
(b) DIRECTORS. At any meeting of the stockholders of the
Corporation held for the election of directors, the holders of Series B
Preferred Stock, voting separately as a series, shall be entitled to elect three
members of the Board of Directors of the Corporation.
(c) OTHER. Without the vote or consent of the holders of at
least a majority of the shares of Series B Preferred Stock then outstanding, the
Corporation may not authorize or create any class or series of capital stock
ranking prior to or on a parity with the Series B Preferred Stock either as to
redemption or liquidation.
4. LIQUIDATION.
(a) PREFERENCE. The Series B Preferred Stock shall rank on a
parity with the Series A Preferred Stock, $.001 par value per share, of the
Corporation (the "Series A Preferred Stock"), with respect to liquidation. All
capital stock of the Corporation other than the Series A Preferred Stock and the
Series B Preferred Stock is referred to herein as the "Junior Securities". In
the event of any liquidation,
19
<PAGE>
dissolution or winding up of the affairs of the Corporation, whether voluntary
or involuntary, each holder of record of the issued and outstanding shares of
Series B Preferred Stock shall be entitled to receive, out of the assets of the
Corporation available for distribution to the holders of shares of Series B
Preferred Stock, prior and in preference to any distribution of any of the
assets of the Corporation to the holders of Junior Securities, an amount in cash
equal to the aggregate Liquidation Value (as defined below) of all shares of
Series B Preferred Stock then held by such holder, plus an amount equal to all
dividends accrued and unpaid on such shares (whether or not declared) up to the
date fixed for distribution. If, upon such liquidation, dissolution or winding
up of the affairs of the Corporation, the assets of the Corporation
distributable among the holders of Series B Preferred Stock, the Series A
Preferred Stock and any other series of Preferred Stock ranking on a parity
therewith in respect thereto or any class or series of capital stock of the
Corporation ranking on a parity therewith in respect thereto shall be
insufficient to permit the payment in full to all such holders of shares of the
preferential amounts payable to them, then the entire assets of the Corporation
available for distribution to such holders of such shares shall be distributed
ratably among such holders in proportion to the respective amounts that would be
payable per share if such assets were sufficient to permit payment in full. Not
less than 30 days prior to the payment date stated therein, the Corporation
shall mail written notice of any such liquidation, dissolution or winding up to
each record holder of the Series B Preferred Stock, setting forth in reasonable
detail the amount of proceeds to be paid with respect to each share of Series B
Preferred Stock and each share of Common Stock in connection with such
liquidation, dissolution or winding up.
(b) After payment of the full amount to which they are
entitled upon liquidation pursuant to Section 4(a), the holders of shares of
Series B Preferred Stock shall be entitled to participate ratably in any
distribution of any remaining assets of the Corporation legally available for
distribution to the holders of Common Stock with the holders of record of the
then issued and outstanding shares of Common Stock, as a single class, on the
basis of the number of shares held by each such holder of Series B Preferred
Stock (for the purposes of this Section 4(b), treating such shares of Series B
Preferred Stock as if converted into shares of Common Stock pursuant to the
provisions of this Certificate).
(c) LIQUIDATION VALUE; ADJUSTMENTS. "The Liquidation Value" of
any particular share of Series B Preferred Stock as of any particular date shall
equal $100.00. The Liquidation Value shall be equitably adjusted by the
Corporation to reflect any stock dividend, stock distribution, stock split or
reverse stock split, combination of shares, subdivision of shares or
reclassification of shares with respect to the Series B Preferred Stock.
5. CONVERSION RIGHTS. The Series B Preferred Stock shall be
convertible as follows:
(a) OPTIONAL CONVERSION. Subject to and upon compliance with
the provisions of this Section 5, the holder of any shares of Series B Preferred
Stock shall have the right at such holder's option, at any time or from time to
time, and without the payment of any additional consideration therefor, to
convert any of such shares of Series B Preferred Stock into fully paid and
nonassessable shares of Common Stock at the Conversion Price (as defined in
Section 5(c) below) in effect on any Conversion Date (as defined in Section 5(d)
below) upon the terms hereinafter set forth.
(b) AUTOMATIC CONVERSION. Each outstanding share of Series B
Preferred Stock shall automatically be converted, without any further act of the
Corporation or its stockholders, at the Conversion Price then in effect, into
fully paid and nonassessable shares of Common Stock on the earlier to occur of
the following:
(i) the date of the closing of an underwritten public
offering pursuant to an effective registration statement under the
Securities Act of 1933, as amended (the "Securities Act"), covering
the offering and sale of Common Stock, or of any equity security
that as a part of a unit includes Common Stock, for the account of
the Corporation, in which the aggregate gross proceeds received by
the Corporation, net of any underwriter discounts or commissions,
equals or exceeds $20,000,000, and in which the public offering
price per share of Common Stock equals or exceeds $9.30 (as
equitably adjusted to reflect any stock dividend, stock
distribution, stock split or reverse stock split, combination of
shares, subdivision of shares or reclassification of shares); and
20
<PAGE>
(ii) the date first occurring after the closing of an
underwritten public offering pursuant to an effective registration
statement under the Securities Act covering the offering and sale of
Common Stock, or of any equity security that as a part of a unit
includes Common Stock, for the account of the Corporation, in which
the aggregate gross proceeds received by the Corporation, net of any
underwriter discounts or commissions, equals or exceeds $20,000,000,
on which the Current Market Price (as defined in the first sentence
of Section 5(j) below) of the Common Stock equals or exceeds $9.30
(as equitably adjusted to reflect any stock dividend, stock
distribution, stock split or reverse stock split, combination of
shares, subdivision of shares or reclassification of shares).
(c) NUMBER OF CONVERSION SHARES. Each share of Series B
Preferred Stock shall be convertible pursuant to Sections 5(a) and 5(b) into a
number of shares of Common Stock determined by dividing (i) the Liquidation
Value (as it may be adjusted pursuant to Section 4(c) hereof) by (ii) the
Conversion Price in effect on any Conversion Date. For the purposes of this
Section 5, the term "Conversion Price" shall initially mean $3.10. In order to
prevent dilution of the conversion rights granted under this Section 5, the
Conversion Price shall be subject to adjustment from time to time pursuant to
Section 5(f).
(d) CONVERSION PROCEDURES. The holder of any shares of Series
B Preferred Stock may exercise the conversion right specified in Section 5(a) by
surrendering to the Corporation or any transfer agent of the Corporation the
certificate or certificates for the shares to be converted, accompanied by
written notice specifying the number of shares to be converted. Upon the
occurrence of automatic conversion pursuant to Section 5(b), the outstanding
shares of Series B Preferred Stock shall be converted automatically without any
further action by the holders of such shares and whether or not the certificates
representing such shares are surrendered to the Corporation or its transfer
agent; provided that the Corporation shall not be obligated to issue to any
holder certificates evidencing the shares of Common Stock issuable upon such
conversion unless certificates evidencing such shares of Series B Preferred
Stock are delivered either to the Corporation or any transfer agent of the
Corporation. Conversion shall be deemed to have been effected on the date when
delivery of notice of an election to convert and of certificates for shares
being converted is made or on a date specified in Section 5(b), as the case may
be, and such date is referred to herein as the "Conversion Date". Subject to the
provisions of Section 5(f)(iv), as promptly as practicable thereafter (and after
surrender of the certificate or certificates representing shares of Series B
Preferred Stock to the Corporation or any transfer agent of the Corporation in
the case of conversion pursuant to Section 5(b)) the Corporation shall issue and
deliver to or upon the written order of such holder a certificate or
certificates for the number of full shares of Common Stock to which such holder
is entitled and a check or cash with respect to any fractional interest in a
share of Common Stock as provided in Section 5(e). Subject to the provisions of
Section 5(f)(iv), the person in whose name the certificate or certificates
21
<PAGE>
for Common Stock are to be issued shall be deemed to have become a holder of
record of such Common Stock on the applicable Conversion Date. Upon conversion
of only a portion of the number of shares covered by a certificate representing
shares of Series B Preferred Stock surrendered for conversion (in the case of
conversion pursuant to Section 5(a)), the Corporation shall issue and deliver to
or upon the written order of the holder of the certificate so surrendered for
conversion, at the expense of the Corporation, a new certificate covering the
number of shares of Series B Preferred Stock representing the unconverted
portion of the certificate so surrendered.
(e) FRACTIONAL SHARES. No fractional shares of Common Stock or
scrip shall be issued upon conversion of shares of Series B Preferred Stock. If
more than one share of Series B Preferred Stock shall be surrendered for
conversion at any one time by the same holder or shall be held by the same
holder at the time of any automatic conversion, the number of full shares of
Common Stock issuable upon conversion thereof shall be computed on the basis of
the aggregate number of shares so surrendered or held, as the case may be.
Instead of any fractional shares of Common Stock which would otherwise be
issuable upon conversion of any shares of Series B Preferred Stock, the
Corporation shall pay out of funds legally available therefor a cash adjustment
in respect of such fractional interest, rounded to the nearest one hundredth
(1/100th) of a share, in an amount equal to that fractional interest of the then
Current Market Price (as defined in Section 5(j) below), rounded to the nearest
cent ($.01).
(f) CONVERSION PRICE ADJUSTMENTS. The Conversion Price shall
be subject to adjustment from time to time as follows:
(i) If and whenever on or after the date of the original
issuance of the Series B Preferred Stock, the Corporation issues or
sells, or in accordance with Section 5(g) is deemed to have issued
or sold, any shares of its Common Stock (other than Excluded Stock)
for a consideration per share less than the Conversion Price in
effect immediately prior to the time of such issue or sale, or
deemed issue or sale then immediately upon such issue or sale or
deemed issue or sale the Conversion Price shall be reduced to the
Conversion Price determined by dividing (A) the sum of (1) the
product derived by multiplying the Conversion Price in effect
immediately prior to such issue or sale or deemed issue or sale by
the number of shares of Common Stock Deemed Outstanding immediately
prior to such issue or sale or deemed issue or sale, plus (2) the
consideration, if any, received by the Corporation upon such issue
or sale or deemed issue or sale, by (B) the number of shares of
Common Stock Deemed Outstanding immediately after such issue or sale
or deemed issue or sale.
22
<PAGE>
(ii) For purposes of this Section 5, "Excluded Stock"
means (A) Common Stock issued or reserved for issuance by the
Company as a dividend on Preferred Stock or upon any subdivision or
split-up of the outstanding shares of any shares of capital stock of
the Company or any recapitalization thereof, or upon conversion of
any shares of Preferred Stock, (B) Common Stock issuable pursuant to
any options, warrants or other rights that are outstanding on the
effective date of this Certificate, (C) Common Stock issued or
issuable in connection with a Board-approved acquisition of a
business by the Company as a result of which the Company owns in
excess of 50% of the voting power of such business, (D) Common Stock
issued or issuable to employees, officers, consultants, directors or
vendors of the Company or pursuant to any Board-approved employee,
officer, consultant or director benefit plan, including without
limitation any stock option plan, and (E) Common Stock issued or
issuable to (1) banks, savings and loan associations, equipment
lessors or similar lending institutions in connection with such
entities providing Board-approved credit facilities or equipment
financings to the Company or (2) any party to any technology
transfer agreement, distribution agreement, marketing agreement or
any other agreement similar thereto, with the Company, as approved
by the Board. For purposes of this Section 5, "Common Stock Deemed
Outstanding" means, at any given time, the number of shares of
Common Stock actually outstanding at such time, plus the number of
shares of Common Stock deemed to be outstanding pursuant to Sections
5(g)(i) and 5(g)(ii) hereof regardless of whether Options (as
defined below) or Convertible Securities (as defined below) are
actually exercised or converted at such time.
(iii) All calculations under this Section 5(f) shall be
made to the nearest cent ($.01) or to the nearest one hundredth
(1/100th) of a share, as the case may be. Any provision of this
Section 5 to the contrary notwithstanding, no adjustment in the
Conversion Price shall be made if the amount of such adjustment
would be less than 1% of the then current Conversion Price until the
end of the calendar year after such adjustment would otherwise have
been required; but any such amount shall be carried forward and an
adjustment with respect thereto shall be made at the time of and
together with any subsequent adjustment which, together with such
amount and any other amount or amounts so carried forward, shall
aggregate 1% of the then current Conversion Price or more, provided
that if the events giving rise to such adjustments occur within
three months of each other, then such adjustments shall be
calculated as if these events giving rise to them had occurred
simultaneously on the date of the first such event.
(iv) In any case in which the provisions of this Section
5(f) shall require that an adjustment shall become effective
immediately after a record date for an event, the Corporation may
defer until the occurrence of such event
23
<PAGE>
(A) issuing to the holder of any share of Series B Preferred Stock
converted after such record date and before the occurrence of such
event the additional shares of Common Stock issuable upon such
conversion by reason of the adjustment required by such event over
and above the shares of Common Stock issuable upon such conversion
before giving effect to such adjustment and (B) paying to such
holder any amount of cash in lieu of a fractional share of Common
Stock pursuant to Section 5(e); provided that the Corporation upon
request shall deliver to such holder a due bill or other appropriate
instrument evidencing such holder's right to receive such additional
shares, and such cash, upon the occurrence of the event requiring
such adjustment.
(g) EFFECT ON CONVERSION PRICE OF CERTAIN EVENTS. For purposes
of determining the adjusted Conversion Price under Section 5(f), the following
shall be applicable:
(i) ISSUANCE OF RIGHTS OR OPTIONS. If the Corporation in
any manner grants or sells any rights to subscribe for or purchase
Common Stock or Convertible Securities ("Options") and the price per
share for which Common Stock is issuable upon the exercise of such
Options, or upon conversion or exchange of any stock or securities
(directly or indirectly) convertible into or exchangeable for Common
Stock ("Convertible Securities") issuable upon exercise of such
Options, is less than the Conversion Price in effect immediately
prior to the time of the granting or sale of such Options, then the
total maximum number of shares of Common Stock issuable upon the
exercise of such Options or upon conversion or exchange of the total
maximum amount of such Convertible Securities issuable upon the
exercise of such Options shall be deemed to be outstanding and to
have been issued and sold by the Corporation at the time of the
granting or sale of such Options for such price per share. For
purposes of this paragraph, the "price per share for which Common
Stock is issuable" shall be determined by dividing (A) the total
amount, if any, received or receivable by the Corporation as
consideration for the granting or sale of such Options, plus the
minimum aggregate amount of additional consideration payable to the
Corporation upon exercise of all such Options, plus in the case of
such Options which relate to Convertible Securities, the minimum
aggregate amount of additional consideration, if any, payable to the
Corporation upon the issuance or sale of such Convertible Securities
and the conversion or exchange thereof, by (B) the total maximum
number of shares of Common Stock issuable upon the exercise of such
Options or upon the conversion or exchange of all such Convertible
Securities issuable upon the exercise of such Options. No further
adjustment of the Conversion Price shall be made when Convertible
Securities are actually issued upon the exercise of such Options or
when Common Stock is actually issued upon the exercise of such
Options or the conversion or exchange of such Convertible
Securities.
24
<PAGE>
(ii) ISSUANCE OF CONVERTIBLE SECURITIES. If the
Corporation in any manner issues or sells any Convertible Securities
and the price per share for which Common Stock is issuable upon
conversion or exchange thereof is less than the Conversion Price in
effect immediately prior to the time of such issue or sale, then the
maximum number of shares of Common Stock issuable upon conversion or
exchange of such Convertible Securities shall be deemed to be
outstanding and to have been issued and sold by the Corporation at
the time of the issuance or sale of such Convertible Securities for
such price per share. For the purposes of this paragraph, the "price
per share for which Common Stock is issuable" shall be determined by
dividing (A) the total amount received or receivable by the
Corporation as consideration for the issue or sale of such
Convertible Securities, plus the minimum aggregate amount of
additional consideration, if any, payable to the Corporation upon
the conversion or exchange thereof, by (B) the total maximum number
of shares of Common Stock issuable upon the conversion or exchange
of all such Convertible Securities. No further adjustment of the
Conversion Price shall be made when Common Stock is actually issued
upon the conversion or exchange of such Convertible Securities, and
if any such issue or sale of such Convertible Securities is made
upon exercise of any Options for which adjustments of the Conversion
Price had been or are to be made pursuant to other provisions of
this Section 5(g), no further adjustment of the Conversion Price
shall be made by reason of such issue or sale.
(iii) CHANGE IN OPTION PRICE OR CONVERSION RATE. If the
purchase price provided for in any Options, the additional
consideration, if any, payable upon the conversion or exchange of
any Convertible Securities or the rate at which any Convertible
Securities are convertible into or exchangeable for Common Stock
changes at any time, the Conversion Price in effect at the time of
such change shall be immediately adjusted to the Conversion Price
which would have been in effect at such time had such Options or
Convertible Securities still outstanding provided for such changed
purchase price, additional consideration or conversion rate, as the
case may be, at the time initially granted, issued or sold; provided
that if such adjustment would result in an increase of the
Conversion Price then in effect, such adjustment shall not be
effective until 30 days after written notice thereof has been given
by the Corporation to all holders of the Series B Preferred Stock.
For purposes of this Section 5(g), if the terms of any Option or
Convertible Security which was outstanding as of the date of
issuance of the Series B Preferred Stock are changed in the manner
described in the immediately preceding sentence, then such Option or
Convertible Security and the Common Stock deemed issuable upon
exercise, conversion or exchange thereof shall be deemed to have
been issued as of the date of such change.
(iv) TREATMENT OF EXPIRED OPTIONS AND UNEXERCISED
CONVERTIBLE
25
<PAGE>
SECURITIES. Upon the expiration of any Option or the termination of
any right to convert or exchange any Convertible Security without
the exercise of any such Option or right, the Conversion Price then
in effect hereunder shall be adjusted immediately to the Conversion
Price which would have been in effect at the time of such expiration
or termination had such Option or Convertible Security, to the
extent outstanding immediately prior to such expiration or
termination, never been issued; provided that if such expiration or
termination would result in an increase in the Conversion Price in
effect, such increase shall not be effective until 30 days after
written notice thereof has been given to all holders of the Series B
Preferred Stock. For purposes of this Section 5(g), the expiration
or termination of any Option or Convertible Security which was
outstanding as of the date of issuance of the Series B Preferred
Stock shall not cause the Conversion Price hereunder to be adjusted
unless, and only to the extent that, a change in the terms of such
Option or Convertible Security caused it to be deemed to have been
issued after the date of issuance of the Series B Preferred Stock.
(v) CALCULATION OF CONSIDERATION RECEIVED. If any Common
Stock, Option or Convertible Security is issued or sold or deemed to
have been issued or sold for cash, the consideration received
therefor shall be deemed to be the gross amount received by the
Corporation therefor (net of any underwriter, placement agent or
broker discounts and commissions). If any Common Stock, Option or
Convertible Security is issued or sold for a consideration other
than cash, the amount of the consideration other than cash received
by the Corporation shall be the fair value of such consideration,
except where such consideration consists of securities, in which
case the amount of consideration received by the Corporation shall
be the Current Market Price thereof as of the date of receipt. If
any Common Stock, Option or Convertible Security is issued to the
owners of the non-surviving entity in connection with any merger in
which the Corporation is the surviving corporation, the amount of
consideration therefor shall be deemed to be the fair value of such
portion of the net assets and business of the non-surviving entity
as is attributable to such Common Stock, Option or Convertible
Security, as the case may be. The fair value of any consideration
other than cash and securities shall be determined jointly by the
Corporation and the holders of a majority of the outstanding Series
B Preferred Stock. If such parties are unable to reach an agreement
within a reasonable period of time, the fair value of such
consideration shall be determined by an independent appraiser
experienced in valuing such type of consideration jointly selected
by the Corporation and the holders of a majority of the outstanding
Series B Preferred Stock. The determination of such appraiser shall
be final and binding upon the parties, and the fees and expenses of
such appraiser shall be borne by the Corporation.
(vi) INTEGRATED TRANSACTIONS. In case any Option is
issued in
26
<PAGE>
connection with the issue or sale of other securities of the
Corporation, together comprising one integrated transaction in which
no specific consideration is allocated to such Option by the parties
thereto, the Option shall be deemed to have been issued for a
consideration of $.01.
(vii) TREASURY SHARES. For the purpose of this Section
5, the number of shares of Common Stock outstanding at any given
time shall not include shares owned or held by or for the account of
the Corporation or any subsidiary, and the disposition of any shares
so owned or held shall be considered an issue or sale of Common
Stock.
(viii)RECORD DATE. If the Corporation takes a record of
the holders of Common Stock for the purpose of entitling them (A) to
receive a dividend or other distribution payable in Common Stock,
Options or in Convertible Securities or (B) to subscribe for or
purchase Common Stock, Options or Convertible Securities, then such
record date shall be deemed to be the date of the issue or sale of
the shares of Common Stock deemed to have been issued or sold upon
the declaration of such dividend or upon the making of such other
distribution or the date of the granting of such right of
subscription or purchase, as the case may be.
(h) SUBDIVISION OR COMBINATION OF COMMON STOCK. If the
Corporation at any time subdivides (by any stock split, stock dividend,
recapitalization or otherwise) one or more classes of its outstanding shares of
Common Stock into a greater number of shares, the Conversion Price in effect
immediately prior to such subdivision shall be proportionately reduced, and if
the Corporation at any time combines (by reverse stock split or otherwise) one
or more classes of its outstanding shares of Common Stock into a smaller number
of shares, the Conversion Price in effect immediately prior to such combination
shall be proportionately increased.
(i) REORGANIZATION, RECLASSIFICATION, CONSOLIDATION, MERGER OR
SALE. Any recapitalization, reorganization, reclassification, consolidation,
merger, sale of all or substantially all of the Corporation's assets or other
transaction, in each case which is effected in such a manner that the holders of
Common Stock are entitled to receive (either directly or upon subsequent
liquidation) stock, securities or assets with respect to or in exchange for
Common Stock, is referred to herein as an "Organic Change". Prior to the
consummation of any Organic Change, the Corporation shall make appropriate
provisions (in form and substance satisfactory to the holders of a majority of
the Series B Preferred Stock then outstanding) to insure that each of the
holders of Series B Preferred Stock shall thereafter have the right to acquire
and receive, in lieu of or in addition to (as the case may be) the shares of
Common Stock immediately theretofore acquirable and receivable upon the
conversion of such holder's Series B Preferred Stock, such shares of stock,
securities or assets as such holder would have received in connection with such
Organic Change if such holder had converted its
27
<PAGE>
Series B Preferred Stock immediately prior to such Organic Change. In each such
case, the Corporation shall also make appropriate provisions (in form and
substance satisfactory to the holders of a majority of the Series B Preferred
Stock then outstanding) to insure that the provisions of this Section 5 and
Sections 4, 6 and 7 hereof shall thereafter be applicable to the Series B
Preferred Stock (including, in the case of any such consolidation, merger or
sale in which the successor entity or purchasing entity is other than the
Corporation, an immediate adjustment of the Conversion Price to the value for
the Common Stock reflected by the terms of such consolidation, merger or sale,
and a corresponding immediate adjustment in the number of shares of Common Stock
acquirable and receivable upon conversion of Series B Preferred Stock, if the
value so reflected is less than the Conversion Price in effect immediately prior
to such consolidation, merger or sale). The Corporation shall not effect any
such consolidation, merger or sale, unless prior to the consummation thereof,
the successor entity (if other than the Corporation) resulting from
consolidation or merger or the entity purchasing such assets assumes by written
instrument (in form and substance satisfactory to the holders of a majority of
the Series B Preferred Stock then outstanding), the obligation to deliver to
each such holder such shares of stock, securities or assets as, in accordance
with the foregoing provisions, such holder may be entitled to acquire.
(j) CURRENT MARKET PRICE. The "Current Market Price" means as
to any security the average of the closing prices of such security's sales on
all domestic or foreign securities exchanges on which such security may at the
time be listed, or, if there have been no sales on any such exchange on any day,
the average of the highest bid and lowest asked prices on all such exchanges at
the end of such day, or, if on any such day security is not so listed, the
average of the representative bid and asked prices quoted in the NASDAQ National
Market or NASDAQ SmallCap Market, as of 4:00 P.M., New York time, on such day,
or, if on any day such security is not quoted in the NASDAQ National Market or
the NASDAQ SmallCap Market (as applicable), the average of the highest bid and
lowest asked prices on such day in the domestic over-the-counter market as
reported by the National Quotation Bureau, Incorporated, or any similar
successor organization, in each such case averaged over a period of 30 days
consisting of the day as of which "Current Market Price" is being determined and
the 29 consecutive business days prior to such day; provided that if such
security is listed on any domestic securities exchange the term "business days"
as used in this sentence means business days on which such exchange is open for
trading. If at any time such security is not listed on any domestic securities
exchange or quoted in the NASDAQ National Market or the NASDAQ SmallCap Market
or the domestic over-the-counter market, the "Current Market Price" shall be the
fair value thereof determined jointly by the Corporation and the holders of
shares of Series B Preferred Stock representing a majority of the shares of
Series B Preferred Stock
28
<PAGE>
then outstanding; provided that if such parties are unable to reach agreement
within a reasonable period of time, such fair value shall be determined by an
appraiser jointly selected by the Corporation and the holders of shares of
Series B Preferred Stock representing a majority of the shares of shares of
Series B Preferred Stock then outstanding. The determination of such appraiser
shall be final and binding on the Corporation and the holders of the shares of
Series B Preferred Stock and the fees and expenses of such appraiser shall be
paid by the Corporation.
(k) STATEMENT REGARDING ADJUSTMENTS. Whenever the Conversion
Price shall be adjusted as provided in this Section 5, the Corporation shall
forthwith file, at the office of any transfer agent for the Series B Preferred
Stock and at the principal office of the Corporation, a statement showing in
detail the method of calculation of such adjustment, the facts requiring such
adjustment and the Conversion Price that shall be in effect after such
adjustment, and the Corporation shall also cause a copy of such statement to be
sent by mail, first class postage prepaid, to each holder of shares of Series B
Preferred Stock at its address appearing on the Corporation's records. Each such
statement shall be signed by the Corporation's chief financial officer. Where
appropriate, such copy may be given in advance and may be included as part of a
notice required to be mailed under the provisions of Section 5(l).
(l) NOTICE TO HOLDERS. In the event the Corporation shall
propose to take any action of the type described in this Section 5, the
Corporation shall give notice to each holder of shares of Series B Preferred
Stock in the manner set forth in Section 5(k), which notice shall specify the
record date, if any, with respect to any such action and the approximate date on
which such action is to take place. Such notice shall also set forth such facts
with respect thereto as shall be reasonably necessary to indicate the effect of
such action (to the extent such effect may be known at the date of such notice)
on the Conversion Price and the number, kind or class of shares or other
securities or property which shall be deliverable upon conversion of shares of
Series B Preferred Stock. In the case of any action which would require the
fixing of a record date, such notice shall be given at least ten calendar days
prior to the date so fixed, and in the case of all other action, such notice
shall be given at least 15 calendar days prior to the taking of such proposed
action. Failure to give such notice, or any defect therein, shall not affect the
legality or validity of any such action.
(m) COSTS. The Corporation shall pay all documentary, stamp,
transfer or other transactional taxes attributable to the issuance or delivery
of shares of Common Stock upon conversion of any shares of Series B Preferred
Stock; provided that the Corporation shall not be required to pay any taxes
which may be payable in respect of any transfer involved in the issuance or
delivery of any certificate for such shares in a name other than that of the
holder of the shares of Series B Preferred Stock in respect of which such shares
are being issued.
(n) DIVIDENDS UPON CONVERSION. In connection with any
conversion of shares of Series B Preferred Stock, the Corporation shall pay
accrued and unpaid dividends thereon in accordance with the provisions of
Section 7(d).
29
<PAGE>
(o) CERTAIN EVENTS. If any event occurs of the type
contemplated by the provisions of Section 5(f)(i) but not expressly provided for
by such provisions, then the Conversion Price shall be adjusted by the
Corporation's Board of Directors in good faith so as to protect the rights of
the holders of Series B Preferred Stock; provided that no such adjustment shall
increase the Conversion Price as otherwise determined pursuant to this Section 5
or decrease the number of shares of Common Stock issuable upon conversion of
each share of Series B Preferred Stock.
6. PURCHASE RIGHTS.
If at any time the Corporation grants, issues or sells any
Options, Convertible Securities or rights to purchase stock, warrants,
securities or other property pro rata to the record holders of any class of
Common Stock (the "Purchase Rights"), then each holder of Series B Preferred
Stock shall be entitled to acquire, upon the terms applicable to such Purchase
Rights, the aggregate Purchase Rights which such holder could have acquired if
such holder had held the number of shares of Common Stock acquirable upon
conversion of such holder's Series B Preferred Stock immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase
Rights, or if no such record is taken, the date as of which the record holders
of Common Stock are to be determined for the grant, issue or sale of such
Purchase Rights.
7. DIVIDENDS.
(a) GENERAL.
(i) The Series B Preferred Stock shall rank on parity
with the Series A Preferred Stock with respect to dividends. During the period
commencing on the date on which the first share of Series B Preferred Stock is
issued and terminating on the fifth anniversary of such date, the holders of the
Series B Preferred Stock shall be entitled to receive, when and as declared by
the Board of Directors out of funds legally available therefor, cumulative
dividends per share of Series B Preferred Stock at the rate per annum equal to
the greater of (A), if any shares of Series A Preferred Stock are then
outstanding, the per annum rate of dividends per share of Series A Preferred
Stock then payable thereon, (B) $6.00 (as shall be equitably adjusted to reflect
any stock dividend, stock distribution, stock split or reverse stock split,
combination of shares, subdivision of shares or reclassification of shares with
respect to the Series A Preferred Stock or Series B Preferred Stock, as the case
may be) and (C) the per annum rate of dividends per share paid by the
Corporation on the Common Stock.
(ii) Dividends on the Series B Preferred Stock will
accrue on each March 31, June 30, September 30 and December 31, occurring after
the date of original issuance (each such date being referred to herein as an
"Accrual Date" and
30
<PAGE>
the three-month period or portion thereof, as the case may be, ending on an
Accrual Date being referred to herein as an "Accrual Period"), whether or not
such dividends have been declared, and whether or not there are funds of the
Corporation legally available for the payment of dividends, and will cease
accruing on September 30, 2001. Dividends will be paid (when and as declared by
the Board of Directors of the Corporation) quarterly, in arrears, on each
February 15, May 15, August 15 and November 15, occurring in 1997, 1998, 1999,
2000 and 2001. Each such dividend shall be paid to the holders of record of
shares of the Series B Preferred Stock as they appear on the stock register of
the Corporation on such record date not exceeding 45 nor less than ten calendar
days preceding the payment date thereof, as shall be fixed by the Board of
Directors of the Corporation. Dividends on account of arrears for any past
dividend periods may be declared and paid at any time, without reference to any
regular dividend payment date, to holders of record on such date, not exceeding
45 nor less than ten calendar days preceding the payment date thereof, as may be
fixed by the Board of Directors of the Corporation. Holders of shares of Series
B Preferred Stock at the close of business on a dividend payment record date
will be entitled to receive the dividend payable with respect to such shares on
the corresponding dividend payment date notwithstanding the conversion thereof
or the Corporation's default on payment of the dividend due on such dividend
payment date. For shares of Series B Preferred Stock surrendered for conversion
during the period from the close of business on any dividend payment record date
to the opening of business on the corresponding dividend payment date, the
Corporation shall pay the dividend to the holder of such shares on the dividend
payment record date. Except as so provided above and in Section 7(d) below, no
payment or adjustment will be made on account of accrued or unpaid dividends
upon conversion of shares of Series B Preferred Stock.
(iii) The Corporation shall pay the dividends on the
Series B Preferred Stock described in Section 7(a)(i), at the Corporation's
option and in its sole discretion, out of funds legally available therefor (A)
in cash, (B) in shares of Series B Preferred Stock having an aggregate
Liquidation Value (as shall be equitably adjusted to reflect any stock dividend,
stock distribution, stock split or reverse stock split, combination of shares,
subdivision of shares or reclassification of shares with respect to the Series B
Preferred Stock) at the time of such payment equal to the amount of the dividend
to be paid, or (C) in any combination of cash and shares of Series B Preferred
Stock that the Corporation may determine in its sole discretion, with the number
of shares of Series B Preferred Stock to be distributed in connection therewith
to be calculated on the basis set forth in Section 7(a)(iii)(B).
(iv) No fractional shares of Series B Preferred Stock or
scrip shall be issued upon payment of any dividends in shares of Series B
Preferred Stock. If more than one share of Series B Preferred Stock shall be
held by the same holder at the time of any dividend payment date, the number of
full shares of Series B Preferred Stock issuable upon payment of such dividends
shall be computed on the basis of the aggregate dividend amount that the
Corporation has determined to pay in Series B
31
<PAGE>
Preferred Stock shares. Instead of any fractional shares of Series B Preferred
Stock which would otherwise be issuable upon payment of such dividends, the
Corporation shall pay out of funds legally available therefor a cash adjustment
in respect of such fractional interest, rounded to the nearest one hundredth
(1/100th) of a share, in an amount equal to that fractional interest of the
Liquidation Value (as shall be equitably adjusted to reflect any stock dividend,
stock distribution, stock split or reverse stock split, combination of shares,
subdivision of shares or reclassification of shares with respect to the Series B
Preferred Stock), rounded to the nearest cent ($.01).
(b) ALLOCATION OF DIVIDENDS. Dividends on the Series B
Preferred Stock, if paid, or if declared and set apart for payment, must be paid
or declared and set apart for payment on all outstanding shares of Series B
Preferred Stock contemporaneously. In the event dividends on the Series B
Preferred Stock and any other series of Preferred Stock ranking on a parity
therewith in respect thereto or any other class or series of capital stock of
the Corporation ranking on a parity therewith in respect thereto are declared
and paid in an amount less than all accumulated and current dividends on all of
such shares, the total amount declared and paid shall be allocated among all of
such shares so that the per share dividend to be declared and paid on each share
is the same percentage of the sum of the accumulated dividends for each such
share. In the event dividends are declared and paid on the Series B Preferred
Stock in a combination of cash and shares of Series B Preferred Stock, the
percentage of the dividend paid in cash and the percentage of the dividend paid
in stock must be the same for each share of Series B Preferred Stock.
(c) DIVIDENDS ON CONVERSION.
(i) Immediately prior to the conversion of any shares of
Series B Preferred Stock into Common Stock, all accrued and unpaid dividends
payable pursuant to Section 7 (whether or not declared) on such shares so
converted (prorated until the date of conversion in respect of the Accrual
Period in which such date occurs) shall be payable, at the Corporation's option
and in its sole discretion, out of funds legally available therefor (A) in cash,
(B) in shares of Series B Preferred Stock, such that the number of shares of
Series B Preferred Stock to be distributed with respect to the portion of the
dividend attributable to each Accrual Period shall have an aggregate Liquidation
Value (as shall be equitably adjusted to reflect any stock dividend, stock
distribution, stock split or reverse stock split, combination of shares,
subdivision of shares or reclassification of shares with respect to the Series B
Preferred Stock) at the time of such payment equal to the amount of the dividend
to be paid, or (C) in any combination of cash and shares of Series B Preferred
Stock that the Corporation may determine in its sole discretion, with the number
of shares of Common Stock to be distributed in connection therewith to be
calculated on the basis set forth in Section 7(c)(i)(B).
(ii) No fractional shares of Series B Preferred Stock or
scrip shall
32
<PAGE>
be issued upon payment of any dividends in shares of Series B Preferred Stock
upon conversion of any shares of Series B Preferred Stock. If more than one
share of Series B Preferred Stock shall be surrendered for conversion at any one
time by the same holder, or shall be held by the same holder at the time of any
automatic conversion, the number of full shares of Series B Preferred Stock
issuable upon payment of such dividends shall be computed on the basis of the
aggregate dividend amount that the Corporation has determined to pay in Series B
Preferred Stock shares. Instead of any fractional shares of Series B Preferred
Stock which would otherwise be issuable upon payment of such dividends, the
Corporation shall pay out of funds legally available therefor a cash adjustment
in respect of such fractional interest, rounded to the nearest one hundredth
(1/100th) of a share, in an amount equal to that fractional interest of the
Liquidation Value (as shall be equitably adjusted to reflect any stock dividend,
stock distribution, stock split or reverse stock split, combination of shares,
subdivision of shares or reclassification of shares with respect to the Series B
Preferred Stock), rounded to the nearest cent ($.01).
8. REACQUIRED SHARES. Any shares of Series B Preferred Stock
redeemed, purchased, converted or otherwise acquired by the Corporation in any
manner whatsoever shall not be reissued as part of such series and shall be
retired promptly after the acquisition thereof. All such shares shall upon their
retirement and the filing of any certificate required in connection therewith
pursuant to the Delaware General Corporation Law become authorized but unissued
shares of Preferred Stock.
SECOND: That said determination of the powers, designation,
preferences and the relative, participating, optional or other rights, and the
qualifications, limitations or restrictions thereof, relating to said series of
Preferred Stock, was duly made by the Board of Directors of the Corporation
pursuant to the provisions of the Restated Certificate of Incorporation of the
Corporation, as amended, and in accordance with the provisions of Section 151 of
the General Corporation Law of the State of Delaware.
33
<PAGE>
IN WITNESS WHEREOF, said Corporation has caused this Certificate to
be signed by Paul M. Frison, its President, on this 13th day of November, 1996.
LIFECELL CORPORATION
By
Paul M. Frison, President
34
<PAGE>
EXHIBIT C
VOTING AGREEMENT
THIS VOTING AGREEMENT (this "AGREEMENT") is made as of November 18,
1996 among LifeCell Corporation, a Delaware corporation (the "COMPANY"), the
Investors (as defined below) and Allstate Insurance Company ("ALLSTATE," and
together with the Investors, the "STOCKHOLDERS").
Vector Later-Stage Equity Fund, L.P., CIBC Wood Gundy
Ventures, Inc., and the other Persons identified as "Investors" on ANNEX A
attached hereto other than Allstate (collectively, the "INVESTORS") and the
Company are entering into a Securities Purchase Agreement simultaneously with
the execution of this Agreement (the "PURCHASE AGREEMENT"), pursuant to which
the Investors are purchasing shares of the Company's Series B Preferred Stock,
par value $.001 per share ("SERIES B PREFERRED"), and warrants to purchase
shares of the Company's common stock, par value $.001 per share (each, a
"WARRANT"). Immediately after the consummation of the transactions contemplated
in the Purchase Agreement, Allstate owns approximately 21% of the voting stock
of the Company. Under the Certificate of Designation (as defined in the Purchase
Agreement), the Investors have the right to designate three representatives (the
"INVESTOR REPRESENTATIVES") to the Company's board of directors (the "BOARD"),
and, in connection with the issuance and sale of the Securities to the
Investors, the Company and the Stockholders have agreed as to the composition of
the entirety of the Board. The Investors desire to enter into this Agreement for
the purpose of determining the Investor Directors and the Additional Outside
Directors (as defined below), the Company desires to enter into this Agreement
for the purpose of determining the Company Directors (as defined below), the
Initial Outside Director (as defined below) and the Additional Outside
Directors, Allstate desires to enter into this Agreement for the purpose of
determining the composition of the Board upon consummation of the issuance of
the Series B Preferred Stock to the Investors, and execution and delivery of
this Agreement is a condition to consummation of the transaction contemplated in
the Purchase Agreement.
The Company and the Stockholders hereby agree as follows:
CERTAIN DEFINITIONS.
Capitalized terms used but not defined herein shall have the
meanings assigned such terms in the Purchase Agreement.
"STOCKHOLDER SHARES" means, as of any particular time, (i) any
Common
35
<PAGE>
Stock purchased or otherwise acquired by any Stockholder, (ii) any Common
Stock issued or issuable directly or indirectly upon conversion of Preferred
Stock or upon exercise of Warrants, in each case, owned by a Stockholder, (iii)
any capital stock or other equity securities issued or issuable directly or
indirectly with respect to Common Stock referred to in clause (i) or clause (ii)
above by way of stock dividend or stock split or in connection with a
combination of shares, recapitalization, merger, consolidation or other
reorganization. For purposes of this Agreement, any Person who holds Preferred
Stock or Warrants shall be deemed to be a Stockholder and the holder of
Stockholder Shares issued or issuable upon conversion of such Preferred Stock or
exercise of such Warrants (as the case may be) in connection with the transfer
thereof or otherwise and regardless of any restriction or limitation on the
conversion or exercise thereof.
BOARD OF DIRECTORS.
1. From and after the date of this Agreement, each holder of
Stockholder Shares shall vote all of its Stockholder Shares and shall take all
other necessary or desirable actions within its control (whether in its capacity
as a stockholder or as an officer or director of the Company or otherwise, and
including, without limitation, attendance at meetings in person or by proxy for
the purposes of obtaining a quorum and execution of written consents in lieu of
meetings), and the Company shall take all necessary and desirable actions within
its control (including, without limitation, calling special Board and
stockholder meetings), so that:
(a) the maximum authorized number of directors on the Board shall be
established initially at nine directors and shall be reduced in accordance with
clauses (viii) and (ix) of this Section 2;
(b) the following individuals shall be elected to the Board:
(i) three representatives (the "INVESTOR DIRECTORS")
designated by holders of a majority of the Underlying Common
Stock (the "MAJORITY INVESTORS"), which Investor Directors
shall include one representative designated by Vector (the
"VECTOR REPRESENTATIVE"), which Vector Representative shall
initially be K. Flynn McDonald, one representative designated
by CIBC-WG (the "CIBC-WG REPRESENTATIVE"), which CIBC-WG
Representative shall initially be Lori G. Koffman, and one
representative (the "MAJORITY INVESTORS REPRESENTATIVE")
selected by the Majority Investors;
(ii) the Chief Executive Officer (who shall initially be
Paul M. Frison) and Stephen A. Livesey (each, a "COMPANY
DIRECTOR") and Michael Cahr (the "INITIAL OUTSIDE DIRECTOR");
36
<PAGE>
(iii) two representatives jointly designated by the
Investor Directors, and the Company Directors (which
designations shall take into account recommendations of a top
tier executive search firm jointly selected by the Investor
Directors and the Company Directors) (the "ADDITIONAL OUTSIDE
DIRECTORS"), which Additional Outside Directors are neither
members of the Company's management nor an employee or an
officer of the Company; and
(iv) one representative (the "MEDTRONIC DIRECTOR")
designated by Medtronic, Inc., a Minnesota corporation
("MEDTRONIC");
(c) the removal from the Board (with or without cause) of any Vector
Representative, any CIBC-WG Representative or any Majority Investors
Representative shall be at the written request of Vector, CIBC-WG or the
Majority Investors, respectively, but only upon such written request and under
no other circumstances;
(d) the removal from the Board (with or without cause) of any
Company Director or the Initial Outside Director shall be at the written request
of the majority of the other directors then in office, but only upon such
written request and under no other circumstances;
(e) the removal from the Board (with or without cause) of the
Medtronic Director shall be only in accordance with and as contemplated by
Section 6.3 of the Investment Agreement dated May 3, 1994 between the Company
and Medtronic (the "MEDTRONIC INVESTMENT AGREEMENT"); provided that the Company
shall not agree to any amendment to such Section 6.3 without the prior consent
of the Majority Investors;
(f) in the event that any Investor Director or any Additional
Outside Director designated hereunder for any reason ceases to serve as a member
of the Board during his or her term of office, the resulting vacancy on the
Board shall be filled in the manner set forth above in clause (ii) of this
Section 2 by a representative designated by the same group that designated the
member that will no longer serve on the Board; provided that if such group fails
to designate a representative to fill such vacancy, the election of an
individual to fill such vacancy shall be accomplished in accordance with the
Company's bylaws and applicable law; provided, further, that the Stockholders
shall thereafter vote to remove such individual if the group which failed to
designate a representative to fill such vacancy pursuant to this Section 2 so
directs;
(g) in the event that the Initial Outside Director for any reason
ceases to serve as a member of the Board during his term of office, the
resulting vacancy shall be filled by the vote of a majority of the other
directors then in office;
37
<PAGE>
(h) in the event that any Company Director (other than the Chief
Executive Officer) for any reason ceases to serve as a member of the Board
during his term of office, the resulting vacancy shall not be filled and the
number of authorized directors on the Board shall be reduced by the number of
such directors who have ceased to serve on the Board; and
(i) at such time when Medtronic no longer has the right to appoint a
director pursuant to Section 6.3 of the Medtronic Investors Agreement, the
number of authorized directors on the Board shall be reduced by one and the
resulting directorship shall not be filled.
2. The Company shall pay all out-of-pocket travel and other expenses
incurred by each director in connection with attending the meetings of the Board
or any committee thereof. So long as any Investor Director serves on the Board
and for 3 years thereafter, the Company shall maintain directors and officers
indemnity insurance coverage satisfactory to the Majority Investors, and the
Company's certificate of incorporation and bylaws shall provide for
indemnification and exculpation of directors to the fullest extent permitted
under applicable law.
REPRESENTATIONS AND WARRANTIES. Each Stockholder represents and
warrants that (i) such Stockholder is the record owner of the number and type of
shares of the Company's capital stock indicated opposite its name on ANNEX A
hereto, (ii) this Agreement has been duly authorized, executed and delivered by
such Stockholder and constitutes the valid and binding obligation of such
Stockholder, enforceable in accordance with its terms, and (iii) such
Stockholder has not granted and is not a party to any proxy, voting trust or
other agreement which is inconsistent with, conflicts with or violates any
provision of this Agreement.
STOCKHOLDER COVENANT. No holder of Stockholder Shares shall grant
any proxy or become party to any voting trust or other agreement which is
inconsistent with, conflicts with or violates any provision of this Agreement.
TERMINATION. This Agreement shall terminate at the later of (i) such
time when all of the shares of Series B Preferred have been converted and (ii)
such time when the Company no longer has any obligation to deliver financial and
other information to certain Investors pursuant to Section 6.8 of the Purchase
Agreement; provided that, notwithstanding the foregoing, Allstate's obligations
under this Agreement shall terminate on the second anniversary of this
Agreement.
COUNTERPARTS. This Agreement may be executed in multiple
counterparts, each of which shall be an original and all of which taken together
shall constitute one and the same agreement.
REMEDIES. Each Stockholder shall be entitled to enforce its rights
under
38
<PAGE>
this Agreement specifically, to recover damages by reason of any breach of
any provision of this Agreement and to exercise all other rights existing in
their favor. Each Stockholder hereby acknowledges that money damages would not
be an adequate remedy for any breach of the provisions of this Agreement and
that each Stockholder may in its sole discretion apply to any court of law or
equity of competent jurisdiction for specific performance and/or injunctive
relief (without posting a bond or other security) in order to enforce or prevent
any violation of the provisions of this Agreement.
NOTICES. Any notice provided for in this Agreement shall be in
writing and shall be either personally delivered, or mailed first class mail
(postage prepaid) or sent by reputable overnight courier service (charges
prepaid) to the Stockholder at the address indicated on the schedules hereto or
at such address or to the attention of such other person (including any
subsequent holder of Stockholder Shares) as the recipient party has specified by
prior written notice to the sending party. Notices shall be deemed to have been
given hereunder when delivered personally, three days after deposit in the U.S.
mail and one day after deposit with a reputable overnight courier service.
AMENDMENT AND WAIVER. This Agreement may be amended, modified and
supplemented, and compliance with any term, covenant, agreement or condition
contained herein may be waived either generally or in particular instances, and
either retroactively or prospectively, only by a written instrument executed by
(a) the Company and (b) the Majority Investors. No course of dealing between or
among any persons having any interest in this Agreement will be deemed effective
to modify, amend or discharge any part of this Agreement or any rights or
obligations of any person under or by reason of this Agreement.
GOVERNING LAW. THE CORPORATE LAW OF THE STATE OF DELAWARE SHALL
GOVERN ALL ISSUES AND QUESTIONS CONCERNING THE RIGHTS OF THE COMPANY AND THE
RIGHTS OF THE STOCKHOLDERS RELATIVE TO THE COMPANY. ALL OTHER ISSUES AND
QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, INTERPRETATION AND
ENFORCEABILITY OF THIS AGREEMENT AND THE EXHIBITS AND SCHEDULES HERETO SHALL BE
GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW
YORK, WITHOUT GIVING EFFECT TO ANY CHOICE OF LAW OR CONFLICT OF LAW RULES OR
PROVISIONS (WHETHER OF THE STATE OF NEW YORK OR ANY OTHER JURISDICTION) THAT
WOULD CAUSE THE APPLICATION OF THE LAWS OF ANY JURISDICTION OTHER THAN THE STATE
OF NEW YORK.
DESCRIPTIVE HEADINGS. The descriptive headings of this Agreement are
inserted for convenience only and do not constitute a part of this Agreement.
* * * *
39
<PAGE>
IN WITNESS WHEREOF, the Company and the Stockholders have executed
this Agreement on the day and year first above written.
LIFECELL CORPORATION
By
Paul M. Frison
President and Chief Executive Officer
VECTOR LATER-STAGE EQUITY FUND, L.P.
By Vector Fund Management, L.P.,
its General Partner
By
Name:
Title:
CIBC WOOD GUNDY VENTURES, INC.
By
Name:
Title:
40
<PAGE>
ALLSTATE INSURANCE COMPANY
By
By
Its Authorized Signatories
41
<PAGE>
STOCKHOLDERS -- ANNEX A
Name and Address Stockholder
- ---------------- -----------
CIBC Wood Gundy Ventures, Inc. 44,800 shares of Series B Preferred
425 Lexington Avenue
New York, NY 10017
The Woodlands Venture Capital Company 2,500 shares of Series B Preferred
2201 Timberloch Place 482,068 shares of Common Stock
The Woodlands, TX 77380 15,000 shares of Series A Preferred
P. William Curreri, M.D. 400 shares of Series B Preferred
217 Berwyn Drive, W. #222 8,238 shares of Common Stock
Mobile, AL 36608 1,250 shares of Series A Preferred
Christopher C. Kraft, Jr. 250 shares of Series B Preferred
Smith Barney Inc. KEO P/S Custodian 1,738 shares of Common Stock
Acct: 721-66059-10-022 1,250 shares of Series A Preferred
14919 Village Elm Street
Houston, TX 77062
Michael H. Richmond 400 shares of Series B Preferred
20 E. Wedgewood Glen
The Woodlands, TX 77381
Stephen Livesey 250 shares of Series B Preferred
3606 Research Forest Drive 100,529 shares of Common Stock
The Woodlands, TX 77381
Michael E. Cahr 500 shares of Series B Preferred
1051 Saxony Drive
Highland Park, IL 60035
Technology Funding Medical Partners I,
L.P. 2,500 shares of Series B Preferred
2000 Alameda de las Pulgas
San Mateo, CA 94403
Vector Later-Stage Equity Fund, L.P. 40,000 shares of Series B Preferred
1751 Lake Cook road, Suite 350
Deerfield, IL 60015
42
<PAGE>
William J. McCluskey 186 shares of Series B Preferred
25 Wisconsin Street
Long Beach, NY 11561
David Saks 500 shares of Series B Preferred
2 Knollcliff Road
Woodcliff Lake, NJ 07675
Joseph Battipaglia 150 shares of Series B Preferred
77 Water Street (10th Floor)
New York, NY 10005
S.B.S.F. Biotechnology Partners, L.P. 1,000 shares of Series B Preferred
c/o Lisa Tuckerman
Spears Benzak Salomon & Farrell
45 Rockefeller Plaza -- 33rd Floor
New York, NY 10111
S.B.S.F. Biotechnology Fund, L.P. 9,000 shares of Series B Preferred
c/o Lisa Tuckerman
Spears Benzak Salomon & Farrell
45 Rockefeller Plaza -- 33rd Floor
New York, NY 10111
Jerome Schachter 500 shares of Series B Preferred
2926 Leanne Court
Northbrook, IL 60062
Paul B. Ankin and Lois F. Ankin, JTWROS 250 shares of Series B Preferred
4233 W. Grove
Skokie, IL 60076
David and Mary Jane Harris, JTWROS 200 shares of Series B Preferred
174 Pacific Street, Apt. 2A
Brooklyn, NY 11021
43
<PAGE>
Richard L. Serrano 50 shares of Series B Preferred
64 Brighton Avenue
Bloomfield, NJ 07003
Charles and Donna Greenberg, JTWROS 1,500 shares of Series B Preferred
503 Pinehurst Court
Roslyn, NY 11576
Michael Gironta 1,000 shares of Series B Preferred
89 Ridgewood Avenue
Glen Ridge NJ 07028
Joseph A. Russo 155 shares of Series B Preferred
3 Midwood Avenue
Verona, NJ 07044
John D. Goldberg 310 shares of Series B Preferred
2500 East Hallandale Beach Blvd.
Suite 500
Hallandale, FL 33009-4838
Robert Sablowsky 465 shares of Series B Preferred
150 East 69th Street, 16A
New York, NY 10021
William J. Strazzullo 80 shares of Series B Preferred
750 Columbus Avenue, 4C
New York, NY 10025
Stephen G. Weiss 330 shares of Series B Preferred
115 Ravin Oaks Lane
Highland Park, IL 60035
Barry Richter 250 shares of Series B Preferred
Tideway
Sandspoint, NY 11050
44
<PAGE>
Chinook Equities, Inc. 500 shares of Series B Preferred
147 East 48th Street
New York, NY 10017
Daniel and Elaine Kleinberg, JTWROS 267 shares of Series B Preferred
3 Centennial Road
Livingston, NJ 07039
Douglas Kleinberg 248 shares of Series B Preferred
200 East 95th Street, Apt. 126
New York, NY 10128
Evan Kleinberg IRA, 155 shares of Series B Preferred
Gruntal & Co., Inc., Custodian
Dated July 19, 1996
3 Centennial Road
Livingston, NJ 07039
45
<PAGE>
John Latshaw 930 shares of Series B Preferred
5049 Wornall #2 C
Kansas City, MO 64112
B. Michael Pisani 775 shares of Series B Preferred
44 Lake Road
Short Hills, NJ 07078
John Cirrito 250 shares of Series B Preferred
29 Rambling Drive
Scotch Plains, NJ 07076
James C. Gale, Trustee 620 shares of Series B Preferred
F/B/O Ariana J. Gale
The James C. Gale Trust,
dated November 21, 1986
315 West 106th Street, Apt. 4A
New York, NY 10025
James C. Gale and Judith S. Haselton JTWROS 1,550 shares of Series B Preferred
315 West 106th Street, Apt. 4A
New York, NY 10025
John S. Bai 217 shares of Series B Preferred
30 West 61st, 27A
New York, NY 10023
Ronald Koenig 310 shares of Series B Preferred
114 No. Village Way
Jupiter, FL 33458
Robert M. Adams 1,550 shares of Series B Preferred
P.O. Box 998
Plandome, NY 11030
Edward A. Kerbs 310 shares of Series B Preferred
8 South Cherry Lane
Rumson, NJ 07760
46
<PAGE>
Bernard B. Salzman IRA, 55 shares of Series B Preferred
Gruntal & Co., Inc., Custodian
Dated May 14, 1982 Acct: 215-67321-1-3-231
20 S. Charles Street
Baltimore, MD 21201
Don A. Sanders 620 shares of Series B Preferred
3100 Texas Commerce Tower
Houston, TX 77002
Jeffrey Keeler 87 shares of Series B Preferred
577 W. 50th Street
Miami Beach, FL 33140
Harbour Court L.P., II 250 shares of Series B Preferred
253 W. 73rd St., Apt. 6D
New York, NY 10023
Attention: Jonathan Greenwald
Namax Corp. 2,000 shares of Series B Preferred
666 Dundee Road, Suite 1801
Northbrook, IL 60062
Attention: Mark Rice, President
Sheldon Drobny 500 shares of Series B Preferred
95 Revere Drive, Suite A
Northbrook, IL 60062
Perry H. Bacon 620 shares of Series B Preferred
5300 Mission Woods Road
Shawnee Mission, KS 66205
James J. Pelts 500 shares of Series B Preferred
29 East Madison Street, Suite 1505
Chicago, IL 60602
Robert Weinstein 217 shares of Series B Preferred
155 West 68th Street 24C New
York, NY 10023
47
<PAGE>
The Marcus L. Koblitz Trust, 25 shares of Series B Preferred
Michael J. Koblitz,
Trustee Est. April 14, 1992
12 Downey Drive
Tenafly, NJ 07670
The Lauren J. Koblitz Trust, 25 shares of Series B Preferred
Michael J. Koblitz,
Trustee Est. April 14, 1992
12 Downey Drive
Tenafly, NJ 07670
Pharmaceutical & Medical Technology Fund 3,000 shares of Series B Preferred
300 Park Avenue New York, NY 10022
Strategic Healthcare Fund 1,000 shares of Series B Preferred
300 Park Avenue New York, NY 10022
Michael J. Koblitz 50 shares of Series B Preferred
12 Downey Drive
Tenafly, NJ 07670
Allstate Insurance Company
Investment Department
Allstate Plaza South 650 761,397 shares of Common Stock
Northbrook, IL 60062 200,000 shares of Series A Prefer
48
<PAGE>
EXHIBIT D
REGISTRATION RIGHTS AGREEMENT
REGISTRATION RIGHTS AGREEMENT (this "AGREEMENT"), dated as of
November 18, 1996, by and among each of the persons named on SCHEDULE 1 annexed
hereto (each, an "INVESTOR" and collectively, the "INVESTORS"), Gruntal & Co.,
Incorporated ("GRUNTAL), and LifeCell Corporation, a Delaware corporation (the
"COMPANY").
W I T N E S S E T H:
WHEREAS, the Investors and the Company have entered into that
certain Securities Purchase Agreement, dated as of the date hereof (the
"PURCHASE AGREEMENT"), whereby the Investors have purchased (a) an aggregate of
124,157 shares of the Series B Preferred Stock, par value $.001 per share (the
"SERIES B PREFERRED STOCK"), of the Company and (b) warrants (the "WARRANTS";
together with the Series B Preferred Stock, the "SECURITIES") to purchase an
aggregate of 2,803,530 shares (the "WARRANT SHARES") of common stock, par value
$.001 per share ("COMMON STOCK"), of the Company.
WHEREAS, the Company has on the date hereof granted to Gruntal, the
Company's placement agent in connection with the transactions evidenced by the
Purchase Agreement, a warrant (the "GRUNTAL WARRANT") to purchase 354,734 shares
(the "GRUNTAL WARRANT SHARES") of Common Stock in connection with such
transactions.
WHEREAS, the Company desires to grant registration rights to (a) the
Investors with respect to the Warrant Shares and the shares of Common Stock into
which the Series B Preferred Stock is convertible and (b) Gruntal with respect
to the Gruntal Warrant Shares.
NOW, THEREFORE, in consideration of the premises and mutual
covenants and conditions contained herein and of other good and valuable
consideration, the receipt and adequacy of which is hereby acknowledged, Company
and the Investors agree as follows:
ARTICLE 12.
DEFINITIONS
All terms not defined herein or below shall have the meanings
ascribed thereto in the Purchase Agreement.
<PAGE>
"EXCHANGE ACT" means the Securities Exchange Act of 1934, as
amended, or any similar federal statute, and the rules and regulations of the
Commission thereunder, all as the same shall be in effect at the time.
"HOLDER" means an Investor or Gruntal, in either case, in its
capacity as a holder of Registrable Securities.
"NASD" shall mean the National Association of Securities Dealers,
Inc.
"REGISTRABLE SECURITIES" means (i) the Warrant Shares, (ii) the
shares of Common Stock issued upon the conversion of shares of the Series B
Preferred Stock issued pursuant to the Purchase Agreement, (iii) the Gruntal
Warrant Shares, (iv) any shares of Common Stock issuable to the Investors
pursuant to the right of first refusal set forth in Section 5 of the Purchase
Agreement, and (v) any additional shares of Common Stock acquired by the Holder
by way of a dividend, stock split or other distribution in respect of the Series
B Preferred Stock. As to any particular Registrable Securities, once issued,
such securities shall cease to be Registrable Securities at such time when (x) a
registration statement with respect to the sale of such securities has been
declared effective by the Commission and such securities have been disposed of
pursuant to such effective registration statement, (y) such securities have been
distributed to the public pursuant to the provisions of Rule 144, or (z) such
securities have ceased to be outstanding. For purposes of this Agreement, a
Person shall be deemed to be a Holder of Registrable Securities, and the
Registrable Securities shall be deemed to be in existence, and such Person shall
be entitled to exercise the rights of a Holder of such Registrable Securities
hereunder, whenever such Person has the right to acquire, directly or
indirectly, such Registrable Securities (upon conversion or exercise in
connection with a transfer of securities or otherwise, but disregarding any
restrictions or limitations upon the exercise of such right), whether or not
such acquisition has actually been effected.
"SECURITIES ACT" means the Securities Act of 1933, as amended, or
any similar federal statute, and the rules and regulations of the Commission
thereunder, all as the same shall be in effect at the time.
"SELLING HOLDER" means an Investor or Gruntal, in either case, in
its capacity as a seller of Registrable Securities pursuant to a registration
statement under the Securities Act.
"UNDERWRITER" means a securities dealer who purchases any
Registrable Securities as principal in an underwritten offering and not as part
of such dealer's market-making activities.
ARTICLE 13.
2
<PAGE>
REGISTRATION RIGHTS
SECTION 13.1 SHELF REGISTRATION.
(a) GENERAL. The Company covenants and agrees with the Investors and
Gruntal that the Company will (i) prepare and file with the Commission no later
than the 75th day following the Closing Date a registration statement under the
Securities Act with respect to the public offering of the Registrable Securities
referred to in clauses (i), (ii) and (iii) of the definition of Registrable
Securities contained in Article I hereof (a "SHELF REGISTRATION"), (ii) use its
best efforts (as used herein the term "best efforts" shall have the meaning
commonly accorded such term as used in registration rights agreements similar to
this Agreement) to have any such registration statement declared effective as
soon as practicable and in any event no later than the 180th day following the
Closing Date and (iii) prepare and file such post-effective amendment or
amendments to such registration statement with respect to Registrable Securities
referred to in clauses (iv) and (v) of the definition of Registrable Securities
contained in Article I hereof. The Company hereby agrees to timely file all
reports required under the Exchange Act for so long as the Company is obligated
to maintain the effectiveness of the registration statement. Once the
registration statement described in this subsection (a) has been declared
effective, the Company shall maintain the registration statement in effect until
(x) all Registrable Securities have been sold pursuant thereto or (y) no
securities are outstanding that constitute Registrable Securities.
(b) EFFECTIVE REGISTRATION. The Shelf Registration shall not be
deemed to have been effected unless it has been declared effective by the
Commission; PROVIDED, that if, after the registration statement has become
effective, the offering of shares of Common Stock pursuant to such Shelf
Registration is or becomes the subject of any stop order, injunction or other
order or requirement of the Commission or any other governmental or
administrative agency, or if any court prevents or otherwise limits the sale of
the shares of Common Stock pursuant to the Shelf Registration at any time within
180 days after the effective date of the registration statement, the Shelf
Registration shall not be deemed to have been effected. If the Shelf
Registration (i) is deemed not to have been effected or (ii) does not remain
effective for a period of at least 180 days beyond the effective date thereof
or, with respect to an underwritten offering of Registrable Securities, until 45
days after the commencement of the distribution by the Holders of the
Registrable Securities included in such registration statement, then the Company
shall continue to be obligated to effect such Shelf Registration pursuant to
this Section 2.1.
(c) OTHER HOLDERS. No securities other than Registrable Securities
shall be included in the Shelf Registration.
(d) SELECTION OF UNDERWRITER. If the Selling Holders so elect at any
time, the offering of such Registrable Securities pursuant to such Shelf
Registration shall be
3
<PAGE>
in the form of an underwritten offering and, if necessary, the Company shall
amend the Shelf Registration to reflect such method of offering. The Selling
Holder holding the largest number of Registrable Securities to be sold in such
underwritten offering shall select one nationally recognized investment banker
to act as the lead managing Underwriter in connection with such offering; and
the Selling Holder holding the second largest number of Registrable Securities
to be sold in such underwritten offering may at its option select one nationally
recognized investment banker to act as the co-managing Underwriter in connection
with such offering.
SECTION 13.2 PIGGY-BACK REGISTRATION.
(a) GENERAL. If at any time the Company proposes to file a
registration statement under the Securities Act with respect to an offering by
the Company for its own account or for the account of any of its respective
security holders (other than a registration statement on Form S-4 or S-8, or any
substitute forms thereof that may be adopted by the Commission), a registration
pursuant to Section 2.1 or any demand registration provided for pursuant to that
certain Underwriters Warrant Agreement dated March 6, 1992, pursuant to which
certain registration rights were granted to Robert Todd Financial Corporation),
then the Company shall give prompt written notice of such proposed filing to the
Holders of Registrable Securities as soon as practicable (but in no event less
than twenty (20) days before the anticipated filing date), and such notice shall
offer such Holders the opportunity to register such number of Registrable
Securities as each such Holder may request (which request shall specify the
Registrable Securities intended to be disposed of by such Holder) (a "PIGGY-BACK
REGISTRATION"). The Company shall use its best efforts to cause the managing
Underwriter or Underwriters of a proposed underwritten offering to permit the
Registrable Securities requested to be included in a Piggy-Back Registration to
be included on the same terms and conditions as any similar securities of the
Company or any other security holder included therein and to permit the sale or
other disposition of such Registrable Securities in accordance with the intended
method of distribution thereof. Any Holder shall have the right to withdraw its
request for inclusion of its Registrable Securities in any registration
statement pursuant to this Section 2.2 by giving written notice to the Company
of its request to withdraw. The Company may withdraw a Piggy-Back Registration
at any time prior to the time it becomes effective.
No registration effected under this Section 2.2, and no failure to
effect a registration under this Section 2.2, shall relieve the Company of its
obligation to effect a Shelf Registration pursuant to Section 2.1, and no
failure to effect a registration under this Section 2.2 and to complete the sale
of Registrable Securities in connection therewith shall relieve the Company of
any other obligation under this Agreement (including, without limitation, the
Company's obligations under Sections 3.2 and 4.1).
(b) REDUCTION. Notwithstanding anything to the contrary contained
herein, if the managing Underwriter or Underwriters of any underwritten offering
described in this Section 2.2 have informed, in writing, the Holders of the
Registrable
4
<PAGE>
Securities requesting inclusion in such offering that it is their opinion that
the total number of shares which the Company, Holders of Registrable Securities
and any other holders of securities of the Company desiring to participate in
such registration intend to include in such offering is such as to materially
and adversely affect the success of such offering, then the number of shares to
be offered shall be reduced or limited in the following order of priority:
FIRST, the number of shares to be offered by all other holders of securities of
the Company (other than the Holders of Registrable Securities and other holders
of securities of the Company who have registration rights, as set forth on
SCHEDULE 2.2(b) annexed hereto (collectively, the "OTHER HOLDERS")) to the
extent necessary to reduce the total number of shares as recommended by such
managing Underwriters; and SECOND, if further reduction or limitation is
required, the number of shares to be offered for the account of the Holders and
the Other Holders shall be reduced or limited on a PRO RATA basis in proportion
to the relative number of securities of the Holders and Other Holders
participating in such registration. If, as a result of the proration provisions
of this Section 2.2, any Holder shall not be entitled to include at least 50% of
the Registrable Securities in a Piggy-Back Registration in which such Holder has
requested to be included, such Holder may elect to withdraw his, her or its
request to include such Holder's Registrable Securities in such registration (a
"WITHDRAWAL ELECTION"); PROVIDED, HOWEVER, that a Withdrawal Election shall be
irrevocable and, after making a Withdrawal Election, a Holder shall no longer
have any right to include Registrable Securities in the Piggy-Back Registration
as to which such Withdrawal Election was made.
ARTICLE 14.
REGISTRATION PROCEDURES
SECTION 14.1 FILINGS; INFORMATION. In connection with the Shelf
Registration (including any underwritten public offering pursuant to Section
2.1(d) hereof) or any Piggyback Registration, the Company will use its best
efforts to effect the registration and the sale of such Registrable Securities
in accordance with the intended method of disposition thereof as quickly as
practicable, and in connection with any such request:
(a) REGISTRATION STATEMENTS. The Company will prepare and file with
the Commission a registration statement with respect to such Registrable
Securities (which, in the case of any underwritten public offering, shall
include such additional information in the prospectus included therein as shall
be reasonably requested by the managing Underwriter or Underwriters) and use its
best efforts to cause such registration statement to become and remain effective
until the completion of the distribution or until the Company's obligations
otherwise terminate hereunder.
(b) AMENDMENTS AND SUPPLEMENTS. The Company will prepare and file
with the Commission such amendments and supplements to such registration
statement and the prospectus used in connection therewith as may be necessary to
keep such registration statement effective for the period specified in
subsection (a)
5
<PAGE>
above and as to comply with the provisions of the Securities Act with respect to
the disposition of all Registrable Securities covered by such registration
statement in accordance with the intended method of disposition set forth in
such registration statement for such period.
(c) COPIES FOR REVIEW. The Company will, as far in advance as
practical, prior to filing a registration statement or prospectus or any
amendment or supplement thereto, furnish copies of such registration statement
as proposed to be filed, together with exhibits thereto, to (i) each Selling
Holder, (ii) not more than one counsel representing all Selling Holders, to be
selected by a majority-in-interest of such Selling Holders, and (iii) each
Underwriter, if any, of the Registrable Securities covered by such registration
statement, which documents will be subject to review and approval by the
foregoing within five (5) days after delivery, and thereafter as far in advance
as practical, furnish to such Selling Holders, counsel and Underwriters, if any,
for their review and comment such number of copies of such registration
statement, each amendment and supplement thereto (in each case including all
exhibits thereto and documents incorporated by reference therein), the
prospectus included in such registration statement (including each preliminary
prospectus) and such other documents or information as such Selling Holders,
counsel or Underwriters may reasonably request in order to facilitate the
disposition of the Registrable Securities owned by such Selling Holders.
(d) STOP ORDERS. After the filing of the registration statement, the
Company will promptly notify each Selling Holder of Registrable Securities
covered by such registration statement of any stop order issued or threatened by
the Commission and take all reasonable actions required to prevent the entry of
such stop order or to remove it if entered.
(e) BLUE SKY. The Company will use its best efforts to (i) register
or qualify the Registrable Securities under such other securities or blue sky
laws of such jurisdictions in the United States as any Selling Holder reasonably
(in light of such Selling Holder's intended plan of distribution) requests, and
(ii) cause such Registrable Securities to be registered with or approved by such
other governmental agencies or authorities in the United States as may be
necessary by virtue of the business and operations of the Company and do any and
all other acts and things that may be reasonably necessary or advisable to
enable such Selling Holder to consummate the disposition of the Registrable
Securities owned by such Selling Holder; PROVIDED, that the Company will not be
required to (x) qualify generally to do business in any jurisdiction where it
would not otherwise be required to qualify but for this subsection (e), (y)
subject itself to taxation in any such jurisdiction or (z) consent to general
service of process in any such jurisdiction.
(f) CERTAIN EVENTS. The Company will immediately notify each Selling
Holder, at any time when a prospectus relating thereto is required to be
delivered under the Securities Act, of the occurrence of an event requiring the
preparation of a
6
<PAGE>
supplement or amendment to such prospectus so that, as thereafter delivered to
the Holders of such Registrable Securities, such prospectus will not contain any
untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading and promptly make
available to each Selling Holder any such supplement or amendment. The Company
will promptly prepare and if required, cause to become effective, such
supplement or amendment and deliver sufficient copies thereof to each Selling
Holder.
(g) AGREEMENTS. The Company and the Selling Holders will enter into
customary agreements (including, if applicable, an underwriting agreement in
customary form and which is reasonably satisfactory to the Company) and take
such other actions as are reasonably required in order to expedite or facilitate
the disposition of such Registrable Securities; and the Selling Holders may, at
their option, require that any or all of the representations, warranties and
covenants of the Company or to or for the benefit of such Underwriters also be
made to and for the benefit of such Selling Holders.
(h) DUE DILIGENCE. The Company will make available to each Selling
Holder (and their counsel) and each Underwriter, if any, subject to restrictions
imposed by the United States federal government or any agency or instrumentality
thereof, copies of all correspondence between the Commission and the Company,
its counsel or auditors and will also make available for inspection by any
Selling Holder, any Underwriter participating in any disposition pursuant to
such registration statement and any attorney, accountant or other professional
retained by any such Selling Holder or Underwriter (collectively, the
"INSPECTORS"), all financial and other records, pertinent corporate documents
and properties of the Company (collectively, the "RECORDS") as shall be
reasonably necessary to enable them to exercise their due diligence
responsibility, and cause the Company's officers and employees to supply all
information reasonably requested by any Inspectors in connection with such
registration statement. Records which the Company determines, in good faith, to
be confidential and which it notifies the Inspectors are confidential shall not
be disclosed by the Inspectors unless (i) the disclosure of such Records is
necessary to avoid or correct a misstatement or omission in such registration
statement or (ii) the disclosure or release of such Records is requested or
required pursuant to oral questions, interrogatories, requests for information
or documents or a subpoena or other order from a court of competent jurisdiction
or other process; PROVIDED, that prior to any disclosure or release pursuant to
clause (ii), the Inspectors shall provide the Company with prompt notice of any
such request or requirement so that the Company may seek an appropriate
protective order or waive such Inspectors' obligation not to disclose such
Records; and, PROVIDED FURTHER, that if failing the entry of a protective order
or the waiver by the Company permitting the disclosure or release of such
Records, the Inspectors, upon advice of counsel, are compelled to disclose such
Records, the Inspectors may disclose that portion of the Records which counsel
has advised the Inspectors that the Inspectors are compelled to disclose. Each
Selling Holder agrees
7
<PAGE>
that information obtained by it solely as a result of such inspections (not
including any information obtained from a third party who, insofar as is known
to the Selling Holder after reasonable inquiry, is not prohibited from providing
such information by a contractual, legal or fiduciary obligation to the Company)
shall be deemed confidential and shall not be used by it as the basis for any
market transactions in the securities of the Company or its affiliates (as
defined in Rule 405 promulgated under the Securities Act) unless and until such
information is made generally available to the public. Each Selling Holder
further agrees that it will, upon learning that disclosure of such Records is
sought in a court of competent jurisdiction, give notice to the Company and
allow the Company, at its expense, to undertake appropriate action to prevent
disclosure of the Records deemed confidential.
(i) SALES EFFORTS. In connection with an underwritten offering, the
Company will participate, to the extent reasonably requested by the managing
Underwriter for the offering or the Selling Holders, in customary efforts to
sell the securities under the offering, including, without limitation,
participating in "road shows"; PROVIDED, that the Company shall not be obligated
to participate in more than one such offering in any 12-month period.
The Company may require each Selling Holder to promptly furnish in
writing to the Company such information regarding the distribution of the
Registrable Securities as the Company may from time to time reasonably request
and such other information as may be legally required in connection with such
registration including, without limitation, all such information as may be
requested by the Commission or the NASD. The Company may exclude from such
registration any Holder who fails to provide such information.
Each Selling Holder agrees that, upon receipt of any notice from the
Company of the happening of any event of the kind described in subsection (f)
hereof, such Selling Holder will forthwith discontinue disposition of
Registrable Securities pursuant to the registration statement covering such
Registrable Securities until such Selling Holder's receipt of the copies of the
supplemented or amended prospectus contemplated by subsection (f) hereof, and,
if so directed by the Company, such Selling Holder will deliver to the Company
all copies, other than permanent file copies then in such Selling Holder's
possession, of the most recent prospectus covering such Registrable Securities
at the time of receipt of such notice.
SECTION 14.2 REGISTRATION EXPENSES. In connection with the Shelf
Registration and any Piggy-Back Registration, the Company shall pay the
following registration expenses incurred in connection with the registration
thereunder (the "REGISTRATION EXPENSES"): (i) all registration and filing fees,
(ii) fees and expenses of compliance with securities or blue sky laws (including
reasonable fees and disbursements of counsel in connection with blue sky
qualifications of the Registrable Securities), (iii) processing, duplicating and
printing expenses, (iv) the Company's internal expenses (including, without
limitation, all salaries and expenses of its officers
8
<PAGE>
and employees performing legal or accounting duties), (v) the fees and expenses
incurred in connection with the listing of the Registrable Securities, (vi)
reasonable fees and disbursements of counsel for the Company and customary fees
and expenses for independent certified public accountants retained by the
Company (including the expenses of any comfort letters or costs associated with
the delivery by independent certified public accountants of a comfort letter or
comfort letters requested but not the cost of any audit other than a year end
audit), (vii) the reasonable fees and expenses of any special experts retained
by the Company in connection with such registration, (viii) reasonable fees and
expenses of one firm of counsel for the Holders to be selected by the Holders of
at least 66.67% of the Registrable Securities to be included in such
registration, and (ix) any other fees and disbursements of underwriters
customarily paid by issuers or sellers of securities. The Company shall have no
obligation to pay any other underwriting fees, discounts or commissions
attributable to the sale of Registrable Securities, or the cost of any special
audit required, such costs to be borne by the Holder or Holders making the
request.
SECTION 27.3 ADVICE BY COMPANY. The Company will keep each Holder
advised as to the completion of any registration contemplated in this Agreement.
At its expense, the Company will furnish promptly to each Holder such number or
copies of prospectuses (including preliminary prospectuses), and all amendments
and supplements thereto, in conformity with the requirements of the Securities
Act, and such other documents as any such Holder from time to time may
reasonably request.
ARTICLE 15.
INDEMNIFICATION AND CONTRIBUTION
SECTION 15.1 INDEMNIFICATION BY THE COMPANY. The Company shall, to
the full extent permitted by law, indemnify and hold harmless each Selling
Holder, its partners, officers, directors, employees and agents, and each
person, if any, who controls such Selling Holder within the meaning of Section
15 of the Securities Act or Section 20 of the Exchange Act, together with the
partners, officers, directors, employees and agents of such controlling person
(collectively, "HOLDER COVERED PERSONS"), from and against any loss, claim,
damage, liability, reasonable attorneys' fees, cost or expense and costs and
expenses of investigating and defending any such claim, joint or several, and
any action in respect thereof (collectively, the "DAMAGES"), to which any such
Holder Covered Person may become subject under the Securities Act or otherwise,
insofar as such Damages (or actions or proceedings, whether commenced or
threatened, in respect thereof) arise out of, or are based upon, any untrue
statement or alleged untrue statement of a material fact contained in any
registration statement or prospectus relating to the Registrable Securities or
any amendment or supplement thereto, or arises out of, or are based upon, any
omission or alleged omission to state therein a material fact required to be
stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading, or any violation by
the Company of any federal or state securities law or
9
<PAGE>
any rule or regulation thereof, except insofar as the same are based upon
information furnished in writing to the Company by a Selling Holder expressly
for use therein, and shall reimburse each Holder Covered Person for any legal
and other expenses reasonably incurred by that Holder Covered Person in
investigating or defending or preparing to defend against any such Damages or
proceedings; PROVIDED, HOWEVER, that the Company shall not be liable to any
Selling Holder to the extent that any such Damages (or action or proceeding in
respect thereof) arise out of or are based upon any untrue statement or omission
made in any preliminary prospectus if (i) such Selling Holder failed to send or
deliver a copy of the final prospectus with or prior to the delivery of written
confirmation of the sale by such Selling Holder to the person asserting the
claim from which such Damages arise, and (ii) the final prospectus would have
corrected such untrue statement or such omission; PROVIDED FURTHER, that the
Company shall not be liable to any Selling Holder in any such case to the extent
that any such Damages arise out of or are based upon any untrue statement or
omission in any prospectus if (x) such untrue statement or omission is corrected
in an amendment or supplement to such prospectus, and (y) having previously been
furnished by or on behalf of the Company with copies of such prospectus as so
amended or supplemented, such Selling Holder thereafter fails to deliver such
prospectus as so amended or supplemented prior to or concurrently with the sale
of a Registrable Security to the person asserting the claim from which such
Damages arise. The Company also agrees to indemnify any Underwriters of the
Registrable Securities, their officers and directors and each person who
controls any such Underwriters on substantially the same basis as that of the
indemnification of the Selling Holders provided in this Section 4.1.
SECTION 15.2 INDEMNIFICATION BY SELLING HOLDERS. Each Selling Holder
shall, to the full extent permitted by law, severally but not jointly, indemnify
and hold harmless the Company, its officers, directors, employees and agents and
each person, if any, who controls the Company within the meaning of Section 15
of the Securities Act or Section 20 of the Exchange Act, together with the
partners, officers, directors, employees and agents of such controlling person
(collectively, "COMPANY COVERED PERSONS"), to the same extent as the foregoing
indemnity from the Company to such Selling Holder, but only with reference to
information related to such Selling Holder, or its plan of distribution,
furnished in writing by such Selling Holder or on such Selling Holder's behalf
expressly for use in any registration statement or prospectus relating to the
Registrable Securities, or any amendment or supplement thereto, or any
preliminary prospectus and the aggregate amount which may be recovered from any
Selling Holder pursuant to the indemnification provided for in this Section 4.2
in connection with any registration and sale of Registrable Securities shall be
limited to the total proceeds received by such Holder from the sale of such
Registrable Securities. In case any action or proceeding shall be brought
against any Company Covered Person in respect of which indemnity may be sought
against such Selling Holder, such Selling Holder shall have the rights and
duties given to the Company Covered Persons, and the Company Covered Persons
shall have the rights and duties given to such Selling Holder, by Section 4.1.
Each Selling Holder also
10
<PAGE>
agrees to indemnify and hold harmless any Underwriters of the Registrable
Securities, their officers and directors and each person who controls such
Underwriters on substantially the same basis as that of the indemnification of
the Company provided in this Section 4.2. The Company shall be entitled to
receive indemnities from Underwriters, selling brokers, dealer managers and
similar securities industry professionals participating in the distribution, to
the same extent as provided above, with respect to information so furnished in
writing by such persons specifically for inclusion in any prospectus or
registration statement.
SECTION 15.3 CONDUCT OF INDEMNIFICATION PROCEEDINGS. Promptly after
receipt by any person in respect of which indemnity may be sought pursuant to
Section 4.1 or 4.2 (an "INDEMNIFIED PARTY") of notice of any claim or the
commencement of any action, the Indemnified Party shall, if a claim in respect
thereof is to be made against the person against whom such indemnity may be
sought (an "INDEMNIFYING PARTY"), notify the Indemnifying Party in writing of
the claim or the commencement of such action; PROVIDED that the failure to
notify the Indemnifying Party shall not relieve it from any liability which it
may have to an Indemnified Party otherwise than under Section 4.1 or 4.2 and
except to the extent of any actual prejudice resulting therefrom. If any such
claim or action shall be brought against an Indemnified Party, and it shall
notify the Indemnifying Party thereof, the Indemnifying Party shall be entitled
to participate therein, and, to the extent that it wishes, jointly with any
other similarly notified Indemnifying Party, to assume the defense thereof with
counsel reasonably satisfactory to the Indemnified Party. After notice from the
Indemnifying Party to the Indemnified Party of its election to assume the
defense of such claim or action, the Indemnifying Party shall not be liable to
the Indemnified Party for any legal or other expenses subsequently incurred by
the Indemnified Party in connection with the defense thereof other than
reasonable costs of investigation; PROVIDED that the Indemnified Party shall
have the right to employ separate counsel to represent the Indemnified Party and
its Controlling Persons who may be subject to liability arising out of any claim
in respect of which indemnity may be sought by the Indemnified Party against the
Indemnifying Party, but the fees and expenses of such counsel shall be for the
account of such Indemnified
11
<PAGE>
Party unless (i) the Indemnifying Party and the Indemnified Party shall have
mutually agreed to the retention of such counsel or (ii) in the reasonable
judgment of the Company and such Indemnified Party, representation of both
parties by the same counsel would be inappropriate due to actual or potential
conflicts of interest between them, it being understood, however, that the
Indemnifying Party shall not, in connection with any one such claim or action or
separate but substantially similar or related claims or actions in the same
jurisdiction arising out of the same general allegations or circumstances, be
liable for the fees and expenses of more than one separate firm of attorneys
(together with appropriate local counsel) at any time for all Indemnified
Parties, or for fees and expenses that are not reasonable. No Indemnifying Party
shall, without the prior written consent of the Indemnified Party, effect any
settlement of any claim or pending or threatened proceeding in respect of which
the Indemnified Party is or could have been a party and indemnity could have
been sought hereunder by such Indemnified Party, unless such settlement includes
an unconditional release of such Indemnified Party from all liability arising
out of such claim or proceeding. Whether or not the defense of any claim or
action is assumed by the Indemnifying Party, such Indemnifying Party will not be
subject to any liability for any settlement made without its consent, which
consent will not be unreasonably withheld.
SECTION 15.4 CONTRIBUTION. If the indemnification provided for in
this Article 4 is unavailable to the Indemnified Parties in respect of any
Damages referred to herein, then each Indemnifying Party, in lieu of
indemnifying such Indemnified Party, shall contribute to the amount paid or
payable by such Indemnified Party as a result of such Damages (i) as between the
Company and the Selling Holders on the one hand and the Underwriters on the
other, in such proportion as is appropriate to reflect the relative benefits
received by the Company and the Selling Holders on the one hand and the
Underwriters on the other from the offering of the Registrable Securities, or if
such allocation is not permitted by applicable law, in such proportion as is
appropriate to reflect not only the relative benefits but also the relative
fault of the Company and the Selling Holders on the one hand and of the
Underwriters on the other in connection with the statements or omissions which
resulted in such Damages, as well as any other relevant equitable
considerations, and (ii) as between the Company on the one hand and each Selling
Holder on the other, in such proportion as is appropriate to reflect the
relative fault of the Company and of each Selling Holder in connection with such
statements or omissions, as well as any other relevant equitable considerations.
The relative benefits received by the Company and the Selling Holders on the one
hand and the Underwriters on the other shall be deemed to be in the same
proportion as the total proceeds from the offering (net of underwriting
discounts and commissions but before deducting expenses) received by the Company
and the Selling Holders bear to the total underwriting discounts and commissions
received by the Underwriters, in each case as set forth in the table on the
cover page of the prospectus. The relative fault of the Company and the Selling
Holders on the one hand and of the Underwriters on the other shall be determined
by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission or alleged omission to state a
material fact relates to information supplied by the Company and the Selling
Holders or by the Underwriters. The relative fault of the Company on the one
hand and of each Selling Holder on the other shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a
material fact or the omission or alleged omission to state a material fact
relates to information supplied by such party, and the parties' relative intent,
knowledge, access to information and opportunity to correct or prevent such
statement or omission.
The Company and the Selling Holders agree that it would not be just
and equitable if contribution pursuant to this Section 4.4 were determined by
PRO RATA allocation (even if the Underwriters were treated as one entity for
such purpose) or by any other method of allocation which does not take account
of the equitable considerations referred to in the immediately preceding
paragraph. The amount paid
12
<PAGE>
or payable by an Indemnified Party as a result of the Damages referred to in the
immediately preceding paragraph shall be deemed to include, subject to the
limitations set forth above, any legal or other expenses reasonably incurred by
such Indemnified Party in connection with investigating or defending any such
action or claim. Notwithstanding the provisions of this Section 4.4, no
Underwriter shall be required to contribute any amount in excess of the amount
by which the total price at which the Registrable Securities underwritten by it
and distributed to the public were offered to the public exceeds the amount of
any damages which such Underwriter has otherwise been required to pay by reason
of such untrue or alleged untrue statement or omission or alleged omission, and
no Selling Holder shall be required to contribute any amount in excess of the
amount by which the total price at which the Registrable Securities of such
Selling Holder were offered to the public (less underwriting discounts and
commissions) exceeds the amount of any damages which such Selling Holder has
otherwise been required to pay by reason of such untrue or alleged untrue
statement or omission or alleged omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation. Each Selling Holder's obligations to contribute
pursuant to this Section 4.4 is several in the proportion that the proceeds of
the offering received by such Selling Holder bears to the total proceeds of the
offering received by all the Selling Holders and not joint.
ARTICLE 16.
MISCELLANEOUS
SECTION 16.1 OTHER REGISTRATION RIGHTS; HOLDBACK. The Company
represents and warrants to the Holders that, except as set forth on SCHEDULE
2.2(b), there is not in effect on the date hereof any agreement by the Company
pursuant to which any holders of securities of the Company have a right to cause
the Company to register or qualify such securities under the Securities Act or
any securities or blue sky laws of any jurisdiction that would conflict in any
material respect with any provision of this Agreement. The Company shall not in
the future grant to any owner or purchaser of shares of capital stock of the
Company registration rights unless (a) such registration rights are made
subordinate to the rights granted hereunder so that each Holder shall have
priority to participate in any piggy-back registration with respect to such
other shares of capital stock of the Company and (b) if the offering by the
Holders is underwritten, such owner or purchaser agrees not to sell any shares
of capital stock of the Company during the period commencing ten (10) days prior
to any such underwritten offering and ending ninety (90) days following any such
underwritten offering (or for such shorter period of time as is sufficient and
appropriate, in the opinion of any managing Underwriter(s)). If requested by
managing Underwriter(s) in any such registration, the Company shall request the
directors and executive officers of the Company to execute and deliver similar
holdback agreements.
SECTION 16.2 PARTICIPATION IN UNDERWRITTEN REGISTRATIONS. No person
may participate in any underwritten registration hereunder unless such person
13
<PAGE>
(a) agrees to sell such person's securities on the basis provided in any
underwriting arrangements approved by the persons entitled hereunder to approve
such arrangements, and (b) completes and executes all questionnaires, powers of
attorney, indemnities, underwriting agreements and other documents reasonably
required under the terms of such underwriting arrangements and these
registration rights. Notwithstanding the foregoing, no Holder of Registrable
Securities shall be required to make any representations or warranties to or
agreements with the Company or the Underwriters other than those customarily
made by selling stockholders in such registrations, including without limitation
representations, warranties or agreements regarding such Holder and its
ownership of the securities being registered on its behalf and such Holder's
intended method of distribution and any other representation required by law.
SECTION 16.3 HOLDBACK AGREEMENT. For so long as the Holder has the
right to have Registrable Securities included in any registration pursuant to
this Agreement, the Holder agrees in connection with any underwritten
registration of the Company's securities, upon the request of the Underwriters
managing such underwritten offering of the Company's securities, not to effect
any public sale or distribution (including any sale pursuant to Rule 144 under
the Securities Act) of any Registrable Securities without the prior written
consent of the Company or such Underwriters, as the case may be, within ten (10)
days prior to or ninety (90) days after the effective date of such registration,
as the Company or the Underwriters may specify.
SECTION 16.4 SUSPENSION OF TRADING. After the Company has filed any
registration statement pursuant to this Agreement, and if such registration
shall be in connection with an underwritten offering of the Company's
securities, upon the request of the managing Underwriter or Underwriters the
Company may suspend the sale of Common Stock for up to ninety (90) days;
PROVIDED, HOWEVER, that no such suspension shall occur on more than one occasion
within any one year period.
SECTION 16.5 RULE 144 AND 144A. The Company covenants that it will
file any reports required to be filed by it under the Securities Act and the
Exchange Act and that it will take such further action as any Holder may
reasonably request, all to the extent required from time to time to enable
Holders to sell Registrable Securities without registration under the Securities
Act within the limitation of the exemptions provided by (a) Rule 144 or Rule
144A under the Securities Act, as such Rules may be amended from time to time,
or (b) any similar rule or regulation hereafter adopted by the Commission. Upon
the request of any Holder, the Company will deliver to such Holder a written
statement as to whether it has complied with such requirements.
SECTION 16.6 SUSPENSION OF OBLIGATION TO FILE. Notwithstanding the
provisions of Section 3.1(a), the Company's obligations to file a registration
statement, or cause such registration statement to become and remain effective,
shall be
14
<PAGE>
suspended for a period not to exceed 90 days if there exists at the
time material non-public information relating to the Company that, in the
reasonable opinion of the Company, should not be disclosed.
SECTION 16.7 GENERAL.
(a) GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED
IN ACCORDANCE WITH THE INTERNAL LAW OF THE STATE OF NEW YORK, WITHOUT GIVING
EFFECT TO PRINCIPLES OF CONFLICTS OF LAW.
(b) NOTICES. All notices or other communications shall be in writing
and shall be personally served or mailed, registered or certified, return
receipt requested, postage prepaid (or by a substantially similar method), or
delivered by a reputable overnight courier service with charges prepaid, or
transmitted by hand delivery or facsimile, addressed as set forth below, or such
other address as such party shall have specified most recently by written
notice:
If to the Company:
LifeCell Corporation
3606 Research Forest Drive
The Woodlands, Texas 77381
Attention: President
Telephone: (713) 367-5368
Telecopy: (713) 363-3360
with a copy to:
Fulbright & Jaworski L.L.P.
1301 McKinney Street, Suite 5100
Houston, Texas 77010-3095
Attention: Robert E. Wilson, Esq.
Telephone: (713) 651-5151
Telecopy: (713) 651-5246
Notice to any Holder shall be sent to the address listed on SCHEDULE
1 or to such other address which the Holder shall have provided in writing in
accordance with this Section 5.7(b).
Notice shall be deemed given or delivered on the date of service or
transmission if personally served or transmitted by telecopier (with telephonic
confirmation of receipt). Notice otherwise sent as provided herein shall be
deemed given or delivered on the third business day following the date of
postmark or on the next business day following delivery of such notice to a
reputable overnight courier service.
15
<PAGE>
(c) BINDING EFFECT. This Agreement and all of the provisions hereof
shall be binding upon and inure to the benefit of the parties hereto and their
respective heirs, successors and permitted assigns.
(d) NO WAIVER. No failure on the part of the Company or the
Investors in exercising any right, power or privilege granted hereunder shall
operate as a waiver thereof or of any other right, power or privilege, nor shall
any single or partial exercise of such right, power or privilege preclude any
other or further exercise thereof or of any other right, power or privilege.
(e) ENTIRE AGREEMENT. This Agreement sets forth the entire agreement
among the parties hereto with respect to the subject matter hereof, and
supersedes any prior oral or written agreements among the parties.
(f) HEADINGS. The headings of this Agreement are solely for the
convenience of the parties and shall not affect the interpretation or effect of
any terms or provisions hereof.
(g) COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed to be an original, but all of which
together shall constitute one and the same document.
(h) SEVERABILITY. In the event that any court or any governmental
authority or agency declares all or any part of any Section of this Agreement to
be unlawful or invalid, such unlawfulness or invalidity shall not serve to
invalidate any other Section of this Agreement, and in the event that only a
portion of any Section is so declared to be unlawful or invalid, such
unlawfulness or invalidity shall not serve to invalidate the balance of such
Section.
(i) AMENDMENTS AND WAIVERS. This Agreement may be amended, modified
and supplemented, and compliance with any term, covenant, agreement or condition
contained herein may be waived either generally or in particular instances, only
by a written instrument executed by the Company and the holders of at least a
majority of the then outstanding Registrable Securities (for this purpose,
treating (i) the Series B Preferred Stock as if it had been converted into
Common Stock and (ii) each of the Warrants and the Gruntal Warrant that is then
exercisable pursuant to its terms as if it had been exercised in full). No
course of dealing between or among any persons having any interest in this
Agreement will be deemed effective to modify, amend or discharge any part of
this Agreement or any rights or obligations of any person under or by reason of
this Agreement.
(j) FURTHER ASSURANCES. Each party shall cooperate and take such
action as may be reasonably requested by another party in order to carry out
16
<PAGE>
the provisions and purposes of this Agreement and the transactions contemplated
hereby.
(k) REMEDIES. In the event of a breach or a threatened breach by any
party to this Agreement of its obligations under this Agreement, any party
injured or to be injured by such breach will be entitled to specific performance
of its rights under this Agreement or to injunctive relief, in addition to being
entitled to exercise all rights provided in this Agreement and granted by law.
The parties agree that the provisions of this Agreement shall be specifically
enforceable, it being agreed by the parties that the remedy at law, inducing
monetary damages, for breach of any such provision will be inadequate
compensation for any loss and that any defense or objection in any action for
specific performance or injunctive relief that a remedy at law would be adequate
is waived.
* * * * *
17
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this Agreement
as of the date first above written.
LIFECELL CORPORATION
By _____________________________________________
Paul M. Frison
President and Chief Executive Officer
VECTOR LATER-STAGE EQUITY FUND, L.P.
By Vector Fund Management, L.P.,
its General Partner
By
Its
CIBC WOOD GUNDY VENTURES, INC.
By
Name:
Title:
18
<PAGE>
GRUNTAL & CO., INCORPORATED
By
Name:
Title:
19
<PAGE>
SCHEDULE 1
INVESTORS
Vector Later-Stage Equity Fund, L.P. Charles and Donna Greenberg
1751 Lake Cook Road, Suite 350 503 Pinehurst Court
Deerfield, Illinois 60015 Roslyn, NY 11576
CIBC Wood Gundy Ventures, Inc. Michael Gironta
425 Lexington Avenue 89 Ridgewood Avenue
New York, New York 10017 Glen Ridge, NJ 07028
The Woodlands Venture Capital Company Joseph A. Russo
2201 Timberloch Place 3 Midwood Avenue
The Woodlands, TX 77380 Verona, NJ 07044
SBSF Biotechnology Fund, L.P. John D. Goldberg
c/o Lisa Tuckerman 2500 East Hallandale Beach Blvd.
Spears Benzak Salomon & Farrell Suite 500
45 Rockefeller Plaza -- 33rd Floor Hallandale, FL 33009-4838
New York, NY 10111
Robert Sablowsky
SBSF Biotechnology Partners, L.P. 150 East 69th Street, 16A
c/o Lisa Tuckerman New York, NY 10021
Spears Benzak Salomon & Farrell
45 Rockefeller Plaza -- 33rd Floor William J. Strazzullo
New York, NY 10111 750 Columbus Avenue, 4C
New York, NY 10025
Jerome Schachter
2926 Leanne Court Joseph Battipaglia
Northbrook, IL 60062 77 Water Street (10th Floor)
New York, NY 10005
Paul B. Ankin and Lois F. Ankin,
as joint tenants Stephen G. Weiss
4233 W. Grove 115 Ravin Oaks Lane
Skokie, IL 60076 Highland Park, IL 60035
David and Mary Jane Harris Barry Richter
174 Pacific Street, Apt. 2A Tideway
Brooklyn, NY 11201 Sandspoint, NY 11050
Richard L. Serrano
64 Brighton Avenue
Bloomfield, NJ 07003
20
<PAGE>
Chinook Equities, Inc. John S. Bai
147 East 48th Street 30 West 61st, 27A
New York, NY 10017 New York, NY 10023
Daniel and Elaine Kleinberg William J. McCluskey
3 Centennial Road 25 Wisconsin Street
Livingston, NJ 07039 Long Beach, NY 11561
Douglas Kleinberg David F. Saks
200 East 95th Street, Apt. 126 2 Knollcliff Road
New York, NY 10128 Woodcliff Lake, NJ 07675
Evan Kleinberg IRA P. William Curreri, M.D.
Gruntal & Co. Custodian 217 Berwyn Drive, W. #222
3 Centennial Road Mobile, Alabama 36608
Livingston, NJ 07039
Christopher C. Kraft, Jr.
John Latshaw Smith Barney Inc. KEO P/S Custodian
5049 Wornall #2C 14919 Village Elm Street
Kansas City, MO 64112 Houston, TX 77062
B. Michael Pisani Michael H. Richmond
44 Lake Road 20 E. Wedgewood Glen
Short Hills, NJ 07078 The Woodlands, TX 77381
John Cirrito Stephen Livesey
29 Rambling Drive 3606 Research Forest Drive
Scotch Plains, NJ 07076 The Woodlands, TX 77381
James C. Gale, Trustee F/B/O Ariana J. Gale Michael E. Cahr
315 W. 106th Street, Apt. 4A 1051 Saxony Drive
New York, NY 10025 Highland Park, IL 60035
James C. Gale and Judith S. Haselton Technology Funding Medical
315 West 106th Street, Apt. 4A Partners I, L.P.
New York, NY 10025 2000 Alameda de las Pulgas
San Mateo, CA 94403
Robert Weinstein
155 West 68th Street, 24C
New York, NY 10023
21
<PAGE>
Ronald Koenig James J. Pelts
114 No. Village Way 29 East Madison Street, Suite 1505
Jupiter, Florida 33458 Chicago, IL 60602
Robert M. Adams The Marcus L. Koblitz Trust
P.O. Box 998 Michael J. Koblitz, Trustee
Plandome, NY 11030 12 Downey Drive
Tenafly, NJ 07670
Edward A. Kerbs
8 South Cherry Lane The Lauren J. Koblitz Trust,
Rumson, NJ 07760 Michael J. Koblitz, Trustee
12 Downey Drive
Bernard B. Salzman IRA, Tenafly, NJ 07670
Gruntal & Co., Inc., Custodian
20 S. Charles Street Pharmaceutical & Medical Technology Fund
Baltimore, MD 21201 300 Park Avenue
New York, NY 10022
Don A. Sanders
3100 Texas Commerce Tower Strategic Healthcare Fund
Houston, TX 77002 300 Park Avenue
New York, NY 10022
Jeffrey Keeler
577 W. 50th Street Michael J. Koblitz
Miami Beach, FL 33140 12 Downey Drive
Tenafly, NJ 07670
Harbour Court L.P., II
253 W. 73rd St., Apt. 6D
New York, NY 10023
Attention: Jonathan Greenwald
Namax Corp.
666 Dundee Road, Suite 1801
Northbrook, IL 60062
Attention: Mark Rice, President
Sheldon Drobny
95 Revere Drive, Suite A
Northbrook, IL 60062
Perry H. Bacon
5300 Mission Woods Road
Shawnee Mission, KS 66205
22
SCHEDULE 2.2(b)
OTHER REGISTRATION RIGHTS
The holders of capital stock listed below pursuant to the Amended and Restated
Registration Rights Agreement, dated February 26, 1992, as amended, by and among
the Company and the holders of capital stock of the Company identified therein:
Allstate Insurance Company
The Woodlands Venture Fund, L.P.
Tenneco Insurance Ventures, Inc.
The Woodlands Venture Capital Company
Board of Regents of the University of Texas System
Technology Funding Partners III, L.P.
Paul M. Frison
Robert Todd Financial Corporation pursuant to the Underwriter's Warrant
Agreement, dated March 6, 1992, between the Company and Robert Todd Financial
Corporation, as amended by First Amendment to Underwriter's Warrant Agreement,
dated January 23, 1993, by and between the Company and Robert Todd Financial
Corporation.
Medtronic, Inc. pursuant to the Investment Agreement, dated March 3, 1994, as
amended, between the Company and Medtronic, Inc.
23
<PAGE>
EXHIBIT E
FORM OF OPINION OF COUNSEL
18 November 1996
The Investors listed on SCHEDULE 1 to the
Securities Purchase Agreement dated
as of November 18, 1996, between
LifeCell Corporation and the Investors
Gruntal & Co., Incorporated
14 Wall Street
New York, New York 10005
Ladies and Gentlemen:
We have acted as counsel to LifeCell Corporation, a Delaware
corporation (the "Company"), in connection with the transactions contemplated by
the Securities Purchase Agreement dated as of November 18, 1996 (the "Securities
Purchase Agreement"), between the Company and the persons named in SCHEDULE 1
thereto (the "Investors") and the Sales Agency Agreement dated October 29, 1996
(the "Sales Agency Agreement"), between the Company and Gruntal & Co.,
Incorporated ("Gruntal"). The Securities Purchase Agreement and the Sales Agency
Agreement each relate to the sale by the Company of an aggregate of 124,157
shares of its Series B Preferred Stock, $.001 par value per share (the "Series B
Preferred Stock"), and stock purchase warrants exercisable for an aggregate of
2,803,530 shares of the Company's Common Stock, $.001 par value per share (the
"Common Stock"). Each capitalized term not otherwise defined herein shall have
the meaning given to it in the Securities Purchase Agreement.
We have examined the Securities Purchase Agreement, the other
Transaction Documents, the Sales Agency Agreement and the Agent's Warrant (as
defined in the Sales Agency Agreement) (together, the Sales Agency Agreement and
the Agent's Warrant are referred to herein as the "Gruntal Documents") and
originals, or copies certified or otherwise identified to our satisfaction, of
such corporate records, certificates of officers of the Company, certificates
and facsimile transmissions of public officials and such other documents as we
have deemed necessary or appropriate for the purpose of this opinion. As to
questions of fact material to this opinion, we have, to the extent we deemed
appropriate, relied on certificates of officers of the Company and on
certificates and facsimile transmissions of government officials. We have
assumed the genuineness of all signatures, the authenticity of all documents,
records and instruments examined by us and the correctness of all statements of
fact contained
1
<PAGE>
therein. We also have examined and relied upon representations as
to factual matters contained in the Securities Purchase Agreement and the Sales
Agency Agreement and in certificates of officers of the Company delivered
pursuant thereto.
Based upon the foregoing, and in reliance thereon, and having due
regard for such legal considerations as we deem relevant, and subject in all
respects to the assumptions, exceptions, qualifications and limitations herein
set forth, we are of the opinion that:
1. The Company has been duly incorporated and organized and is validly
existing and in good standing under the laws of the State of Delaware.
2. The Company is duly qualified as a foreign corporation to transact
business in, and is in good standing in, the State of Texas.
3. The Company has all necessary corporate power and authority to
execute, deliver and perform its obligations under each of the Transaction
Documents and Gruntal Documents, and the Company has all necessary corporate
power and authority to own its properties and to conduct its business as
described in the Memorandum.
4. Each of the Transaction Documents and Gruntal Documents has been
duly authorized, executed and delivered by the Company, and each such agreement
or instrument is a valid and binding obligation of the Company, enforceable
against the Company in accordance with its terms.
5. The Certificate of Designation has been duly adopted by the
Company's Board of Directors, has been duly filed with the Secretary of State of
Delaware and has become effective under the laws of the State of Delaware, and,
upon issuance thereof in accordance with the Securities Purchase Agreement or
Certificate of Designation, as the case may be, shares of Series B Preferred
Stock will bear the designations, powers, preferences and relative,
participating, optional and other special rights, and the qualifications,
limitations or restrictions thereof, set forth in the Certificate of
Designation.
6. Upon issuance thereof in accordance with the Securities Purchase
Agreement, each share of Series B Preferred Stock issued to an Investor at the
Closing will be validly issued and outstanding, fully paid and nonassessable,
and there are no statutory or, to our knowledge, contractual preemptive rights
of stockholders or rights of first refusal with respect to the issuance of such
share of Series B Preferred Stock.
7. The certificates representing shares of Series B Preferred Stock
purchased by the Investors at the Closing have been duly authorized by the
Company and are in due and proper form under the Delaware General Corporation
Law.
8. The shares of Common Stock issuable upon conversion of the Series B
Preferred Stock have been duly authorized and reserved for issuance by the
Company, there are no statutory or, to our knowledge, contractual preemptive
rights of stockholders or rights of first refusal with respect to the issuance
of such shares of Common Stock and the shares of Common Stock to be issued upon
conversion of the Series B Preferred Stock shall upon such issuance in
accordance with the terms of the Certificate of Designation be validly issued,
fully paid and nonassessable.
2
<PAGE>
9. The shares of Common Stock issuable upon exercise of the Warrants
have been duly authorized and reserved for issuance by the Company, there are no
statutory or, to our knowledge, contractual preemptive rights of stockholders or
rights of first refusal with respect to the issuance of such shares of Common
Stock and the shares of Common Stock to be issued upon exercise of the Warrants
shall upon such issuance in accordance with the respective terms of each such
Warrant be validly issued, fully paid and nonassessable.
10. The shares of Common Stock issuable upon exercise of the Agent's
Warrant have been duly authorized and reserved for issuance by the Company,
there are no statutory or, to our knowledge, contractual preemptive rights of
stockholders or rights of first refusal with respect to the issuance of such
shares of Common Stock and the shares of Common Stock to be issued upon exercise
of the Agent's Warrant shall upon such issuance in accordance with the terms of
the Agent's Warrant be validly issued, fully paid and nonassessable.
11. Other than as set forth in SCHEDULE 3.4-CONFLICTS to the Agreement,
as may be required pursuant to the "Blue Sky" provisions of any applicable state
securities laws and the filing of a Form D pursuant to Regulation D under the
Securities Act, the execution and delivery by the Company of the Transaction
Documents and the Gruntal Documents, the offering, sale and issuance of the
shares of Series B Preferred Stock, the issuance of shares of Common Stock upon
conversion of the Series B Preferred Stock, the issuance of shares of Common
Stock upon exercise of the Warrants, the issuance of shares of Common Stock upon
exercise of the Agent's Warrant and the fulfillment of and the compliance with
the respective terms thereof by the Company do not and shall not (a) conflict
with or result in a breach of the terms, conditions or provisions of, (b)
constitute a default under, (c) result in the creation of any lien, mortgage,
security interest, charge or other encumbrance upon the Company's capital stock
or assets pursuant to, (d) give any third party the right to accelerate any
obligation under, (e) result in a violation of or (f) require any authorization,
consent, approval, exemption or other action by or notice to any court or
administrative or governmental body pursuant to, the Certificate of
Incorporation, the Certificate of Designation, the By-Laws, any law, statute,
rule or regulation to which the Company is subject, or, to our knowledge, any
agreement, instrument, order, judgment or decree to which the Company is
subject.
12. The offering, sale and issuance of shares of Series B Preferred
Stock and the Warrants under the Securities Purchase Agreement, the issuance of
shares of Common Stock upon conversion of the Series B Preferred Stock and the
issuance of shares of Common Stock upon exercise of the Warrants (assuming for
such purpose that such shares were issued on the Closing Date) do not require
registration under the Securities Act.
13. The offering, sale and issuance of the Agent's Warrant under the
Sales Agency Agreement and the issuance of shares of Common Stock upon exercise
of the Agent's Warrant (assuming for such purpose that such shares were issued
on the Closing Date) do not require registration under the Securities Act.
14. The Company has authorized capital stock consisting of 25,000,000
shares of Common Stock and 2,000,000 shares of Preferred Stock of which 300,000
shares have been designated as Series A Preferred Stock and 182,205 shares have
been designated as Series B Preferred Stock. All of the issued and outstanding
shares of Common Stock and Series A Preferred Stock have been duly authorized
and validly issued and are fully paid and nonassessable.
3
<PAGE>
15. Except as set forth on SCHEDULE 3.2--CAPITAL STOCK to the
Agreement, to our knowledge, there are no (a) outstanding shares of capital
stock or securities convertible into or exchangeable or exercisable for shares
of the Company's capital stock or for shares of stock or securities convertible
into or exchangeable or exercisable for shares of the Company's capital stock,
(b) outstanding options for the purchase of, or any agreements providing for the
issuance (contingent or otherwise) of, or any commitments or claims of any
character relating to, any such capital stock or any shares of stock or
securities convertible into or exchangeable or exercisable for any such capital
stock, or (c) obligations (contingent or otherwise) of the Company to
repurchase, exchange or otherwise acquire or retire any shares of such capital
stock or any shares of stock or securities convertible into or exchangeable or
exercisable for any such capital stock, except pursuant to the Securities
Purchase Agreement, the Certificate of Incorporation or the Certificate of
Designation.
The opinions rendered in numbered paragraph 4 above regarding the
enforceability of the Transaction Documents and the Gruntal Documents are
subject to the following:
(a) The enforceability of the Transaction Documents and the
Gruntal Documents may be limited or adversely affected by (i)
bankruptcy, insolvency, reorganization, moratorium,
liquidation, rearrangement, probate, conservatorship,
fraudulent transfer, fraudulent conveyance and other similar
laws (including court decisions) now or hereafter in effect
and affecting the rights and remedies of creditors generally
or providing for the relief of debtors, (ii) the refusal of a
particular court to grant equitable remedies, including, but
without limiting the generality of the foregoing, specific
performance and injunctive relief and (iii) general principles
of equity (regardless of whether such remedies are sought in a
proceeding in equity or at law).
(b) In rendering such opinions, we express no opinion as to the
enforceability of any provisions of any Transaction Document
or Gruntal Document (i) restricting access of any Person to
courts or to legal or equitable remedies, (ii) purporting to
waive or affect rights, claims, defenses or other benefits
bestowed by law to the extent that any of the same cannot be
waived or so affected, (iii) relating to rights to indemnity
or contribution to the extent prohibited by public policy or
to the extent indemnification or contribution is required for
losses or expenses caused by gross negligence, willful
misconduct, fraud or illegal action on the part of an
indemnified party, (iv) purporting to waive or to otherwise
affect the rights of third parties or (v) to the extent that
the Company's obligations would require the Company's
directors to take action inconsistent with their fiduciary
duties or would require the taking of any action within the
control of the Company's stockholders other than parties to
the Transaction Documents or the Gruntal Documents.
In rendering the opinions expressed in numbered paragraph 4 above, we
have assumed that each of the parties (other than the Company) to the
Transaction Documents and the Gruntal Documents and the other documents and
instruments relied upon by us has all requisite power and authority validly to
execute and deliver the documents or instruments to which it is a party and to
effect the transactions contemplated thereby.
4
<PAGE>
In rendering the opinions expressed in numbered paragraph 11 above with
respect to any law, statute, rule or regulation, our opinion is based on a
review of laws, rules and regulations, which, in our experience, are normally
applicable to transactions of the type contemplated by the Transaction Documents
and the Gruntal Documents.
In rendering the opinions expressed in numbered paragraph 11 above with
respect to any agreement or instrument, our opinion is limited to the agreements
and instruments listed or referred to in SCHEDULE 3.14- CONTRACTS to the
Securities Purchase Agreement (other than those agreements or instruments listed
or referred to in ANNEX 3.13 to SCHEDULE 3.13-PROPRIETARY RIGHTS to the
Securities Purchase Agreement or SCHEDULE 3.18- INSURANCE to the Securities
Purchase Agreement).
In rendering the opinions expressed in numbered paragraph 12 above, we
have relied upon the representations and warranties of each Investor set forth
in Section 4 of the Securities Purchase Agreement and the representations and
warranties of Gruntal set forth in Sections 5(b)(i) through (iv) of the Sales
Agency Agreement and assumed that such representations and warranties were true
and accurate as of the Closing Date.
In rendering the opinions expressed in numbered paragraph 13 above, we
have relied upon the representations and warranties of Gruntal set forth in
Sections 5(b)(v) and (vi) of the Sales Agency Agreement and assumed that such
representations and warranties were true and accurate as of the Closing Date.
References herein to the "internal laws" of a jurisdiction are to the
laws of that jurisdiction, other than that jurisdiction's conflict-of-law
statutes and rules.
The opinions expressed herein relate solely to, are based solely upon
and are limited exclusively to the internal laws of the State of New York, the
internal laws of the State of Texas, the Delaware General Corporation Law and
federal laws of the United States of America, to the extent applicable.
This letter and the opinions expressed herein are furnished pursuant to
Section 7.10 of the Securities Purchase Agreement and Section 8(a)(iv) of the
Sales Agency Agreement and are solely for the benefit of, and may be relied upon
only by, the Investors, Gruntal and KeyCorp Shareholder Services, Inc., transfer
agent and registrar for the Series B Preferred Stock. This letter and the
opinions expressed herein may not be used or relied upon by any Investor,
Gruntal or KeyCorp Shareholder Services, Inc. for any other purpose and may not
be relied upon for any purpose by any other person without our prior written
consent.
Very truly yours,
Fulbright & Jaworski L.L.P.
5
EXHIBIT 10.16
VOTING AGREEMENT
THIS VOTING AGREEMENT (this "AGREEMENT") is made as of November
18, 1996 among LifeCell Corporation, a Delaware corporation (the "COMPANY"), the
Investors (as defined below) and Allstate Insurance Company ("ALLSTATE," and
together with the Investors, the "STOCKHOLDERS").
Vector Later-Stage Equity Fund, L.P., CIBC Wood Gundy Ventures,
Inc., and the other Persons identified as "Investors" on ANNEX A attached hereto
other than Allstate (collectively, the "INVESTORS") and the Company are entering
into a Securities Purchase Agreement simultaneously with the execution of this
Agreement (the "PURCHASE AGREEMENT"), pursuant to which the Investors are
purchasing shares of the Company's Series B Preferred Stock, par value $.001 per
share ("SERIES B PREFERRED"), and warrants to purchase shares of the Company's
common stock, par value $.001 per share (each, a "WARRANT"). Immediately after
the consummation of the transactions contemplated in the Purchase Agreement,
Allstate owns approximately 21% of the voting stock of the Company. Under the
Certificate of Designation (as defined in the Purchase Agreement), the Investors
have the right to designate three representatives (the "INVESTOR
REPRESENTATIVES") to the Company's board of directors (the "BOARD"), and, in
connection with the issuance and sale of the Securities to the Investors, the
Company and the Stockholders have agreed as to the composition of the entirety
of the Board. The Investors desire to enter into this Agreement for the purpose
of determining the Investor Directors and the Additional Outside Directors (as
defined below), the Company desires to enter into this Agreement for the purpose
of determining the Company Directors (as defined below), the Initial Outside
Director (as defined below) and the Additional Outside Directors, Allstate
desires to enter into this Agreement for the purpose of determining the
composition of the Board upon consummation of the issuance of the Series B
Preferred Stock to the Investors, and execution and delivery of this Agreement
is a condition to consummation of the transaction contemplated in the Purchase
Agreement.
The Company and the Stockholders hereby agree as follows:
1. CERTAIN DEFINITIONS.
Capitalized terms used but not defined herein shall have the
meanings assigned such terms in the Purchase Agreement.
"STOCKHOLDER SHARES" means, as of any particular time, (i) any
Common Stock purchased or otherwise acquired by any Stockholder, (ii) any Common
Stock issued or issuable directly or indirectly upon conversion of Preferred
Stock or upon exercise of Warrants, in each case, owned by a Stockholder, (iii)
any capital stock or other equity securities issued or issuable directly or
indirectly with respect to Common Stock referred to in clause (i) or clause (ii)
above by way of stock dividend or stock split or in connection with a
combination of shares, recapitalization, merger, consolidation or other
reorganization. For purposes of this Agreement, any Person who holds
- 1 -
<PAGE>
Preferred Stock or Warrants shall be deemed to be a Stockholder and the holder
of Stockholder Shares issued or issuable upon conversion of such Preferred Stock
or exercise of such Warrants (as the case may be) in connection with the
transfer thereof or otherwise and regardless of any restriction or limitation on
the conversion or exercise thereof.
2. BOARD OF DIRECTORS.
(a) From and after the date of this Agreement, each holder of
Stockholder Shares shall vote all of its Stockholder Shares and shall take all
other necessary or desirable actions within its control (whether in its capacity
as a stockholder or as an officer or director of the Company or otherwise, and
including, without limitation, attendance at meetings in person or by proxy for
the purposes of obtaining a quorum and execution of written consents in lieu of
meetings), and the Company shall take all necessary and desirable actions within
its control (including, without limitation, calling special Board and
stockholder meetings), so that:
(i) the maximum authorized number of directors on the Board shall
be established initially at nine directors and shall be reduced in accordance
with clauses (viii) and (ix) of this Section 2;
(ii) the following individuals shall be elected to the Board:
(A) three representatives (the "INVESTOR
DIRECTORS") designated by holders of a majority of the
Underlying Common Stock (the "MAJORITY INVESTORS"), which
Investor Directors shall include one representative
designated by Vector (the "VECTOR REPRESENTATIVE"), which
Vector Representative shall initially be K. Flynn
McDonald, one representative designated by CIBC-WG (the
"CIBC-WG REPRESENTATIVE"), which CIBC- WG Representative
shall initially be Lori G. Koffman, and one representative
(the "MAJORITY INVESTORS REPRESENTATIVE") selected by the
Majority Investors;
(B) the Chief Executive Officer (who shall
initially be Paul M. Frison) and Stephen A. Livesey (each,
a "COMPANY DIRECTOR") and Michael Cahr (the "INITIAL
OUTSIDE DIRECTOR");
(C) two representatives jointly designated by the
Investor Directors, and the Company Directors (which
designations shall take into account recommendations of a
top tier executive search firm jointly selected by the
Investor Directors and the Company Directors) (the
"ADDITIONAL OUTSIDE DIRECTORS"), which Additional Outside
Directors are neither members of the Company's management
nor an employee or an officer of the Company; and
(D) one representative (the "MEDTRONIC DIRECTOR")
designated by Medtronic, Inc., a Minnesota corporation
("MEDTRONIC");
- 2 -
<PAGE>
(iii) the removal from the Board (with or without cause) of any
Vector Representative, any CIBC-WG Representative or any Majority Investors
Representative shall be at the written request of Vector, CIBC-WG or the
Majority Investors, respectively, but only upon such written request and under
no other circumstances;
(iv) the removal from the Board (with or without cause) of any
Company Director or the Initial Outside Director shall be at the written request
of the majority of the other directors then in office, but only upon such
written request and under no other circumstances;
(v) the removal from the Board (with or without cause) of the
Medtronic Director shall be only in accordance with and as contemplated by
Section 6.3 of the Investment Agreement dated May 3, 1994 between the Company
and Medtronic (the "MEDTRONIC INVESTMENT AGREEMENT"); provided that the Company
shall not agree to any amendment to such Section 6.3 without the prior consent
of the Majority Investors;
(vi) in the event that any Investor Director or any Additional
Outside Director designated hereunder for any reason ceases to serve as a member
of the Board during his or her term of office, the resulting vacancy on the
Board shall be filled in the manner set forth above in clause (ii) of this
Section 2 by a representative designated by the same group that designated the
member that will no longer serve on the Board; provided that if such group fails
to designate a representative to fill such vacancy, the election of an
individual to fill such vacancy shall be accomplished in accordance with the
Company's bylaws and applicable law; provided, further, that the Stockholders
shall thereafter vote to remove such individual if the group which failed to
designate a representative to fill such vacancy pursuant to this Section 2 so
directs;
(vii) in the event that the Initial Outside Director for any
reason ceases to serve as a member of the Board during his term of office, the
resulting vacancy shall be filled by the vote of a majority of the other
directors then in office;
(viii) in the event that any Company Director (other than the
Chief Executive Officer) for any reason ceases to serve as a member of the Board
during his term of office, the resulting vacancy shall not be filled and the
number of authorized directors on the Board shall be reduced by the number of
such directors who have ceased to serve on the Board; and
(ix) at such time when Medtronic no longer has the right to
appoint a director pursuant to Section 6.3 of the Medtronic Investors Agreement,
the number of authorized directors on the Board shall be reduced by one and the
resulting directorship shall not be filled.
(b) The Company shall pay all out-of-pocket travel and other
expenses incurred by each director in connection with attending the meetings of
the Board or any committee thereof. So long as any Investor Director serves on
the Board and for 3 years thereafter, the Company shall maintain directors and
officers indemnity insurance coverage satisfactory to the Majority Investors,
and the Company's certificate of incorporation and bylaws shall provide for
indemnification and exculpation of directors to the fullest extent permitted
under applicable law.
- 3 -
<PAGE>
3. REPRESENTATIONS AND WARRANTIES. Each Stockholder represents and
warrants that (i) such Stockholder is the record owner of the number and type of
shares of the Company's capital stock indicated opposite its name on ANNEX A
hereto, (ii) this Agreement has been duly authorized, executed and delivered by
such Stockholder and constitutes the valid and binding obligation of such
Stockholder, enforceable in accordance with its terms, and (iii) such
Stockholder has not granted and is not a party to any proxy, voting trust or
other agreement which is inconsistent with, conflicts with or violates any
provision of this Agreement.
4. STOCKHOLDER COVENANT. No holder of Stockholder Shares shall grant any
proxy or become party to any voting trust or other agreement which is
inconsistent with, conflicts with or violates any provision of this Agreement.
5. TERMINATION. This Agreement shall terminate at the later of (i) such
time when all of the shares of Series B Preferred have been converted and (ii)
such time when the Company no longer has any obligation to deliver financial and
other information to certain Investors pursuant to Section 6.8 of the Purchase
Agreement; provided that, notwithstanding the foregoing, Allstate's obligations
under this Agreement shall terminate on the second anniversary of this
Agreement.
6. COUNTERPARTS. This Agreement may be executed in multiple
counterparts, each of which shall be an original and all of which taken together
shall constitute one and the same agree ment.
7. REMEDIES. Each Stockholder shall be entitled to enforce its rights
under this Agreement specifically, to recover damages by reason of any breach of
any provision of this Agreement and to exercise all other rights existing in
their favor. Each Stockholder hereby acknowledges that money damages would not
be an adequate remedy for any breach of the provisions of this Agreement and
that each Stockholder may in its sole discretion apply to any court of law or
equity of competent jurisdiction for specific performance and/or injunctive
relief (without posting a bond or other security) in order to enforce or prevent
any violation of the provisions of this Agreement.
8. NOTICES. Any notice provided for in this Agreement shall be in
writing and shall be either personally delivered, or mailed first class mail
(postage prepaid) or sent by reputable overnight courier service (charges
prepaid) to the Stockholder at the address indicated on the schedules hereto or
at such address or to the attention of such other person (including any
subsequent holder of Stockholder Shares) as the recipient party has specified by
prior written notice to the sending party. Notices shall be deemed to have been
given hereunder when delivered personally, three days after deposit in the U.S.
mail and one day after deposit with a reputable overnight courier service.
9. AMENDMENT AND WAIVER. This Agreement may be amended, modified and
supplemented, and compliance with any term, covenant, agreement or condition
contained herein may be waived either generally or in particular instances, and
either retroactively or prospectively, only by a written instrument executed by
(a) the Company and (b) the Majority Investors. No course
- 4 -
<PAGE>
of dealing between or among any persons having any interest in this Agreement
will be deemed effective to modify, amend or discharge any part of this
Agreement or any rights or obligations of any person under or by reason of this
Agreement.
10. GOVERNING LAW. THE CORPORATE LAW OF THE STATE OF DELAWARE SHALL
GOVERN ALL ISSUES AND QUESTIONS CONCERNING THE RIGHTS OF THE COMPANY AND THE
RIGHTS OF THE STOCKHOLDERS RELATIVE TO THE COMPANY. ALL OTHER ISSUES AND
QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, INTERPRETATION AND
ENFORCEABILITY OF THIS AGREEMENT AND THE EXHIBITS AND SCHEDULES HERETO SHALL BE
GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW
YORK, WITHOUT GIVING EFFECT TO ANY CHOICE OF LAW OR CONFLICT OF LAW RULES OR
PROVISIONS (WHETHER OF THE STATE OF NEW YORK OR ANY OTHER JURISDICTION) THAT
WOULD CAUSE THE APPLICATION OF THE LAWS OF ANY JURISDICTION OTHER THAN THE STATE
OF NEW YORK.
11. DESCRIPTIVE HEADINGS. The descriptive headings of this Agreement are
inserted for convenience only and do not constitute a part of this Agreement.
* * * *
- 5 -
<PAGE>
IN WITNESS WHEREOF, the Company and the Stockholders have
executed this Agreement on the day and year first above written.
LIFECELL CORPORATION
By PAUL M. FRISON
Paul M. Frison
President and Chief Executive Officer
VECTOR LATER-STAGE EQUITY FUND, L.P.
By Vector Fund Management,
L.P., its General Partner
By Unreadable Signature
Name:__________________
Title:President
CIBC WOOD GUNDY VENTURES, INC.
By/s/LORI KOFFMAN
Name:Lori Koffman
Title:Managing Director
<PAGE>
ALLSTATE INSURANCE COMPANY
ByUnreadable Signature
By________________________
Its Authorized Signatories
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ DON E. ROOSE, JR.
(Signature)
Name:Don E. Roose, Jr.
Vice President and Controller
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 6th day of November, 1996.
/S/ STEPHEN LIVESEY
(Signature)
Name:Stephen Livesey
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ CHRISTOPHER C. KRAFT JR.
(Signature)
Name: Christopher C. Kraft Jr.
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ P. WILLIAM CURRERI, M.D.
(Signature)
Name: P. William Curreri
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ DAVID SAKS
(Signature)
Name: David Saks
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ JOHN S. BAI
(Signature)
Name: John S. Bai
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ROBERT WEINSTEIN
(Signature)
Name: Robert Weinstein
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ JAMES C. GALE JUDITH S. HASELTON
(Signature)
Name: James C. Gale & Judith S. Haselton
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ JAMES C. GALE, TRUSTEE
(Signature)
Name: James C. Gale, Trustee F/B/O
Ariana J. Gale
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/S/ JOHN CIRRITO
(Signature)
Name:John Cirrito
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ B. MICHAEL PISANI
(Signature)
Name: B. Michael Pisani
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/S/ JOHN LATSHAW
(Signature)
Name:John Latshaw
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ EVAN KLEINBERG
(Signature)
Name: Evan Kleinberg
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ DOUGLAS KLEINBERG
(Signature)
Name:Douglas Kleinberg
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ DANIEL KLEINBERG ELAINE KLEINBERG
(Signature)
Name:Daniel & Elaine Kleinberg
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ALLEN L. BOORSTEIN
(Signature)
Name: Allen L. Boorstein
General Partner
Chinook Equities
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/S/ BARRY RICHTER
(Signature)
Name:Barry Richter
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ STEPHEN G. WEISS
(Signature)
Name:Stephen G. Weiss
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ JOSEPH BATTIPAGLIA
(Signature)
Name:Joseph Battipaglia
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ WILLIAM J. STRAZZULLO
(Signature)
Name:William J. Strazzullo
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ROBERT SABLOWSKY
(Signature)
Name:Robert Sablowsky
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/S/ JOHN D. GOLDBERG
(Signature)
Name:John D. Goldberg
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ JOSEPH A. RUSSO
(Signature)
Name:Joseph A. Russo
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 31st day of October, 1996.
/S/ MICHAEL GIRONTA
(Signature)
Name: Michael Gironta
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ DONNA GREENBERG CHARLES L. GREENBERG
(Signature)
Name: Donna Greenberg Charles L. Greenberg
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ RICHARD L. SERRANO
(Signature)
Name:Richard L. Serrano
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ DAVID HARRIS MARY JANE HARRIS
(Signature)
Name:David Harris Mary Jane Harris
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ PAUL B. ANKIN LOIS F. ANKIN
(Signature)
Name:Paul B. Ankin & Lois F. Ankin
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ JEROME SCHACHTER
(Signature)
Name: Jerome Schachter
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ JEROME SCHACHTER
(Signature)
Name: Jerome Schachter
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ LISA B. TUCKERMAN
(Signature)
Name: Lisa B. Tuckerman
Managing Director of the General Partner
S.B.S.F. Biotechnology Partners, L.P.
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ MICHAEL J. KOBLITZ
(Signature)
Name: Michael J. Koblitz Trustee
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ SHELDON DROBNY
(Signature)
Name: Sheldon Drobny
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 5th day of November, 1996.
/S/ PERRY H. BACON
(Signature)
Name: Perry H. Bacon
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ JAMES J. PELTS
(Signature)
Name: James J. Pelts
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ ROBERT WEINSTEIN
(Signature)
Name: Robert Weinstein
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/S/ THOMAS J. TOY
(Signature)
Name: Technology Funding Medical
Partners, L.L.P.
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/S/ RONALD KOENIG
(Signature)
Name: Ronald Koenig
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ROBERT M. ADAMS
(Signature)
Name: Robert M. Adams
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ F.A. KERBS
(Signature)
Name: F.A. Kerbs
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ BERNARD B. SALZMAN
(Signature)
Name: Bernard B. Salzman IRA,
Gruntal & Co., Inc., Custodian
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ MICHAEL H. RICHMOND
(Signature)
Name: Michael H. Richmond
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 2nd day of November, 1996.
/S/ MICHAEL E. CAHR
Signature)
Name: Michael E. Cahr
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 11th day of November, 1996.
/S/ DON A. SANDERS
(Signature)
Name: Don A. Sanders
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ JEFFREY KEELER
(Signature)
Name: Jeffrey R. Keeler
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ JONATHAN GREENWALD - GENERAL PARTNER
(Signature)
Name: Jonathan Greenwald - General
Partner
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ MARK RICE
(Signature)
Name: Mark Rice - Namax Corp -
President
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ LISA B. TUCKERMAN
(Signature)
Name: Lisa B. Tuckerman
Managing Director of the General Partner
S.B.S.C. Biotechnology Fund, L.P.
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 6th day of November, 1996.
/S/ FREDERIC GREENBERG
(Signature)
Name: Frederic Greenberg
<PAGE>
[VOTING AGREEMENT]
SIGNATURE PAGE TO VOTING AGREEMENT BETWEEN LIFECELL CORPORATION (THE
"COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF THE COMPANY'S
SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE COMPANY'S
PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 6th day of November, 1996.
/S/ MICHAEL J. KOBLITZ
(Signature)
Name: Michael J. Koblitz
<PAGE>
STOCKHOLDERS -- ANNEX A
Stockholder
<TABLE>
<CAPTION>
Name and Address Shares
- ----------------------------------------------- ------------------------------------
<S> <C>
CIBC Wood Gundy Ventures, Inc. 44,800 shares of Series B Preferred
425 Lexington Avenue
New York, NY 10017
The Woodlands Venture Capital Company 2,500 shares of Series B Preferred
2201 Timberloch Place 482,068 shares of Common Stock
The Woodlands, TX 77380 15,000 shares of Series A Preferred
P. William Curreri, M.D. 400 shares of Series B Preferred
217 Berwyn Drive, W. #222 8,238 shares of Common Stock
Mobile, AL 36608 1,250 shares of Series A Preferred
Christopher C. Kraft, Jr. 250 shares of Series B Preferred
Smith Barney Inc. KEO P/S Custodian 1,738 shares of Common Stock
Acct: 721-66059-10-022 1,250 shares of Series A Preferred
14919 Village Elm Street
Houston, TX 77062
Michael H. Richmond 400 shares of Series B Preferred
20 E. Wedgewood Glen
The Woodlands, TX 77381
Stephen Livesey 250 shares of Series B Preferred
3606 Research Forest Drive 100,529 shares of Common Stock
The Woodlands, TX 77381
Michael E. Cahr 500 shares of Series B Preferred
1051 Saxony Drive
Highland Park, IL 60035
Technology Funding Medical Partners I, L.P. 2,500 shares of Series B Preferred
2000 Alameda de las Pulgas
San Mateo, CA 94403
Vector Later-Stage Equity Fund, L.P. 40,000 shares of Series B Preferred
1751 Lake Cook road, Suite 350
Deerfield, IL 60015
William J. McCluskey 186 shares of Series B Preferred
25 Wisconsin Street
Long Beach, NY 11561
David Saks 500 shares of Series B Preferred
2 Knollcliff Road
Woodcliff Lake, NJ 07675
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
Stockholder
Name and Address Shares
- ----------------------------------------------- -------------------------------------
<S> <C>
Joseph Battipaglia 150 shares of Series B Preferred
77 Water Street (10th Floor)
New York, NY 10005
S.B.S.F. Biotechnology Partners, L.P. 1,000 shares of Series B Preferred
c/o Lisa Tuckerman
Spears Benzak Salomon & Farrell
45 Rockefeller Plaza -- 33rd Floor
New York, NY 10111
S.B.S.F. Biotechnology Fund, L.P. 9,000 shares of Series B Preferred
c/o Lisa Tuckerman
Spears Benzak Salomon & Farrell
45 Rockefeller Plaza -- 33rd Floor
New York, NY 10111
Jerome Schachter 500 shares of Series B Preferred
2926 Leanne Court
Northbrook, IL 60062
Paul B. Ankin and Lois F. Ankin, JTWROS 250 shares of Series B Preferred
4233 W. Grove
Skokie, IL 60076
David and Mary Jane Harris, JTWROS 200 shares of Series B Preferred
174 Pacific Street, Apt. 2A
Brooklyn, NY 11021
Richard L. Serrano 50 shares of Series B Preferred
64 Brighton Avenue
Bloomfield, NJ 07003
Charles and Donna Greenberg, JTWROS 1,500 shares of Series B Preferred
503 Pinehurst Court
Roslyn, NY 11576
Michael Gironta 1,000 shares of Series B Preferred
89 Ridgewood Avenue
Glen Ridge NJ 07028
Joseph A. Russo 155 shares of Series B Preferred
3 Midwood Avenue
Verona, NJ 07044
John D. Goldberg 310 shares of Series B Preferred
2500 East Hallandale Beach Blvd.
Suite 500
Hallandale, FL 33009-4838
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
Stockholder
Name and Address Shares
- ----------------------------------------------- -------------------------------------
<S> <C>
Robert Sablowsky 465 shares of Series B Preferred
150 East 69th Street, 16A
New York, NY 10021
William J. Strazzullo 80 shares of Series B Preferred
750 Columbus Avenue, 4C
New York, NY 10025
Stephen G. Weiss 330 shares of Series B Preferred
115 Ravin Oaks Lane
Highland Park, IL 60035
Barry Richter 250 shares of Series B Preferred
Tideway
Sandspoint, NY 11050
Chinook Equities, Inc. 500 shares of Series B Preferred
147 East 48th Street
New York, NY 10017
Daniel and Elaine Kleinberg, JTWROS 267 shares of Series B Preferred
3 Centennial Road
Livingston, NJ 07039
Douglas Kleinberg 248 shares of Series B Preferred
200 East 95th Street, Apt. 126
New York, NY 10128
Evan Kleinberg IRA, 155 shares of Series B Preferred
Gruntal & Co., Inc., Custodian
Dated July 19, 1996
3 Centennial Road
Livingston, NJ 07039
John Latshaw 930 shares of Series B Preferred
5049 Wornall #2 C
Kansas City, MO 64112
B. Michael Pisani 775 shares of Series B Preferred
44 Lake Road
Short Hills, NJ 07078
John Cirrito 250 shares of Series B Preferred
29 Rambling Drive
Scotch Plains, NJ 07076
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
Stockholder
Name and Address Shares
- ----------------------------------------------- -------------------------------------
<S> <C>
James C. Gale, Trustee 620 shares of Series B Preferred
F/B/O Ariana J. Gale
The James C. Gale Trust, dated November 21,
1986
315 West 106th Street, Apt. 4A
New York, NY 10025
James C. Gale and Judith S. Haselton JTWROS 1,550 shares of Series B Preferred
315 West 106th Street, Apt. 4A
New York, NY 10025
John S. Bai 217 shares of Series B Preferred
30 West 61st, 27A
New York, NY 10023
Ronald Koenig 310 shares of Series B Preferred
114 No. Village Way
Jupiter, FL 33458
Robert M. Adams 1,550 shares of Series B Preferred
P.O. Box 998
Plandome, NY 11030
Edward A. Kerbs 310 shares of Series B Preferred
8 South Cherry Lane
Rumson, NJ 07760
Bernard B. Salzman IRA, 55 shares of Series B Preferred
Gruntal & Co., Inc., Custodian
Dated May 14, 1982 Acct: 215-67321-1-3-231
20 S. Charles Street
Baltimore, MD 21201
Don A. Sanders 620 shares of Series B Preferred
3100 Texas Commerce Tower
Houston, TX 77002
Jeffrey Keeler 87 shares of Series B Preferred
577 W. 50th Street
Miami Beach, FL 33140
Harbour Court L.P., II 250 shares of Series B Preferred
253 W. 73rd St., Apt. 6D
New York, NY 10023
Attention: Jonathan Greenwald
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
Stockholder
Name and Address Shares
- ----------------------------------------------- -------------------------------------
<S> <C>
Namax Corp. 2,000 shares of Series B Preferred
666 Dundee Road, Suite 1801
Northbrook, IL 60062
Attention: Mark Rice, President
Sheldon Drobny 500 shares of Series B Preferred
95 Revere Drive, Suite A
Northbrook, IL 60062
Perry H. Bacon 620 shares of Series B Preferred
5300 Mission Woods Road
Shawnee Mission, KS 66205
James J. Pelts 500 shares of Series B Preferred
29 East Madison Street, Suite 1505
Chicago, IL 60602
Robert Weinstein 217 shares of Series B Preferred
155 West 68th Street 24C
New York, NY 10023
The Marcus L. Koblitz Trust, 25 shares of Series B Preferred
Michael J. Koblitz, Trustee Est. April 14, 1992
12 Downey Drive
Tenafly, NJ 07670
The Lauren J. Koblitz Trust, 25 shares of Series B Preferred
Michael J. Koblitz, Trustee Est. April 14, 1992
12 Downey Drive
Tenafly, NJ 07670
Pharmaceutical & Medical Technology Fund 3,000 shares of Series B Preferred
300 Park Avenue
New York, NY 10022
Strategic Healthcare Fund 1,000 shares of Series B Preferred
300 Park Avenue
New York, NY 10022
Michael J. Koblitz 50 shares of Series B Preferred
12 Downey Drive
Tenafly, NJ 07670
Allstate Insurance Company
Investment Department
Allstate Plaza South 650 761,397 shares of Common Stock
Northbrook, IL 60062 200,000 shares of Series A Preferred
</TABLE>
<PAGE>
EXHIBIT 10.17
REGISTRATION RIGHTS AGREEMENT
REGISTRATION RIGHTS AGREEMENT (this "AGREEMENT"), dated as of
November 18, 1996, by and among each of the persons named on SCHEDULE 1 annexed
hereto (each, an "INVESTOR" and collectively, the "INVESTORS"), Gruntal & Co.,
Incorporated ("GRUNTAL), and LifeCell Corporation, a Delaware corporation (the
"COMPANY").
W I T N E S S E T H:
WHEREAS, the Investors and the Company have entered into that
certain Securities Purchase Agreement, dated as of the date hereof (the
"PURCHASE AGREEMENT"), whereby the Investors have purchased (a) an aggregate of
124,157 shares of the Series B Preferred Stock, par value $.001 per share (the
"SERIES B PREFERRED STOCK"), of the Company and (b) warrants (the "WARRANTS";
together with the Series B Preferred Stock, the "SECURITIES") to purchase an
aggregate of 2,803,530 shares (the "WARRANT SHARES") of common stock, par value
$.001 per share ("COMMON STOCK"), of the Company.
WHEREAS, the Company has on the date hereof granted to Gruntal, the
Company's placement agent in connection with the transactions evidenced by the
Purchase Agreement, a warrant (the "GRUNTAL WARRANT") to purchase 354,734 shares
(the "GRUNTAL WARRANT SHARES") of Common Stock in connection with such
transactions.
WHEREAS, the Company desires to grant registration rights to (a) the
Investors with respect to the Warrant Shares and the shares of Common Stock into
which the Series B Preferred Stock is convertible and (b) Gruntal with respect
to the Gruntal Warrant Shares.
NOW, THEREFORE, in consideration of the premises and mutual
covenants and conditions contained herein and of other good and valuable
consideration, the receipt and adequacy of which is hereby acknowledged, Company
and the Investors agree as follows:
ARTICLE 1.
DEFINITIONS
All terms not defined herein or below shall have the meanings
ascribed thereto in the Purchase Agreement.
"EXCHANGE ACT" means the Securities Exchange Act of 1934, as
amended, or any similar federal statute, and the rules and regulations of the
Commission thereunder, all as the same shall be in effect at the time.
"HOLDER" means an Investor or Gruntal, in either case, in its
capacity as a holder of Registrable Securities.
"NASD" shall mean the National Association of Securities Dealers,
Inc.
<PAGE>
"REGISTRABLE SECURITIES" means (i) the Warrant Shares, (ii) the
shares of Common Stock issued upon the conversion of shares of the Series B
Preferred Stock issued pursuant to the Purchase Agreement, (iii) the Gruntal
Warrant Shares, (iv) any shares of Common Stock issuable to the Investors
pursuant to the right of first refusal set forth in Section 5 of the Purchase
Agreement, and (v) any additional shares of Common Stock acquired by the Holder
by way of a dividend, stock split or other distribution in respect of the Series
B Preferred Stock. As to any particular Registrable Securities, once issued,
such securities shall cease to be Registrable Securities at such time when (x) a
registration statement with respect to the sale of such securities has been
declared effective by the Commission and such securities have been disposed of
pursuant to such effective registration statement, (y) such securities have been
distributed to the public pursuant to the provisions of Rule 144, or (z) such
securities have ceased to be outstanding. For purposes of this Agreement, a
Person shall be deemed to be a Holder of Registrable Securities, and the
Registrable Securities shall be deemed to be in existence, and such Person shall
be entitled to exercise the rights of a Holder of such Registrable Securities
hereunder, whenever such Person has the right to acquire, directly or
indirectly, such Registrable Securities (upon conversion or exercise in
connection with a transfer of securities or otherwise, but disregarding any
restrictions or limitations upon the exercise of such right), whether or not
such acquisition has actually been effected.
"SECURITIES ACT" means the Securities Act of 1933, as amended, or
any similar federal statute, and the rules and regulations of the Commission
thereunder, all as the same shall be in effect at the time.
"SELLING HOLDER" means an Investor or Gruntal, in either case, in
its capacity as a seller of Registrable Securities pursuant to a registration
statement under the Securities Act.
"UNDERWRITER" means a securities dealer who purchases any
Registrable Securities as principal in an underwritten offering and not as part
of such dealer's market-making activities.
ARTICLE 2.
REGISTRATION RIGHTS
SECTION 2.1 SHELF REGISTRATION.
(a) GENERAL. The Company covenants and agrees with the Investors and
Gruntal that the Company will (i) prepare and file with the Commission no later
than the 75th day following the Closing Date a registration statement under the
Securities Act with respect to the public offering of the Registrable Securities
referred to in clauses (i), (ii) and (iii) of the definition of Registrable
Securities contained in Article I hereof (a "SHELF REGISTRATION"), (ii) use its
best efforts (as used herein the term "best efforts" shall have the meaning
commonly accorded such term as used in registration rights agreements similar to
this Agreement) to have any such registration statement declared effective as
soon as practicable and in any event no later than the 180th day following the
Closing Date and (iii) prepare and file such post-effective amendment or
amendments to such registration statement with respect to Registrable Securities
referred to in clauses (iv) and (v) of the definition of Registrable Securities
contained in Article I hereof. The Company hereby agrees to timely file all
reports required under the Exchange Act for so long as the Company is obligated
to maintain the effectiveness of the registration statement. Once the
registration statement described
- 2 -
<PAGE>
in this subsection (a) has been declared effective, the Company shall maintain
the registration statement in effect until (x) all Registrable Securities have
been sold pursuant thereto or (y) no securities are outstanding that constitute
Registrable Securities.
(b) EFFECTIVE REGISTRATION. The Shelf Registration shall not be
deemed to have been effected unless it has been declared effective by the
Commission; PROVIDED, that if, after the registration statement has become
effective, the offering of shares of Common Stock pursuant to such Shelf
Registration is or becomes the subject of any stop order, injunction or other
order or requirement of the Commission or any other governmental or
administrative agency, or if any court prevents or otherwise limits the sale of
the shares of Common Stock pursuant to the Shelf Registration at any time within
180 days after the effective date of the registration statement, the Shelf
Registration shall not be deemed to have been effected. If the Shelf
Registration (i) is deemed not to have been effected or (ii) does not remain
effective for a period of at least 180 days beyond the effective date thereof
or, with respect to an underwritten offering of Registrable Securities, until 45
days after the commencement of the distribution by the Holders of the
Registrable Securities included in such registration statement, then the Company
shall continue to be obligated to effect such Shelf Registration pursuant to
this Section 2.1.
(c) OTHER HOLDERS. No securities other than Registrable Securities
shall be included in the Shelf Registration.
(d) SELECTION OF UNDERWRITER. If the Selling Holders so elect at any
time, the offering of such Registrable Securities pursuant to such Shelf
Registration shall be in the form of an underwritten offering and, if necessary,
the Company shall amend the Shelf Registration to reflect such method of
offering. The Selling Holder holding the largest number of Registrable
Securities to be sold in such underwritten offering shall select one nationally
recognized investment banker to act as the lead managing Underwriter in
connection with such offering; and the Selling Holder holding the second largest
number of Registrable Securities to be sold in such underwritten offering may at
its option select one nationally recognized investment banker to act as the
co-managing Underwriter in connection with such offering.
SECTION 2.2 PIGGY-BACK REGISTRATION.
(a) GENERAL. If at any time the Company proposes to file a
registration statement under the Securities Act with respect to an offering by
the Company for its own account or for the account of any of its respective
security holders (other than a registration statement on Form S-4 or S-8, or any
substitute forms thereof that may be adopted by the Commission), a registration
pursuant to Section 2.1 or any demand registration provided for pursuant to that
certain Underwriters Warrant Agreement dated March 6, 1992, pursuant to which
certain registration rights were granted to Robert Todd Financial Corporation),
then the Company shall give prompt written notice of such proposed filing to the
Holders of Registrable Securities as soon as practicable (but in no event less
than twenty (20) days before the anticipated filing date), and such notice shall
offer such Holders the opportunity to register such number of Registrable
Securities as each such Holder may request (which request shall specify the
Registrable Securities intended to be disposed of by such Holder) (a "PIGGY-BACK
REGISTRATION"). The Company shall use its best efforts to cause the managing
Underwriter or Underwriters of a proposed underwritten offering to permit the
Registrable Securities requested to
- 3 -
<PAGE>
be included in a Piggy-Back Registration to be included on the same terms and
conditions as any similar securities of the Company or any other security holder
included therein and to permit the sale or other disposition of such Registrable
Securities in accordance with the intended method of distribution thereof. Any
Holder shall have the right to withdraw its request for inclusion of its
Registrable Securities in any registration statement pursuant to this Section
2.2 by giving written notice to the Company of its request to withdraw. The
Company may withdraw a Piggy-Back Registration at any time prior to the time it
becomes effective.
No registration effected under this Section 2.2, and no failure to
effect a registration under this Section 2.2, shall relieve the Company of its
obligation to effect a Shelf Registration pursuant to Section 2.1, and no
failure to effect a registration under this Section 2.2 and to complete the sale
of Registrable Securities in connection therewith shall relieve the Company of
any other obligation under this Agreement (including, without limitation, the
Company's obligations under Sections 3.2 and 4.1).
(b) REDUCTION. Notwithstanding anything to the contrary contained
herein, if the managing Underwriter or Underwriters of any underwritten offering
described in this Section 2.2 have informed, in writing, the Holders of the
Registrable Securities requesting inclusion in such offering that it is their
opinion that the total number of shares which the Company, Holders of
Registrable Securities and any other holders of securities of the Company
desiring to participate in such registration intend to include in such offering
is such as to materially and adversely affect the success of such offering, then
the number of shares to be offered shall be reduced or limited in the following
order of priority: FIRST, the number of shares to be offered by all other
holders of securities of the Company (other than the Holders of Registrable
Securities and other holders of securities of the Company who have registration
rights, as set forth on SCHEDULE 2.2(B) annexed hereto (collectively, the "OTHER
HOLDERS")) to the extent necessary to reduce the total number of shares as
recommended by such managing Underwriters; and SECOND, if further reduction or
limitation is required, the number of shares to be offered for the account of
the Holders and the Other Holders shall be reduced or limited on a PRO RATA
basis in proportion to the relative number of securities of the Holders and
Other Holders participating in such registration. If, as a result of the
proration provisions of this Section 2.2, any Holder shall not be entitled to
include at least 50% of the Registrable Securities in a Piggy-Back Registration
in which such Holder has requested to be included, such Holder may elect to
withdraw his, her or its request to include such Holder's Registrable Securities
in such registration (a "WITHDRAWAL ELECTION"); PROVIDED, HOWEVER, that a
Withdrawal Election shall be irrevocable and, after making a Withdrawal
Election, a Holder shall no longer have any right to include Registrable
Securities in the Piggy-Back Registration as to which such Withdrawal Election
was made.
ARTICLE 3.
REGISTRATION PROCEDURES
SECTION 3.1 FILINGS; INFORMATION. In connection with the Shelf
Registration (including any underwritten public offering pursuant to Section
2.1(d) hereof) or any Piggyback Registration, the Company will use its best
efforts to effect the registration and the sale of such Registrable Securities
in accordance with the intended method of disposition thereof as quickly as
practicable, and in connection with any such request:
- 4 -
<PAGE>
(a) REGISTRATION STATEMENTS. The Company will prepare and file with
the Commission a registration statement with respect to such Registrable
Securities (which, in the case of any underwritten public offering, shall
include such additional information in the prospectus included therein as shall
be reasonably requested by the managing Underwriter or Underwriters) and use its
best efforts to cause such registration statement to become and remain effective
until the completion of the distribution or until the Company's obligations
otherwise terminate hereunder.
(b) AMENDMENTS AND SUPPLEMENTS. The Company will prepare and file
with the Commission such amendments and supplements to such registration
statement and the prospectus used in connection therewith as may be necessary to
keep such registration statement effective for the period specified in
subsection (a) above and as to comply with the provisions of the Securities Act
with respect to the disposition of all Registrable Securities covered by such
registration statement in accordance with the intended method of disposition set
forth in such registration statement for such period.
(c) COPIES FOR REVIEW. The Company will, as far in advance as
practical, prior to filing a registration statement or prospectus or any
amendment or supplement thereto, furnish copies of such registration statement
as proposed to be filed, together with exhibits thereto, to (i) each Selling
Holder, (ii) not more than one counsel representing all Selling Holders, to be
selected by a majority-in-interest of such Selling Holders, and (iii) each
Underwriter, if any, of the Registrable Securities covered by such registration
statement, which documents will be subject to review and approval by the
foregoing within five (5) days after delivery, and thereafter as far in advance
as practical, furnish to such Selling Holders, counsel and Underwriters, if any,
for their review and comment such number of copies of such registration
statement, each amendment and supplement thereto (in each case including all
exhibits thereto and documents incorporated by reference therein), the
prospectus included in such registration statement (including each preliminary
prospectus) and such other documents or information as such Selling Holders,
counsel or Underwriters may reasonably request in order to facilitate the
disposition of the Registrable Securities owned by such Selling Holders.
(d) STOP ORDERS. After the filing of the registration statement, the
Company will promptly notify each Selling Holder of Registrable Securities
covered by such registration statement of any stop order issued or threatened by
the Commission and take all reasonable actions required to prevent the entry of
such stop order or to remove it if entered.
(e) BLUE SKY. The Company will use its best efforts to (i) register
or qualify the Registrable Securities under such other securities or blue sky
laws of such jurisdictions in the United States as any Selling Holder reasonably
(in light of such Selling Holder's intended plan of distribution) requests, and
(ii) cause such Registrable Securities to be registered with or approved by such
other governmental agencies or authorities in the United States as may be
necessary by virtue of the business and operations of the Company and do any and
all other acts and things that may be reasonably necessary or advisable to
enable such Selling Holder to consummate the disposition of the Registrable
Securities owned by such Selling Holder; PROVIDED, that the Company will not be
required to (x) qualify generally to do business in any jurisdiction where it
would not otherwise be required to qualify but for this subsection (e), (y)
subject itself to taxation in any such jurisdiction or (z) consent to general
service of process in any such jurisdiction.
- 5 -
<PAGE>
(f) CERTAIN EVENTS. The Company will immediately notify each Selling
Holder, at any time when a prospectus relating thereto is required to be
delivered under the Securities Act, of the occurrence of an event requiring the
preparation of a supplement or amendment to such prospectus so that, as
thereafter delivered to the Holders of such Registrable Securities, such
prospectus will not contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made,
not misleading and promptly make available to each Selling Holder any such
supplement or amendment. The Company will promptly prepare and if required,
cause to become effective, such supplement or amendment and deliver sufficient
copies thereof to each Selling Holder.
(g) AGREEMENTS. The Company and the Selling Holders will enter into
customary agreements (including, if applicable, an underwriting agreement in
customary form and which is reasonably satisfactory to the Company) and take
such other actions as are reasonably required in order to expedite or facilitate
the disposition of such Registrable Securities; and the Selling Holders may, at
their option, require that any or all of the representations, warranties and
covenants of the Company or to or for the benefit of such Underwriters also be
made to and for the benefit of such Selling Holders.
(h) DUE DILIGENCE. The Company will make available to each Selling
Holder (and their counsel) and each Underwriter, if any, subject to restrictions
imposed by the United States federal government or any agency or instrumentality
thereof, copies of all correspondence between the Commission and the Company,
its counsel or auditors and will also make available for inspection by any
Selling Holder, any Underwriter participating in any disposition pursuant to
such registration statement and any attorney, accountant or other professional
retained by any such Selling Holder or Underwriter (collectively, the
"INSPECTORS"), all financial and other records, pertinent corporate documents
and properties of the Company (collectively, the "RECORDS") as shall be
reasonably necessary to enable them to exercise their due diligence
responsibility, and cause the Company's officers and employees to supply all
information reasonably requested by any Inspectors in connection with such
registration statement. Records which the Company determines, in good faith, to
be confidential and which it notifies the Inspectors are confidential shall not
be disclosed by the Inspectors unless (i) the disclosure of such Records is
necessary to avoid or correct a misstatement or omission in such registration
statement or (ii) the disclosure or release of such Records is requested or
required pursuant to oral questions, interrogatories, requests for information
or documents or a subpoena or other order from a court of competent jurisdiction
or other process; PROVIDED, that prior to any disclosure or release pursuant to
clause (ii), the Inspectors shall provide the Company with prompt notice of any
such request or requirement so that the Company may seek an appropriate
protective order or waive such Inspectors' obligation not to disclose such
Records; and, PROVIDED FURTHER, that if failing the entry of a protective order
or the waiver by the Company permitting the disclosure or release of such
Records, the Inspectors, upon advice of counsel, are compelled to disclose such
Records, the Inspectors may disclose that portion of the Records which counsel
has advised the Inspectors that the Inspectors are compelled to disclose. Each
Selling Holder agrees that information obtained by it solely as a result of such
inspections (not including any information obtained from a third party who,
insofar as is known to the Selling Holder after reasonable inquiry, is not
prohibited from providing such information by a contractual, legal or fiduciary
obligation to the Company) shall be deemed confidential and shall not be used by
it as the
- 6 -
<PAGE>
basis for any market transactions in the securities of the Company or its
affiliates (as defined in Rule 405 promulgated under the Securities Act) unless
and until such information is made generally available to the public. Each
Selling Holder further agrees that it will, upon learning that disclosure of
such Records is sought in a court of competent jurisdiction, give notice to the
Company and allow the Company, at its expense, to undertake appropriate action
to prevent disclosure of the Records deemed confidential.
(i) SALES EFFORTS. In connection with an underwritten offering, the
Company will participate, to the extent reasonably requested by the managing
Underwriter for the offering or the Selling Holders, in customary efforts to
sell the securities under the offering, including, without limitation,
participating in "road shows"; PROVIDED, that the Company shall not be obligated
to participate in more than one such offering in any 12-month period.
The Company may require each Selling Holder to promptly furnish in
writing to the Company such information regarding the distribution of the
Registrable Securities as the Company may from time to time reasonably request
and such other information as may be legally required in connection with such
registration including, without limitation, all such information as may be
requested by the Commission or the NASD. The Company may exclude from such
registration any Holder who fails to provide such information.
Each Selling Holder agrees that, upon receipt of any notice from the
Company of the happening of any event of the kind described in subsection (f)
hereof, such Selling Holder will forthwith discontinue disposition of
Registrable Securities pursuant to the registration statement covering such
Registrable Securities until such Selling Holder's receipt of the copies of the
supplemented or amended prospectus contemplated by subsection (f) hereof, and,
if so directed by the Company, such Selling Holder will deliver to the Company
all copies, other than permanent file copies then in such Selling Holder's
possession, of the most recent prospectus covering such Registrable Securities
at the time of receipt of such notice.
SECTION 3.2 REGISTRATION EXPENSES. In connection with the Shelf
Registration and any Piggy-Back Registration, the Company shall pay the
following registration expenses incurred in connection with the registration
thereunder (the "REGISTRATION EXPENSES"): (i) all registration and filing fees,
(ii) fees and expenses of compliance with securities or blue sky laws (including
reasonable fees and disbursements of counsel in connection with blue sky
qualifications of the Registrable Securities), (iii) processing, duplicating and
printing expenses, (iv) the Company's internal expenses (including, without
limitation, all salaries and expenses of its officers and employees performing
legal or accounting duties), (v) the fees and expenses incurred in connection
with the listing of the Registrable Securities, (vi) reasonable fees and
disbursements of counsel for the Company and customary fees and expenses for
independent certified public accountants retained by the Company (including the
expenses of any comfort letters or costs associated with the delivery by
independent certified public accountants of a comfort letter or comfort letters
requested but not the cost of any audit other than a year end audit), (vii) the
reasonable fees and expenses of any special experts retained by the Company in
connection with such registration, (viii) reasonable fees and expenses of one
firm of counsel for the Holders to be selected by the Holders of at least 66.67%
of the Registrable Securities to be included in such registration, and (ix) any
other fees and disbursements of underwriters customarily paid by issuers or
sellers of securities. The Company
- 7 -
<PAGE>
shall have no obligation to pay any other underwriting fees, discounts or
commissions attributable to the sale of Registrable Securities, or the cost of
any special audit required, such costs to be borne by the Holder or Holders
making the request.
SECTION 3.3 ADVICE BY COMPANY. The Company will keep each Holder
advised as to the completion of any registration contemplated in this Agreement.
At its expense, the Company will furnish promptly to each Holder such number or
copies of prospectuses (including preliminary prospectuses), and all amendments
and supplements thereto, in conformity with the requirements of the Securities
Act, and such other documents as any such Holder from time to time may
reasonably request.
ARTICLE 4.
INDEMNIFICATION AND CONTRIBUTION
SECTION 4.1 INDEMNIFICATION BY THE COMPANY. The Company shall, to
the full extent permitted by law, indemnify and hold harmless each Selling
Holder, its partners, officers, directors, employees and agents, and each
person, if any, who controls such Selling Holder within the meaning of Section
15 of the Securities Act or Section 20 of the Exchange Act, together with the
partners, officers, directors, employees and agents of such controlling person
(collectively, "HOLDER COVERED PERSONS"), from and against any loss, claim,
damage, liability, reasonable attorneys' fees, cost or expense and costs and
expenses of investigating and defending any such claim, joint or several, and
any action in respect thereof (collectively, the "DAMAGES"), to which any such
Holder Covered Person may become subject under the Securities Act or otherwise,
insofar as such Damages (or actions or proceedings, whether commenced or
threatened, in respect thereof) arise out of, or are based upon, any untrue
statement or alleged untrue statement of a material fact contained in any
registration statement or prospectus relating to the Registrable Securities or
any amendment or supplement thereto, or arises out of, or are based upon, any
omission or alleged omission to state therein a material fact required to be
stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading, or any violation by
the Company of any federal or state securities law or any rule or regulation
thereof, except insofar as the same are based upon information furnished in
writing to the Company by a Selling Holder expressly for use therein, and shall
reimburse each Holder Covered Person for any legal and other expenses reasonably
incurred by that Holder Covered Person in investigating or defending or
preparing to defend against any such Damages or proceedings; PROVIDED, HOWEVER,
that the Company shall not be liable to any Selling Holder to the extent that
any such Damages (or action or proceeding in respect thereof) arise out of or
are based upon any untrue statement or omission made in any preliminary
prospectus if (i) such Selling Holder failed to send or deliver a copy of the
final prospectus with or prior to the delivery of written confirmation of the
sale by such Selling Holder to the person asserting the claim from which such
Damages arise, and (ii) the final prospectus would have corrected such untrue
statement or such omission; PROVIDED FURTHER, that the Company shall not be
liable to any Selling Holder in any such case to the extent that any such
Damages arise out of or are based upon any untrue statement or omission in any
prospectus if (x) such untrue statement or omission is corrected in an amendment
or supplement to such prospectus, and (y) having previously been furnished by or
on behalf of the Company with copies of such prospectus as so amended or
supplemented, such Selling Holder thereafter fails to deliver such prospectus as
so amended or supplemented prior to or concurrently with the sale of a
Registrable Security to the person asserting
- 8 -
<PAGE>
the claim from which such Damages arise. The Company also agrees to indemnify
any Underwriters of the Registrable Securities, their officers and directors and
each person who controls any such Underwriters on substantially the same basis
as that of the indemnification of the Selling Holders provided in this Section
4.1.
SECTION 4.2 INDEMNIFICATION BY SELLING HOLDERS. Each Selling Holder
shall, to the full extent permitted by law, severally but not jointly, indemnify
and hold harmless the Company, its officers, directors, employees and agents and
each person, if any, who controls the Company within the meaning of Section 15
of the Securities Act or Section 20 of the Exchange Act, together with the
partners, officers, directors, employees and agents of such controlling person
(collectively, "COMPANY COVERED PERSONS"), to the same extent as the foregoing
indemnity from the Company to such Selling Holder, but only with reference to
information related to such Selling Holder, or its plan of distribution,
furnished in writing by such Selling Holder or on such Selling Holder's behalf
expressly for use in any registration statement or prospectus relating to the
Registrable Securities, or any amendment or supplement thereto, or any
preliminary prospectus and the aggregate amount which may be recovered from any
Selling Holder pursuant to the indemnification provided for in this Section 4.2
in connection with any registration and sale of Registrable Securities shall be
limited to the total proceeds received by such Holder from the sale of such
Registrable Securities. In case any action or proceeding shall be brought
against any Company Covered Person in respect of which indemnity may be sought
against such Selling Holder, such Selling Holder shall have the rights and
duties given to the Company Covered Persons, and the Company Covered Persons
shall have the rights and duties given to such Selling Holder, by Section 4.1.
Each Selling Holder also agrees to indemnify and hold harmless any Underwriters
of the Registrable Securities, their officers and directors and each person who
controls such Underwriters on substantially the same basis as that of the
indemnification of the Company provided in this Section 4.2. The Company shall
be entitled to receive indemnities from Underwriters, selling brokers, dealer
managers and similar securities industry professionals participating in the
distribution, to the same extent as provided above, with respect to information
so furnished in writing by such persons specifically for inclusion in any
prospectus or registration statement.
SECTION 4.3 CONDUCT OF INDEMNIFICATION PROCEEDINGS. Promptly after
receipt by any person in respect of which indemnity may be sought pursuant to
Section 4.1 or 4.2 (an "INDEMNIFIED PARTY") of notice of any claim or the
commencement of any action, the Indemnified Party shall, if a claim in respect
thereof is to be made against the person against whom such indemnity may be
sought (an "INDEMNIFYING PARTY"), notify the Indemnifying Party in writing of
the claim or the commencement of such action; PROVIDED that the failure to
notify the Indemnifying Party shall not relieve it from any liability which it
may have to an Indemnified Party otherwise than under Section 4.1 or 4.2 and
except to the extent of any actual prejudice resulting therefrom. If any such
claim or action shall be brought against an Indemnified Party, and it shall
notify the Indemnifying Party thereof, the Indemnifying Party shall be entitled
to participate therein, and, to the extent that it wishes, jointly with any
other similarly notified Indemnifying Party, to assume the defense thereof with
counsel reasonably satisfactory to the Indemnified Party. After notice from the
Indemnifying Party to the Indemnified Party of its election to assume the
defense of such claim or action, the Indemnifying Party shall not be liable to
the Indemnified Party for any legal or other expenses subsequently incurred by
the Indemnified Party in connection with the defense thereof other than
reasonable costs of investigation; PROVIDED that the Indemnified Party shall
have the right to employ
- 9 -
<PAGE>
separate counsel to represent the Indemnified Party and its Controlling Persons
who may be subject to liability arising out of any claim in respect of which
indemnity may be sought by the Indemnified Party against the Indemnifying Party,
but the fees and expenses of such counsel shall be for the account of such
Indemnified Party unless (i) the Indemnifying Party and the Indemnified Party
shall have mutually agreed to the retention of such counsel or (ii) in the
reasonable judgment of the Company and such Indemnified Party, representation of
both parties by the same counsel would be inappropriate due to actual or
potential conflicts of interest between them, it being understood, however, that
the Indemnifying Party shall not, in connection with any one such claim or
action or separate but substantially similar or related claims or actions in the
same jurisdiction arising out of the same general allegations or circumstances,
be liable for the fees and expenses of more than one separate firm of attorneys
(together with appropriate local counsel) at any time for all Indemnified
Parties, or for fees and expenses that are not reasonable. No Indemnifying Party
shall, without the prior written consent of the Indemnified Party, effect any
settlement of any claim or pending or threatened proceeding in respect of which
the Indemnified Party is or could have been a party and indemnity could have
been sought hereunder by such Indemnified Party, unless such settlement includes
an unconditional release of such Indemnified Party from all liability arising
out of such claim or proceeding. Whether or not the defense of any claim or
action is assumed by the Indemnifying Party, such Indemnifying Party will not be
subject to any liability for any settlement made without its consent, which
consent will not be unreasonably withheld.
SECTION 4.4 CONTRIBUTION. If the indemnification provided for in
this Article 4 is unavailable to the Indemnified Parties in respect of any
Damages referred to herein, then each Indemnifying Party, in lieu of
indemnifying such Indemnified Party, shall contribute to the amount paid or
payable by such Indemnified Party as a result of such Damages (i) as between the
Company and the Selling Holders on the one hand and the Underwriters on the
other, in such proportion as is appropriate to reflect the relative benefits
received by the Company and the Selling Holders on the one hand and the
Underwriters on the other from the offering of the Registrable Securities, or if
such allocation is not permitted by applicable law, in such proportion as is
appropriate to reflect not only the relative benefits but also the relative
fault of the Company and the Selling Holders on the one hand and of the
Underwriters on the other in connection with the statements or omissions which
resulted in such Damages, as well as any other relevant equitable
considerations, and (ii) as between the Company on the one hand and each Selling
Holder on the other, in such proportion as is appropriate to reflect the
relative fault of the Company and of each Selling Holder in connection with such
statements or omissions, as well as any other relevant equitable considerations.
The relative benefits received by the Company and the Selling Holders on the one
hand and the Underwriters on the other shall be deemed to be in the same
proportion as the total proceeds from the offering (net of underwriting
discounts and commissions but before deducting expenses) received by the Company
and the Selling Holders bear to the total underwriting discounts and commissions
received by the Underwriters, in each case as set forth in the table on the
cover page of the prospectus. The relative fault of the Company and the Selling
Holders on the one hand and of the Underwriters on the other shall be determined
by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission or alleged omission to state a
material fact relates to information supplied by the Company and the Selling
Holders or by the Underwriters. The relative fault of the Company on the one
hand and of each Selling Holder on the other shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a
material fact or the omission or alleged omission to state a material fact
relates to information
- 10 -
<PAGE>
supplied by such party, and the parties' relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission.
The Company and the Selling Holders agree that it would not be just
and equitable if contribution pursuant to this Section 4.4 were determined by
PRO RATA allocation (even if the Underwriters were treated as one entity for
such purpose) or by any other method of allocation which does not take account
of the equitable considerations referred to in the immediately preceding
paragraph. The amount paid or payable by an Indemnified Party as a result of the
Damages referred to in the immediately preceding paragraph shall be deemed to
include, subject to the limitations set forth above, any legal or other expenses
reasonably incurred by such Indemnified Party in connection with investigating
or defending any such action or claim. Notwithstanding the provisions of this
Section 4.4, no Underwriter shall be required to contribute any amount in excess
of the amount by which the total price at which the Registrable Securities
underwritten by it and distributed to the public were offered to the public
exceeds the amount of any damages which such Underwriter has otherwise been
required to pay by reason of such untrue or alleged untrue statement or omission
or alleged omission, and no Selling Holder shall be required to contribute any
amount in excess of the amount by which the total price at which the Registrable
Securities of such Selling Holder were offered to the public (less underwriting
discounts and commissions) exceeds the amount of any damages which such Selling
Holder has otherwise been required to pay by reason of such untrue or alleged
untrue statement or omission or alleged omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation. Each Selling Holder's obligations to contribute
pursuant to this Section 4.4 is several in the proportion that the proceeds of
the offering received by such Selling Holder bears to the total proceeds of the
offering received by all the Selling Holders and not joint.
ARTICLE 5.
MISCELLANEOUS
SECTION 5.1 OTHER REGISTRATION RIGHTS; HOLDBACK. The Company
represents and warrants to the Holders that, except as set forth on SCHEDULE
2.2(B), there is not in effect on the date hereof any agreement by the Company
pursuant to which any holders of securities of the Company have a right to cause
the Company to register or qualify such securities under the Securities Act or
any securities or blue sky laws of any jurisdiction that would conflict in any
material respect with any provision of this Agreement. The Company shall not in
the future grant to any owner or purchaser of shares of capital stock of the
Company registration rights unless (a) such registration rights are made
subordinate to the rights granted hereunder so that each Holder shall have
priority to participate in any piggy-back registration with respect to such
other shares of capital stock of the Company and (b) if the offering by the
Holders is underwritten, such owner or purchaser agrees not to sell any shares
of capital stock of the Company during the period commencing ten (10) days prior
to any such underwritten offering and ending ninety (90) days following any such
underwritten offering (or for such shorter period of time as is sufficient and
appropriate, in the opinion of any managing Underwriter(s)). If requested by
managing Underwriter(s) in any such registration, the Company shall request the
directors and executive officers of the Company to execute and deliver similar
holdback agreements.
- 11 -
<PAGE>
SECTION 5.2 PARTICIPATION IN UNDERWRITTEN REGISTRATIONS. No person
may participate in any underwritten registration hereunder unless such person
(a) agrees to sell such person's securities on the basis provided in any
underwriting arrangements approved by the persons entitled hereunder to approve
such arrangements, and (b) completes and executes all questionnaires, powers of
attorney, indemnities, underwriting agreements and other documents reasonably
required under the terms of such underwriting arrangements and these
registration rights. Notwithstanding the foregoing, no Holder of Registrable
Securities shall be required to make any representations or warranties to or
agreements with the Company or the Underwriters other than those customarily
made by selling stockholders in such registrations, including without limitation
representations, warranties or agreements regarding such Holder and its
ownership of the securities being registered on its behalf and such Holder's
intended method of distribution and any other representation required by law.
SECTION 5.3 HOLDBACK AGREEMENT. For so long as the Holder has the
right to have Registrable Securities included in any registration pursuant to
this Agreement, the Holder agrees in connection with any underwritten
registration of the Company's securities, upon the request of the Underwriters
managing such underwritten offering of the Company's securities, not to effect
any public sale or distribution (including any sale pursuant to Rule 144 under
the Securities Act) of any Registrable Securities without the prior written
consent of the Company or such Underwriters, as the case may be, within ten (10)
days prior to or ninety (90) days after the effective date of such registration,
as the Company or the Underwriters may specify.
SECTION 5.4 SUSPENSION OF TRADING. After the Company has filed any
registration statement pursuant to this Agreement, and if such registration
shall be in connection with an underwritten offering of the Company's
securities, upon the request of the managing Underwriter or Underwriters the
Company may suspend the sale of Common Stock for up to ninety (90) days;
PROVIDED, HOWEVER, that no such suspension shall occur on more than one occasion
within any one year period.
SECTION 5.5 RULE 144 AND 144A. The Company covenants that it will
file any reports required to be filed by it under the Securities Act and the
Exchange Act and that it will take such further action as any Holder may
reasonably request, all to the extent required from time to time to enable
Holders to sell Registrable Securities without registration under the Securities
Act within the limitation of the exemptions provided by (a) Rule 144 or Rule
144A under the Securities Act, as such Rules may be amended from time to time,
or (b) any similar rule or regulation hereafter adopted by the Commission. Upon
the request of any Holder, the Company will deliver to such Holder a written
statement as to whether it has complied with such requirements.
SECTION 5.6 SUSPENSION OF OBLIGATION TO FILE. Notwithstanding the
provisions of Section 3.1(a), the Company's obligations to file a registration
statement, or cause such registration statement to become and remain effective,
shall be suspended for a period not to exceed 90 days if there exists at the
time material non-public information relating to the Company that, in the
reasonable opinion of the Company, should not be disclosed.
SECTION 5.7 GENERAL.
- 12 -
<PAGE>
(a) GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED
IN ACCORDANCE WITH THE INTERNAL LAW OF THE STATE OF NEW YORK, WITHOUT GIVING
EFFECT TO PRINCIPLES OF CONFLICTS OF LAW.
(b) NOTICES. All notices or other communications shall be in writing
and shall be personally served or mailed, registered or certified, return
receipt requested, postage prepaid (or by a substantially similar method), or
delivered by a reputable overnight courier service with charges prepaid, or
transmitted by hand delivery or facsimile, addressed as set forth below, or such
other address as such party shall have specified most recently by written
notice:
If to the Company:
LifeCell Corporation
3606 Research Forest Drive
The Woodlands, Texas 77381
Attention: President
Telephone: (713) 367-5368
Telecopy: (713) 363-3360
with a copy to:
Fulbright & Jaworski L.L.P.
1301 McKinney Street, Suite 5100
Houston, Texas 77010-3095
Attention: Robert E. Wilson, Esq.
Telephone: (713) 651-5151
Telecopy: (713) 651-5246
Notice to any Holder shall be sent to the address listed on SCHEDULE
1 or to such other address which the Holder shall have provided in writing in
accordance with this Section 5.7(b).
Notice shall be deemed given or delivered on the date of service or
transmission if personally served or transmitted by telecopier (with telephonic
confirmation of receipt). Notice otherwise sent as provided herein shall be
deemed given or delivered on the third business day following the date of
postmark or on the next business day following delivery of such notice to a
reputable overnight courier service.
(c) BINDING EFFECT. This Agreement and all of the provisions hereof
shall be binding upon and inure to the benefit of the parties hereto and their
respective heirs, successors and permitted assigns.
(d) NO WAIVER. No failure on the part of the Company or the
Investors in exercising any right, power or privilege granted hereunder shall
operate as a waiver thereof or of any other right, power or privilege, nor shall
any single or partial exercise of such right, power or privilege preclude any
other or further exercise thereof or of any other right, power or privilege.
- 13 -
<PAGE>
(e) ENTIRE AGREEMENT. This Agreement sets forth the entire agreement
among the parties hereto with respect to the subject matter hereof, and
supersedes any prior oral or written agreements among the parties.
(f) HEADINGS. The headings of this Agreement are solely for the
convenience of the parties and shall not affect the interpretation or effect of
any terms or provisions hereof.
(g) COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed to be an original, but all of which
together shall constitute one and the same document.
(h) SEVERABILITY. In the event that any court or any governmental
authority or agency declares all or any part of any Section of this Agreement to
be unlawful or invalid, such unlawfulness or invalidity shall not serve to
invalidate any other Section of this Agreement, and in the event that only a
portion of any Section is so declared to be unlawful or invalid, such
unlawfulness or invalidity shall not serve to invalidate the balance of such
Section.
(i) AMENDMENTS AND WAIVERS. This Agreement may be amended, modified
and supplemented, and compliance with any term, covenant, agreement or condition
contained herein may be waived either generally or in particular instances, only
by a written instrument executed by the Company and the holders of at least a
majority of the then outstanding Registrable Securities (for this purpose,
treating (i) the Series B Preferred Stock as if it had been converted into
Common Stock and (ii) each of the Warrants and the Gruntal Warrant that is then
exercisable pursuant to its terms as if it had been exercised in full). No
course of dealing between or among any persons having any interest in this
Agreement will be deemed effective to modify, amend or discharge any part of
this Agreement or any rights or obligations of any person under or by reason of
this Agreement.
(j) FURTHER ASSURANCES. Each party shall cooperate and take such
action as may be reasonably requested by another party in order to carry out the
provisions and purposes of this Agreement and the transactions contemplated
hereby.
(k) REMEDIES. In the event of a breach or a threatened breach by any
party to this Agreement of its obligations under this Agreement, any party
injured or to be injured by such breach will be entitled to specific performance
of its rights under this Agreement or to injunctive relief, in addition to being
entitled to exercise all rights provided in this Agreement and granted by law.
The parties agree that the provisions of this Agreement shall be specifically
enforceable, it being agreed by the parties that the remedy at law, inducing
monetary damages, for breach of any such provision will be inadequate
compensation for any loss and that any defense or objection in any action for
specific performance or injunctive relief that a remedy at law would be adequate
is waived.
* * * * *
- 14 -
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this Agreement
as of the date first above written.
LIFECELL CORPORATION
By /s/PAUL M. FRISON
Paul M. Frison
President and Chief Executive Officer
VECTOR LATER-STAGE EQUITY FUND, L.P.
By Vector Fund Management, L.P., its General Partner
By Unreadable Signature
Its President
CIBC WOOD GUNDY VENTURES, INC.
By /s/LORI KOFFMAN
Name:Lori Koffman
Title:Managing Director
- 15 -
<PAGE>
GRUNTAL & CO., INCORPORATED
By
Name:
Title:
- 16 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ DAVID SAKS
(Signature)
Name: David Saks
- 17 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
The Woodlands Venture Capital Company
By: /S/ DON E. ROOSE, JR.
(Signature)
Name: Don E. Roose, Jr.
Vice President and Controller
- 18 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ CHRISTOPHER C. KRAFT, JR.
(Signature)
Name: Christopher C. Kraft, Jr.
- 19 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ P. WILLIAM CURRERI, M.D.
(Signature)
Name: P. William Curreri
- 20 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 6th day of November, 1996.
/S/ STEPHEN LIVESEY
(Signature)
Name: Stephen Livesey
- 21 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ LISA B. TUCKERMAN
(Signature)
Name: Lisa B. Tuckerman
Managing Director of the General
Partner, S.B.S.F. Biotechnology
Partners, L.P.
- 22 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ JEROME SCHACHTER
(Signature)
Name: Jerome Schachter
- 23 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ JOHN S. BAI
(Signature)
Name: John S. Bai
- 24 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ROBERT WEINSTEIN
(Signature)
Name: Robert Weinstein
- 25 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ JAMES C. GALE /S/ JUDITH S. HASELTON
(Signature)
Name: James C. Gale
Judith S. Haselton
- 26 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ JAMES C. GALE, TRUSTEE
(Signature)
Name: James C. Gale, Trustee F/B/O
Ariana J. Gale
- 27 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/S/ JOHN CIRRITO
(Signature)
Name: John Cirrito
- 28 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ B. MICHAEL PISANI
(Signature)
Name: B. Michael Pisani
- 29 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/S/ JOHN LATSHAW
(Signature)
Name: John Latshaw
- 30 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ EVAN KLEINBERG
(Signature)
Name: Evan Kleinberg
- 31 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ DOUGLAS KLEINBERG
(Signature)
Name: Douglas Kleinberg
- 32 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ DANIEL KLEINBERG
/S/ ELAINE KLEINBERG
(Signature)
Name: Daniel & Elaine Kleinberg
- 33 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ALLEN L. BOORSTEIN
(Signature)
Name: Allen L. Boorstein,
General Partner
Chinook Equities
- 34 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/S/ BARRY RICHTER
(Signature)
Name: Barry Richter
- 35 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ STEPHEN G. WEISS
(Signature)
Name: Stephen G. Weiss
- 36 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ JOSEPH BATTIPAGLIA
(Signature)
Name: Joseph Battipaglia
- 37 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ WILLIAM J. STRAZZULLO
(Signature)
Name: William J. Strazullo
- 38 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ROBERT SABLOWSKY
(Signature)
Name: Robert Sablowsky
- 39 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/S/ JOHN D. GOLDBERG
(Signature)
Name: John D. Goldberg
- 40 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ JOSEPH A. RUSSO
(Signature)
Name: Jospeh A. Russo
- 41 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 31st day of October, 1996.
/S/ MICHAEL GIRONTA
(Signature)
Name: Michael Gironta
- 42 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ DONNA GREENBERG
/S/ CHARLES L. GREENBERG
(Signature)
Name: Donna Greenberg
Charles L. Greenberg
- 43 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ RICHARD L. SERRANO
(Signature)
Name: Richard L. Serrano
- 44 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/S/ DAVID HARRIS /S/ MARY JANE HARRIS
(Signature)
Name: David Harris Mary Jane Harris
- 45 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ PAUL B. ANKIN
/S/ LOIS F. ANKIN
(Signature)
Name: Paul B. Ankin & Lois F. Ankin
- 46 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ JEROME SCHACHTER
(Signature)
Name: Jerome Schachter
- 47 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ MICHAEL J. KOBLITZ
(Signature)
Name: Michael J. Koblitz, as Trustee
- 48 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ SHELDON DROBNY
(Signature)
Name: Sheldon Drobny
- 49 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 5th day of November, 1996.
/S/ PERRY H. BACON
(Signature)
Name: Perry H. Bacon
- 50 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ JAMES J. PELTS
(Signature)
Name: James J. Pelts
- 51 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ ROBERT WEINSTEIN
(Signature)
Name: Robert Weinstein
- 52 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
TECHNOLOGY FUNDING MEDICAL
PARTNERS L.L.P.
By: Technology Funding, Inc.
Managing General Partner
By:/S/ THOMAS J. TOY
Name: Thomas J. Toy
Vice President
- 53 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 2nd day of November, 1996.
/S/ RONALD KOENIG
(Signature)
Name: Ronald Koenig
- 54 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ROBERT M. ADAMS
(Signature)
Name: Robert M. Adams
- 55 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ E. A. KERBS
(Signature)
Name: E. A. Kerbs
- 56 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/Bernard B. Salzman
(Signature)
Name: Bernard B. Salzman IRA
Gruntal & Co. Custodian
- 57 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ MICHAEL H. RICHMOND
(Signature)
Name: Michael H. Richmond
- 58 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 2nd day of November, 1996.
/S/ MICHAEL E. CAHR
(Signature)
Name: Michael E. Cahr
- 59 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 11th day of November, 1996.
/S/ DON E. SANDERS
(Signature)
Name: Don E. Sanders
- 60 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ JEFFREY R. KEELER
(Signature)
Name: Jeffrey R. Keeler
- 61 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ JONATHAN GREENWALD AS GENERAL PARTNER
(Signature)
Name: Jonathan Greenwald as General Partner
- 62 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ MARK RICE
(Signature)
Name: Mark Rice
Namax Corp. - President
- 63 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ LISA B. TUCKERMAN
(Signature)
Name: Lisa B. Tuckerman
Managing Director of the General
Partner, S.B.S.F. Biotechnology
Fund, L.P.
- 64 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 6th day of November, 1996.
/S/ FREDERIC GREENBERG
(Signature)
Name: Frederic Greenberg
- 65 -
<PAGE>
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 6th day of November, 1996.
/S/ MICHAEL J. KOBLITZ
(Signature)
Name: Michael J. Koblitz
- 66 -
<PAGE>
SCHEDULE 1
INVESTORS
Vector Later-Stage Equity Fund, L.P.
1751 Lake Cook Road, Suite 350
Deerfield, Illinois 60015
CIBC Wood Gundy Ventures, Inc.
425 Lexington Avenue
New York, New York 10017
The Woodlands Venture Capital Company
2201 Timberloch Place
The Woodlands, TX 77380
SBSF Biotechnology Fund, L.P.
c/o Lisa Tuckerman
Spears Benzak Salomon & Farrell
45 Rockefeller Plaza -- 33rd Floor
New York, NY 10111
SBSF Biotechnology Partners, L.P.
c/o Lisa Tuckerman
Spears Benzak Salomon & Farrell
45 Rockefeller Plaza -- 33rd Floor
New York, NY 10111
Jerome Schachter
2926 Leanne Court
Northbrook, IL 60062
Paul B. Ankin and Lois F. Ankin,
as joint tenants
4233 W. Grove
Skokie, IL 60076
David and Mary Jane Harris
174 Pacific Street, Apt. 2A
Brooklyn, NY 11201
Richard L. Serrano
64 Brighton Avenue
Bloomfield, NJ 07003
Charles and Donna Greenberg
503 Pinehurst Court
Roslyn, NY 11576
Michael Gironta
89 Ridgewood Avenue
Glen Ridge, NJ 07028
Joseph A. Russo
3 Midwood Avenue
Verona, NJ 07044
John D. Goldberg
2500 East Hallandale Beach Blvd.
Suite 500
Hallandale, FL 33009-4838
Robert Sablowsky
150 East 69th Street, 16A
New York, NY 10021
William J. Strazzullo
750 Columbus Avenue, 4C
New York, NY 10025
Joseph Battipaglia
77 Water Street (10th Floor)
New York, NY 10005
Stephen G. Weiss
115 Ravin Oaks Lane
Highland Park, IL 60035
Barry Richter
Tideway
Sandspoint, NY 11050
Chinook Equities, Inc.
147 East 48th Street
- 67 -
<PAGE>
New York, NY 10017
Daniel and Elaine Kleinberg
3 Centennial Road
Livingston, NJ 07039
Douglas Kleinberg
200 East 95th Street, Apt. 126
New York, NY 10128
Evan Kleinberg IRA
Gruntal & Co. Custodian
3 Centennial Road
Livingston, NJ 07039
John Latshaw
5049 Wornall #2C
Kansas City, MO 64112
B. Michael Pisani
44 Lake Road
Short Hills, NJ 07078
John Cirrito
29 Rambling Drive
Scotch Plains, NJ 07076
James C. Gale, Trustee F/B/O Ariana J. Gale
315 W. 106th Street, Apt. 4A
New York, NY 10025
James C. Gale and Judith S. Haselton
315 West 106th Street, Apt. 4A
New York, NY 10025
Robert Weinstein
155 West 68th Street, 24C
New York, NY 10023
John S. Bai
30 West 61st, 27A
New York, NY 10023
William J. McCluskey
25 Wisconsin Street
Long Beach, NY 11561
- 68 -
<PAGE>
David F. Saks
2 Knollcliff Road
Woodcliff Lake, NJ 07675
P. William Curreri, M.D.
217 Berwyn Drive, W. #222
Mobile, Alabama 36608
Christopher C. Kraft, Jr.
Smith Barney Inc. KEO P/S Custodian
14919 Village Elm Street
Houston, TX 77062
Michael H. Richmond
20 E. Wedgewood Glen
The Woodlands, TX 77381
Stephen Livesey
3606 Research Forest Drive
The Woodlands, TX 77381
Michael E. Cahr
1051 Saxony Drive
Highland Park, IL 60035
Technology Funding Medical Partners I, L.P.
2000 Alameda de las Pulgas
San Mateo, CA 94403
Ronald Koenig
114 No. Village Way
Jupiter, Florida 33458
Robert M. Adams
P.O. Box 998
Plandome, NY 11030
Edward A. Kerbs
8 South Cherry Lane
Rumson, NJ 07760
Bernard B. Salzman IRA,
Gruntal & Co., Inc., Custodian
20 S. Charles Street
Baltimore, MD 21201
Don A. Sanders
3100 Texas Commerce Tower
Houston, TX 77002
Jeffrey Keeler
577 W. 50th Street
Miami Beach, FL 33140
Harbour Court L.P., II
253 W. 73rd St., Apt. 6D
New York, NY 10023
Attention: Jonathan Greenwald
Namax Corp.
666 Dundee Road, Suite 1801
Northbrook, IL 60062
Attention: Mark Rice, President
Sheldon Drobny
95 Revere Drive, Suite A
Northbrook, IL 60062
Perry H. Bacon
5300 Mission Woods Road
Shawnee Mission, KS 66205
James J. Pelts
29 East Madison Street, Suite 1505
Chicago, IL 60602
The Marcus L. Koblitz Trust
Michael J. Koblitz, Trustee
12 Downey Drive
Tenafly, NJ 07670
The Lauren J. Koblitz Trust,
Michael J. Koblitz, Trustee
12 Downey Drive
Tenafly, NJ 07670
- 69 -
<PAGE>
Pharmaceutical & Medical Technology Fund
300 Park Avenue
New York, NY 10022
Strategic Healthcare Fund
300 Park Avenue
New York, NY 10022
Michael J. Koblitz
12 Downey Drive
Tenafly, NJ 07670
SCHEDULE 2.2(B)
OTHER REGISTRATION RIGHTS
The holders of capital stock listed below pursuant to the Amended and Restated
Registration Rights Agreement, dated February 26, 1992, as amended, by and among
the Company and the holders of capital stock of the Company identified therein:
Allstate Insurance Company
The Woodlands Venture Fund, L.P.
Tenneco Insurance Ventures, Inc.
The Woodlands Venture Capital Company
Board of Regents of the University of Texas System
Technology Funding Partners III, L.P.
Paul M. Frison
Robert Todd Financial Corporation pursuant to the Underwriter's Warrant
Agreement, dated March 6, 1992, between the Company and Robert Todd Financial
Corporation, as amended by First Amendment to Underwriter's Warrant Agreement,
dated January 23, 1993, by and between the Company and Robert Todd Financial
Corporation.
Medtronic, Inc. pursuant to the Investment Agreement, dated March 3, 1994, as
amended, between the Company and Medtronic, Inc.
- 70 -
EXHIBIT 10.18
This Warrant was originally issued on November 18, 1996, and such issuance
was not registered under the Securities Act of 1933, as amended. The
transfer of this Warrant and the securities obtainable upon exercise
thereof is subject to the conditions on transfer specified in the
Securities Purchase Agreement, dated as of November 18, 1996 (as amended
and modified from time to time), between the issuer hereof (the "COMPANY")
and the initial holder hereof, and the Company reserves the right to
refuse the transfer of such security until such conditions have been
fulfilled with respect to such transfer. Upon written request, a copy of
such conditions shall be furnished by the Company to the holder hereof
without charge.
LIFECELL CORPORATION
STOCK PURCHASE WARRANT
Date of Issuance: November 18, 1996 Certificate No. BW-___
FOR VALUE RECEIVED, LIFECELL Corporation, a Delaware corporation (the
"COMPANY"), hereby grants to _________________________________________ or its
registered assigns (the "REGISTERED HOLDER") the right to purchase from the
Company __________ shares of the Company's Common Stock, par value $.001 per
share ("COMMON STOCK"), at a price per share of $4.13 (as adjusted from time to
time hereunder, the "EXERCISE PRICE"). This Warrant is one of several warrants
(collectively, the "WARRANTS") issued by the Company to certain investors
pursuant to the Securities Purchase Agreement, dated as of November 18, 1996
(the "PURCHASE AGREEMENT"). Certain capitalized terms used herein are defined in
Section 5 hereof. The amount and kind of securities obtainable pursuant to the
rights granted hereunder and the purchase price for such securities are subject
to adjustment pursuant to the provisions contained in this Warrant.
This Warrant is subject to the following provisions:
Section 1. EXERCISE OF WARRANT.
1A. EXERCISE PERIOD. Subject to the provisions of Paragraph 1B, the
Registered Holder may exercise, in whole or in part (but not as to a fractional
share of Common Stock), the purchase rights represented by this Warrant at any
time and from time to time after the Date of Issuance to and including the fifth
anniversary thereof (the "EXERCISE PERIOD"). The Company shall give the
Registered Holder written notice of the expiration of the rights hereunder at
least 30 days but not more than 90 days prior to the end of the Exercise Period.
In the event the Company fails to give the Registered Holder such notice, the
Exercise Period shall continue until and terminate on the thirtieth calendar day
following the day the Company gives such notice.
1
<PAGE>
1B. MANDATORY EXERCISE. Notwithstanding the provisions of Paragraph 1A,
during the period commencing with the second anniversary of the Date of Issuance
through the Exercise Period (the "MANDATORY EXERCISE PERIOD"), upon written
notice from the Company evidencing that the Current Market Price equals or
exceeds an amount equal to three times the then Exercise Price (the "MANDATORY
EXERCISE NOTICE"), the Registered Holder shall exercise all (but not as to any
fractional share of Common Stock) of the purchase rights represented by this
Warrant; provided that, notwithstanding the foregoing, the Registered Holder
shall have no obligation pursuant to this Paragraph 1B to exercise any portion
of the purchase rights represented by this Warrant on any date if on such date
or at any time during the 30 consecutive trading day period ending immediately
prior to such date the Common Stock is not listed or admitted to trading on any
national securities exchange and is not traded over the counter and reported by
Nasdaq or any comparable system. for purposes of this paragraph, "CURRENT MARKET
PRICE" means, at any date during the Mandatory Exercise Period, the average of
the daily closing price per share of Common Stock for the 30 consecutive trading
day period during the Mandatory Exercise Period ending on the trading day
immediately before such date ( as adjusted for any stock dividend, split,
combination or reclassification that took effect during such 30 trading day
period). The closing price for each day shall be the last reported sale price on
the principal national securities exchange on which Common Stock is listed or
admitted to trading or if not listed or admitted to trading on any national
securities exchange, as reported by Nasdaq, if such security is traded over the
counter and quoted in the Nasdaq National Market or Nasdaq Small Cap Market, or
if such equity security is so traded, but not so quoted, the closing bid price
of Common Stock as reported by Nasdaq or any comparable system. The Registered
Holder shall be required to exercise pursuant to Paragraph 1C all of the then
unexercised purchase rights represented by this Warrant no earlier than the 30th
day following the Registered Holder's receipt of the Mandatory Exercise Notice.
1C. EXERCISE PROCEDURE.
(i) This Warrant shall be deemed to have been exercised at such time
when the Company has received all of the following items (the "EXERCISE TIME"):
(a) a completed Exercise Agreement, as described in Paragraph
1D, executed by the Person exercising all or part of the purchase rights
represented by this Warrant (the "PURCHASER");
(b) this Warrant;
(c) if this Warrant is not registered in the name of the
Purchaser, an Assignment or Assignments in the form set forth in EXHIBIT I
hereto evidencing the assignment of this Warrant to the Purchaser, in
which case the Registered Holder shall have complied with the provisions
set forth in Section 7 hereof; and
2
<PAGE>
(d) either (1) a check payable to the Company in an amount
equal to the product of the Exercise Price multiplied by the number of
shares of Common Stock being purchased upon such exercise (the "AGGREGATE
EXERCISE PRICE"), (2) the surrender to the Company of debt or equity
securities of the Company or any of its wholly-owned Subsidiaries having a
Market Price equal to the Aggregate Exercise Price of the shares of Common
Stock being purchased upon such exercise (provided that for purposes of
this subparagraph 1C(i)(d), the Market Price of any note or other debt
security or any preferred stock shall be deemed to be equal to the
aggregate outstanding principal amount or liquidation value thereof plus
all accrued and unpaid interest thereon or accrued or declared and unpaid
dividends thereon) or (3) a written notice to the Company that the
Purchaser is exercising this Warrant (or a portion thereof) by authorizing
the Company to withhold from issuance a number of shares of Common Stock
issuable upon such exercise of this Warrant which when multiplied by the
Market Price of the Common Stock is equal to the Aggregate Exercise Price
(and such withheld shares shall no longer be issuable under this Warrant).
(ii) Certificates for shares of Common Stock purchased upon exercise
of this Warrant shall be delivered by the Company to the Purchaser as soon as
practicable but in any event within ten business days after the date of the
Exercise Time. Unless this Warrant has expired or all of the purchase rights
represented hereby have been exercised, the Company shall prepare a new Warrant,
substantially identical hereto, representing the rights formerly represented by
this Warrant which have not expired or been exercised and shall within such
ten-day period, deliver such new Warrant to the Person designated for delivery
in the Exercise Agreement.
(iii) The shares of Common Stock issuable upon the exercise of this
Warrant shall be deemed to have been issued to the Purchaser at the Exercise
Time, and the Purchaser shall be deemed for all purposes to have become the
record holder of such shares of Common Stock at the Exercise Time.
(iv) The issuance of certificates for shares of Common Stock issued
upon exercise of this Warrant shall be made without charge to the Registered
Holder for any issuance tax in respect thereof or other cost incurred by the
Company in connection with such exercise and the related issuance of shares of
Common Stock. Each share of Common Stock issuable upon exercise of this Warrant
shall, upon payment of the Exercise Price therefor, be fully paid and
nonassessable and free from all liens and charges with respect to the issuance
thereof.
(v) The Company shall not close its books against the transfer of
this Warrant or of any share of Common Stock issued or issuable upon the
exercise of this Warrant in any manner which interferes with the timely exercise
of this Warrant. The Company shall from time to time take all such action as may
be necessary to assure that the par value per share of the unissued Common Stock
acquirable upon exercise of this Warrant is at all times equal to or less than
the Exercise Price then in effect.
3
<PAGE>
(vi) The Company shall assist and cooperate with the Registered
Holder or the Purchaser, as the case may be, in connection with any governmental
filings or any governmental approvals required to be made or obtained by the
Registered Holder or the Purchaser, as the case may be, prior to or in
connection with any exercise of this Warrant (including, without limitation,
making any filings required to be made by the Company).
(vii) Notwithstanding any other provision hereof, if an exercise of
any portion of this Warrant is to be made in connection with a registered public
offering or the sale of the Company, such exercise may, at the election of the
holder hereof, be conditioned upon the consummation of the public offering or
sale of the Company in which case such exercise shall not be deemed to be
effective until the consummation of such transaction.
(viii) The Company shall at all times reserve and keep available out
of its authorized but unissued shares of Common Stock solely for the purpose of
issuance upon the exercise of the Warrants, such number of shares of Common
Stock issuable upon the exercise of all outstanding Warrants. All shares of
Common Stock which are so issuable shall, when issued, be duly and validly
issued, fully paid and nonassessable and free from all taxes, liens and charges.
The Company shall take all such actions as may be necessary to assure that all
such shares of Common Stock may be so issued without violation of any applicable
law or governmental regulation or any requirements of any domestic or foreign
securities exchange upon which shares of Common Stock may be listed (except for
official notice of issuance which shall be immediately delivered by the Company
upon each such issuance) including without limitation, the Nasdaq National
Market or the Nasdaq Small Cap Market (as the case may be). The Company shall
not take any action which would cause the number of authorized but unissued
shares of Common Stock to be less than the number of such shares required to be
reserved hereunder for issuance upon exercise of the Warrants.
1D. EXERCISE AGREEMENT. Upon any exercise of this Warrant, the Exercise
Agreement shall be substantially in the form set forth in EXHIBIT II hereto,
except that if the shares of Common Stock are not to be issued in the name of
the Person in whose name this Warrant is registered, the Exercise Agreement
shall also state the name of the Person to whom the certificates for the shares
of Common Stock are to be issued, and if the number of shares of Common Stock to
be issued does not include all shares of Common Stock purchasable hereunder, it
shall also state the name of the Person to whom a new Warrant for the
unexercised portion of the rights hereunder is to be delivered. Such Exercise
Agreement shall be dated the actual date of execution thereof.
1E. FRACTIONAL SHARES. If a fractional share of Common Stock would, but
for the provisions of Paragraph 1A and Paragraph 1B, as the case may be, be
issuable upon exercise of the rights represented by this Warrant, the Company
shall, within ten business days after the date of the Exercise Time, deliver to
the Purchaser a check payable to the Purchaser in lieu of such fractional share
in an amount equal to the difference between the Market Price of such fractional
share as of the date of the Exercise Time and the Exercise Price of such
fractional share.
4
<PAGE>
Section 2. ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF SHARES. In order to
prevent dilution of the rights granted under this Warrant, the Exercise Price
shall be subject to adjustment from time to time as provided in this Section 2,
and the number of shares of Common Stock obtainable upon exercise of this
Warrant shall be subject to adjustment from time to time as provided in this
Section 2.
2A. ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF SHARES UPON ISSUANCE OF
COMMON STOCK.
(i) If and whenever on or after the Date of Issuance of this Warrant
the Company issues or sells, or in accordance with paragraph 2B is deemed to
have issued or sold, any shares of Common Stock (other than the Excluded Stock)
for a consideration per share less than the Exercise Price in effect immediately
prior to such time, then immediately upon such issue or sale the Exercise Price
shall be reduced to the Exercise Price determined by dividing
(A) the sum of (y) the product derived by multiplying the
Exercise Price in effect immediately prior to such issue or sale and the number
of shares of Common Stock Deemed Outstanding immediately prior to such issue or
sale plus (z) the consideration, if any, received by the Company upon such issue
or sale, by
(B) the number of shares of Common Stock Deemed Outstanding
immediately after such issue or sale.
(ii) Upon each such adjustment of the Exercise Price hereunder, the
number of shares of Warrant Stock acquirable upon exercise of this Warrant shall
be adjusted to the number of shares determined by multiplying the Exercise Price
in effect immediately prior to such adjustment by the number of shares of
Warrant Stock acquirable upon exercise of this Warrant immediately prior to such
adjustment and dividing the product thereof by the Exercise Price resulting from
such adjustment.
(iii) For purposes of this Section 2, "EXCLUDED STOCK" means (1)
Common Stock issued or reserved for issuance by the Company as a dividend on
Preferred Stock or upon any subdivision or split-up of the outstanding shares of
any shares of capital stock of the Company or any recapitalization thereof, or
upon conversion of any shares of Preferred Stock, (2) Common Stock issuable
pursuant to any portion or warrants or other rights that are outstanding on the
date of Issuance identified on SCHEDULE 3-2 CAPITAL STOCK to the Purchase
Agreement, (3) Common Stock of the Company issued or issuable in connection with
a Board-approved acquisition of a business by the Company as a result of which
the Company owns in excess of 50% of the voting power of such business, (4)
Common Stock issued or issuable to employees, officers, consultants, directors
or vendors of the Company or pursuant to any Board-approved employee, officer,
consultant or director benefit plan, including without limitation any
Board-approved stock option plan, and (5) Common Stock issued or issuable to (x)
banks, savings and loan associations, equipment lessors or similar lending
institutions in connection with such entities providing Board-approved credit
facilities or equipment financings to the company or (y) any party to any
technology transfer agreement,
5
<PAGE>
distribution agreement, marketing agreement or any other agreement similar
thereto, with the Company, as approved by the Board.
2B. EFFECT ON EXERCISE PRICE OF CERTAIN EVENTS. For purposes of
determining the adjusted Exercise Price under Paragraph 2A, the following shall
be applicable:
(i) ISSUANCE OF RIGHTS OR OPTIONS. If the company in any manner
grants or sells any Options and the price per share for which Common Stock is
issuable upon the exercise of such Options, or upon conversion or exchange of
any Convertible Securities issuable upon exercise of such Options, is less than
the Exercise Price in effect immediately prior to the time of the granting the
sale of such Options, then the total maximum number of shares of Common Stock
issuable upon the exercise of such Options, or upon conversion or exchange of
the total maximum amount of such Convertible Securities issuable upon the
exercise of such Options, shall be deemed to be outstanding and to have ben
issued and sold by the Company at such time for such price per share. For
purposes of this paragraph, the "PRICE PER SHARE FOR WHICH COMMON STOCK IS
ISSUABLE UPON EXERCISE OF SUCH OPTIONS OR UPON CONVERSION OR EXCHANGE OF SUCH
CONVERTIBLE SECURITIES" is determined by dividing (A) the result of (i) the
total amount, if any, received or receivable by the Company as consideration for
the granting or sale of such Options, plus (ii) the minimum aggregate amount of
additional consideration payable to the Company upon the exercise of all such
Option, plus (iii) in the case of such Options which are exercisable into
Convertible Securities, the minimum aggregate amount of additional
consideration, if any, payable to the Company upon the issuance or sale of such
Convertible Securities and the conversation or exchange thereof, by (B) the
total maximum number of shares of Common Stock issuable upon exercise of such
Options or upon the conversion or exchange of all such Convertible Securities
issuable upon the exercise of such Options. No further adjustment of the
Exercise Price shall be made upon the actual issuance of such Common Stock or of
such Convertible securities upon the exercise of such Options or upon the actual
issuance of such Common Stock upon conversion or exchange of such Convertible
Securities.
(ii) ISSUANCE OF CONVERTIBLE SECURITIES. If the Company in any
manner issues or sells any Convertible Securities and the price per share for
which Common Stock is issuable upon conversion or exchange thereof is less than
the Exercise Price in effect immediately prior to the time of such issue or
sale, then the maximum number of shares of Common Stock issuable upon conversion
or exchange of such Convertible Securities shall be deemed to be outstanding and
to have been issued and sold by the Company for such price per share. For the
purposes of this paragraph, the "PRICE PER SHARE FOR WHICH COMMON STOCK IS
ISSUABLE UPON CONVERSION OR EXCHANGE THEREOF" is determined by dividing (A) the
result of (i) the total amount received or receivable by the Company as
consideration for the issue or sale of such Convertible Securities, plus (ii)
the minimum aggregate amount of additional consideration, if any, payable to the
Company upon the conversation or exchange thereof, by (B) the total maximum
number of shares of Common Stock issuable upon the conversion or exchange of all
such Convertible Securities. No further adjustment of the Exercise Price shall
be made upon the actual issue of such Common Stock upon conversion or exchange
of such
6
<PAGE>
Convertible Securities, and if any such issue or sale of such Convertible
Securities is made upon exercise of any Options for which adjustments of the
Exercise Price had been or are to be made pursuant to other provisions of this
Paragraph 2B, no further adjustment of the Exercise Price shall be made by
reason of such issue or sale.
(iii) CHANGE IN OPTION PRICE OR CONVERSION RATE. If the purchase
price provided for in any Options, the additional consideration, if any, payable
upon the issue, conversion or exchange of any Convertible Securities, or the
rate at which any Convertible Securities are convertible into or exchangeable
for Common Stock changes at any time, the Exercise Price in effect at the time
of such change shall be adjusted immediately to the Exercise Price which would
have been in effect at such time had such Options or Convertible Securities
still outstanding provided for such changed purchase price, additional
consideration or changed conversion rate, as the case may be, at the time
initially granted, issued or sold and the number of shares of Warrant Stock
shall be correspondingly adjusted; provided that if such adjustment would result
in an increase of the Exercise Price then in effect, such adjustment shall not
be effective until 30 days after written notice thereof has been given by the
Company to all holders of the Warrants. For purposes of this Paragraph 2B, if
the terms of any Option or Convertible Security which was outstanding as of the
date of issuance of this Warrant are changed in the manner described in the
immediately preceding sentence, then such Option or Convertible Security and the
Common Stock deemed issuable upon exercise, conversation or exchange thereof
shall be deemed to have been issued as of the date of such change; provided that
no such change shall at any time cause the Exercise Price hereunder to be
increased.
(iv) TREATMENT OF EXPIRED OPTIONS AND UNEXERCISED CONVERTIBLE
SECURITIES. Upon the expiration of any Option or the termination of any right to
convert or exchange any Convertible Securities without the exercise of such
Option or right, the Exercise Price then in effect and the number of shares of
Warrant Stock acquirable hereunder shall be adjusted immediately to the Exercise
Price and the number of shares which would have been in effect at the time of
such expiration or termination had such Option or Convertible Securities to the
extent outstanding immediately prior to such expiration or termination, never
been issued; provided that if such expiration or termination would result in an
increase in the Exercise Price then in effect, such increase shall not be
effective until 30 days after written notice thereof has been given to all
holders of the Warrants. For purposes of this Paragraph 2B, the expiration or
termination of any Option or Convertible Security which was d as of the date of
issuance of this Warrant shall not cause the Exercise Price hereunder to be
adjusted unless, and only to the extent that, a change in the terms of such
Option or Convertible Security caused it to be deemed to have been issued after
the date of issuance of this Warrant.
(v) CALCULATION OF CONSIDERATION RECEIVED. If any Common Stock,
Options or Convertible Securities are issued or sold or deemed to have been
issued or sold for cash, the consideration received therefor shall be deemed to
be the gross amount (net of any underwriter, placement agent or broker discounts
and commissions) received by the Company therefor. In case any Common Stock,
Options or Convertible
7
<PAGE>
Securities are issued or sold for a consideration other than cash, the amount of
the consideration other than cash received by the Company shall be the fair
value of such consideration, except where such consideration consists of
securities, in which case the amount of consideration received by the Company
shall be the Market Price thereof as of the date of receipt. In case any Common
Stock, Options or Convertible Securities are issued to the owners of the
non-surviving entity in connection with any merger in which the Company is the
surviving entity the amount of consideration therefor shall be deemed to be the
fair value of such portion of the net assets and business of the nonsurviving
entity as is attributable to such Common Stock, Options or Convertible
Securities, as the case may be. The fair value of any consideration other than
cash or securities shall be determined jointly by the Company and the Registered
Holders of the Warrants representing a majority of the shares of the Warrant
Stock obtainable upon exercise of such Warrants. If such parties are unable to
reach agreement within a reasonable period of time, such fair value shall be
determined by an appraiser jointly selected by the Company and the Registered
Holders of the Warrants representing a majority of the shares of Warrant Stock
obtainable upon exercise of such Warrants. The determination of such appraiser
shall be final and binding on the Company and the Registered Holders of such
Warrants, and the fees and expenses of such appraiser shall be paid by the
Company.
(vi) INTEGRATED TRANSACTIONS. In case any Option is issued in
connection with the issue or sale of other securities of the Company, together
comprising one integrated transaction in which no specific consideration is
allocated to such Options by the parties thereto, the Options shall be deemed to
have been issued without consideration.
(vii) TREASURY SHARES. The number of shares of Common Stock
outstanding at any given time does not include shares owned or held by or for
the account of the Company or any subsidiary, and the disposition of any shares
so owned or held shall be considered an issue or sale of Common Stock.
(viii) RECORD DATE. If the Company takes a record of the holders of
Common Stock for the purpose of entitling them (A) to receive a dividend or
other distribution payable in Common Stock, Options or in Convertible Securities
of (B) to subscribe for or purchase Common Stock, Options or Convertible
Securities, then such record date shall be deemed to be the date of the issue or
sale of the shares of Common Stock deemed to have been issued or sold upon the
declaration of such dividend or the making of such other distribution or the
date of the granting of such right of subscription or purchase, as the case may
be.
2C. SUBDIVISION OR COMBINATION OF COMMON STOCK. If the Company at any time
subdivides (by any stock split, stock dividend, recapitalization or otherwise)
one or more classes of its outstanding shares of Common Stock into a greater
number of shares, the Exercise Price in effect immediately prior to such
subdivision shall be proportionately reduced and the number of shares of Warrant
Stock obtainable upon exercise of this Warrant shall be proportionately
increased. If the Company at any time combines (by reverse stock split or
otherwise) one or more classes of its outstanding
8
<PAGE>
shares of Common Stock into a smaller number of shares, the Exercise Price in
effect immediately prior to such combination shall be proportionately increased
and the number of shares of Warrant Stock obtainable upon exercise of this
Warrant shall be proportionately decreased.
2D. REORGANIZATION, RECLASSIFICATION, CONSOLIDATION, MERGER OR SALE. Any
recapitalization, reorganization, reclassification, consolidation, merger, sale
of all or substantially all of the Company's assets or other transaction, which
in each case is effective in such a way that the holders of Common Stock are
entitled to receive (either directly or upon subsequent liquidation) stock,
securities or assets with respect to or in exchange for Common Stock is referred
to herein as "ORGANIC CHANGE". Prior to the consummation of any Organic Change,
the Company shall make appropriate provision (in form and substance satisfactory
to the Registered Holders of the Warrants representing a majority of the shares
of Warrant Stock obtainable upon exercise of all Warrants then outstanding) to
insure that each of the Registered Holders of the Warrants shall thereafter have
the right to acquire and receive, in lieu of or addition to (as the case may be)
the shares of Warrant Stock immediately theretofore acquirable and receivable
upon the exercise of such holder's Warrant, such shares of stock, securities or
assets as may be issued or payable with respect to or in exchange for the number
of shares of Warrant Stock immediately theretofore acquirable and receivable
upon exercise of such holder's Warrant had such Organic Change not taken place.
In any such case, the Company shall make appropriate provision (in form and
substance satisfactory to the Registered Holders of the Warrants representing a
majority of the shares of Warrant Stock obtainable upon exercise of all of the
Warrants then outstanding) with respect to such Registered Holders' rights and
interests to insure that the provisions of this Section 2 and Sections 3 and 4
hereof shall thereafter be applicable to the Warrants (including, in the case of
any such consolidation, merger or sale in which the successor entity or
purchasing entity is other than the Company and in which the value for the
Common Stock reflected by the terms of such consolidation, merger or sale is
less than the Base Price in effect immediately prior to such consolidation,
merger or sale, an immediate adjustment of the Exercise Price to the product of
such Exercise Price immediately prior to such consolidation, merger or sale
multiplied by the ratio of such value of the Common Stock divided by the Base
Price in effect immediately prior to such consolidation, merger or sale and a
corresponding immediate adjustment in the number of shares of Warrant Stock
acquirable and receivable upon exercise of the Warrants). The Company shall not
effect any such consolidation, merger or sale, unless prior to the consummation
thereof, the successor entity (if other than the Company) resulting from
consolidation or merger or the entity purchasing such assets assumes by written
instrument (in form and substance satisfactory to the Registered Holders of the
Warrants representing a majority of the Warrant Stock obtainable upon exercise
of all of the Warrants then outstanding), the obligation to deliver to each such
Registered Holder such shares of stock, securities or assets as, in accordance
with the foregoing provisions, such Registered Holder may be entitled to
acquire.
2E. CERTAIN EVENTS. If any event occurs of the type contemplated by the
provisions of Section 2A but not expressly provided for by such provisions, then
the
9
<PAGE>
Exercise Price and the number of shares of Warrant Stock obtainable upon
exercise of this Warrant shall be adjusted by the Corporation's Board of
Directors in good faith so as to protect the rights of the holders of the
Warrants; provided that no such adjustment shall increase the Exercise Price or
decrease the number of shares of Warrant Stock obtainable as otherwise
determined pursuant to this Section 2.
2F. NOTICES.
(i) Immediately upon any adjustment of the Exercise Price, the
Company shall give written notice thereof to the Registered Holder, setting
forth in reasonable detail and certifying the calculation of such adjustment.
(ii) The Company shall give written notice to the Registered Holder
at least 20 days prior to the date on which the Company closes its books or
takes a record (A) with respect to any dividend or distribution upon shares of
Common Stock, (B) with respect to any pro rata subscription offer to holders of
Common Stock or (C) for determining rights to vote with respect to any Organic
Change, dissolution or liquidation.
(iii) The Company shall also give written notice to the Registered
Holders at least 20 days prior to the date on which any Organic Change,
dissolution or liquidation shall take place.
Section 3. LIQUIDATING DIVIDENDS. If the Company declares or pays a
dividend upon shares of Common Stock payable otherwise than in cash out of
earnings or earned surplus (determined in accordance with generally accepted
accounting principles, consistently applied) except for a stock dividend payable
in shares of Common Stock (a "LIQUIDATING DIVIDEND"), then the Company shall pay
to the Registered Holder at the time of payment thereof the Liquidating Dividend
which would have been paid to the Registered Holder on the Warrant Stock had
this Warrant been fully exercised immediately prior to the date on which a
record is taken for such Liquidating Dividend, or, if no record is taken, the
date as of which the record holders of Common Stock entitled to such dividends
are to be determined.
Section 4. PURCHASE RIGHTS. If at any time the Company grants, issues or
sells any Options, Convertible Securities or warrants, securities or other like
property pro rate to the record holders of any class of Common Stock (the
"PURCHASE RIGHTS"), then the Registered Holder shall be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights
which such Registered Holder could have acquired if such Registered Holder had
held the number of shares of Common Stock acquirable upon complete exercise of
this Warrant immediately before the date on which a record is taken for the
grant, issuance or sale of such Purchase Rights, or, if no such record is taken,
the date as of which the record holders of Common Stock are to be determined for
the grant, issue or sale of such Purchase Rights.
Section 5. DEFINITIONS. The following terms have meanings set forth below:
10
<PAGE>
"BOARD" means the Company's Board of Directors.
"COMMON STOCK" means the Company's Common Stock, $0.001 par value, and
except for purposes of the shares obtainable upon exercise of this Warrant, any
capital stock of any class of the Company hereafter authorized which is not
limited to a fixed sum or percentage of par or stated value in respect to the
rights of the holders thereof to participate in dividends or in the distribution
of assets upon any liquidation, dissolution or winding up of the Company.
"COMMON STOCK DEEMED OUTSTANDING" means, at any given time, the number of
shares of Common Stock actually outstanding at such time, plus the number of
shares of Common Stock deemed to be outstanding pursuant to paragraphs 2B(i) and
2B(ii) hereof regardless of whether the Options or Convertible Securities are
actually exercisable or convertible at such time.
"CONVERTIBLE SECURITIES" means any stock or securities (directly or
indirectly) convertible into or exchangeable for Common Stock.
"MARKET PRICE" means as to any security the average of the closing prices
of such security's sales on all domestic or foreign securities exchanges on
which such security may at the time be listed, or, if there have been no sales
on any such exchange on any day, the average of the highest bid and lowest asked
prices on all such exchanges at the end of such day, or, if on any day such
security is not so listed, the average of the representative bid and asked
prices quoted in the Nasdaq National Market or Nasdaq Small Cap Market, as of
4:00 P.M., New York time, on such day, or, if on any day such security is not
quoted in the Nasdaq National Market or the Nasdaq Small Cap Market (as
applicable), the average of the highest bid and lowest asked prices on such day
in the domestic over-the-counter market as reported by the National Quotation
Bureau, Incorporated, or any similar successor organization, in each such case
averaged over a period of 30 days consisting of the day as of which "MARKET
PRICE" is being determined and the 29 consecutive business days prior to such
day; provided that if such security is listed on any domestic securities
exchange the term "BUSINESS DAYS" as used in this sentence means business days
on which such exchange is open for trading. If at any time such security is not
listed on any domestic securities exchange or quoted in the Nasdaq National
Market System or the Nasdaq Small Cap Market or the domestic over-the-counter
market, the "MARKET PRICE" shall be the fair value thereof determined jointly by
the Company and the Registered Holders of Warrants representing a majority of
the Common Stock purchasable upon exercise of all the Warrants then outstanding,
provided that if such parties are unable to reach agreement within a reasonable
period of time, such fair value shall be determined by an appraiser jointly
selected by the Company and the Registered Holders of the Warrants representing
a majority of the shares of Common Stock purchasable upon exercise of all the
Warrants then outstanding. The determination of such appraiser shall be final
and binding on the Company and the Registered Holders of the Warrants, and the
fees and expenses of such appraiser shall be paid by the Company.
11
<PAGE>
"OPTION" means any rights to subscribe for or purchase Common Stock or
Convertible Securities.
"PERSON" means an individual, a partnership, a joint venture, a
corporation, a limited liability company, a trust, an unincorporated
organization and a government or any department or agency thereof.
"WARRANT STOCK" means Common Stock; provided that if there is a change
such that the securities issuable upon exercise of the Warrants are issued by an
entity other than the Company or there is a change in the type or class of
securities so issuable, then the term "WARRANT STOCK" shall mean one share of
the security issuable upon exercise of the Warrants if such security is issuable
in shares, or shall mean the smallest unit in which such security is issuable if
such security is not issuable in shares.
Other capitalized terms used in this Warrant but not defined herein shall
have the meanings set forth in the Purchase Agreement.
Section 6. NO VOTING RIGHTS; LIMITATIONS OF LIABILITY. This Warrant shall
not entitle the holder hereof to any voting rights or other rights as a
stockholder of the Company. No provision hereof, in the absence of affirmative
action by the Registered Holder to purchase Common Stock, and no enumeration
herein of the rights or privileges of the Registered Holder shall give rise to
any liability of such holder for the Exercise Price of Common Stock acquirable
by exercise hereof or as a stockholder of the Company.
Section 7. WARRANT TRANSFERABLE. Subject to the transfer conditions
referred to in the legend endorsed hereon, this Warrant and all rights hereunder
are transferable, in whole or in part, without charge to the Registered Holder,
upon surrender of this Warrant with a properly executed Assignment (in the form
of EXHIBIT I hereto) at the principal office of the Company.
Section 8. WARRANT EXCHANGEABLE FOR DIFFERENT DENOMINATIONS. This Warrant
is exchangeable, upon the surrender hereof by the Registered Holder at the
principal office of the Company, for new Warrants of like tenor representing in
the aggregate the purchase rights hereunder, and each of such new Warrants shall
represent such portion of such rights as is designated by the Registered Holder
at the time of such surrender. The date the Company initially issues this
Warrant shall be deemed to be the "DATE OF ISSUANCE" hereof regardless of the
number of times new certificates representing the unexpired and unexercised
rights formerly represented by this Warrant shall be issued. All Warrants
representing portions of the rights hereunder are referred to herein as the
"WARRANTS."
Section 9. REPLACEMENT. Upon receipt of evidence reasonably satisfactory
to the Company (an affidavit of the Registered Holder shall be satisfactory) of
the ownership and the loss, theft, destruction or mutilation of any certificate
evidencing this Warrant, and in the case of any such loss, theft or destruction,
upon receipt of indemnity reasonably satisfactory to the Company (provided that
if the holder is a financial
12
<PAGE>
institution or other institutional investor its own agreement shall be
satisfactory), or in the case of any such mutilation upon surrender of such
certificate of like kind representing the same rights represented by such loss,
stolen, destroyed or mutilated certificate and dated the date of such loss,
stolen, destroyed or mutilated certificate.
Section 10. NOTICES. Except as otherwise expressly provided herein, all
notices referred to in this Warrant shall be in writing and shall be delivered
personally, sent by reputable overnight courier service (charges prepaid) or
sent by registered or certified mail, return receipt requested, postage prepaid
and shall b deemed to have been given when so delivered, sent or deposited in
the U.S. Mail (i) to the Company, at its principal executive offices and (ii) to
the Registered Holder of this Warrant, at such holder's address as it appears in
the records of the Company (unless otherwise indicated by any such holder).
Section 11. AMENDMENT AND WAIVER. Except as otherwise provided herein, the
provisions of the Warrants may be amended and the Company may take any action
herein prohibited, or omit to perform any act herein required to be performed by
it, only if the Company has obtained the written consent of the Registered
Holders of Warrants representing a majority of the shares of Common Stock
obtainable upon exercise of all of the Warrants then outstanding; provided that
no such action may change the Exercise Price of the Warrants or the number of
shares or class of stock obtainable upon exercise of each Warrant without the
written consent of the Registered Holders of Warrants representing at least 80%
of the shares of Common Stock obtainable upon exercise of the Warrants then
outstanding.
Section 12. DESCRIPTIVE HEADINGS; GOVERNING LAW. The descriptive headings
of the several Sections and paragraphs of this Warrant are inserted for
convenience only and do not constitute a part of this Warrant. The corporation
laws of the State of Delaware shall govern all issues concerning the rights of
the Company and all rights of the Company's stockholders relative to the
Company. All other questions concerning the construction, validity, enforcement
and interpretation of this Warrant shall be governed by the internal law of the
State of New York, without giving effect to any choice of law or conflict of law
provision or rule (whether of the State of New York or any other jurisdictions)
that would cause the application of the laws of any jurisdictions other than the
State of New York.
* * * * * *
13
<PAGE>
IN WITNESS WHEREOF, the Company has caused this Warrant to be signed by
its duly authorized officer and to be dated the Date of Issuance.
LIFECELL CORPORATION
By /s/ PAUL M. FRISON
Paul M. Frison
President and Chief Executive Officer
14
<PAGE>
EXHIBIT I
ASSIGNMENT
FOR VALUE RECEIVED, __________________hereby sells, assigns and transfers
all of the rights of the undersigned under the attached Warrant (Certificate No.
BW- ) with respect to the number of shares of the Common Stock covered thereby
set forth below, unto:
NAMES OF ASSIGNEE ADDRESS NO. OF SHARES
Signature
Witness
15
<PAGE>
EXHIBIT II
EXERCISE AGREEMENT
To: Dated:
The undersigned, pursuant to the provisions set forth in the attached
Warrant (Certificate No. BW- ), hereby agrees to subscribe for the purchase of
shares of the Common Stock covered by such Warrant and makes payment herewith in
full therefor at the price per share provided by such Warrant.
Signature
Witness
16
<PAGE>
SCHEDULE 10.19
TO EXHIBIT 10.19
NAME NO. OF SHARES
CIBC Wood Gundy Ventures, Inc. 1,011,612
The Woodlands Venture Capital Company 56,451
P. William Curreri, M.D. 9,032
Christopher C. Kraft, Jr., 5,645
Smith Barney Inc. KEO P/S Custodian
Michael H. Richmond 9,032
Stephen Livesey 5,645
Michael E. Cahr 11,290
Technology Funding Medical Partners I, L.P. 56,451
Vector Later-Stage Equity Fund, L.P. 903,225
William J. McCluskey 4,200
David Saks 11,290
Joseph Battipaglia 3,387
S.B.S.F. Biotechnology Partners, L.P. 22,580
S.B.S.F. Biotechnology Fund, L.P. 203,225
Jerome Schachter 11,290
Paul B. Ankin and Lois F. Ankin 5,645
David and Mary Jane Harris 4,516
Richard L. Serrano 1,129
Charles and Donna Greenberg 33,870
Michael Gironta 22,580
Joseph A. Russo 3,500
John D. Goldberg 7,000
Robert Sablowsky 10,500
William J. Strazzullo 1,806
Stephen G. Weiss 7,451
Barry Richter 5,645
<PAGE>
NAME NO. OF SHARES
Chinook Equities, Inc. 11,290
Daniel and Elaine Kleinberg 6,029
Douglas Kleinberg 5,600
Evan Kleinberg IRA, 3,500
Gruntal & Co., Inc., Custodian
John Latshaw 21,000
B. Michael Pisani 17,500
John Cirrito 5,645
James C. Gale, Trustee F/B/O Ariana J. Gale 14,000
The James C. Gale Trust
James C. Gale and Judith S. Haselton 35,000
John S. Bai 4,900
Ronald Koenig 7,000
Robert M. Adams 35,000
Edward A. Kerbs 7,000
Bernard B. Salzman IRA, 1,241
Gruntal & Co., Inc., Custodian
Don A. Sanders 14,000
Jeffrey Keeler 1,964
Harbour Court L.P., II 5,645
Namax Corp. 45,161
Sheldon Drobny 11,290
Perry H. Bacon 14,000
James J. Pelts 11,290
Robert Weinstein 4,900
The Marcus L. Koblitz Trust, Michael J. Koblitz, 564
Trustee
The Lauren J. Koblitz Trust, Michael J. Koblitz, 564
Trustee
Pharmaceutical & Medical Technology Fund 67,741
-2-
<PAGE>
Strategic Healthcare Fund 22,580
Michael J. Koblitz 1,129
-3-
EXHIBIT 11.1
YEAR TO DATE ENDED DECEMBER 31, 1996
WEIGHTED AVERAGE SHARES OUTSTANDING:
- --------------------------------------------------------------------------------
Weighted Average Shares Outstanding
at December 31, 1996 4,542,519
=========
Before effect of preferred dividends.
accretion of preferred stock
and warrant exercises ($4,089,714) ($0.90)
Effect of preferred dividends,
accretion of preferred stock
and warrant exercises (1,071,035) (0.24)
Loss per share after effect of
preferred dividends, accretion
of preferred stock and warrant ----------------------
exercises ($5,160,749) ($1.14)
======================
EXHIBIT 23.1
CONSENT OF PUBLIC ACCOUNTANTS
As independent public accountants, we hereby consent to the incorporation
of our report included in this Form 10-K, into the Company's previously filed
Registration Statements File No. 33-90740 and File No. 333-20093.
ARTHUR ANDERSEN LLP
Houston, Texas
March 31, 1997
<TABLE> <S> <C>
<ARTICLE> 5
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-END> DEC-31-1996
<CASH> 10,748,250
<SECURITIES> 0
<RECEIVABLES> 436,839
<ALLOWANCES> 0
<INVENTORY> 839,821
<CURRENT-ASSETS> 12,077,690
<PP&E> 1,623,666
<DEPRECIATION> 1,145,568
<TOTAL-ASSETS> 12,890,015
<CURRENT-LIABILITIES> 1,192,911
<BONDS> 0
0
5,291,599
<COMMON> 4,900
<OTHER-SE> 4,900,605
<TOTAL-LIABILITY-AND-EQUITY> 12,890,015
<SALES> 2,012,205
<TOTAL-REVENUES> 2,945,570
<CGS> 1,281,353
<TOTAL-COSTS> 2,214,718
<OTHER-EXPENSES> 4,955,648
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (4,089,714)
<INCOME-TAX> 0
<INCOME-CONTINUING> (4,089,714)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (4,089,714)
<EPS-PRIMARY> (1.14)
<EPS-DILUTED> 0
</TABLE>
